<SEC-DOCUMENT>0001144204-12-028735.txt : 20120514
<SEC-HEADER>0001144204-12-028735.hdr.sgml : 20120514
<ACCEPTANCE-DATETIME>20120514171316
ACCESSION NUMBER:		0001144204-12-028735
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		12
CONFORMED PERIOD OF REPORT:	20120331
FILED AS OF DATE:		20120514
DATE AS OF CHANGE:		20120514

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TG THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001001316
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				363898269
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32639
		FILM NUMBER:		12839719

	BUSINESS ADDRESS:	
		STREET 1:		787 SEVENTH AVENUE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019
		BUSINESS PHONE:		(212) 554-4484

	MAIL ADDRESS:	
		STREET 1:		787 SEVENTH AVENUE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MANHATTAN PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20030310

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ATLANTIC TECHNOLOGY VENTURES INC
		DATE OF NAME CHANGE:	20000330

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ATLANTIC PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19960703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>v312751_10q.htm
<DESCRIPTION>QUARTERLY REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 10-Q</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Wingdings"><B>x</B></FONT><B>&nbsp;
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the quarterly period ended March
31, 2012</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OR</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Wingdings"><B>&uml;</B></FONT><B>&nbsp;
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the transition period from <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>to<U>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number 000-30929</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 20%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TG THERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified
in its charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: bold 11pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; text-align: center; font: bold 11pt Times New Roman, Times, Serif">Delaware</TD>
    <TD STYLE="width: 50%; text-align: center; font: bold 11pt Times New Roman, Times, Serif">13-4087132</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; font-size: 10pt">(State or other jurisdiction of incorporation or organization)</TD>
    <TD STYLE="text-align: center; font-size: 10pt">(I.R.S. Employer Identification No.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>787 Seventh Avenue</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>New York, New York 10019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address including zip code of principal
executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(212) 554-4484</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant's telephone number, including
area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>MANHATTAN PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name, former address and former
fiscal year, if changed since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Indicate by check mark whether the registrant:
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Yes <FONT STYLE="font-family: Wingdings">x</FONT>
No <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Indicate by check mark whether the registrant
has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted
and posted pursuant to Rule 405 of Regulation S-T (&sect;232.405 of this chapter) during the preceding 12 months (or for such shorter
period that the registrant was required to submit and post such files).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font: 10pt Wingdings">x</FONT>
<FONT STYLE="font-size: 10pt">Yes <FONT STYLE="font-family: Wingdings">&uml;</FONT> No</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of
&ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo; in Rule 12b-2
of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 90%; border-collapse: collapse; font-family: Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 69%; text-align: left; font-size: 10pt">Large accelerated filer <FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD STYLE="width: 31%; text-align: right; font-size: 10pt">Accelerated filer <FONT STYLE="font-family: Wingdings">&uml;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; font-size: 10pt">Non-accelerated filer <FONT STYLE="font-family: Wingdings">&uml;</FONT> (Do not check if smaller reporting company)</TD>
    <TD STYLE="text-align: right; font-size: 10pt">Smaller reporting company <FONT STYLE="font-family: Wingdings">x</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Indicate by checkmark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Yes <FONT STYLE="font-family: Wingdings">&uml;</FONT>
No <FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">There were 14,917,658 shares of the registrant&rsquo;s
common stock, $0.001 par value, outstanding as of May 10, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TG THERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 10-Q</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR THE QUARTER ENDED MARCH 31, 2012</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 13%; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 75%; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: center; font-weight: normal; text-decoration: none; font-style: normal; border-bottom: Black 1pt solid">Page</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-style: normal; font-weight: normal; text-decoration: none">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD COLSPAN="2" STYLE="text-align: justify">SPECIAL CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS</TD>
    <TD STYLE="text-align: right; font-weight: normal; font-style: normal; text-decoration: none">3</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; font-weight: bold">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-weight: bold">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-weight: normal; font-style: normal; text-decoration: none">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: justify; font-weight: bold">PART I</TD>
    <TD STYLE="text-align: justify; font-weight: bold">FINANCIAL INFORMATION</TD>
    <TD STYLE="text-align: right; font-weight: normal; font-style: normal; text-decoration: none">4</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-style: normal; font-weight: normal; text-decoration: none">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: justify">Item 1</TD>
    <TD STYLE="text-align: justify">Financial Statements:</TD>
    <TD STYLE="text-align: right; font-style: normal; font-weight: normal; text-decoration: none">4</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-style: normal; font-weight: normal; text-decoration: none">&nbsp;</TD></TR>
<TR STYLE="text-align: right; vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in; text-align: left">Condensed Consolidated Balance Sheets as of March 31, 2012 (unaudited) and December 31, 2011</TD>
    <TD STYLE="font-style: normal; font-weight: normal; text-decoration: none">4</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-style: normal; font-weight: normal; text-decoration: none">&nbsp;</TD></TR>
<TR STYLE="text-align: right; vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in; text-align: left">Condensed Consolidated Statements of Operations for
    the three months ended March 31, 2012 and the Cumulative Period ended March 31, 2012 (unaudited)</TD>
    <TD STYLE="font-style: normal; font-weight: normal; text-decoration: none">5</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-style: normal; font-weight: normal; text-decoration: none">&nbsp;</TD></TR>
<TR STYLE="text-align: right; vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in; text-align: left">Condensed Consolidated Statement of Stockholders&rsquo; Equity for the three months ended March 31, 2012 (unaudited)</TD>
    <TD STYLE="font-style: normal; font-weight: normal; text-decoration: none">6</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-style: normal; font-weight: normal; text-decoration: none">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="padding-left: 0.1in; text-align: left; text-indent: -0.1in">Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2012 and the Cumulative Period ended March 31, 2012 (unaudited)</TD>
    <TD STYLE="text-align: right; font-style: normal; font-weight: normal; text-decoration: none; vertical-align: bottom">7</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-style: normal; font-weight: normal; text-decoration: none">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">Notes to Condensed Consolidated Financial Statements (unaudited)</TD>
    <TD STYLE="text-align: right; font-style: normal; font-weight: normal; text-decoration: none">8</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-style: normal; font-weight: normal; text-decoration: none">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Item 2</TD>
    <TD STYLE="padding-left: 0.1in; text-align: left; text-indent: -0.1in">Management's Discussion and Analysis of Financial Condition and Results of Operations</TD>
    <TD STYLE="text-align: right; font-style: normal; font-weight: normal; text-decoration: none">19</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-style: normal; font-weight: normal; text-decoration: none">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Item 3</TD>
    <TD STYLE="text-align: left">Quantitative and Qualitative Disclosures About Market Risk</TD>
    <TD STYLE="text-align: right; font-style: normal; font-weight: normal; text-decoration: none">25</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-style: normal; font-weight: normal; text-decoration: none">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: justify">Item 4</TD>
    <TD STYLE="text-align: justify">Controls and Procedures</TD>
    <TD STYLE="text-align: right; font-style: normal; font-weight: normal; text-decoration: none">25</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-style: normal; font-weight: normal; text-decoration: none">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: justify; font-weight: bold">PART II</TD>
    <TD STYLE="text-align: justify; font-weight: bold">OTHER INFORMATION</TD>
    <TD STYLE="text-align: right; font-weight: normal; font-style: normal; text-decoration: none">26</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-style: normal; font-weight: normal; text-decoration: none">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: justify">Item 1</TD>
    <TD STYLE="text-align: justify">Legal Proceedings</TD>
    <TD STYLE="text-align: right; font-style: normal; font-weight: normal; text-decoration: none">26</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-style: normal; font-weight: normal; text-decoration: none">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Item 1A</TD>
    <TD STYLE="text-align: left">Risk Factors</TD>
    <TD STYLE="text-align: right; font-style: normal; font-weight: normal; text-decoration: none">26</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-style: normal; font-weight: normal; text-decoration: none">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: justify">Item 6</TD>
    <TD STYLE="text-align: justify">Exhibits</TD>
    <TD STYLE="text-align: right; font-style: normal; font-weight: normal; text-decoration: none">45</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>SPECIAL CAUTIONARY NOTICE REGARDING FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Certain matters discussed
in this report, including matters discussed under the caption &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition
and Results of Operations,&rdquo; may constitute forward-looking statements for purposes of the Securities Act of 1933, as amended,
or the Securities Act, and the Securities Exchange Act of 1934, as amended, or the Exchange Act, and involve known and unknown
risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different
from the future results, performance or achievements expressed or implied by such forward-looking statements. The words &quot;anticipate,&quot;
&quot;believe,&quot; &quot;estimate,&quot; &quot;may,&quot; &quot;expect&quot; and similar expressions are generally intended to
identify forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking
statements due to a variety of factors, including, without limitation, those discussed under the captions &ldquo;Risk Factors,&rdquo;
&ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo; and elsewhere in this
report, as well as other factors which may be identified from time to time in our other filings with the Securities and Exchange
Commission, (&ldquo;SEC&rdquo;), or in the documents where such forward-looking statements appear. All written or oral forward-looking
statements attributable to us are expressly qualified in their entirety by these cautionary statements. Such forward-looking statements
include, but are not limited to, statements about our:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">expectations for increases or decreases in expenses;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">expectations for the clinical and pre-clinical development, manufacturing, regulatory approval, and
commercialization of our pharmaceutical product candidates or any other products we may acquire or in-license;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">use of clinical research centers and other contractors;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">expectations for incurring capital expenditures to expand our research and development and manufacturing
capabilities;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">expectations for generating revenue or becoming profitable on a sustained basis;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">expectations or ability to enter into marketing and other partnership agreements;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">expectations or ability to enter into product acquisition and in-licensing transactions;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">expectations or ability to build our own commercial infrastructure to manufacture, market and sell
our drug candidates;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">acceptance of our products by doctors, patients or payors;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">ability to compete against other companies and research institutions</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">ability to secure adequate protection for our intellectual property;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">ability to attract and retain key personnel;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">availability of reimbursement for our products;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">estimates of the sufficiency of our existing cash and cash equivalents and investments to finance
our operating requirements, including expectations regarding the value and liquidity of our investments;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">volatility of stock price;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">expected losses; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">expectations for future capital requirements.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The forward-looking statements
contained in this report reflect our views and assumptions only as of the date this report is signed. Except as required by law,
we assume no responsibility for updating any forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We qualify all of our
forward-looking statements by these cautionary statements. In addition, with respect to all of our forward-looking statements,
we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform
Act of 1995.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART I. FINANCIAL INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>ITEM 1. FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TG Therapeutics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(a Development Stage Company)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Condensed Consolidated Balance Sheets</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid">March 31, 2012</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid">December 31, 2011</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: right">(Unaudited)</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: right">(See Note 1)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">Assets</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Current assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 68%; text-align: left; padding-left: 9pt">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">20,923,750</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">9,748,491</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Other current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">79,030</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">87,176</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,002,780</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,835,667</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">In-process research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,441,839</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,441,839</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Goodwill</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">629,752</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">629,752</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">Total assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">27,074,371</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">15,907,258</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Liabilities and equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Current liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Notes payable, current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">677,778</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">877,778</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Accounts payable and accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">467,524</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">666,640</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Interest payable, current portion</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">76,793</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">61,941</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Total current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,222,095</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,606,359</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Notes payable, noncurrent portion, at fair value</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,664,697</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,664,697</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,886,792</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,271,056</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Commitments and contingencies</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Equity:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">TG Therapeutics, Inc. and subsidiaries</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.24in; padding-right: 0.24in">Preferred stock, $0.001 par value per share (10,000,000 shares authorized, 1,108,816 and 413,388 issued and outstanding as of March 31, 2012 and December 31, 2011, respectively, aggregate liquidation value of $22,176,320 and $8,267,760 at March 31, 2012 and December 31, 2011, respectively)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,109</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">413</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.24in; padding-right: 0.24in">Common stock, $0.001 par value per share (500,000,000 shares authorized, 5,061,399 shares issued and outstanding at March 31, 2012 and December 31, 2011)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,061</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,061</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0.12in">Contingently issuable shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: 0.12in">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,841,334</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,472,115</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0.12in">Deficit accumulated in development stage</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(11,109,164</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(853,074</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Total TG Therapeutics, Inc. and subsidiaries equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,738,346</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,624,521</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Non-controlling interest in subsidiary</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9,449,233</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">11,681</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">21,187,579</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9,636,202</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">Total liabilities and equity</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">27,074,371</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">15,907,258</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.5in"><I>The accompanying
notes are an integral part of the condensed consolidated financial statements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0"><B>TG Therapeutics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0">(a Development Stage Company)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0">Condensed Consolidated Statements of Operations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; text-decoration: none">
    <TD NOWRAP STYLE="text-align: left; text-decoration: none">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; text-decoration: none">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; text-decoration: none"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-decoration: none"><B STYLE="text-decoration: none">Three&nbsp;months&nbsp;ended</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-decoration: none"><B STYLE="text-decoration: none"><U STYLE="text-decoration: none">March&nbsp;31,&nbsp;2012&nbsp;</U></B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; text-decoration: none">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; text-decoration: none">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; text-decoration: none"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-decoration: none"><B STYLE="text-decoration: none">Cumulative</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-decoration: none"><B STYLE="text-decoration: none">period&nbsp;ending</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-decoration: none"><B STYLE="text-decoration: none"><U STYLE="text-decoration: none">March&nbsp;31,&nbsp;2012&nbsp;</U></B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; text-decoration: none">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-left: 0.5in">Costs and expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-left: 0.5in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-left: 0.5in">Research and development:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 65%; text-align: left; padding-left: 9pt">Non-cash stock expense associated with in-licensing agreement</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">16,578,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">16,875,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Other research and development</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">163,353</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">193,636</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.5in; padding-left: 0.5in">Total research and development</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">16,741,353</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">17,068,636</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-left: 0.5in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-left: 0.5in">General and administrative:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Non-cash compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">188,509</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">275,003</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Other general and administrative</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">455,492</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">923,689</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Total general and administrative</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">644,001</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,198,692</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-left: 0.5in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.5in; padding-left: 0.5in">Total costs and expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">17,385,354</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">18,267,328</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-left: 0.5in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.5in; padding-left: 0.5in">Operating loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(17,385,354</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(18,267,328</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-left: 0.5in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-left: 0.5in">Other (income) expense:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,668</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,668</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">220,149</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">227,246</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Change in fair value of non-current notes payable</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(205,297</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(205,297</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.5in; padding-left: 0.5in">Total other (income) expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">11,184</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">18,281</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-left: 0.5in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-left: 0.5in">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(17,396,538</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(18,285,609</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.5in; padding-left: 0.5in">Net loss attributable to non-controlling interest</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(7,140,448</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(7,176,445</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.5in; padding-left: 0.5in">Net loss attributable to TG Therapeutics, Inc. and subsidiaries</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(10,256,090</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(11,109,164</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-left: 0.5in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.5in; padding-left: 0.5in">Basic and diluted net loss per common share</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2.03</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-left: 0.5in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Weighted average shares used in computing basic and diluted net loss per common share</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,061,399</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.5in"><I>The accompanying
notes are an integral part of the condensed consolidated financial statements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TG Therapeutics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(a Development Stage Company)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Condensed Consolidated Statement of Equity<BR>
for the three months ended March 31, 2012&#9;(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Preferred&nbsp;stock</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common&nbsp;stock</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Additional <BR>paid-in</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Contingently <BR>issuable</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Non- <BR>controlling <BR>interest&nbsp;in</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Deficit <BR>accumulated <BR>in&nbsp;the <BR>development</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">capital</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">shares</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">subsidiary</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">stage</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 37%; text-align: left; text-indent: -8.1pt; padding-left: 8.1pt">Balance at January 1, 2012</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%; text-align: right">413,388</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 4%; text-align: right">413</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%; text-align: right">5,061,399</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 4%; text-align: right">5,061</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 4%; text-align: right">10,472,115</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 4%; text-align: right">6</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 4%; text-align: right">11,681</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 4%; text-align: right">(853,074</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 4%; text-align: right">9,636,202</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.1pt; padding-left: 8.1pt">Changes during the period:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -8.1pt; padding-left: 8.1pt">Compensation in respect of restricted preferred stock granted to employees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">188,509</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">188,509</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.1pt; padding-left: 8.1pt">Preferred stock issued at $20.00 per share, net of expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">695,428</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">696</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,180,710</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,181,406</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -8.1pt; padding-left: 8.1pt">Shares issued in subsidiary to non-controlling interest in connection with in-licensing agreement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,578,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,578,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; text-decoration: none">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-decoration: none">Net loss</TD><TD STYLE="padding-bottom: 1pt; text-decoration: none">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; text-decoration: none">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; text-decoration: none">&nbsp;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left; text-decoration: none">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-decoration: none">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; text-decoration: none">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; text-decoration: none">&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left; text-decoration: none">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-decoration: none">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; text-decoration: none">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; text-decoration: none">&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left; text-decoration: none">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-decoration: none">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; text-decoration: none">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; text-decoration: none">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left; text-decoration: none">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-decoration: none">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; text-decoration: none">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; text-decoration: none">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left; text-decoration: none">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-decoration: none">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; text-decoration: none">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; text-decoration: none">&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left; text-decoration: none">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-decoration: none">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; text-decoration: none">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; text-decoration: none">(7,140,448</TD><TD STYLE="padding-bottom: 1pt; text-align: left; text-decoration: none">)</TD><TD STYLE="padding-bottom: 1pt; text-decoration: none">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; text-decoration: none">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; text-decoration: none">(10,256,090</TD><TD STYLE="padding-bottom: 1pt; text-align: left; text-decoration: none">)</TD><TD STYLE="padding-bottom: 1pt; text-decoration: none">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; text-decoration: none">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; text-decoration: none">(17,396,538</TD><TD STYLE="padding-bottom: 1pt; text-align: left; text-decoration: none">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -8.1pt; padding-left: 8.1pt">Balance at March 31, 2012</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,108,816</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,109</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,061,399</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,061</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">22,841,334</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">9,449,233</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(11,109,164</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">21,187,579</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.5in"><I>The accompanying
notes are an integral part of the condensed consolidated financial statements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.5in"><I>&nbsp;</I></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TG Therapeutics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(a Development Stage Company)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Condensed Consolidated Statements of Cash
Flows<BR>
(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; text-decoration: none">
    <TD NOWRAP STYLE="text-align: left; text-decoration: none">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; text-decoration: none">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; text-decoration: none"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-decoration: none"><B STYLE="text-decoration: none">Three months ended </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-decoration: none"><B STYLE="text-decoration: none"><U STYLE="text-decoration: none">March 31, 2012</U></B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; text-decoration: none">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; text-decoration: none">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; text-decoration: none"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-decoration: none"><B STYLE="text-decoration: none">Cumulative period </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-decoration: none"><B STYLE="text-decoration: none">ended March 31, </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-decoration: none"><B STYLE="text-decoration: none"><U STYLE="text-decoration: none">2012 </U></B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; text-decoration: none">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">CASH FLOWS FROM OPERATING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">(17,396,538</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">(18,285,609</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Stock compensation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">188,509</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">275,003</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Stock issued in connection with in-licensing agreement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,578,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,875,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -8.1pt; padding-left: 8.1pt">Changes in assets and liabilities, net of effects of acquisition:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 17.8pt">Decrease in other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,147</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,740</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 17.8pt">Increase in accounts payable and accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(254,604</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">153,706</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -8.1pt; padding-left: 17.8pt">Increase in interest payable</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">14,852</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">21,949</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Net cash used in operating activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(861,634</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(948,211</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">CASH FLOWS FROM INVESTING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.1pt; padding-left: 8.1pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Cash acquired in connection with acquisition</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,386</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Net cash provided by investing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,386</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -13.5pt; padding-left: 13.5pt">CASH FLOWS FROM FINANCING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -13.5pt; padding-left: 13.5pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -13.5pt; padding-left: 13.5pt">Payments of short-term loans</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(200,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(200,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -13.5pt; padding-left: 13.5pt">Proceeds from sale of common stock, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,824,682</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -13.5pt; padding-left: 13.5pt">Proceeds from sale of preferred stock, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,257,309</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,257,309</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -13.5pt; padding-left: 13.5pt">Offering costs paid</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(20,416</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(20,416</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -13.5pt; padding-left: 13.5pt">Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">12,036,893</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">21,861,575</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -13.5pt; padding-left: 13.5pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -13.5pt; padding-left: 13.5pt">NET INCREASE IN CASH AND CASH EQUIVALENTS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,175,259</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,923,750</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -13.5pt; padding-left: 13.5pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -13.5pt; padding-left: 13.5pt">Cash and cash equivalents at beginning of period</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9,748,491</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -13.5pt; padding-left: 13.5pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -13.5pt; padding-left: 13.5pt">CASH AND CASH EQUIVALENTS AT END OF PERIOD</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">20,923,750</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">20,923,750</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -13.5pt; padding-left: 13.5pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -13.5pt; padding-left: 13.5pt">NON-CASH TRANSACTIONS:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -13.5pt; padding-left: 13.5pt">Conversion of notes payable to preferred stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">55,271</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -13.5pt; padding-left: 13.5pt">Accrued financing costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">55,487</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">116,626</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.5in"><I>The accompanying
notes are an integral part of the condensed consolidated financial statements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TG Therapeutics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(a Development Stage Company)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Notes to Condensed Consolidated Financial
Statements (unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>Unless the context requires otherwise,
references in this report to &ldquo;TG&rdquo; &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us&rdquo; and &ldquo;our&rdquo; refer
to TG Therapeutics, Inc.(formerly known as Manhattan Pharmaceuticals, Inc.) and our subsidiaries.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>NOTE 1 &ndash; ORGANIZATION AND SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Description of Business</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We are a biopharmaceutical
company focused on the acquisition, development and commercialization of innovative and medically important pharmaceutical products
for the treatment of cancer and other underserved therapeutic needs. We aim to acquire rights to these technologies by licensing
or otherwise acquiring an ownership interest, funding their research and development and eventually either out-licensing or bringing
the technologies to market. Currently we are developing TGTX-1101 (ublituximab), a novel, third generation monoclonal antibody
that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. We also hold the development rights
to AST-726, a nasally delivered product for the treatment of Vitamin B<SUB>12</SUB> deficiency, and AST-915, an orally delivered
treatment for essential tremor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The accompanying unaudited
condensed consolidated financial statements were prepared in accordance with U.S. generally accepted accounting principles (&ldquo;GAAP&rdquo;)
for interim financial information and with the instructions to Form 10-Q and Article&nbsp;10 of Regulation&nbsp;S-X. Accordingly,
they may not include all of the information and footnotes required by GAAP for complete financial statements. All adjustments that
are, in the opinion of management, of a normal recurring nature and are necessary for a fair presentation of the consolidated financial
statements have been included. Nevertheless, these consolidated financial statements should be read in conjunction with the audited
consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2011. The results
of operations for the three months ended March 31, 2012 are not necessarily indicative of the results that may be expected for
the entire fiscal year or any other interim period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">On December 29, 2011,
the Company entered into and consummated an exchange transaction agreement (the &ldquo;Exchange Transaction&rdquo;) with Opus Point
Partners, LLC (&ldquo;Opus&rdquo;) and TG Biologics, Inc. (formerly known as TG Therapeutics, Inc.) (&ldquo;TG Bio&rdquo;). The
stockholders of TG Bio received the majority of the voting shares of the Company, therefore, the merger was accounted for as a
reverse acquisition whereby TG Bio was the accounting acquirer (legal acquiree) and the Company was the accounting acquiree (legal
acquirer) under the acquisition method of accounting. TG Bio was incorporated in Delaware in November 2010, but did not commence
operations until April 2011, thus the accompanying consolidated financial statements do not include comparative financial information
for the three months ended March 31, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">On April 30, 2012, the
Company filed a Certificate of Amendment to its Certificate of Incorporation to change its name from Manhattan Pharmaceuticals,
Inc. (&ldquo;Manhattan&rdquo;) to TG Therapeutics, Inc. In conjunction with this change, the subsidiary formerly named TG Therapeutics,
Inc. filed a Certificate of Amendment changing its name to TG Biologics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><B><I>Liquidity and
Capital Resources</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">We
have incurred operating losses since our inception and expect to continue to incur operating losses for the foreseeable future
and may never become profitable. As of March 31, 2012, we have an accumulated deficit of $11,109,164.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our primary source of
cash has been proceeds from the private placement of equity securities. We have not yet commercialized any of our drug candidates
and cannot be sure if we will ever be able to do so. Even if we commercialize one or more of our drug candidates, we may not become
profitable. Our ability to achieve profitability depends on a number of factors, including our ability to obtain regulatory approval
for our drug candidates, successfully complete any post-approval regulatory obligations and successfully commercialize our drug
candidates alone or in partnership. We may continue to incur substantial operating losses even if we begin to generate revenues
from our drug candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">On December 30, 2011,
we <FONT STYLE="color: black">completed the first closing of the private placement of our securities, issuing 4,929,523 shares
of Company </FONT>$0.001 par value common stock<FONT STYLE="color: black"> (&ldquo;Common Stock &ldquo;) at a price per share of
$2.25 for total gross proceeds, before placement commissions and expenses, of $11,091,425 (the &ldquo;2011 Equity PIPE&rdquo;).&nbsp;Investors
also received warrants to purchase 1,232,381 shares of Common Stock. The warrants have an exercise price of $2.25 per share and
are exercisable for five years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In 2012, we completed
two additional closings of the 2011 Equity PIPE. These closings were held on January 31, 2012, and February 24, 2012. In these
closings, the Company issued 695,428 shares of our Series A preferred stock (&ldquo;Company Preferred Stock&rdquo;) at a price
per share of $20.00, for total gross proceeds, before placement commissions and expenses, of $13,908,560. E<FONT STYLE="background-color: white">ach
share of Company Preferred Stock is convertible into 8.89 shares of Common Stock, provided that such conversion rights are subject
to sufficient available authorized shares of Common Stock.</FONT> Investors also received warrants to purchase 1,545,396 shares
of Common Stock. The warrants have an exercise price of $2.25 per share and are exercisable for five years.&nbsp;<FONT STYLE="background-color: white">The
shares of Company Preferred Stock and warrants sold in these closings were offered and sold to accredited investors, including
members of management, without registration under the Securities Act, or state securities laws, in reliance on the exemptions provided
by Section&nbsp;4(2) of the Securities Act, and Regulation&nbsp;D promulgated thereunder and in reliance on similar exemptions
under applicable state laws. Accordingly, the securities issued in the Offering have not been registered under the Securities Act,
and until so registered, these securities may not be offered or sold in the United States absent registration or availability of
an applicable exemption from registration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our Common Stock is quoted
on <FONT STYLE="color: black">the OTC Bulletin Board<FONT STYLE="font-family: Times New Roman, Times, Serif"> </FONT></FONT>and
trades under the symbol &ldquo;TGTX.OB.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Reverse Stock Split</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="background-color: white">On
April 30, 2012, the Company effected a reverse split of its Common Stock at a ratio of 56.25 for 1, pursuant to a previously obtained
stockholder authorization. All share amounts and per share prices in this Quarterly Report on Form 10-Q have been retroactively
adjusted to reflect the effect of our reverse stock split, on a fifty six and one quarter (56.25) for one (1) basis, unless otherwise
indicated.&nbsp;&nbsp;The exercise price for all stock options and warrants and the conversion price for convertible securities
in the accompanying condensed consolidated financial statements have been adjusted to reflect the reverse stock split by multiplying
the original exercise or conversion price by fifty six and one quarter (56.25).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Cash and Cash Equivalents</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We treat liquid investments with original
maturities of less than three months when purchased as cash and cash equivalents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Research and Development Costs</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Research and development
costs are expensed as incurred. Nonrefundable advance payments for goods or services that will be used or rendered for future research
and development activities are deferred and amortized over the period that the goods are delivered or the related services are
performed, subject to an assessment of recoverability. We make estimates of costs incurred in relation to external clinical research
organizations, or CROs, and clinical site costs. We analyze the progress of clinical trials, including levels of patient enrollment,
invoices received and contracted costs when evaluating the adequacy of the amount expensed and the related prepaid asset and accrued
liability. Significant judgments and estimates must be made and used in determining the accrued balance and expense in any accounting
period. We review and accrue CRO expenses and clinical trial study expenses based on work performed and rely upon estimates of
those costs applicable to the stage of completion of a study. Accrued CRO costs are subject to revisions as such trials progress
to completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. With
respect to clinical site costs, the financial terms of these agreements are subject to negotiation and vary from contract to contract.
Payments under these contracts may be uneven, and depend on factors such as the achievement of certain events, the successful recruitment
of patients, the completion of portions of the clinical trial or similar conditions. The objective of our policy is to match the
recording of expenses in our financial statements to the actual services received and efforts expended. As such, expense accruals
related to clinical site costs are recognized based on our estimate of the degree of completion of the event or events specified
in the specific clinical study or trial contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>In-Process Research and Development</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0in; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal">All
acquired research and development projects are recorded at their fair value as of the date acquisition. The fair values are assessed
annually in the fourth quarter to ascertain if there has been any impairment of the recorded value. If there is an impairment,
the asset is written down to its current fair value by the recording of an expense. Impairment testing consists of a comparison
of the fair value of the in-process research and development with its carrying amount.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Income Taxes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Income taxes are accounted
for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable
to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective
tax bases, operating losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates
expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.
The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes
the enactment date. If the likelihood of realizing the deferred tax assets or liability is less than &ldquo;more likely than not,&rdquo;
a valuation allowance is then created.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We, and our subsidiaries,
file income tax returns in the U.S. Federal jurisdiction and in various states. We have tax net operating loss carryforwards that
are subject to examination for a number of years beyond the year in which they were generated for tax purposes. Since a portion
of these net operating loss carryforwards may be utilized in the future, many of these net operating loss carryforwards will remain
subject to examination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We recognize interest
and penalties related to uncertain income tax positions in income tax expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Stock-Based Compensation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We recognize all share-based
payments to employees and to non-employee directors as compensation for service on our board of directors as compensation expense
in the consolidated financial statements based on the fair values of such payments. Stock-based compensation expense recognized
each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period.
Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from
those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For share-based payments to consultants
and other third-parties, compensation expense is determined at the &ldquo;measurement date.&rdquo; The expense is recognized over
the vesting period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain.
We record compensation expense based on the fair value of the award at the reporting date. The awards to consultants and other
third-parties are then revalued, or the total compensation is recalculated based on the then current fair value, at each subsequent
reporting date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Basic and Diluted Net (Loss) Income
Per Share of Common Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Basic net income (loss)
per share of Common Stock is calculated by dividing net income (loss) applicable to the Common Stock by the weighted-average number
of the Common Stock outstanding for the period. Diluted net loss per share of Common Stock is the same as basic net income (loss)
per share of Common Stock since potentially dilutive securities from stock options, stock warrants and convertible preferred stock
would have an antidilutive effect either because the Company incurred a net loss during the period presented or because such potentially
dilutive securities were out of the money and the Company realized net income during the period presented. The amounts of potentially
dilutive securities excluded from the calculation were 14,154,452 at March 31, 2012. During the three months ended March 31, 2012,
the Company incurred a net loss; therefore, all of the dilutive securities are excluded from the computation of diluted earnings
per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Impairment</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Long lived assets are
reviewed for an impairment loss when circumstances indicate that the carrying value of long-lived tangible and intangible assets
with finite lives may not be recoverable. Management&rsquo;s policy in determining whether an impairment indicator exists, a triggering
event, comprises measurable operating performance criteria as well as qualitative measures. If an analysis is necessitated by the
occurrence of a triggering event, we make certain assumptions in determining the impairment amount. If the carrying amount of an
asset exceeds its estimated future cash flows, an impairment charge is recognized for the difference between the carrying value
and the estimated fair value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Goodwill is reviewed for
impairment annually or when events arise that could indicate that an impairment exists. We test for goodwill impairment using a
two-step process. The first step compares the fair value of the reporting unit with the unit's carrying value, including goodwill.
When the carrying value of the reporting unit is greater than fair value, the unit&rsquo;s goodwill may be impaired, and the second
step must be completed to measure the amount of the goodwill impairment charge, if any. In the second step, the implied fair value
of the reporting unit&rsquo;s goodwill is compared with the carrying amount of the unit&rsquo;s goodwill. If the carrying amount
is greater than the implied fair value, the carrying value of the goodwill must be written down to its implied fair value. We will
continue to perform impairment tests annually at December 31 and whenever events or changes in circumstances suggest that the carrying
value of goodwill may not be recoverable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 2 &ndash; FAIR VALUE MEASUREMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We measure certain financial
assets and liabilities at fair value on a recurring basis in the financial statements. The hierarchy ranks the quality and reliability
of inputs, or assumptions, used in the determination of fair value and requires financial assets and liabilities carried at fair
value to be classified and disclosed in one of the following three categories:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">Level 1 &ndash; quoted prices in active markets for identical assets and liabilities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">Level 2 &ndash; inputs other than Level 1 quoted prices that are directly or indirectly observable;
and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">Level 3 &ndash; unobservable inputs that are not corroborated by market data.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">As of December 31, 2011
and March 31, 2012, the fair values of cash and cash equivalents, other current assets, notes and interest payable, current portion,
accounts payable and accrued expenses, and interest payable, noncurrent approximate their carrying value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="background-color: white">Upon
the merger between Manhattan and Ariston Pharmaceuticals, Inc. (&ldquo;Ariston&rdquo;) in March 2010, Ariston issued $15,452,793
of five-year 5% notes payable (the &ldquo;5% Notes&rdquo;) in satisfaction of several note payable issuances.&nbsp;&nbsp;The 5%
Notes and accrued and unpaid interest thereon are convertible at the option of the holder into Common Stock at the conversion price
of $1,125 per share.&nbsp;&nbsp;Ariston agreed to make quarterly payments on the 5% Notes&nbsp;equal to 50% of the net product
cash flow received from the exploitation or commercialization of Ariston&rsquo;s product candidates, AST-726 and AST-915.&nbsp;&nbsp;The
Company has no obligations under the 5% Notes aside from a) 50% of the net product cash flows from Ariston&rsquo;s product candidates,
if any, payable to noteholders; and b) the conversion feature, discussed above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In connection with the
Exchange Transaction in December 2011, the Company performed a valuation of the assets and liabilities of Manhattan immediately
prior to the transaction. <FONT STYLE="color: black; background-color: white">The cumulative liability including accrued and unpaid
interest of these notes was approximately $16,876,000 immediately prior to the Exchange Transaction, $16,883,000 at December 31,
2011, and $17,089,000 at March 31, 2012. </FONT>As these notes payable are tied directly to net product cash flows derived from
the preexisting products of the Company, this note and accrued interest was recorded at fair value of $4,664,697 as of the date
of the Exchange Transaction. No payments have been made on these notes as of March 31, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We elected the fair value
option for valuing our the 5% Notes upon the completion of the reverse merger with TG Bio, as discussed above. The Company elected
the fair value option in order to reflect in our financial statements the assumptions that market participants use in evaluating
these financial instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The valuation methods
used to estimate the 5% Notes&rsquo; fair value was a discounted cash flow model, where the expected cash flows of AST-726 and
AST-915 are discounted to the present using a yield that incorporates compensation for the probability of success in clinical development
and marketing, among other factors. The discount rate used in this discounted cash flow model approximated 20% at December 31,
2011 and March 31, 2012. The assumptions, assessments and projections of future revenues are subject to uncertainties, are difficult
to predict and require significant judgment. The use of different assumptions, applying different judgment to inherently subjective
matters and changes in future market conditions could result in significantly different estimates of fair value and the differences
could be material to our consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The following table provides
the fair value measurements of applicable financial liabilities as of December 31, 2011 and March 31, 2012:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Financial&nbsp;liabilities&nbsp;at&nbsp;fair&nbsp;value&nbsp;<BR> as&nbsp;of&nbsp;December&nbsp;31,&nbsp;2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Level 1</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Level 2</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Level 3</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 48%; text-align: left; padding-bottom: 1pt">5% Notes</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">4,664,697</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">4,664,697</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0.12in">Totals</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,664,697</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,664,697</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Financial&nbsp;liabilities&nbsp;at&nbsp;fair&nbsp;value&nbsp;<BR> as&nbsp;of&nbsp;March&nbsp;31,&nbsp;2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Level 1</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Level 2</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Level 3</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 48%; text-align: left; padding-bottom: 1pt">5% Notes</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">4,664,697</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">4,664,697</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0.12in">Totals</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,664,697</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,664,697</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Level 3 amounts above
represent the fair value of the 5% Notes and related accrued interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The following table summarizes
the changes in Level 3 instruments during the three months ended March 31, 2012:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 87%; text-align: left">Fair value at December 31, 2011</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">4,664,697</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Interest accrued on face value of 5% Notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">205,297</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Change in fair value of Level 3 liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(205,297</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Fair value at March 31, 2012</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,664,697</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The change in the fair
value of the Level 3 liabilities is reported in other (income) expense in the accompanying condensed consolidated statement of
operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 3 - ACQUISITION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">On December 29, 2011,
the Company completed a reverse acquisition of privately held TG Bio, a Delaware Corporation. The acquisition was effected pursuant
to an Exchange Transaction Agreement (the &ldquo;Agreement&rdquo;) dated December 29, 2011 by and among the Company, TG Bio and
Opus, the largest shareholder of TG Bio. In accordance with the terms of the Agreement, 95% of the holders of common stock of TG
Bio (one (1) minority shareholder of TG Bio holding in aggregate 132,000 shares of common stock of TG Bio did not participate)
surrendered their TG Bio common stock. The Agreement caused the Company to issue to TG Bio&rsquo;s shareholders 281,250 shares
of Company Preferred Stock. <FONT STYLE="color: black; background-color: white">Each share of Company Preferred Stock is convertible
into 8.89 shares of the Common Stock provided that such conversion rights are subject to sufficient available authorized shares
of Common Stock. </FONT>The Company Preferred Stock has the same voting rights (on an as-converted basis), and other attributes
as Common Stock. The Company Preferred Stock will automatically be exchanged for Common Stock when sufficient authorized shares
are available to allow for such conversion. The Company Preferred Stock issued in connection with the Agreement, provided the former
TG Bio shareholders with direct and/or indirect ownership of approximately 95% of the Company&rsquo;s outstanding Company Common
Stock immediately following the consummation of the transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Company Preferred
Stock issued (and the underlying Common Stock once converted) are not registered for resale and, therefore, shall remain subject
to the rights and restrictions of Rule 144. All Company Preferred Stock received by the TG Bio shareholders in exchange for their
shares of TG Bio common stock will not be registered for resale prior to six (6) months following December 29, 2011 and, therefore,
shall remain subject to the rights and restrictions of Rule 144 prior to any such registration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Company Preferred
Stock issued in connection with the agreement provided the former TG Bio shareholders with direct and/or indirect ownership of
approximately 95% of the Company&rsquo;s outstanding common stock as of December 29, 2011. Based on fair value of the Company&rsquo;s
Common Stock of $0.04 per share, the purchase price was $295,933, plus the fair value of restricted stock assumed of $82,305. In
connection with the Exchange Transaction, the Company incurred $231,580 of acquisition related costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">A summary of the purchase
price calculation is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 74%; text-align: left; text-indent: -12.6pt; padding-left: 12.6pt">Number of shares of Manhattan common stock outstanding at the time of the transaction</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">131,526</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Multiplied by Manhattan&rsquo;s fair value of the Common Stock</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2.25</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1pt; text-align: right">295,933</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Fair value of restricted stock assumed</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">82,305</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 12.6pt">Total purchase price</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">378,238</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The purchase price has
been allocated as follows based on the fair values of the assets and liabilities acquired:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 87%; text-align: left; text-indent: -0.25in; padding-left: 0.25in">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">10,386</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.25in; padding-left: 0.25in">Other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">90,769</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.25in; padding-left: 0.25in">In-process research and development acquired</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,441,840</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.25in; padding-left: 0.36in">Total identifiable assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,542,995</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.25in; padding-left: 0.25in">Accounts payable and accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">197,191</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.25in; padding-left: 0.25in">Notes payable (ICON and Swiss Pharma)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">939,718</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.25in; padding-left: 0.25in">5% notes payable and accrued interest</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,657,600</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.25in; padding-left: 0.36in">Total identifiable liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,794,509</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.25in; padding-left: 0.25in">Net identifiable liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(251,514</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.25in; padding-left: 0.25in">Goodwill</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">629,752</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.25in; padding-left: 0.36in">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">378,238</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">A valuation was performed
to determine the fair value of certain identifiable intangible assets of Manhattan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The fair value of certain
identifiable intangible assets was determined using the income approach. This method starts with a forecast of the expected future
net cash flows. These cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the
risk of achieving the asset&rsquo;s projected cash flows. The present value of the estimated cash flows are then added to the present
value equivalent of the residual value of the asset, if any, at the end of the discrete projection period to estimate the fair
value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The valuations are based
on information that is available as of the acquisition date and the expectations and assumptions that have been deemed reasonable
by our management. No assurance can be given, however, that the underlying assumptions or events associated with such assets will
occur as projected. For these reasons, among others, the actual results may vary from the projected results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The following supplemental
pro forma information presents the financial results as if the transaction had occurred on January 1, 2011 for the three months
ended March 31, 2011.&nbsp;This supplemental pro forma information has been prepared for comparative purposes and does not purport
to be indicative of what would have occurred had the acquisition been made on January 1, 2011, nor are they indicative of future
results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Revenue</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 82%; text-align: left; padding-bottom: 2.5pt">Net income</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 15%; border-bottom: Black 2.5pt double; text-align: right">3,832,383</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Basic and diluted income per common share</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1.51</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>NOTE 4 - STOCKHOLDERS' EQUITY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Preferred Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our amended and restated
certificate of incorporation authorizes the issuance of up to 10,000,000 shares of preferred stock, $0.001 par value, with rights
senior to those of our common stock, <FONT STYLE="color: black; background-color: white">issuable in one or more series. Upon issuance,
the Company can determine the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges
could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms
and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the
rights of common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="color: black; background-color: white">There
were 1,108,816 shares of Company Preferred Stock outstanding as of March 31, 2012. </FONT>In connection with the Exchange Transaction,
the Company filed a Certificate of Designation with respect to its Company Preferred Stock with the Secretary of State of the State
of Delaware.&nbsp;&nbsp;The Company Preferred Stock ranks senior to the Common Stock with regard to dividend rights, and has a
liquidation preference of $20 per share over the Common Stock and any other junior securities.&nbsp;The Company Preferred Stock
is automatically convertible into 8.89 shares of Common Stock provided that, prior to conversion, the Company has sufficient authorized
Common Stock to effect such conversion.&nbsp;&nbsp;The Company Preferred Stock also automatically converts upon a change of control
of the Company or the sale of substantially all of the assets of the Company.&nbsp;&nbsp;The Company Preferred Stock votes on an
as-converted basis with the Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In conjunction with the
reverse split effected on April 30, 2012 (as discussed in Note 1), our Company Preferred Stock automatically converted to 9,856,259
shares of Common Stock as of that date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Common Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our amended and restated
certificate of incorporation authorizes the issuance of up to 500,000,000 shares of $0.001 par value common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">On December 30, 2011,
we <FONT STYLE="color: black">completed the first closing of the private placement of our securities, issuing 4,929,523 shares
of Common Stock at a price per share of $2.25 for total gross proceeds, before placement commissions and expenses, of $11,091,425
(the &ldquo;2011 Equity PIPE&rdquo;).&nbsp;Investors also received warrants to purchase 1,232,381 shares of Common Stock. The warrants
have an exercise price of $2.25 per share and are exercisable for five years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In 2012, we completed
two additional closings of the 2011 Equity PIPE. These closings were held on January 31, 2012, and February 24, 2012. In these
closings, the Company issued 695,428 shares of our Company Preferred Stock at a price per share of $20.00 for total gross proceeds,
before placement commissions and expenses, of $13,908,560. E<FONT STYLE="background-color: white">ach share of Company Preferred
Stock is convertible into 8.89 shares of Common Stock provided that such conversion rights are subject to sufficient available
authorized shares of Common Stock.</FONT> Investors also received warrants to purchase 1,545,396 shares of Common Stock. The warrants
have an exercise price of $2.25 per share and are exercisable for five years.&nbsp;<FONT STYLE="background-color: white">The shares
of Company Preferred Stock and warrants sold in these closings were offered and sold to accredited investors, including members
of management, without registration under the Securities Act, or state securities laws, in reliance on the exemptions provided
by Section&nbsp;4(2) of the Securities Act, and Regulation&nbsp;D promulgated thereunder and in reliance on similar exemptions
under applicable state laws. Accordingly, the securities issued in the offering have not been registered under the Securities Act,
and until so registered, these securities may not be offered or sold in the United States absent registration or availability of
an applicable exemption from registration. The placement agent received cash commissions equal to 10% of the gross proceeds of
the offering, five-year warrants to purchase shares of the Company&rsquo;s stock equal to 10% of shares sold in the offering, and
a non-accountable expense allowance equal to two percent of the gross proceeds of the offering for their expenses.&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Equity Incentive Plans</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">A summary of the status
of the Company&rsquo;s stock options as of March 31, 2012 and changes during the period then ended is presented below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>



<P STYLE="margin: 0"></P>
<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><U>Stock Options</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The following table summarizes
stock option activity for the three months ended March 31, 2012:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Number</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of&nbsp;shares</B></P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Weighted-</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>average</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>exercise&nbsp;price</B></P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Weighted-</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>average</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Contractual</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Term</B></P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Aggregate</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Intrinsic<BR>
Value</B></P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">(in years)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 48%; text-align: left">Outstanding at December 31, 2011</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">3,379</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1,315.62</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">6.39</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Forfeited</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,475</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">720.45</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Expired</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Outstanding at March 31, 2012</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">904</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,945.09</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2.49</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Vested and expected to vest at March 31, 2012</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">904</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,945.09</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2.49</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Exercisable at March 31, 2012</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">898</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,963.46</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2.43</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">As of March 31, 2012,
the total compensation cost related to unvested option awards not yet recognized is less than $1,000. The weighted average period
over which it is expected to be recognized is approximately 1 year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><U>Restricted Stock</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Certain employees have
been awarded restricted Company Preferred Stock. The restricted stock vesting consists of milestone and time-based vesting. The
following table summarizes restricted share activity for the three months ended March 31, 2012:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Number&nbsp;of Shares</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Restricted&nbsp;Series&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>A Preferred</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Stock<SUP>(1)</SUP></B></P></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Weighted&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Average</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Grant&nbsp;Date&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Fair Value</B></P></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Aggregate</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Intrinsic</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Value</B></P></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCFFCC">
    <TD STYLE="width: 45%">Outstanding at December 31, 2011</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 15%; text-align: right">129,375</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">$</TD>
    <TD STYLE="width: 15%; text-align: right">20.00</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 15%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt">Granted</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCFFCC">
    <TD STYLE="padding-left: 9pt">Vested</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9pt">Forfeited</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">&mdash;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right">&mdash;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCFFCC">
    <TD STYLE="padding-bottom: 2.25pt">Outstanding at March 31, 2012</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right">129,375</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">$</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right">20.00</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">$</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right">7,762,500</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: -1pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><SUP>(1)
</SUP></B></FONT>The restricted Company Preferred Stock listed in the table above was granted in connection with the Exchange
Transaction to certain executives as discussed above. Each share of Company Preferred Stock is convertible into 8.89 shares of
the Company&rsquo;s Common Stock, provided that such conversion right is subject to sufficient available authorized shares of
the registrant&rsquo;s common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Total expense associated
with restricted stock was $188,509 during the three months ended March 31, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><U>Warrants</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The following table summarizes
warrant activity for the three months ended March 31, 2012:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Warrants</B></P></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Weighted-</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>average</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>exercise price</B></P></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><B>Aggregate<BR>
    Intrinsic <BR>
    Value</B></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCFFCC">
    <TD STYLE="width: 45%">Outstanding at December 31, 2011</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 15%; text-align: right">2,118,768</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">$</TD>
    <TD STYLE="width: 15%; text-align: right">4.62</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 15%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt">Issued</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">2,163,555</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">2.31</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCFFCC">
    <TD STYLE="padding-left: 9pt">Exercised</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white; text-decoration: none">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9pt; text-decoration: none">Expired</TD>
    <TD STYLE="padding-bottom: 1pt; text-decoration: none">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-decoration: none">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-decoration: none">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right; text-decoration: none">(1,449</TD>
    <TD STYLE="padding-bottom: 1pt; text-decoration: none">)</TD>
    <TD STYLE="padding-bottom: 1pt; text-decoration: none">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-decoration: none"></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right; text-decoration: none">2,812.50</TD>
    <TD STYLE="padding-bottom: 1pt; text-decoration: none"></TD>
    <TD STYLE="padding-bottom: 1pt; text-decoration: none"></TD>
    <TD STYLE="padding-bottom: 1pt; text-decoration: none"></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right; text-decoration: none">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-decoration: none">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCFFCC">
    <TD STYLE="padding-bottom: 2.25pt">Outstanding at March 31, 2012</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right">4,280,874</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">$</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right">2.50</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">$</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right">&mdash;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B><I></I></B>During the three months
ended March 31, 2011, as part of the 2011 Equity PIPE, we issued warrants to purchase up to 1,545,396 shares of our Company Common
Stock to investors in the 2011 Equity PIPE, none of which have been exercised as of March 31, 2012. The warrants have an exercise
price of $2.25 per warrant share. In addition, we issued to the placement agent in the transaction warrants to purchase up to
618,159 shares of our Company Common Stock at an exercise price of $2.48 per warrant share, none of which have been exercised
as of March 31, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Stock-Based Compensation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The fair value of stock
options granted is estimated at the date of grant using the Black-Scholes pricing model. The expected term of options granted
is derived from historical data and the expected vesting period. Expected volatility is based on the historical volatility of
our common stock. The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term
of the option in effect at the time of the grant. We have assumed no expected dividend yield, as dividends have never been paid
to stock or option holders and will not be paid for the foreseeable future. The Company did not grant any stock options during
the three months ended March 31, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The following table summarizes
stock-based compensation expense information about stock options and restricted stock for the three months ended March 31, 2012:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 87%; text-align: left; text-indent: -14.2pt; padding-left: 14.2pt">Stock-based compensation expense associated with restricted stock</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">188,509</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -14.2pt; padding-left: 14.2pt">Stock-based compensation expense associated with option grants</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -14.2pt; padding-left: 14.2pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">188,509</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>NOTE 5 &ndash; NOTES PAYABLE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The following is a summary
of notes payable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March&nbsp;31,&nbsp;2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,&nbsp;2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Current <BR>portion,&nbsp;net</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Non- <BR>current <BR>portion,&nbsp;net</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Current <BR>portion,&nbsp;net</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Non- <BR>current <BR>portion,&nbsp;net</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 40%; text-align: left">Non-interest Bearing Note Payable, Net</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">200,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">200,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Convertible 5% Notes Payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,664,697</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,664,697</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,664,697</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,664,697</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">ICON Convertible Note</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">677,778</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">677,778</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">677,778</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">677,778</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">677,778</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,664,697</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,342,475</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">877,778</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,664,697</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,542,475</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We assumed the preceding
notes payable as the result of the Exchange Transaction. Accordingly, a valuation was performed and these notes have been presented
at their fair value on the date of the transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Non-Interest Bearing Note Payable</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In October 2009, Manhattan
entered into a Settlement Agreement and Mutual Release with Swiss Pharma Contract LTD (&ldquo;Swiss Pharma&rdquo;) pursuant to
which Manhattan agreed to pay Swiss Pharma $200,000 and issue to Swiss Pharma an interest free promissory note due on October
27, 2011 in the principal amount of $250,000 in full satisfaction of a September 5, 2008 arbitration award. In November 2011,
Manhattan renegotiated the $250,000 promissory note due October 27, 2011 in which the amount of the promissory note was reduced
to $200,000 and the maturity date was extended to February 15, 2012. This amount was paid on February 14, 2012 in full settlement
of this note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Convertible 5% Notes Payable</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">On March 8, 2010, Manhattan
entered into an Agreement and Plan of Merger (the &quot;Merger Agreement&quot;) by and among the Company, Ariston Pharmaceuticals,
Inc., a Delaware corporation (&quot;Ariston&quot;) and Ariston Merger Corp., a Delaware corporation and wholly-owned subsidiary
of the Company (the &quot;Merger Sub&quot;).&nbsp; Pursuant to the terms and conditions set forth in the Merger Agreement, on
March 8, 2010, the Merger Sub merged with and into Ariston (the &quot;Merger&quot;), with Ariston being the surviving corporation
of the Merger.&nbsp; As a result of the Merger, Ariston became a wholly-owned subsidiary of the Company.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The 5% Notes and accrued
and unpaid interest thereon are convertible at the option of the holder into Common Stock at the conversion price of $1,125 per
share.&nbsp;&nbsp;Ariston agreed to make quarterly payments on the 5% Notes equal to 50% of the net product cash flow received
from the exploitation or commercialization of Ariston&rsquo;s product candidates, AST-726 and AST-915.&nbsp;&nbsp;<FONT STYLE="color: black">The
Company has no obligations under the 5% Notes aside from a) 50% of the net product cash flows from Ariston&rsquo;s product candidates,
if any, payable to noteholders; and b) the conversion feature, discussed above.</FONT> Interest accrues monthly, is added to principal
on an annual basis, every March 8, and is payable at maturity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In connection with the
Exchange Transaction in December 2011, the Company performed a valuation of the assets and liabilities of Manhattan immediately
prior to the transaction. <FONT STYLE="color: black">The cumulative liability including accrued and unpaid interest of these notes
was approximately $16,876,000 immediately prior to the Exchange Transaction, $16,883,000 at December 31, 2011, and $17,089,000
at March 31, 2012. </FONT>As these notes payable are tied directly to net product cash flows derived from the preexisting products
of the Company, this note and accrued interest was recorded at fair value as of the date of the Exchange Transaction. No payments
have been made on these notes as of March 31, 2012. See Note 2 for further details.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>ICON Convertible Note Payable</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In connection with the
merger with Ariston as discussed above, Ariston satisfied an account payable of $1,275,188 to ICON Clinical Research Limited (&ldquo;ICON&rdquo;)
through the payment of $275,188 in cash and the issuance of a three-year 5% note payable (the &ldquo;ICON Note&rdquo;).&nbsp;&nbsp;The
principal was to be repaid in 36 monthly installments of $27,778 commencing in April 2010.&nbsp;&nbsp;Interest was payable monthly
in arrears. &nbsp;&nbsp;On March 1, 2011, Ariston entered into an amended and restated convertible promissory note (the &ldquo;Amended
ICON Note&rdquo;) with ICON. The principal terms of the Amended ICON Note are that monthly payments of principal and interest
will be waived for the thirteen month period ended December 31, 2011 (the &ldquo;Waiver Period&rdquo;) in exchange for a single
payment of $100,000 on March 31, 2011, an increase in the interest on the Amended ICON Note from 5% to 8% per annum during the
Waiver Period and a balloon payment on January 31, 2012. The Amended ICON Note is convertible at the option of the holder into
the Company&rsquo;s Common Stock at the conversion price of $562.50 per share. During the three months ended March 31, 2012, the
Company recorded $14,852 of interest expense on the Amended ICON Note. At March 31, 2012, the principal amount of the Amended
ICON Note was $677,778, of which the entire balance has been classified as current, and interest payable on the Amended ICON Note
was $76,793, and is reflected as notes payable, current portion, net, and interest payable, current portion, net, respectively,
in the accompanying balance sheet as of March 31, 2012. This note is currently in default as the Company did not make the balloon
payment due on January 31, 2012, or the monthly installment payments due in February 2012 and March 2012. The Company is currently
attempting to negotiate a settlement or alternative arrangement in satisfaction of this note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>NOTE 6 &ndash; LICENSE AGREEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In April 2011, TG
Bio, acquired from LFB Biotechnologies, a fully owned subsidiary of France based LFB S.A., an option (the &ldquo;License Option&rdquo;)
for exclusive worldwide rights (except France/Belgium) to develop and market ublituximab (&ldquo;TGTX-1101&rdquo;), a monoclonal
antibody that targets a specific epitope on the B-cell lymphocyte CD20 antigen. In exchange for the License Option, TG Bio issued
132,000 shares of its common stock to LFB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="color: black">On
January 30, 2012, TG Bio exercised the License Option and </FONT>entered into an exclusive license agreement with LFB Biotechnologies,
GTC Biotherapeutics and LFB/GTC LLC, all wholly-owned subsidiaries of LFB Group, relating to the development of ublituximab (the
&ldquo;License Agreement&rdquo;)<FONT STYLE="color: black">. </FONT>Under the License Agreement, we have acquired the exclusive
worldwide rights (exclusive of France/Belgium) for the development and commercialization of TGTX-1101 (ublituximab). To date,
we have made no payments to LFB Group and LFB Group is eligible to receive payments of up to an aggregate of approximately $31.0
million upon our successful achievement of certain clinical development, regulatory and sales milestones, in addition to royalty
payments on net sales of ublituximab. The license will terminate on a country by country basis upon the expiration of the last
licensed patent right or 15 years after the first commercial sale of a product in such country, unless the agreement is earlier
terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In connection with
the license agreement, our subsidiary TG Biologics issued 7,368,000 shares of its common stock to LFB, and the Company agreed
to contribute $15 million, less applicable fees and expenses associated with the financing, to TG Bio to fund the development
of ublituximab under the License Agreement in exchange for 7,500,000 shares of TG Bio common stock. The Company recognized approximately
$16,578,000 of non-cash research and development expense during the three months ended March 31, 2012 in connection with the issuance
of these shares. In addition, in connection with the issuance of 7,368,000 shares of TG Bio common stock, the Company and TG Bio
provided LFB Group the option to,&nbsp;in its sole discretion, elect to convert all, and not less than all, of the shares of TG
Bio common stock into 7,500,000 shares of the Company&rsquo;s Common Stock. This option may be exercised by LFB Group at any time
before May 14, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Furthermore, should
LFB Group choose to exercise the option for Company Common Stock, the Board of Directors of the Company shall appoint&nbsp;an
individual designated by LFB Group to serve as a director of the Company until the next annual meeting of the stockholders and
until his or her successor has been duly elected. Thereafter the Board of Directors of the Company shall nominate a designee named
by LFB Group for election at each annual meeting of the stockholders until such time as LFB Group owns less than 10% of the outstanding
Company Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>NOTE 7 &ndash; RELATED PARTY TRANSACTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">On December 30, 2011,
OPN Capital Markets (&ldquo;OPNCM&rdquo;) and its affiliated broker-dealer, National Securities Corporation (&ldquo;NSC&rdquo;
and collectively with OPNCM, &ldquo;National&rdquo;), both affiliates of National Holdings Corporation (&ldquo;National Holdings&rdquo;),
entered into a Placement Agency Agreement (the &ldquo;PAA&rdquo;) with the Company in connection with the initial closing of the
2011 Equity PIPE, offering of up to $25 million of stock and warrants of the Company.&nbsp;&nbsp;Pursuant to the PAA, National
acted as the Company&rsquo;s placement agent for 2011 Equity PIPE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Until April 2012, Michael
S. Weiss was a director and Non-Executive Chairman of the Board of Directors of National Holdings.&nbsp;&nbsp;He is also a stockholder
of National Holdings and, when combined with his ownership indirectly through Opus and its affiliates, beneficially owns 23.6%
of National Holdings, the parent company of NSC.&nbsp;Mr. Weiss disclaims such beneficiary ownership other than to the extent
of his pecuniary interest. In addition, at the time, Opus and NSC were parties to a 50/50 joint venture that shared profits from
OPNCM, the investment banking division of NSC that was responsible for managing the Offering. This joint venture was dissolved
in April 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company completed the initial closing of the 2011 Equity PIPE on December 30, 2011, </FONT><FONT STYLE="color: black">issuing
4,929,523 shares of Common Stock at a price per share of $2.25 for total gross proceeds, before placement commissions and expenses,
of $11,091,425 (the &ldquo;2011 Equity PIPE&rdquo;).&nbsp;Investors also received warrants to purchase 1,232,381 shares of Common
Stock. The warrants have an exercise price of $2.25 per share and are exercisable for five years</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">.
The Company </FONT><FONT STYLE="color: black">completed two additional closings of the 2011 Equity PIPE. These closings were held
on January 31, 2012 and February 24, 2012. In these closings, the Company issued 695,428 shares of our Company Preferred Stock
(&ldquo;Preferred Stock&rdquo;) at a price per share of $20.00 for total gross proceeds, before placement commissions and expenses,
of $13,908,560. Each share of Company Preferred Stock is convertible into 8.89 shares of Common Stock provided that such conversion
rights are subject to sufficient available authorized shares of Common Stock. Investors will also receive warrants to purchase
1,545,396 shares of Common Stock. The warrants have an exercise price of $2.25 per share and are exercisable for five years.&nbsp;
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0in; text-indent: 0.5in; text-align: left">As
placement agent, National received cash commissions equal to 10% of the gross proceeds of the 2011 Equity PIPE, five-year warrants
to purchase shares of Company Preferred Stock equal to 10% of shares sold in the 2011 Equity PIPE, and a non-accountable expense
allowance equal to two percent of the gross proceeds of the 2011 Equity PIPE for National&rsquo;s expenses (not including up to
$80,000 of National&rsquo;s legal expenses and any blue sky fees, both of which the Company also reimbursed).&nbsp;In addition
to acting as placement, National provided advisory services in connection with the Exchange Transaction and received an advisory
fee of $150,000 for such services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>NOTE 8 &ndash; SUBSEQUENT EVENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">On April 30, 2012, the
Company filed a Certificate of Amendment to its Certificate of Incorporation to change its name from Manhattan Pharmaceuticals,
Inc. to TG Therapeutics, Inc. In conjunction with this change, the subsidiary formerly named TG Therapeutics, Inc. filed a Certificate
of Amendment changing its name to TG Biologics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">On April 30, 2012,
the Company effected a reverse split of its Common Stock at a ratio of 56.25 for 1, pursuant to a previously obtained
shareholder authorization. All share amounts and per share prices in this Quarterly Report on Form 10-Q have been
retroactively adjusted to reflect the effect of our reverse stock split, on a fifty six and one quarter (56.25) for one (1)
basis, unless otherwise indicated.&nbsp;&nbsp;The exercise price for all stock options and warrants and the conversion price
for convertible securities in the accompanying condensed consolidated financial statements have been adjusted to reflect the
reverse stock split by multiplying the original exercise or conversion price by fifty six and one quarter (56.25).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>ITEM 2. MANAGEMENT&rsquo;S DISCUSSION
AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The following discussion
and analysis contains forward-looking statements about our plans and expectations of what may happen in the future. Forward-looking
statements are based on a number of assumptions and estimates that are inherently subject to significant risks and uncertainties,
and our results could differ materially from the results anticipated by our forward-looking statements as a result of many known
or unknown factors, including, but not limited to, those factors discussed in &ldquo;Risk Factors.&rdquo; See also the &ldquo;Special
Cautionary Notice Regarding Forward-Looking Statements&rdquo; set forth at the beginning of this report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">You should read the following
discussion and analysis in conjunction with the unaudited consolidated financial statements, and the related footnotes thereto,
appearing elsewhere in this report, and in conjunction with management&rsquo;s discussion and analysis and the audited consolidated
financial statements included in our annual report on Form 10-K for the year ended December 31, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>OVERVIEW</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We are a biopharmaceutical
company focused on the acquisition, development and commercialization of innovative and medically important pharmaceutical products
for the treatment of cancer and other underserved therapeutic needs. We aim to acquire rights to these technologies by licensing
or otherwise acquiring an ownership interest, funding their research and development and eventually either out-licensing or bringing
the technologies to market. Currently we are developing ublituximab (TGTX-1101), a novel, third generation monoclonal antibody
that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Developed for the treatment
of B-cell proliferative disorders, including Non-Hodgkin&rsquo;s Lymphoma (&ldquo;NHL&rdquo;) and Chronic Lymphocytic Leukemia
(&ldquo;CLL&rdquo;), anti-CD20 antibodies target and aid in the depletion of B-cell lymphocytes. Anti-CD20 antibodies have also
been shown to be effective in treating select autoimmune diseases such as Rheumatoid Arthritis (&ldquo;RA&rdquo;) and Systemic
Lupus Erythematosus (&ldquo;SLE&rdquo;), along with the neurological disorder Multiple Sclerosis (&ldquo;MS&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our portfolio of product
candidates is summarized below:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">TGTX-1101
                                                                                                              (ublituximab), an
                                                                                                              anti-CD20 monoclonal
                                                                                                              antibody for oncology
                                                                                                              and B-cell related
                                                                                                              disorders</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">AST-726,
                                                                                                              a nasally delivered&nbsp;&nbsp;form
                                                                                                              of hydroxocobalamin
                                                                                                              for the treatment
                                                                                                              of vitamin B12 deficiency</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We also actively evaluate
complimentary products, technologies and companies for in-licensing, parthership, acquisition and/or investment opportunities.
To date, we have not received approval for the sale of any of our drug candidates in any market and, therefore, have not generated
any product sales from our drug candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>TGTX-1101 (ublituximab)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>Overview</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">TGTX-1101 (&ldquo;LFB-R603&rdquo;
or &ldquo;R603&rdquo;) is a chimeric murine/human monoclonal antibody with the generic name &ldquo;ublituximab&rdquo; that targets
the CD20 antigen found on the surface of B-cell lymphocytes and has been developed to aid in the depletion of circulating B-cells.
We hold exclusive worldwide rights (excepting France/Belgium) to develop and commercialize ublituximab for all indications, including
the treatment of cancer and autoimmune diseases such as Non-Hodgkin&rsquo;s Lymphoma (&ldquo;NHL&rdquo;) and Chronic Lymphocytic
Leukemia (&ldquo;CLL&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Multiple preclinical
studies both<I> in vitro </I>and <I>in vivo</I> produced data that support the activity and potency of ublituximab as an efficient
and selective B-cell targeting anti-CD20 antibody with the ability to effectively deplete B lymphocytes in both malignant laboratory
cell models as well as NHL and CLL patient donor cell lines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Generally, anti-CD20
antibodies are believed to exert their B-cell depletion effects through three primary mechanisms: direct or programmed cell death
(&ldquo;DCD&rdquo; or &ldquo;PCD&rdquo;), complement dependent cytotoxicity (&ldquo;CDC&rdquo;), and antibody dependent cell-mediated
cytotoxicity (&ldquo;ADCC&rdquo;). Ublituximab has been specifically bio-engineered to enhance the ADCC effects, which we believe
enhances its ability to deplete B-cells and may improve its anit-cancer effects as compared to Rituxan&reg;, the leading anti-CD20
monoclonal anti-body, which had worldwide sales in 2011 of $7 billion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">A two part dose escalating
Phase I clinical trial was recently completed in France in which ublituximab was introduced in relapsed or refractory CLL patients.
In Part 1 of the study, 21 CLL patients in escalating dosage cohorts received once weekly infusions of ublituximab over the course
of 4 weeks, with an additional 12 patients in Part 2 of the study receiving weekly infusions of ublituximab at a higher flat dose
for 8 weeks. According to the investigators, results of Part 2 indicate single agent ublituximab therapy was well tolerated with
primary adverse events including infusion related reactions, neutropenia, transient rises in liver enzymes, pyrexia and thrombocytopenia.
Though the primary endpoint of this Phase I clinical study was to assess the safety and tolerability of ublituximab in CLL patients,
robust B-cell depletion and an encouraging rate of partial responses may suggest preliminary evidence of efficacy. A portion of
the data from Part 2 of this study was presented at the 53<SUP>rd</SUP> Annual American Society of Hematology Meeting in San Diego,
CA. The Company intends to utilize the data generated from patients in the recently completed Phase I clinical trial to design
and conduct future Phase I, II and III studies in the United States and internationally.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Manufacturing of ublituximab
is currently performed by our partner, LFB Biotechnologies, using mammalian cells with plans to explore a second manufacturing
method utilizing a transgenic animal vector developed by GTC Biotherapeutics, a wholly owned subsidiary of LFB S.A. To date, both
LFB and GTC have invested in excess of a combined $60 million in direct expenses related to the development of ublituximab.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>AST-726</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">AST-726 is a nasally
delivered form of hydroxocobalamin for the treatment of Vitamin B12 deficiency.&nbsp; The Company acquired global rights to AST-726
as part of the Ariston acquisition. AST-726 has demonstrated pharmacokinetic equivalence to a marketed intramuscular injection
product for Vitamin B12 remediation.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Company is currently
reviewing its development plans for AST-726, which may include: (1) ceasing further development and attempting to sell or license
AST-726, (2) continuing development as originally contemplated under the SPA or (3) evaluating and implementing alternative development
plans. No decision has been made as to which approach to execute. A final decision is expected to take 6-12 months, but may occur
earlier or later.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>AST-915</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Company has a sponsored
research arrangement for AST-915, an orally delivered treatment for essential tremor, which is currently ongoing and we expect
to conclude in June 2012. It is unlikely that the Company will continue the development of AST-915 thereafter, but a final determination
will be reserved until development activities have concluded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>RECENT DEVELOPMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>TGTX-1101 (ublituximab)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="color: black">On
January 30, 2012, TG Bio exercised the License Option and </FONT>entered into an exclusive license agreement with LFB Biotechnologies,
GTC Biotherapeutics, and LFB/GTC LLC, all wholly-owned subsidiaries of LFB Group, relating to the development of ublituximab<FONT STYLE="color: black">.
</FONT>Under the License Agreement, we have acquired the exclusive worldwide rights (exclusive of France/Belgium) for the development
and commercialization of TGTX-1101 (ublituximab). To date, we have made no payments to LFB Group and LFB Group is eligible to
receive payments of up to an aggregate of approximately $31.0 million upon our successful achievement of certain clinical development,
regulatory and sales milestones, in addition to royalty payments on net sales of ublituximab. The license will terminate on a
country by country basis upon the expiration of the last licensed patent right or 15 years after the first commercial sale of
a product in such country, unless the agreement is earlier terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In March 2012, the Company
submitted to the U.S. Food and Drug Adminstration (&ldquo;FDA&rdquo;) an Investigational New Drug Application (&ldquo;IND&rdquo;)
for TGTX-1101 (ublituximab). The Company received notification of acceptance of this IND in April of 2012, permitting the initiation
of clinical trials for TGTX-1101 in oncology patients in the US. Pursuant to the acceptance of this IND, the Company intends to
initiate a Phase I/II study with ublituximab in the second quarter of 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>GENERAL CORPORATE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We have not earned any
revenues from the commercial sale of any of our drug candidates or from any other source.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our research and development
expenses consist primarily of expenses related to in-licensing of new product candidates, fees paid to consultants and outside
service providers for clinical and laboratory development, facilities-related and other expenses relating to the design, development,
manufacture, testing and enhancement of our drug candidates and technologies. We expense our research and development costs as
they are incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our general and administrative
expenses consist primarily of salaries and related expenses for executive, finance and other administrative personnel, recruitment
expenses, professional fees and other corporate expenses, including investor relations, legal activities and facilities-related
expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our results of operations
include non-cash compensation expense as a result of the grants of stock options and restricted stock. Compensation expense for
awards of options and restricted stock granted to employees and directors represents the fair value of the award recorded over
the respective vesting periods of the individual awards. The expense is included in the respective categories of expense in the
consolidated statements of operations. We expect to continue to incur significant non-cash compensation expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">For awards of options
and restricted stock to consultants and other third-parties, compensation expense is determined at the &ldquo;measurement date.&rdquo;
The expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation
expense remains uncertain. We record compensation expense based on the fair value of the award at the reporting date. The awards
to consultants and other third-parties are then revalued, or the total compensation is recalculated based on the then current
fair value, at each subsequent reporting date. This results in a change to the amount previously recorded in respect of the equity
award grant, and additional expense or a reversal of expense may be recorded in subsequent periods based on changes in the assumptions
used to calculate fair value, such as changes in market price, until the measurement date is reached and the compensation expense
is finalized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In addition, certain
restricted stock issued to employees vest upon the achievement of certain milestones; therefore, the total expense is uncertain
until the milestone is probable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our clinical trials will
be lengthy and expensive. Even if these trials show that our drug candidates are effective in treating certain indications, there
is no guarantee that we will be able to record commercial sales of any of our drug candidates in the near future. In addition,
we expect losses to continue as we continue to fund in-licensing and development of new drug candidates. As we continue our development
efforts, we may enter into additional third-party collaborative agreements and may incur additional expenses, such as licensing
fees and milestone payments. In addition, we may need to establish the commercial infrastructure required to manufacture, market
and sell our drug candidates following approval, if any, by the FDA, which would result in us incurring additional expenses. As
a result, our quarterly results may fluctuate and a quarter-by-quarter comparison of our operating results may not be a meaningful
indication of our future performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>RESULTS OF OPERATIONS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Three months ended March 31, 2012</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I>Non-cash Stock Expense
Associated with In-licensing Agreement.</I> Non-cash stock expense associated with in-licensing agreement totaled $16,578,000
for the three months ended March 31, 2012. This expense primarily related to a one-time non-cash expense of $16,578,000 recorded
in conjunction with the stock issued to LFB Group for the license to TGTX-1101. We expect these non-cash expenses to decrease
substantially over the remainder of 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I>Other Research and
Development Expenses</I>. Other research and development expenses totaled $163,353 for the three months ended March 31, 2012.
We expect our other research and development costs to increase substantially in 2012 due to the commencement of our clinical development
program for TGTX-1101.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I>Non-Cash Compensation
Expense (General and Administrative).</I> Non-cash compensation expense (general and administrative) related to equity incentive
grants equaled $188,509 for the three months ended March 31, 2012. The non-cash compensation expense was related to the period&rsquo;s
expense for restricted stock grants to our chief executive officer and chief financial officer. We expect non-cash compensation
expense (general and administrative) to increase in 2012 as we hire additional personnel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I>Other General and
Administrative Expenses</I>. Other general and administrative expenses totaled $455,492 for the three months ended March 31, 2012.
This expense was primarily related to legal and personnel costs. We expect our other general and administrative expenses to increase
in 2012 as we hire additional staff, and build out our organization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I>Other (Income) Expenses</I>.
Other (income) expenses totaled $11,184 for the three months ended March 31, 2012. This amount consists of interest expense on
our short-term note payable, partially offset by interest income from our bank deposits and the change in fair value of the 5%
Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>LIQUIDITY AND CAPITAL RESOURCES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our primary source of
cash has been proceeds from the private placement of equity securities. We have not yet commercialized any of our drug candidates
and cannot be sure if we will ever be able to do so. Even if we commercialize one or more of our drug candidates, we may not become
profitable. Our ability to achieve profitability depends on a number of factors, including our ability to obtain regulatory approval
for our drug candidates, successfully complete any post-approval regulatory obligations and successfully commercialize our drug
candidates alone or in partnership. We may continue to incur substantial operating losses even if we begin to generate revenues
from our drug candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">As of March 31, 2012,
we had $20,923,750 in cash and cash equivalents. We currently anticipate that our cash and cash equivalents as of March 31, 2012
to be sufficient to fund our anticipated operating cash requirements for approximately 24 months from March 31, 2012. The actual
amount of cash that we will need to operate is subject to many factors, including, but not limited to, the timing, design and
conduct of clinical trials for our drug candidates. We are dependent upon significant financing to provide the cash necessary
to execute our current operations, including the commercialization of any of our drug candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Cash used in operating
activities for the three months ended March 31, 2012 was $861,634, which primarily related to general and administrative and research
and development expenses associated with TG commencing operations and development of TGTX-1101.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">For the three months
ended March 31, 2012, net cash provided by financing activities of $12,036,893, related primarily to net proceeds from the issuance
of the Company&rsquo;s preferred stock, partially offset by the repayment of a short-term loan. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B><I>2011 Equity PIPE</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">On
December 30, 2011, we <FONT STYLE="color: black">completed the first closing of the private placement of our securities, issuing
4,929,523 shares of Common Stock at a price per share of $2.25 for total gross proceeds, before placement commissions and expenses,
of $11,091,425 (the &ldquo;2011 Equity PIPE&rdquo;).&nbsp;Investors also received warrants to purchase 1,232,381 shares of Common
Stock. The warrants have an exercise price of $2.25 per share and are exercisable for five years. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In 2012, we completed
two additional closings of the 2011 Equity PIPE. These closings were held on January 31, 2012 and February 24, 2012. In these
closings, the Company issued 695,428 shares of our Company Preferred Stock at a price per share of $20.00 for total gross proceeds,
before placement commissions and expenses, of $13,908,560. Each share of Company Preferred Stock is convertible into 8.89 shares
of Common Stock provided that such conversion rights are subject to sufficient available authorized shares of Common Stock. Investors
also received warrants to purchase 1,545,396 shares of Common Stock. The warrants have an exercise price of $2.25 per share and
are exercisable for five years.&nbsp;The shares of Company Preferred Stock and warrants sold in these closings were offered and
sold to accredited investors, including members of management, without registration under the Securities Act, or state securities
laws, in reliance on the exemptions provided by Section&nbsp;4(2) of the Securities Act, and Regulation&nbsp;D promulgated thereunder
and in reliance on similar exemptions under applicable state laws. Accordingly, the securities issued in the offering have not
been registered under the Securities Act, and until so registered, these securities may not be offered or sold in the United States
absent registration or availability of an applicable exemption from registration. The placement agent received cash commissions
equal to 10% of the gross proceeds of the offering, five-year warrants to purchase shares of the Company&rsquo;s stock equal to
10% of shares sold in the offering, and a non-accountable expense allowance equal to two percent of the gross proceeds of the
offering for their expenses.&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>OFF-BALANCE SHEET ARRANGEMENTS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We have not entered into
any transactions with unconsolidated entities whereby we have financial guarantees, subordinated retained interests, derivative
instruments or other contingent arrangements that expose us to material continuing risks, contingent liabilities, or any other
obligations under a variable interest in an unconsolidated entity that provides us with financing, liquidity, market risk or credit
risk support.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>CRITICAL ACCOUNTING POLICIES </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The discussion and analysis
of our financial condition and results of operations is based upon our consolidated financial statements, which have been prepared
in accordance with U.S. generally accepted accounting principles. The preparation of these consolidated financial statements requires
us to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent
assets and liabilities at the date of our financial statements and the reported amounts of revenues and expenses during the applicable
period. Actual results may differ from these estimates under different assumptions or conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We define critical accounting
policies as those that are reflective of significant judgments and uncertainties and which may potentially result in materially
different results under different assumptions and conditions. In applying these critical accounting policies, our management uses
its judgment to determine the appropriate assumptions to be used in making certain estimates. These estimates are subject to an
inherent degree of uncertainty. Our critical accounting policies include the following: &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I>Stock Compensation</I>.
We have granted stock options and restricted stock to employees, directors and consultants, as well as warrants to other third
parties. For employee and director grants, the value of each option award is estimated on the date of grant using the Black-Scholes
option-pricing model. The Black-Scholes model takes into account volatility in the price of our stock, the risk-free interest
rate, the estimated life of the option, the closing market price of our stock and the exercise price. We base our estimates of
our stock price volatility on the historical volatility of our common stock and our assessment of future volatility; however,
these estimates are neither predictive nor indicative of the future performance of our stock. For purposes of the calculation,
we assumed that no dividends would be paid during the life of the options and warrants. The estimates utilized in the Black-Scholes
calculation involve inherent uncertainties and the application of management judgment. In addition, we are required to estimate
the expected forfeiture rate and only recognize expense for those equity awards expected to vest. As a result, if other assumptions
had been used, our recorded stock-based compensation expense could have been materially different from that reported. In addition,
because some of the options and warrants issued to employees, consultants and other third-parties vest upon the achievement of
certain milestones, the total expense is uncertain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Total compensation expense
for options and restricted stock issued to consultants is determined at the &ldquo;measurement date.&rdquo; The expense is recognized
over the vesting period for the options and restricted stock. Until the measurement date is reached, the total amount of compensation
expense remains uncertain. We record stock-based compensation expense based on the fair value of the equity awards at the reporting
date. These equity awards are then revalued, or the total compensation is recalculated based on the then current fair value, at
each subsequent reporting date. This results in a change to the amount previously recorded in respect of the equity award grant
and additional expense or a reversal of expense may be recorded in subsequent periods based on changes in the assumptions used
to calculate fair value, such as changes in market price, until the measurement date is reached and the compensation expense is
finalized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I>In-Process Research
and Development</I>. All acquired research and development projects are recorded at their fair value as of the date acquisition.
The fair values are assessed as of the balance sheet date to ascertain if there has been any impairment of the recorded value.
If there is an impairment, the asset is written down to its current fair value by the recording of an expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I>Accruals for Clinical
Research Organization and Clinical Site Costs. </I>We make estimates of costs incurred in relation to external clinical research
organizations (&ldquo;CRO&rsquo;s&rdquo;), and clinical site costs. We analyze the progress of clinical trials, including levels
of patient enrollment, invoices received and contracted costs when evaluating the adequacy of the amount expensed and the related
prepaid asset and accrued liability. Significant judgments and estimates must be made and used in determining the accrued balance
and expense in any accounting period. <FONT STYLE="font-family: Times New Roman, Times, Serif">We review and accrue CRO expenses
and clinical trial study expenses based on work performed and rely upon estimates of those costs applicable to the stage of completion
of a study. &nbsp;Accrued CRO costs are subject to revisions as such trials progress to completion. Revisions are charged to expense
in the period in which the facts that give rise to the revision become known. </FONT>With respect to clinical site costs, the
financial terms of these agreements are subject to negotiation and vary from contract to contract. Payments under these contracts
may be uneven and depend on factors such as the achievement of certain events, the successful recruitment of patients, the completion
of portions of the clinical trial or similar conditions. The objective of our policy is to match the recording of expenses in
our financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical site
costs are recognized based on our estimate of the degree of completion of the event or events specified in the specific clinical
study or trial contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I>Accounting Related
to Goodwill.</I> As of March 31, 2012, there was approximately $630,000 of goodwill on our consolidated balance sheets. Goodwill
is reviewed for impairment annually or when events arise that could indicate that an impairment exists. We test for goodwill impairment
using a two-step process. The first step compares the fair value of the reporting unit with the unit's carrying value, including
goodwill. When the carrying value of the reporting unit is greater than fair value, the unit&rsquo;s goodwill may be impaired,
and the second step must be completed to measure the amount of the goodwill impairment charge, if any. In the second step, the
implied fair value of the reporting unit&rsquo;s goodwill is compared with the carrying amount of the unit&rsquo;s goodwill. If
the carrying amount is greater than the implied fair value, the carrying value of the goodwill must be written down to its implied
fair value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We are required to perform
impairment tests annually at December 31 and whenever events or changes in circumstances suggest that the carrying value of an
asset may not be recoverable. For all of our acquisitions, various analyses, assumptions and estimates were made at the time of
each acquisition that were used to determine the valuation of goodwill and intangibles. In future years, the possibility exists
that changes in forecasts and estimates from those used at the acquisition date could result in impairment indicators.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I>Accounting for Income
Taxes</I>. In preparing our consolidated financial statements, we are required to estimate our income taxes in each of the jurisdictions
in which we operate. This process involves management estimation of our actual current tax exposure and assessment of temporary
differences resulting from differing treatment of items for tax and accounting purposes. These differences result in deferred
tax assets and liabilities. We must then assess the likelihood that our deferred tax assets will be recovered from future taxable
income and, to the extent we believe that recovery is not likely, we must establish a valuation allowance. To the extent we establish
a valuation allowance or increase this allowance in a period, we must include an expense within the tax provision in the consolidated
statement of operations. Significant management judgment is required in determining our provision for income taxes, our deferred
tax assets and liabilities and any valuation allowance recorded against our net deferred tax assets. We have fully offset our
deferred tax assets with a valuation allowance. Our lack of earnings history and the uncertainty surrounding our ability to generate
taxable income prior to the reversal or expiration of such deferred tax assets were the primary factors considered by management
in maintaining the valuation allowance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I>Fair Value of 5% Notes
Payable.</I> We measure certain financial assets and liabilities at fair value on a recurring basis in the financial statements.
The hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires
financial assets and liabilities carried at fair value to be classified and disclosed in one of three categories.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We elected the fair value
option for valuing our Convertible 5% Notes Payable upon the completion of the reverse merger with TG Bio, as discussed above.
The Company elected the fair value option in order to reflect in our financial statements the assumptions that market participants
use in evaluating these financial instruments.<FONT STYLE="color: black"> </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In connection with the
Exchange Transaction in December 2011, the Company performed a valuation of the assets and liabilities of Manhattan immediately
prior to the transaction. <FONT STYLE="color: black">The cumulative liability including accrued and unpaid interest of these notes
was approximately $16,876,000 immediately prior to the Exchange Transaction, $16,883,000 at December 31, 2011, and $17,089,000
at March 31, 2012. </FONT>As these notes payable are tied directly to net product cash flows derived from the preexisting products
of the Company, this note was recorded at fair value as of the date of the Exchange Transaction. No payments have been made on
these notes as of March 31, 2012. The fair value of the 5% Notes Payable was approximately $4,664,697 as of December 31, 2011
and March 31, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The valuation methods
used to estimate the 5% Notes&rsquo; fair value was a discounted cash flow model, where the expected cash flows of AST-726 and
AST-915 are discounted to the present using a yield that incorporates compensation for the probability of success in clinical
development and marketing, among other factors. The discount rate used in this discounted cash flow model approximated 20% at
December 31, 2011 and March 31, 2012. The assumptions, assessments and projections of future revenues are subject to uncertainties,
are difficult to predict and require significant judgment. The use of different assumptions, applying different judgment to inherently
subjective matters and changes in future market conditions could result in significantly different estimates of fair value and
the differences could be material to our consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES
ABOUT MARKET RISK </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The primary objective
of our investment activities is to preserve principal while maximizing our income from investments and minimizing our market risk.
We invest in government and investment-grade corporate debt in accordance with our investment policy. Some of the securities in
which we invest have market risk. This means that a change in prevailing interest rates, and/or credit risk, may cause the fair
value of the investment to fluctuate. For example, if we hold a security that was issued with a fixed interest rate at the then-prevailing
rate and the prevailing interest rate later rises, the fair value of our investment will probably decline. As of March 31, 2012,
our portfolio of financial instruments consists of cash equivalents, including bank deposits. Due to the short-term nature of
our investments, we believe there is no material exposure to interest rate risk, and/or credit risk, arising from our investments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>ITEM 4. CONTROLS AND PROCEDURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Evaluation of Disclosure Controls and
Procedures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">As of March 31, 2012,
management carried out, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer,
an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules
13a-15(e) and 15d-15(e) under the Exchange Act). Our disclosure controls and procedures are designed to provide reasonable assurance
that information we are required to disclose in the reports that we file or submit under the Exchange Act is recorded, processed,
summarized and reported within the time periods specified in applicable rules and forms. Based upon that evaluation, our Chief
Executive Officer and Chief Financial Officer concluded that, as of March 31, 2012, our disclosure controls and procedures were
not effective. This conclusion was reached because a lack of segregation of duties exists, as all financial and accounting duties
are performed by the Chief Financial Officer. The Company intends to address this deficiency by hiring additional accounting personnel
to alleviate the segregation of duties issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Internal Control Over Financial Reporting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">There were no changes
in our internal control over financial reporting during the quarter ended March 31, 2012, that have materially affected, or are
reasonably likely to materially affect, our internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART II. OTHER INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>ITEM 1. LEGAL PROCEEDINGS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We, and our subsidiaries,
are not a party to, and our property is not the subject of, any material pending legal proceedings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>ITEM 1A. RISK FACTORS<BR STYLE="mso-special-character:
line-break">
<BR STYLE="mso-special-character: line-break">
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">You should carefully consider the following
risks and uncertainties. If any of the following occurs, our business, financial condition or operating results could be materially
harmed. These factors could cause the trading price of our common stock to decline, and you could lose all or part of your investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><U>Risks Related to the Company&rsquo;s
Business and Industry</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Because the Company has in-licensed
its product candidates from third parties, any dispute with or non-performance by its licensors will adversely affect its ability
to develop and commercialize the applicable product candidates. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our product candidates
have been in-licensed from third parties. Under the terms of our license agreements, the licensors generally will have the right
to terminate such agreement in the event of a material breach by us. The licensors will also have the right to terminate the agreement
in the event we fail to use diligent and reasonable efforts to develop and commercialize the product candidate worldwide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">If there is any conflict,
dispute, disagreement or issue of non-performance between us and our licensing partners regarding our rights or obligations under
the license agreements, including any such conflict, dispute or disagreement arising from our failure to satisfy payment obligations
under such agreement, our ability to develop and commercialize the affected product candidate and our ability to enter into collaboration
or marketing agreements for the affected product candidate may be adversely affected. Any loss of our rights under these license
agreements would delay or completely terminate its product development efforts for the affected product candidate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>We do not have full internal development
capabilities, and are thus reliant upon our partners and third parties to generate clinical, preclinical and quality data necessary
to support the regulatory applications needed to conduct clinical trials and file for marketing approval.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In order to submit an
Investigational New Drug application (&ldquo;IND&rdquo;) and Biologics License Application (&ldquo;BLA&rdquo;) to the FDA, it
is necessary to submit all information on the clinical, non-clinical, chemistry, manufacturing, controls and quality aspects of
the product candidate. We rely on our licensing partners and, in some cases, third parties, to provide this data. If we are unable
to obtain this data, or the data is not sufficient to meet the regulatory requirements, we may experience significant delays in
our development programs. Additionally, an IND must be active in each division in which we intend to conduct clinical trials.
While we maintain an active IND for ublituximab enabling the conduct of studies in the FDA&rsquo;s Division of Hematology and
Oncology; there can be no assurance given that we will be successful in obtaining an active IND for ublituximab in any other division
under whose supervision we may seek to develop ublituximab.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>We are highly dependent on the success
of our product candidates and cannot give any assurance that these or any future product candidates will be successfully commercialized.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We are a development-stage
biopharmaceutical company, and do not currently have any commercial products that generate revenues or any other sources of revenue.
We may never be able to successfully develop marketable products. Our pharmaceutical development methods are unproven and may
not lead to commercially viable products for any of several reasons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">If we are unable to develop,
or receive regulatory approval for or successfully commercialize any of our product candidates, we will not be able to generate
product revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Because the results of preclinical
studies and early clinical trials are not necessarily predictive of future results, any product candidate we advance into clinical
trials may not have favorable results in later clinical trials, if any, or receive regulatory approval.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Pharmaceutical development
has inherent risk. We will be required to demonstrate through adequate and well-controlled clinical trials that our product candidates
are effective with a favorable benefit-risk profile for use in diverse populations for their target indications before we can
seek regulatory approvals for their commercial sale. Success in early clinical trials does not mean that later clinical trials
will be successful because product candidates in later-stage clinical trials may fail to demonstrate sufficient safety or efficacy
despite having progressed through initial clinical testing. Companies frequently suffer significant setbacks in advanced clinical
trials, even after earlier clinical trials have shown promising results. In addition, there is typically an extremely high rate
of attrition from the failure of pharmaceutical candidates proceeding through clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We plan on conducting
additional Phase I and II clinical trials for ublituximab. If the results from these trials are different from those found in
the completed Phase I clinical trial of ublituximab, we may need to terminate or revise our clinical development plan, which could
extend the time for conducting our development program and could have a material adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Any product candidates we may advance
into clinical development are subject to extensive regulation, which can be costly and time consuming, cause unanticipated delays
or prevent the receipt of the required approvals to commercialize our product candidates. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The clinical development,
manufacturing, labeling, storage, record-keeping, advertising, promotion, import, export, marketing and distribution of our product
candidates or any future product candidates are subject to extensive regulation by the FDA in the United States and by comparable
health authorities worldwide or in foreign markets. In the United States, we are not permitted to market our product candidates
until we receive approval of a BLA or NDA from the FDA. The process of obtaining BLA and NDA approval is expensive, often takes
many years and can vary substantially based upon the type, complexity and novelty of the products involved. Approval policies
or regulations may change and the FDA has substantial discretion in the pharmaceutical approval process, including the ability
to delay, limit or deny approval of a product candidate for many reasons. In addition, the FDA may require post-approval clinical
trials or studies which also may be costly. The FDA approval for a limited indication or approval with required warning language,
such as a boxed warning, could significantly impact our ability to successfully market our product candidates. Finally, the FDA
may require adoption of a Risk Evaluation and Mitigation Strategy (REMS) requiring prescriber training, post-market registries,
or otherwise restricting the marketing and dissemination of these products. Despite the time and expense invested in clinical
development of product candidates, regulatory approval is never guaranteed. Assuming successful clinical development, we intend
to seek product approvals in countries outside the United States. As a result, we would be subject to regulation by the European
Medicines Agency (&ldquo;EMA&rdquo;), as well as the other regulatory agencies in many of these countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Approval procedures vary
among countries and can involve additional product testing and additional administrative review periods. The time required to
obtain approval in other countries might differ from that required to obtain FDA approval. Regulatory approval in one country
does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may negatively
impact the regulatory process in others. As in the United States, the regulatory approval process in Europe and in other countries
is a lengthy and challenging process. The FDA, EMA and any of the applicable European and other regulatory bodies can delay, limit
or deny approval of a product candidate for many reasons, including:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">the
                                                                                                              FDA or comparable
                                                                                                              foreign regulatory
                                                                                                              authorities may
                                                                                                              disagree with the
                                                                                                              design or implementation
                                                                                                              of our clinical
                                                                                                              trials;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">we
                                                                                                              may be unable to
                                                                                                              demonstrate to the
                                                                                                              satisfaction of
                                                                                                              the FDA or comparable
                                                                                                              foreign regulatory
                                                                                                              authorities that
                                                                                                              a product candidate
                                                                                                              is safe and effective
                                                                                                              for any indication;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">the
                                                                                                              FDA may not accept
                                                                                                              clinical data from
                                                                                                              trials which are
                                                                                                              conducted by individual
                                                                                                              investigators or
                                                                                                              in countries where
                                                                                                              the standard of
                                                                                                              care is potentially
                                                                                                              different from the
                                                                                                              United States;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">the
                                                                                                              results of clinical
                                                                                                              trials may not meet
                                                                                                              the level of statistical
                                                                                                              significance required
                                                                                                              by the FDA or comparable
                                                                                                              foreign regulatory
                                                                                                              authorities for
                                                                                                              approval;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">we
                                                                                                              may be unable to
                                                                                                              demonstrate that
                                                                                                              a product candidate's
                                                                                                              clinical and other
                                                                                                              benefits outweigh
                                                                                                              its safety risks;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">the
                                                                                                              FDA or comparable
                                                                                                              foreign regulatory
                                                                                                              authorities may
                                                                                                              disagree with our
                                                                                                              interpretation of
                                                                                                              data from preclinical
                                                                                                              studies or clinical
                                                                                                              trials;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">the
                                                                                                              data collected from
                                                                                                              clinical trials
                                                                                                              of our product candidates
                                                                                                              may not be sufficient
                                                                                                              to support the submission
                                                                                                              of a BLA or other
                                                                                                              submission or to
                                                                                                              obtain regulatory
                                                                                                              approval in the
                                                                                                              United States or
                                                                                                              elsewhere;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">the
                                                                                                              FDA or comparable
                                                                                                              foreign regulatory
                                                                                                              authorities may
                                                                                                              fail to approve
                                                                                                              the manufacturing
                                                                                                              processes or facilities
                                                                                                              of third-party manufacturers
                                                                                                              with which we or
                                                                                                              our collaborators
                                                                                                              contract for clinical
                                                                                                              and commercial supplies;
                                                                                                              or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">the
                                                                                                              approval policies
                                                                                                              or regulations of
                                                                                                              the FDA or comparable
                                                                                                              foreign regulatory
                                                                                                              authorities may
                                                                                                              significantly change
                                                                                                              in a manner rendering
                                                                                                              our clinical data
                                                                                                              insufficient for
                                                                                                              approval.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In addition, recent events
raising questions about the safety of certain marketed pharmaceuticals may result in increased cautiousness by the FDA and other
regulatory authorities in reviewing new pharmaceuticals based on safety, efficacy or other regulatory considerations and may result
in significant delays in obtaining regulatory approvals. Regulatory approvals for our product candidates may not be obtained without
lengthy delays, if at all.&nbsp; Any delay in obtaining, or inability to obtain, applicable regulatory approvals would prevent
us from commercializing our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Any product candidate we advance into
clinical trials may cause unacceptable adverse events or have other properties that may delay or prevent their regulatory approval
or commercialization or limit their commercial potential. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Unacceptable adverse
events caused by any of our product candidates that we take into clinical trials could cause either us or regulatory authorities
to interrupt, delay or halt clinical trials and could result in the denial of regulatory approval by the FDA or other regulatory
authorities for any or all targeted indications. This, in turn, could prevent us from commercializing the affected product candidate
and generating revenues from its sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We have not yet completed
testing of any of our product candidates for the treatment of the indications for which we intend to seek product approval in
humans, and we currently do not know the extent that adverse events, if any, will be observed in patients who receive any of its
product candidates. To date, clinical trials using ublituximab and our other product candidates have demonstrated a toxicity profile
that was deemed acceptable by the investigators performing such studies. Such interpretation may not be shared by future investigators
or by the FDA and in the case of ublituximab, even if deemed acceptable for oncology applications, like the completed clinical
trial, it may not be acceptable for diseases outside the oncology setting, and likewise for any other product candidates we may
develop. Additionally, the severity, duration and incidence of adverse events may increase in larger study populations. With respect
to ublituximab, the toxicity when manufactured under different conditions is not known, nor is the toxicity of transgenically
derived ublituximab, and it is possible that additional and/or different adverse events may appear upon the human use of those
formulations and those adverse events may arise with greater frequency, intensity and duration than in the current formulation.
If any of our product candidates cause unacceptable adverse events in clinical trials, we may not be able to obtain marketing
approval and generate revenues from its sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">If any of our product
candidates receives marketing approval and we, or others, later identify unacceptable adverse events caused by the product, a
number of significant negative consequences could result, including:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">regulatory
                                                                                                              authorities may
                                                                                                              withdraw their approval
                                                                                                              of the affected
                                                                                                              product;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">regulatory
                                                                                                              authorities may
                                                                                                              require a more significant
                                                                                                              clinical benefit
                                                                                                              for approval to
                                                                                                              offset the risk;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">regulatory
                                                                                                              authorities may
                                                                                                              require the addition
                                                                                                              of labeling statements
                                                                                                              that could diminish
                                                                                                              the usage of the
                                                                                                              product or otherwise
                                                                                                              limit the commercial
                                                                                                              success of the affected
                                                                                                              product;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">we
                                                                                                              may be required
                                                                                                              to change the way
                                                                                                              the product is administered,
                                                                                                              conduct additional
                                                                                                              clinical trials
                                                                                                              or change the labeling
                                                                                                              of the product;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">we
                                                                                                              may choose to discontinue
                                                                                                              sale of the product;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">we
                                                                                                              could be sued and
                                                                                                              held liable for
                                                                                                              harm caused to patients;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">we
                                                                                                              may not be able
                                                                                                              to enter into collaboration
                                                                                                              agreements on acceptable
                                                                                                              terms and execute
                                                                                                              on our business
                                                                                                              model; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">our
                                                                                                              reputation may suffer.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Any one or a combination
of these events could prevent us from obtaining regulatory approval and achieving or maintaining market acceptance of the affected
product or could substantially increase the costs and expenses of commercializing the affected product, which in turn could delay
or prevent us from generating any revenues from the sale of the affected product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>We may experience delays in the commencement
of our clinical trials or in the receipt of data from preclinical and clinical trials conducted by third parties, which could
result in increased costs and delay its ability to pursue regulatory approval. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Delays in the commencement
of clinical trials and delays in the receipt of data from preclinical or clinical trials conducted by third parties could significantly
impact our product development costs. Before we can initiate clinical trials in the United States for our product candidates,
we need to submit the results of preclinical testing, usually in animals, to the FDA as part of an IND, along with other information
including information about product chemistry, manufacturing and controls and its proposed clinical trial protocol for its product
candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">While we currently maintain
an active IND for cell derived ublituximab, we plan to rely on preclinical and clinical trial data from third parties for the
IND submissions for transgenically derived ublituximab and any other product candidates we may develop. If receipt of that data
is delayed for any reason, including reasons outside of our control, it will delay our plans for IND filings, and clinical trial
plans. This, in turn, will delay our ability to make subsequent regulatory filings and ultimately, to commercialize our products
if regulatory approval is obtained. If those third parties do not make this data available to us, we will likely, on our own,
have to develop all the necessary preclinical and clinical data which will lead to additional delays and increase the costs of
our development of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Before we can test any
product candidate in human clinical trials the product candidate enters the preclinical testing stage. Preclinical tests include
laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies to assess the potential safety
and activity of the pharmaceutical product candidate. The conduct of the preclinical tests must comply with federal regulations
and requirements including good laboratory practices (GLP).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We must submit the results
of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature
and a proposed clinical protocol, to the FDA as part of the IND. The IND automatically becomes effective 30 days after receipt
by the FDA, unless the FDA places the IND on a clinical hold within that 30-day time period. In such a case, the Company and the
FDA must resolve any outstanding concerns before the clinical trials can begin. The FDA may also impose clinical holds on a product
candidate at any time before or during clinical trials due to safety concerns or non-compliance. Accordingly, we cannot be sure
that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise
that suspend or terminate such clinical trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The FDA may require that
we conduct additional preclinical testing for any product candidate before it allows us to initiate the clinical testing under
any IND, which may lead to additional delays and increase the costs of our preclinical development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Even assuming an active
IND for a product candidate, we do not know whether our planned clinical trials for any such product candidate will begin on time,
or at all. The commencement of clinical trials can be delayed for a variety of reasons, including delays in:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">obtaining
                                                                                                              regulatory clearance
                                                                                                              to commence a clinical
                                                                                                              trial;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">identifying,
                                                                                                              recruiting and training
                                                                                                              suitable clinical
                                                                                                              investigators;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">reaching
                                                                                                              agreement on acceptable
                                                                                                              terms with prospective
                                                                                                              contract research
                                                                                                              organizations (&ldquo;CROs&rdquo;)
                                                                                                              and trial sites,
                                                                                                              the terms of which
                                                                                                              can be subject to
                                                                                                              extensive negotiation,
                                                                                                              may be subject to
                                                                                                              modification from
                                                                                                              time to time and
                                                                                                              may vary significantly
                                                                                                              among different
                                                                                                              CROs and trial sites;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">obtaining
                                                                                                              sufficient quantities
                                                                                                              of a product candidate
                                                                                                              for use in clinical
                                                                                                              trials;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">obtaining
                                                                                                              institutional review
                                                                                                              board (&ldquo;IRB&rdquo;)
                                                                                                              or ethics committee
                                                                                                              approval to conduct
                                                                                                              a clinical trial
                                                                                                              at a prospective
                                                                                                              site;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">identifying,
                                                                                                              recruiting and enrolling
                                                                                                              patients to participate
                                                                                                              in a clinical trial;
                                                                                                              and</TD></TR></TABLE>



<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">retaining patients who have initiated a clinical trial but may withdraw due to adverse events from
the therapy, insufficient efficacy, fatigue with the clinical trial process or personal issues.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Any delays in the commencement
of our clinical trials will delay our ability to pursue regulatory approval for our product candidates. In addition, many of the
factors that cause, or lead to, a delay in the commencement of clinical trials may also ultimately lead to the denial of regulatory
approval of a product candidate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Delays in the completion of clinical
testing could result in increased costs to the Company and delay our ability to generate product revenues. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Once a clinical trial
has begun, patient recruitment and enrollment may be slower than we anticipate. Clinical trials may also be delayed as a result
of ambiguous or negative interim results. Further, a clinical trial may be suspended or terminated by us, an Institutional Review
Board (&ldquo;IRB&rdquo;), an ethics committee or a Data Monitoring Committee overseeing the clinical trial, any of our clinical
trial sites with respect to that site or the FDA or other regulatory authorities due to a number of factors, including:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">inspection of the clinical trial operations or clinical trial site by the FDA or other regulatory
authorities resulting in the imposition of a clinical hold;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">unforeseen safety issues or any determination that the clinical trial presents unacceptable health
risks; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">lack of adequate funding to continue the clinical trial.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Changes in regulatory
requirements and guidance also may occur and we may need to amend clinical trial protocols to reflect these changes. Amendments
may require us to resubmit our clinical trial protocols to IRBs for re-examination, which may impact the costs, timing and successful
completion of a clinical trial. If we experience delays in the completion of, or if we must terminate, any clinical trial of any
product candidate that we advance into clinical trials, our ability to obtain regulatory approval for that product candidate will
be delayed and the commercial prospects, if any, for the product candidate may be harmed. In addition, many of these factors may
also ultimately lead to the denial of regulatory approval of a product candidate. Even if we ultimately commercialize any of our
product candidates, other therapies for the same indications may have been introduced to the market during the period we have been
delayed and such therapies may have established a competitive advantage over our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>We intend to rely on third parties to
help conduct our planned clinical trials. If these third parties do not meet their deadlines or otherwise conduct the trials as
required, we may not be able to obtain regulatory approval for or commercialize our product candidates when expected or at all.
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We intend to use CROs
to assist in the conduct of our planned clinical trials and will rely upon medical institutions, clinical investigators and contract
laboratories to conduct our trials in accordance with our clinical protocols. Our future CROs, investigators and other third parties
may play a significant role in the conduct of these trials and the subsequent collection and analysis of data from the clinical
trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">There is no guarantee
that any CROs, investigators and other third parties will devote adequate time and resources to our clinical trials or perform
as contractually required. If any third parties upon whom we rely for administration and conduct of our clinical trials fail to
meet expected deadlines, fail to adhere to its clinical protocols or otherwise perform in a substandard manner, our clinical trials
may be extended, delayed or terminated, and we may not be able to commercialize our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">If any of our clinical
trial sites terminate for any reason, we may experience the loss of follow-up information on patients enrolled in our ongoing clinical
trials unless we are able to transfer the care of those patients to another qualified clinical trial site. In addition, principal
investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive cash
or equity compensation in connection with such services. If these relationships and any related compensation result in perceived
or actual conflicts of interest, the integrity of the data generated at the applicable clinical trial site may be jeopardized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>As the product candidates for which
we hold an exclusive license agreement, are still under development; manufacturing and process improvements implemented in the
production of ublituximab, or any of our product candidates, may affect their ultimate activity or function. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">TGTX-1101 (ublituximab)
is in the initial stages of development and is currently manufactured in small batches for use in pre-clinical and clinical studies.
Process improvements implemented to date have, and process improvements in the future may change the activity of the antibody,
which may affect the safety and efficacy of the product. No assurance can be given that the material manufactured from any of the
optimized processes will perform comparably to ublituximab as manufactured to date and used in currently available pre-clinical
data and in early clinical trials reported in this or any previous filing. Additionally, future clinical trial results will be
subject to the same level of uncertainty if, following such trials, additional process improvements are made, including without
limitation, the introduction of transgenically derived ublituximab.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>If we fail to adequately understand
and comply with the local laws and customs as we expand into new international markets, these operations may incur losses or otherwise
adversely affect our business and results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We expect to operate a
portion of our business in certain countries through subsidiaries or through supply and marketing arrangements. In those countries,
where we have limited experience in operating subsidiaries and in reviewing equity investees, we will be subject to additional
risks related to complying with a wide variety of national and local laws, including restrictions on the import and export of certain
intermediates, drugs, technologies and multiple and possibly overlapping tax structures. In addition, we may face competition in
certain countries from companies that may have more experience with operations in such countries or with international operations
generally. We may also face difficulties integrating new facilities in different countries into our existing operations, as well
as integrating employees hired in different countries into our existing corporate culture. If we do not effectively manage our
operations in these subsidiaries and review equity investees effectively, or if we fail to manage our alliances, we may lose money
in these countries and it may adversely affect our business and results of our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>If our competitors develop treatments
for the target indications for which any of our product candidates may be approved, that are approved more quickly, marketed more
effectively or demonstrated to be more effective than our product candidates, our commercial opportunity will be reduced or eliminated.
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We operate in a highly
competitive segment of the biotechnology and biopharmaceutical market. We face competition from numerous sources, including commercial
pharmaceutical and biotechnology enterprises, academic institutions, government agencies, and private and public research institutions.
Many of our competitors have significantly greater financial, product development, manufacturing and marketing resources. Large
pharmaceutical companies have extensive experience in clinical testing and obtaining regulatory approval for drugs. Additionally,
many universities and private and public research institutes are active in cancer research, some in direct competition with us.
We may also compete with these organizations to recruit scientists and clinical development personnel. Smaller or early-stage companies
may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The cancer indications
for which we are developing our product, TGTX-1101, have a number of established therapies with which we will compete. Most major
pharmaceutical companies and many biotechnology companies are aggressively pursuing new cancer development programs for the treatment
of NHL, CLL, and other B-cell proliferative malignancies, including both therapies with traditional, as well as novel, mechanisms
of action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">If approved, we expect
TGTX-1101 to compete directly with Roche Group&rsquo;s Rituxan&reg; (Rituximab), Spectrum Pharmaceutical&rsquo;s Zevalin&reg; (Y<SUP>90</SUP>-Ibritumomab
Tiuxetan), GlaxoSmithKline&rsquo;s Bexxar&reg; (I<SUP>131</SUP>-Tositumomab), Dr. Reddy&rsquo;s Laboratories&rsquo; Reditux&reg;,
and Genmab and GlaxoSmithKline&rsquo;s Arzerra&reg; (Ofatumomab) among others, each of which is currently approved for the treatment
of various diseases including NHL and CLL. New developments, including the development of other pharmaceutical technologies and
methods of treating disease, occur in the pharmaceutical and life sciences industries at a rapid pace.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">These developments may
render our product candidates obsolete or noncompetitive. Compared to us, many of our potential competitors have substantially
greater:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">research and development resources, including personnel and technology;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">regulatory experience;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">pharmaceutical development, clinical trial and pharmaceutical commercialization experience;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">experience and expertise in exploitation of intellectual property rights; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">capital resources.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">As a result of these factors,
our competitors may obtain regulatory approval of their products more rapidly than us or may obtain patent protection or other
intellectual property rights that limit our ability to develop or commercialize our product candidates. Our competitors may also
develop products for the treatment of lymphoma or CLL that are more effective, better tolerated, more useful and less costly than
ours and may also be more successful in manufacturing and marketing their products. Our competitors may succeed in obtaining approvals
from the FDA and foreign regulatory authorities for their product candidates sooner than we do for our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We will also face competition
from these third parties in recruiting and retaining qualified personnel, establishing clinical trial sites and enrolling patients
for clinical trials and in identifying and in-licensing new product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>We rely completely on third parties
to manufacture our preclinical and clinical pharmaceutical supplies and we intend to rely on third parties to produce commercial
supplies of any approved product candidate, and our commercialization of any of our product candidates could be stopped, delayed
or made less profitable if those third parties fail to obtain approval of the FDA, fail to provide us with sufficient quantities
of pharmaceutical product or fail to do so at acceptable quality levels or prices. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The facilities used by
our contract manufacturers to manufacture our product candidates must be approved by the FDA pursuant to inspections that will
be conducted only after we submit a BLA or NDA to the FDA, if at all. We do not control the manufacturing process of our product
candidates and are completely dependent on our contract manufacturing partners for compliance with the FDA&rsquo;s requirements
for manufacture of finished pharmaceutical products (good manufacturing practices, GMP). If our contract manufacturers cannot successfully
manufacture material that conforms to our specifications and the FDA&rsquo;s strict regulatory requirements of safety, purity and
potency, we will not be able to secure and/or maintain FDA approval for our product candidates. In addition, we have no control
over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel.
If our contract manufacturers cannot meet FDA standards, we may need to find alternative manufacturing facilities, which would
significantly impact our ability to develop, obtain regulatory approval for or market our product candidates. Our partner, LFB,
is currently exploring long-term, scalable contract manufacturers for ublituximab and/or the build-out of such capabilities. No
assurance can be given that a long-term, scalable manufacturer can be identified or that they can make clinical and commercial
supplies of ublituximab at an appropriate scale and cost to make it commercially feasible. If they are unable to do so, it could
have a material adverse impact on our business. If that is the case, we may need to rely exclusively on transgenically manufactured
material, which may introduce additional risk and uncertainty the extent of which cannot be fully determined today.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In addition, the Company
does not have the capability to package finished products for distribution to hospitals and other customers. Prior to commercial
launch, we intend to enter into agreements with one or more alternate fill/finish pharmaceutical product suppliers so that we can
ensure proper supply chain management once we are authorized to make commercial sales of our product candidates. If we receive
marketing approval from the FDA, we intend to sell pharmaceutical product finished and packaged by such suppliers. We have not
entered into long-term agreements with our current contract manufacturers or with any fill/finish suppliers, and though we intend
to do so prior to commercial launch of our product candidates in order to ensure that we maintain adequate supplies of finished
product, we may be unable to enter into such an agreement or do so on commercially reasonable terms, which could have a material
adverse impact upon our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In most cases, our manufacturing
partners are single source suppliers. It is expected that our manufacturing partners will be sole source suppliers from single
site locations for the foreseeable future. Given this, any disruption of supply from these partners could have a material, long-term
impact on our ability to supply products for clinical trials or commercial sale. Additionally, the proprietary transgenic technology
that supports the manufacture of transgenically derived ublituximab is not easily transferrable, if at all, and it is expected
that GTC will be the sole supplier of transgenically derived ublituximab at a single site for the foreseeable future. If the Company&rsquo;s
suppliers do not deliver sufficient quantities of ublituximab on a timely basis, or at all, and in accordance with applicable specifications,
there could be a significant interruption of our supply of ublituximab, which would adversely affect clinical development and commercialization
of the product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Clinical trials of our transgenically
produced products may be unsuccessful or delayed, which may prevent us from meeting our anticipated development timeline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Company and its collaborators
must demonstrate through preclinical and clinical trials that our transgenically produced products are safe and effective for use
in humans. Clinical trials are expensive and may take several years. Several factors could prevent or delay completion of these
trials, including an inability to enroll the required number of patients or demonstrate adequately the safety or efficacy of the
product for humans. If safety concerns develop, regulatory authorities could stop or delay trials of transgenically derived ublituximab
or any other product candidate evaluated by the Company. Furthermore, the results from early clinical trials are often not predictive
of results in later clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">To our knowledge, Pharming
Group N.V. and GTC Biotherapeutics, Inc. are the only other entities to have completed human clinical trials sufficient to support
the filing for regulatory approval of a product produced from a transgenic mammal. If we are unable to complete all clinical trials
and to satisfy any requirements that may be required by the FDA or the EMA for approval of transgenically derived ublituximab,
it could have a material adverse effect on our business and operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Any transgenically produced products
for which we obtain regulatory approval will be subject to continuing review and extensive regulatory requirements, which could
affect their manufacture and marketing.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">If and when the FDA or
other foreign agencies approve our transgenically produced products under development, the manufacture and marketing of these products
will be subject to continuing regulation and product approvals may be withdrawn if problems occur after initial approval. Post-approval
regulation includes compliance with current Quality Systems Regulations and Good Manufacturing Practices, (&ldquo;QSR/GMP&rdquo;),
adverse event reporting requirements and prohibitions on promoting a product for unapproved uses. In addition, the FDA could require
us to conduct post-approval clinical trials or studies. We will also be required to obtain additional approvals for any significant
alterations in the product&rsquo;s labeling or manufacturing process. Enforcement actions resulting from failure to comply with
QSR/GMP requirements could result in fines, suspensions of approvals, recalls of products, operating restrictions and criminal
prosecutions, and affect the manufacture and marketing of our transgenically produced products. The FDA or other regulatory agencies
could withdraw a previously approved product from the market upon receipt of newly discovered information, including a failure
to comply with regulatory requirements and the occurrence of unanticipated problems with products, including adverse events, manufacturing
and quality problems, following approval. Any of these withdrawals could adversely affect our operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>The Company may face public concerns
about genetic engineering in animals.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The activities of the
Company&rsquo;s development and manufacturing affiliate involve genetic engineering in animals. The success of our potential commercial
products will depend in part on public acceptance of the use of genetic engineering. Public attitudes may be influenced by claims
and perceptions that these types of activities are unsafe and our products may not gain the acceptance of the public or the medical
community. Negative public reaction to genetic engineering activities in general could result in greater restrictive legislation
and regulations involving nuclear transfer and other methodologies which could impede our ability to conduct our business efficiently,
delay preclinical studies or future clinical trials, or prevent us or our partners from obtaining regulatory approvals or commercializing
transgenically produced products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Our transgenically produced products
may be subject to technology risks that may restrict or prevent their development and commercialization.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Developing products based
on transgenic technology is subject to significant development risks. Each DNA construct is unique and it is possible that it might
not be expressed in the transgenic animal&rsquo;s milk at a level that is commercially viable. Purifying the recombinant protein
out of the milk to use as a biotherapeutic may be too difficult to be commercially feasible. In addition, production of the recombinant
protein may have negative effects on the health of either the mammary gland or more systematically on the animal as a whole. This
would compromise the ability of the animal to produce the recombinant protein. Directing the mammary gland to produce additional
proteins in the milk could negatively affect lactation, thereby shutting down milk production. The mammary gland may also modify
a protein in such a manner that it is non-functional or harmful in humans. It is also possible that there may be disease agents
present in the animals that would prevent the use of products<B> </B>derived from these animals. If an as yet unknown disease was
identified that could not be effectively mitigated, government agencies may confiscate or destroy the animals, or prevent the utilization
of their milk. Any of these governmental actions would prevent the use of the recombinant proteins and may result in a material
adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>We may not be able to recover from any
catastrophic event affecting our suppliers&rsquo; animals or facilities.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">While our suppliers have
measures in place to minimize and recover from catastrophic events that may substantially destroy their animal herd(s), these measures
may not be adequate to recover production processes quickly enough to support critical timelines, collaborator needs, or market
demands. These catastrophic events may include, but are not limited to, animal diseases that breach biosecurity measures or weather
events such as tornadoes, earthquakes or fires. In addition, these catastrophic events may render some or all of the products at
the affected facilities unusable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>We currently have no marketing and sales
organization and no experience in marketing pharmaceutical products. If we are unable to establish sales and marketing capabilities
or fail to enter into agreements with third parties to market and sell any products we may develop, we may not be able to effectively
market and sell our products and generate product revenue. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We do not currently have
the infrastructure for the sales, marketing and distribution of our biotechnology products, and we must build this infrastructure
or make arrangements with third parties to perform these functions in order to commercialize our products. We plan to either develop
internally or enter into collaborations or other commercial arrangements to develop further, promote and sell all or a portion
of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The establishment and
development of a sales force, either by us or jointly with a development partner, or the establishment of a contract sales force
to market any products we may develop will be expensive and time-consuming and could delay any product launch, and we cannot be
certain that we or our development partners would be able to successfully develop this capability. If the Company or its development
partners are unable to establish sales and marketing capability or any other non-technical capabilities necessary to commercialize
any products we may develop, we will need to contract with third parties to market and sell such products. We currently possess
limited resources and may not be successful in establishing our own internal sales force or in establishing arrangements with third
parties on acceptable terms, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>If any product candidate that the Company
successfully develops does not achieve broad market acceptance among physicians, patients, healthcare payors, and the medical community,
the revenues that we generate from its sales will be limited. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Even if our product candidates
receive regulatory approval, they may not gain market acceptance among physicians, patients, healthcare payors, and the medical
community. Coverage and reimbursement of our product candidates by third-party payors, including government payors, generally is
also necessary for commercial success. The degree of market acceptance of any of our approved products will depend on a number
of factors, including:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">the efficacy and safety as demonstrated in clinical trials;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">the clinical indications for which the product is approved;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">acceptance by physicians, major operators of cancer clinics and patients of the product as a safe
and effective treatment;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">the potential and perceived advantages of product candidates over alternative treatments;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">the safety of product candidates seen in a broader patient group, including its use outside the approved
indications;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">the cost of treatment in relation to alternative treatments;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">the availability of adequate reimbursement and pricing by third parties and government authorities;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">relative convenience and ease of administration;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">the prevalence and severity of adverse events; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">the effectiveness of our sales and marketing efforts.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">If any product candidate
is approved but does not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors and patients, we may
not generate sufficient revenue from these products and we may not become or remain profitable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>If product liability lawsuits are brought
against the Company, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We face an inherent risk
of product liability exposure related to the testing of our product candidates in human clinical trials, and will face an even
greater risk if we sell our product candidates commercially. An individual may bring a liability claim against the Company if one
of our product candidates causes, or merely appears to have caused, an injury. If we cannot successfully defend our self against
product liability claims, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may
result in:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">decreased demand for our product candidates;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">impairment to our business reputation;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">withdrawal of clinical trial participants;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">costs of related litigation;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">distraction of management&rsquo;s attention from our primary business;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">substantial monetary awards to patients or other claimants;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">the inability to commercialize our product candidates; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">loss of revenues.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We do not currently carry
product liability insurance. However, we intend to obtain product liability insurance coverage for our clinical trials prior to
the commencement of any such trials. Further, we intend to expand our insurance coverage to include the sale of commercial products
if marketing approval is obtained for any of our product candidates. However, we may be unable to obtain this product liability
insurance on commercially reasonable terms and with insurance coverage that will be adequate to satisfy any liability that may
arise. On occasion, large judgments have been awarded in class action or individual lawsuits relating to marketed pharmaceuticals.
A successful product liability claim or series of claims brought against the Company could cause its stock price to decline and,
if judgments exceed our insurance coverage, could decrease our cash and adversely affect our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Reimbursement may be limited or unavailable
in certain market segments for our product candidates, which could make it difficult for us to sell our products profitably.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We intend to seek approval
to market our future products in both the United States and in countries and territories outside the United States. If we obtain
approval in one or more foreign countries, we will be subject to rules and regulations in those countries relating to our product.
In some foreign countries, particularly in the European Union, the pricing of prescription pharmaceuticals and biologics is subject
to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after
the receipt of marketing approval for a product candidate. In addition, market acceptance and sales of our product candidates will
depend significantly on the availability of adequate coverage and reimbursement from third-party payors for any of our product
candidates and may be affected by existing and future healthcare reform measures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Government authorities
and third-party payors, such as private health insurers and health maintenance organizations, decide which pharmaceuticals they
will pay for and establish reimbursement levels. Reimbursement by a third-party payor may depend upon a number of factors, including
the third-party payor&rsquo;s determination that use of a product is:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">a covered benefit under its health plan;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">safe, effective and medically necessary;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">appropriate for the specific patient;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">cost-effective; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">neither experimental nor investigational.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Obtaining coverage and
reimbursement approval for a product from a government or other third-party payor is a time consuming and costly process that could
require that we provide supporting scientific, clinical and cost-effectiveness data for the use of our products to the payor. We
may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. If reimbursement of our
future products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, we may be unable to
achieve or sustain profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In both the United States
and certain foreign countries, there have been a number of legislative and regulatory changes to the healthcare system that could
impact our ability to sell our products profitably. In particular, the Medicare Modernization Act of 2003 revised the payment methodology
for many products reimbursed by Medicare, resulting in lower rates of reimbursement for many types of drugs, and added a prescription
drug benefit to the Medicare program that involves commercial plans negotiating drug prices for their members. Since 2003, there
have been a number of other legislative and regulatory changes to the coverage and reimbursement landscape for pharmaceuticals.
Most recently, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of
2010, collectively, the &ldquo;Affordable Care Act,&rdquo; was enacted. The Affordable Care Act contains a number of provisions,
including those governing enrollment in federal healthcare programs, the increased use of comparative effectiveness research on
healthcare products, reimbursement and fraud and abuse changes, and a new regulatory pathway for the approval of biosimilar biological
products, all of which will impact existing government healthcare programs and will result in the development of new programs.
An expansion in the government&rsquo;s role in the U.S. healthcare industry may further lower rates of reimbursement for pharmaceutical
and biotechnology products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">There have been, and likely
will continue to be, legislative and regulatory proposals at the federal and state levels directed at broadening the availability
of healthcare and containing or lowering the cost of healthcare products and services. The Company cannot predict the initiatives
that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and
other payors of healthcare services to contain or reduce costs of healthcare may adversely affect:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">the demand for any products for which we may obtain regulatory approval;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">our ability to set a price that we believe is fair for our products;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">our ability to generate revenues and achieve or maintain profitability;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">the level of taxes that the Company is required to pay; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">the availability of capital.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In addition, governments
may impose price controls, which may adversely affect our future profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>The Company will need to increase the
size of its organization and the scope of our outside vendor relationships, and we may experience difficulties in managing this
growth. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">As of March 31, 2012,
the Company has 5 full and part time employees. Over time, we will need to expand our managerial, operational, financial and other
resources in order to manage and fund our operations and clinical trials, continue research and development activities, and commercialize
our product candidates. Our management and scientific personnel, systems and facilities currently in place may not be adequate
to support our future growth. Our need to effectively manage our operations, growth, and various projects requires that we:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">manage our clinical trials effectively;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">manage our internal development efforts effectively while carrying out our contractual obligations
to licensors, contractors and other third parties;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">continue to improve our operational, financial and management controls and reporting systems and procedures;
and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">attract and retain sufficient numbers of talented employees.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We may utilize the services
of outside vendors or consultants to perform tasks including clinical trial management, statistics and analysis, regulatory affairs,
formulation development and other pharmaceutical development functions. Our growth strategy may also entail expanding our group
of contractors or consultants to implement these tasks going forward. Because we rely on a substantial number of consultants, effectively
outsourcing many key functions of our business, we will need to be able to effectively manage these consultants to ensure that
they successfully carry out their contractual obligations and meet expected deadlines. However, if we are unable to effectively
manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason,
our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for our product
candidates or otherwise advance its business. There can be no assurance that we will be able to manage our existing consultants
or find other competent outside contractors and consultants on economically reasonable terms, or at all. If the Company is not
able to effectively expand its organization by hiring new employees and expanding its groups of consultants and contractors, we
may be unable to successfully implement the tasks necessary to further develop and commercialize our product candidates and, accordingly,
may not achieve our research, development and commercialization goals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>If the Company fails to attract and
keep key management and clinical development personnel, we may be unable to successfully develop or commercialize our product candidates.
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We will need to expand
and effectively manage our managerial, operational, financial and other resources in order to successfully pursue our clinical
development and commercialization efforts for our product candidates and future product candidates. We are highly dependent on
the development, regulatory, commercial and financial expertise of the members of our senior management. The loss of the services
of any of our senior management could delay or prevent the further development and potential commercialization of our product candidates
and, if we are not successful in finding suitable replacements, could harm our business. We do not maintain &ldquo;key man&rdquo;
insurance policies on the lives of these individuals. We will need to hire additional personnel as the Company continues to expand
its manufacturing, research and development activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our success depends on
our continued ability to attract, retain and motivate highly qualified management and scientific personnel and we may not be able
to do so in the future due to the intense competition for qualified personnel among biotechnology, pharmaceutical and other businesses.
Our industry has experienced a high rate of turnover of management personnel in recent years. If the Company is not able to attract
and retain the necessary personnel to accomplish its business objectives, we may experience constraints that will impede significantly
the achievement of our development objectives, our ability to raise additional capital, and our ability to implement our business
strategy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>If the Company fails to comply with
healthcare regulations, it could face substantial penalties and its business, operations and financial condition could be adversely
affected. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In addition to FDA restrictions
on the marketing of pharmaceutical and biotechnology products, several other types of state and federal laws have been applied
to restrict certain marketing practices in the pharmaceutical and medical device industries in recent years, as well as consulting
or other service agreements with physicians or other potential referral sources. These laws include anti-kickback statutes and
false claims statutes that prohibit, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration
to induce, or, in return for, purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item
or service reimbursable under Medicare, Medicaid or other federally-financed healthcare programs, and knowingly presenting, or
causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false
statement to get a false claim paid. The majority of states also have statutes or regulations similar to the federal anti-kickback
law and false claims laws, which apply to items and services reimbursed under Medicaid and other state programs, or, in several
states, apply regardless of the payor. Although there are a number of statutory exemptions and regulatory safe harbors protecting
certain common activities from prosecution, the exemptions and safe harbors are drawn narrowly, and any practices we adopt may
not, in all cases, meet all of the criteria for safe harbor protection from anti-kickback liability. Sanctions under these federal
and state laws may include civil monetary penalties, exclusion of a manufacturer&rsquo;s products from reimbursement under government
programs, criminal fines and imprisonment. Any challenge to its business practices under these laws could have a material adverse
effect on our business, financial condition, and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>The Company uses biological and hazardous
materials, and any claims relating to improper handling, storage or disposal of these materials could be time consuming or costly.
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We use hazardous materials,
including chemicals and biological agents and compounds, which could be dangerous to human health and safety or the environment.
Our operations also produce hazardous waste products. Federal, state and local laws and regulations govern the use, generation,
manufacture, storage, handling and disposal of these materials and wastes. Compliance with applicable environmental laws and regulations
may be expensive, and current or future environmental laws and regulations may impair our pharmaceutical development efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In addition, we cannot
entirely eliminate the risk of accidental injury or contamination from these materials or wastes. If one of our employees was accidentally
injured from the use, storage, handling or disposal of these materials or wastes, the medical costs related to his or her treatment
would be covered by our workers&rsquo; compensation insurance policy. However, we do not carry specific biological or hazardous
waste insurance coverage and our property and casualty and general liability insurance policies specifically exclude coverage for
damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination
or injury, we could be held liable for damages or penalized with fines in an amount exceeding our resources, and our clinical trials
or regulatory approvals could be suspended, or operations otherwise affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>All product candidate development timelines
and projections in this filing are based on the assumption of further financing.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The timelines and projections
in this filing are predicated upon the assumption that we will raise additional financing in the future to continue the development
of our product candidates. In the event the Company does not successfully raise subsequent financing, our product development activities
will necessarily be curtailed commensurate with the magnitude of the shortfall. If our product development activities are slowed
or stopped, we would be unable to meet the timelines and projections outlined in this filing. Failure to progress our product candidates
as anticipated will have a negative effect on our business, future prospects, and ability to obtain further financing on acceptable
terms (if at all), and the value of the enterprise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><U>Risks Relating to Acquisitions</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Acquisitions, investments and strategic
alliances that we may make in the future may use significant resources, result in disruptions to our business or distractions of
our management, may not proceed as planned, and could expose us to unforeseen liabilities.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We may seek to expand
our business through the acquisition of, investments in and strategic alliances with companies, technologies, products, and services,
such as the Exchange Transaction between the Company and TG Bio. Acquisitions, investments and strategic alliances involve a number
of special problems and risks, including, but not limited to:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">difficulty integrating acquired technologies, products, services, operations and personnel with the
existing businesses;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">diversion of management&rsquo;s attention in connection with both negotiating the acquisitions and
integrating the businesses;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">strain on managerial and operational resources as management tries to oversee larger operations;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">difficulty implementing and maintaining effective internal control over financial reporting at businesses
that we acquire, particularly if they are not located near our existing operations;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">exposure to unforeseen liabilities of acquired companies;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">potential costly and time-consuming litigation, including stockholder lawsuits;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">potential issuance of securities to equity holders of the company being acquired with rights that
are superior to the rights of holders of our common stock, or which may have a dilutive effect on our stockholders;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">risk of loss of invested capital;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">the need to incur additional debt or use cash; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">the requirement to record potentially significant additional future operating costs for the amortization
of intangible assets.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">As a result of these or
other problems and risks, businesses we acquire may not produce the revenues, earnings, or business synergies that we anticipated,
and acquired products, services, or technologies might not perform as we expected. As a result, we may incur higher costs and realize
lower revenues than we had anticipated. We may not be able to successfully address these problems and we cannot assure you that
the acquisitions will be successfully identified and completed or that, if acquisitions are completed, the acquired businesses,
products, services, or technologies will generate sufficient revenue to offset the associated costs or other negative effects on
our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Any of these risks can
be greater if an acquisition is large relative to our size. Failure to effectively manage our growth through acquisitions could
adversely affect our growth prospects, business, results of operations, financial condition and cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><U>Risks Relating to the Company&rsquo;s
Intellectual Property</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>The Company&rsquo;s success depends
upon our ability to protect our intellectual property and proprietary technologies, and the intellectual property protection for
our product candidates depends significantly on third parties. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our commercial success
depends on obtaining and maintaining patent protection and trade secret protection for our product candidates and their formulations
and uses, as well as successfully defending these patents against third-party challenges. If LFB Biotechnologies or any of our
other licensors fails to appropriately prosecute and maintain patent protection for these product candidates, our ability to develop
and commercialize these product candidates may be adversely affected and we may not be able to prevent competitors from making,
using and selling competing products. This failure to properly protect the intellectual property rights relating to these product
candidates could have a material adverse effect on our financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Currently, the composition
of matter patent and several method of use patents for ublituximab in various indications and settings have been applied for but
have not yet been issued. The patent application process is subject to numerous risks and uncertainties, and there can be no assurance
that we or our partners will be successful in protecting our product candidates by obtaining and defending patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">These risks and uncertainties
include the following:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">the patent applications that we or our partners file may not result in any patents being issued;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">patents that may be issued or in-licensed may be challenged, invalidated, modified, revoked or circumvented,
or otherwise may not provide any competitive advantage;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">as of March 16, 2013, the U.S. will convert from a &ldquo;first to invent&rdquo; to a &ldquo;first
to file&rdquo; system. After this time if we do not win the filing race, we will not be entitled to inventive priority;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">our competitors, many of which have substantially greater resources than we do, and many of which
have made significant investments in competing technologies, may seek, or may already have obtained, patents that will limit, interfere
with, or eliminate its ability to make, use, and sell our potential products either in the United States or in international markets;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">there may be significant pressure on the U.S. government and other international governmental bodies
to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful
as a matter of public policy regarding worldwide health concerns; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">countries other than the United States may have less restrictive patent laws than those upheld by
United States courts, allowing foreign competitors the ability to exploit these laws to create, develop, and market competing products.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">If patents are not issued
that protect ublituximab, it could have a material adverse effect on our financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In addition to patents,
we and our partners also rely on trade secrets and proprietary know-how. Although we have taken steps to protect our trade secrets
and unpatented know-how, including entering into confidentiality agreements with third parties, and confidential information and
inventions agreements with employees, consultants and advisors, third parties may still obtain this information or we may be unable
to protect its rights. If any of these events occurs, or we otherwise lose protection for our trade secrets or proprietary know-how,
the value of this information may be greatly reduced.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Patent protection and
other intellectual property protection are crucial to the success of our business and prospects, and there is a substantial risk
that such protections will prove inadequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>If the Company or its partners are sued
for infringing intellectual property rights of third parties, it will be costly and time consuming, and an unfavorable outcome
in that litigation would have a material adverse effect on our business. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our commercial success
also depends upon our ability and the ability of any of our future collaborators to develop, manufacture, market and sell our product
candidates without infringing the proprietary rights of third parties. Numerous United States and foreign issued patents and pending
patent applications, which are owned by third parties, exist in the fields in which we are developing products, some of which may
be directed at claims that overlap with the subject matter of our intellectual property. For example, Roche has the Cabilly patents
in the U.S. that block the commercialization of antibody products derived from a single cell line, like ublituximab. Also, Roche,
Biogen Idec, and Genentech hold patents for the use of anti-CD20 antibodies utilized in the treatment of CLL in the U.S. While
these patents have been challenged, to the best of our knowledge, those matters were settled in a way that permitted additional
anti-CD20 antibodies to be marketed for CLL. If those patents are still enforced at the time we are intending to launch ublituximab,
then we will need to either prevail in a litigation to challenge those patents or negotiate a settlement agreement with the patent
holders. If we are unable to do so we may be forced to delay the launch of ublituximab or launch at the risk of litigation for
patent infringement, which may have a material adverse effect on the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In addition, because patent
applications can take many years to issue, there may be currently pending applications, unknown to us, which may later result in
issued patents that our product candidates or proprietary technologies may infringe. Similarly, there may be issued patents relevant
to our product candidates of which we are not aware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">There is a substantial
amount of litigation involving patent and other intellectual property rights in the biotechnology and biopharmaceutical industries
generally. If a third party claims that we or any collaborators of ours infringe their intellectual property rights, we may have
to:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">obtain licenses, which may not be available on commercially reasonable terms, if at all;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">abandon an infringing product candidate or redesign its products or processes to avoid infringement;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">pay substantial damages, including treble damages and attorneys&rsquo; fees, which we may have to
pay if a court decides that the product or proprietary technology at issue infringes on or violates the third party&rsquo;s rights;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">pay substantial royalties, fees and/or grant cross licenses to our technology; and/or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">defend litigation or administrative proceedings which may be costly whether we win or lose, and which
could result in a substantial diversion of our financial and management resources.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">No assurance can be given
that patents issued to third parties do not exist, have not been filed, or could not be filed or issued, which contain claims covering
its products, technology or methods that may encompass all or portionis of our products and methods. Given the number of patents
issued and patent applications filed in our technical areas or fields, we believe there is a risk that third parties may allege
they have patent rights encompassing our products or methods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Other product candidates
that we may in-license or acquire could be subject to similar risks and uncertainties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>We may be involved in lawsuits to protect
or enforce our patents or the patents of our licensors, which could be expensive, time consuming and unsuccessful. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Competitors may infringe
our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement
claims, which typically are very expensive, time-consuming and disruptive of day-to-day business operations. In addition, in an
infringement proceeding, a court may decide that a patent of ours or our licensors is not valid or is unenforceable, or may refuse
to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question.
An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held
unenforceable, or interpreted narrowly. The adverse result could also put related patent applications at risk of not issuing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Interference proceedings
provoked by third parties or brought by the U.S. Patent and Trademark Office (&ldquo;PTO&rdquo;) may be necessary to determine
the priority of inventions with respect to our patents or patent applications or those of our collaborators or licensors. An unfavorable
outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party.
Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Litigation or
interference proceedings may fail and, even if successful, may result in substantial costs and distract its management and other
employees. We may not be able to prevent, alone or with our licensors, misappropriation of our trade secrets or confidential information,
particularly in countries where the laws may not protect those rights as fully as in the United States. Moreover, as of March 16,
2013, the U.S. will convert from a &ldquo;first to invent&rdquo; to a &ldquo;first to file&rdquo; system. After that time, should
there be any innovations that we invented first, but on which we filed the patent application second, we will have limited options
available to reclaim invention priority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Furthermore, because of
the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of
our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public
announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors
perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>The Company may be subject to claims
that its consultants or independent contractors have wrongfully used or disclosed alleged trade secrets of their other clients
or former employers to it. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">As is common in the biotechnology
and pharmaceutical industry, we engage the services of consultants to assist us in the development of our product candidates. Many
of these consultants were previously employed at, may have previously been, or are currently providing consulting services to,
other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although no claims against
us are currently pending, we may be subject to claims that these consultants or the Company has inadvertently or otherwise used
or disclosed trade secrets or other proprietary information of their former employers or their former or current customers. Litigation
may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could
result in substantial costs and be a distraction to management and day-to-day business operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><U>Risks Relating to the Company&rsquo;s
Finances and Capital Requirements</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>The Company will need to raise additional
capital to continue to operate its business. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">As of March 31, 2012,
we had net cash on hand of approximately $20,924,000. We believe that our cash on hand will sustain our operations for the next
24 months. As a result, we will need additional capital to continue our operations beyond that time. We will need to seek additional
sources of financing in the future, which might not be available on favorable terms, if at all, to continue our operations. If
we do not succeed in raising additional funds on acceptable terms, we might be unable to complete planned preclinical and clinical
trials or obtain approval of any of our product candidates from the FDA or any foreign regulatory authorities. In addition, we
could be forced to discontinue product development, reduce or forego sales and marketing efforts and forego attractive business
opportunities. Any additional sources of financing will likely involve the issuance of the Company&rsquo;s equity securities, which
would have a dilutive effect on your holdings of our capital stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Currently, none of our
product candidates have been approved by the FDA or any foreign regulatory authority for sale. Therefore, for the foreseeable future,
we will have to fund all of our operations and capital expenditures from cash on hand and amounts raised in future offerings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>We have a history of operating losses,
expect to continue to incur losses, and are unable to predict the extent of future losses or when it will become profitable, if
ever. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Company was incorporated
in December 1993. We have not yet demonstrated an ability to obtain regulatory approval for or commercialize a product candidate.
Our short operating history makes it difficult to evaluate our business prospects and consequently, any predictions about our future
performance may not be as accurate as they could be if we had a history of successfully developing and commercializing pharmaceutical
or biotechnology products. The Company&rsquo;s prospects must be considered in light of the uncertainties, risks, expenses and
difficulties frequently encountered by companies in their early stages of operations and the competitive environment in which we
operate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Company has never
been profitable, and, as of March 31, 2012, we had an accumulated deficit of approximately $11,109,000. We have generated operating
losses in all periods since the Company was incorporated. We expect to make substantial expenditures resulting in increasing operating
costs in the future and our accumulated deficit may increase significantly as we expand development and clinical trial efforts
for our product candidates. Our losses have had, and are expected to continue to have, an adverse impact on our working capital,
total assets and stockholders&rsquo; equity. Because of the risks and uncertainties associated with product development, we are
unable to predict the extent of any future losses or when we will become profitable, if ever. Even if we achieve profitability,
we may not be able to sustain or increase profitability on an ongoing basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>We have not generated any revenue from
our product candidates and may never become profitable. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our ability to become
profitable depends upon our ability to generate significant continuing revenues. To obtain significant continuing revenues, we
must succeed, either alone or with others, in developing, obtaining regulatory approval for and manufacturing and marketing our
product candidates (or utilize early access programs to generate such revenue). To date, our product candidates have not generated
any revenues, and we do not know when, or if, we will generate any revenue. Our ability to generate revenue depends on a number
of factors, including, but not limited to:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">successful completion of preclinical studies of its product candidates;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left; vertical-align: top">successful commencement and completion of clinical trials of its product candidates and any future
product candidates we advance into clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">achievement of regulatory approval for our product candidates and any future product candidates we
advance into clinical trials (unless we successfully utilize early access programs which allow for revenue generation prior to
approval);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">manufacturing commercial quantities of our products at acceptable cost levels if regulatory approvals
are obtained;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">successful sales, distribution and marketing of our future products, if any; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">our entry into collaborative arrangements or co-promotion agreements to market and sell our products.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">If the Company is unable
to generate significant continuing revenues, we will not become profitable and we may be unable to continue our operations without
continued funding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>We will need substantial additional
funding and may be unable to raise capital when needed, which would force us to delay, reduce or eliminate our development programs
or commercialization efforts. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We expect to spend substantial
amounts on development, including significant amounts on conducting clinical trials for our product candidates, manufacturing clinical
supplies and expanding our pharmaceutical development programs. We expect that our monthly cash used by operations will continue
to increase for the next several years. We anticipate that we will continue to incur operating losses for the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We will require substantial
additional funds to support our continued research and development activities, as well as the anticipated costs of preclinical
studies and clinical trials, regulatory approvals, and eventual commercialization. We anticipate that we will incur operating losses
for the foreseeable future. We have based these estimates, however, on assumptions that may prove to be wrong, and we could expend
our available financial resources much faster than we currently expect. Further, we will need to raise additional capital to fund
our operations and continue to conduct clinical trials to support potential regulatory approval of marketing applications. Future
capital requirements will also depend on the extent to which we acquire or in-license additional product candidates. We currently
have no commitments or agreements relating to any of these types of transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The amount and timing
of our future funding requirements will depend on many factors, including, but not limited to, the following:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">the progress of our clinical trials, including expenses to support the trials and milestone payments
that may become payable under our license agreements;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">the costs and timing of regulatory approvals;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">the costs and timing of clinical and commercial manufacturing supply arrangements for each product
candidate;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">the costs of establishing sales or distribution capabilities;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">the success of the commercialization of our products;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">our ability to establish and maintain strategic collaborations, including licensing and other arrangements;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">the costs involved in enforcing or defending patent claims or other intellectual property rights;
and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">the extent to which we in-license or invest in other indications or product candidates.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Until the Company can
generate a sufficient amount of product revenue and achieve profitability, we expect to finance future cash needs through public
or private equity offerings, debt financings or corporate collaboration and licensing arrangements, as well as through interest
income earned on cash balances. If we were to be unable to raise additional capital, we would have to significantly delay, scale
back or discontinue one or more of our pharmaceutical development programs. We also may be required to relinquish, license or otherwise
dispose of rights to product candidates or products that it would otherwise seek to develop or commercialize itself on terms that
are less favorable than might otherwise be available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Raising additional funds by issuing
securities or through licensing or lending arrangements may cause dilution to our existing stockholders, restrict our operations
or require us to relinquish proprietary rights. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Company may raise
additional funds through public or private equity offerings, debt financings or licensing arrangements. To the extent that we raise
additional capital by issuing equity securities, the share ownership of existing stockholders will be diluted. Any future debt
financing we enter into may involve covenants that restrict our operations, including limitations on our ability to incur liens
or additional debt, pay dividends, redeem our stock, make certain investments and engage in certain merger, consolidation or asset
sale transactions, among other restrictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In addition, if we raise
additional funds through licensing arrangements, it may be necessary to relinquish potentially valuable rights to our product candidates,
or grant licenses on terms that are not favorable to us. If adequate funds are not available, our ability to achieve profitability
or to respond to competitive pressures would be significantly limited and we may be required to delay, significantly curtail or
eliminate the development of one or more of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>We are controlled by current officers,
directors and principal stockholders.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our directors, executive
officers and principal stockholders beneficially own approximately 26% percent of our outstanding voting stock, including shares
underlying outstanding options and warrants. Our directors, officers and principal stockholders, taken as a whole, have the ability
to exert substantial influence over the election of our Board of Directors and&nbsp;the outcome of issues submitted to our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Our stock price is, and we expect it
to remain, volatile, which could limit investors&rsquo; ability to sell stock at a profit.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">During the last two fiscal
years, our stock price has traded at a low of $0.9844 in the fourth quarter of 2011 to a high of $239.59 in the second quarter
of 2010. The volatile price of our stock makes it difficult for investors to predict the value of their investment, to sell shares
at a profit at any given time, or to plan purchases and sales in advance. A variety of factors may affect the market price of our
common stock. These include, but are not limited to:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">The global economic crisis, which affected stock prices of many companies, and particularly many small
pharmaceutical companies like ours;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">publicity regarding actual or potential clinical results relating to products under development by
our competitors or us;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">delay or failure in initiating, completing or analyzing nonclinical or clinical trials or the unsatisfactory
design or results of these trials;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">achievement or rejection of regulatory approvals by our competitors or us;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">announcements of technological innovations or new commercial products by our competitors or us;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">developments concerning proprietary rights, including patents;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">developments concerning our collaborations;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">regulatory developments in the United States and foreign countries;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">economic or other crises and other external factors;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">period-to-period fluctuations in our revenues and other results of operations;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">changes in financial estimates by securities analysts; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">sales of our common stock.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We will not be able to
control many of these factors, and we believe that period-to-period comparisons of our financial results will not necessarily be
indicative of our future performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In addition, the stock
market in general, and the market for biotechnology companies in particular, has experienced extreme price and volume fluctuations
that may have been unrelated or disproportionate to the operating performance of individual companies. These broad market and industry
factors may seriously harm the market price of our common stock, regardless of our operating performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our Common Stock is not listed on
a national exchange and there is a limited market for the Common Stock which may make it more difficult for you to sell your stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our Common Stock is
quoted on the OTC Bulletin Board under the symbol &quot;TGTX.OB.&quot; There is a limited trading market for our Common Stock which
negatively impacts the liquidity of our Common Stock not only in terms of the number of shares that can be bought and sold at a
given price, but also through delays in the timing of transactions and reduction in security analysts&rsquo; and the media&rsquo;s
coverage of us. Accordingly, there can be no assurance as to the liquidity of any markets that may develop for the Common Stock,
the ability of holders of our Common Stock to sell the Common Stock, or the prices at which holders may be able to sell the Common
Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The fact that our common stock is
not listed on a national exchange may negatively impact our ability to attract investors and to use our common stock to raise capital
to fund our operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In order to maintain liquidity
in our common stock, we depend upon the continuing availability of a market on which our securities may be traded. We need to raise
substantial additional funds in the future to continue our operations and the fact that our common stock is not listed on a national
exchange may impact our ability to attract investors and to use our common stock to raise sufficient capital to continue to fund
our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we fail to file periodic reports
with the SEC our common stock may be removed from the OTCBB.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Pursuant to the Over-The-Counter
Bulletin Board (&quot;OTCBB&quot;) rules relating to the timely filing of periodic reports with the SEC, any OTCBB issuer which
fails to file a periodic report (Form 10-Q's or 10-K's) by the due date of such report (as extended by the filing of a Form 12b-25),
three (3) times during any twenty-four (24) month period is automatically de-listed from the OTCBB. In the event an issuer is de-listed,
such issuer would not be eligible to be re-listed on the OTCBB for a period of one-year, during which time any subsequent late
filing would reset the one-year period of de-listing. If the Company is late in its filings three (3) times in any twenty-four
(24) month period and is de-listed from the OTCBB, the Common Stock would likely be listed for trading only on the &ldquo;Pink
Sheets,&rdquo; which generally provide an even less liquid market than the OTCBB. In such event, investors may find it more difficult
to trade the Common Stock or to obtain accurate, current information concerning market prices for the Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>There is a risk of market fraud.
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">OTCBB securities are
frequent targets of fraud or market manipulation. Not only because of their generally low price, but also because the OTCBB reporting
requirements for these securities are less stringent than for listed or NASDAQ traded securities, and no exchange requirements
are imposed. Dealers may dominate the market and set prices that are not based on competitive forces. Individuals or groups may
create fraudulent markets and control the sudden, sharp increase of price and trading volume and the equally sudden collapse of
market prices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Penny stock regulations may impose
certain restrictions on marketability of our securities.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Securities and Exchange
Commission has adopted Rule 15g-9 which establishes the definition of a &ldquo;penny stock,&rdquo; for the purposes relevant to
us, as any equity security that has a market price of less than $5.00 per share or with an exercise price of less than $5.00 per
share, subject to certain exceptions. For any transaction involving a penny stock, unless exempt, the rules require:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">that a broker or dealer approve a person&rsquo;s account for transactions in penny stocks; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">the broker or dealer receives from the investor a written agreement to the transaction, setting forth
the identity and quantity of the penny stock to be purchased.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In order to approve a
person&rsquo;s account for transactions in penny stocks, the broker or dealer must:&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">obtain financial information and investment experience objectives of the person; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">make a reasonable determination that the transactions in penny stocks are suitable for that person
and the person has sufficient knowledge and experience in financial matters to be capable of evaluating the risks of transactions
in penny stocks.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The broker or dealer must
also deliver, prior to any transaction in a penny stock, a disclosure schedule prescribed by the Commission relating to the penny
stock market, which, in highlight form:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">sets forth the basis on which the broker or dealer made the suitability determination; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">that the broker or dealer received a signed, written agreement from the investor prior to the transaction.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Generally, brokers
may be less willing to execute transactions in securities subject to the &ldquo;penny stock&rdquo; rules. This may make it more
difficult for investors to dispose of our Common Stock and cause a decline in the market value of our stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Disclosure also must
be made about the risks of investing in penny stocks in both public offerings and in secondary trading and about the commissions
payable to both the broker-dealer and the registered representative, current quotations for the securities and the rights and remedies
available to an investor in cases of fraud in penny stock transactions. Finally, monthly statements have to be sent disclosing
recent price information for the penny stock held in the account and information on the limited market in penny stocks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have not paid dividends in the
past and do not expect to pay dividends in the future, and any return on investment may be limited to the value of your stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We have never paid
dividends on our Common Stock and do not anticipate paying any dividends for the foreseeable future. You should not rely on an
investment in our stock if you require dividend income. Further, you will only realize income on an investment in our stock in
the event you sell or otherwise dispose of your shares at a price higher than the price you paid for your shares. Such a gain would
result only from an increase in the market price of our Common Stock, which is uncertain and unpredictable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ITEM
6. EXHIBITS</B></FONT><B> </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: -1in">The exhibits
listed on the Exhibit Index are included with this report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: left">3.1</TD>
    <TD STYLE="width: 84%; text-align: left">Amended and Restated Certificate of Incorporation of TG Therapeutics, Inc., dated April 26, 2012.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">3.2</TD>
    <TD STYLE="text-align: left">Restated Bylaws of TG Therapeutics, Inc., dated May 14, 2012.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">10.1</TD>
    <TD STYLE="text-align: left">Amended and Restated TG Therapeutics, Inc. 2012 Incentive Plan, dated May 14, 2012.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">24</TD>
    <TD STYLE="text-align: left">Powers of Attorney for Laurence N. Charney, William J. Kennedy and Mark Schoenebaum.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">31.1</TD>
    <TD STYLE="text-align: left">Certification of Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated May 14, 2012.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">31.2</TD>
    <TD STYLE="text-align: left">Certification of Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated May 14, 2012.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">32.1</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Certification of Chief Executive Officer pursuant to 18 U.S.C. &sect;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, dated </FONT>May 14, 2012<FONT STYLE="font-family: Times New Roman, Times, Serif">. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">32.2</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Certification of Chief Financial Officer pursuant to 18 U.S.C. &sect;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, dated </FONT>May 14, 2012<FONT STYLE="font-family: Times New Roman, Times, Serif">. </FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">TG THERAPEUTICS, INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 4%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 47%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: </FONT>May 14, 2012<FONT STYLE="font-family: Times New Roman, Times, Serif"> </FONT></TD>
    <TD STYLE="text-align: left">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Sean A. Power</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>Chief Financial Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>Principal Financial and Accounting Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 46; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
following exhibits are included as part of this Quarterly Report on Form 10-Q:</FONT><B> </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: left">3.1</TD>
    <TD STYLE="width: 84%; text-align: left">Amended and Restated Certificate of Incorporation of TG Therapeutics, Inc., dated April 26, 2012.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">3.2</TD>
    <TD STYLE="text-align: left">Restated Bylaws of TG Therapeutics, Inc., dated May 14, 2012.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">10.1</TD>
    <TD STYLE="text-align: left">Amended and Restated TG Therapeutics, Inc. 2012 Incentive Plan, dated May 14, 2012.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">24</TD>
    <TD STYLE="text-align: left">Powers of Attorney for Laurence N. Charney, William J. Kennedy and Mark Schoenebaum.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">31.1</TD>
    <TD STYLE="text-align: left">Certification of Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated May 14, 2012.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">31.2</TD>
    <TD STYLE="text-align: left">Certification of Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated May 14, 2012.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">32.1 </TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Certification of Chief Executive Officer pursuant to 18 U.S.C. &sect;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, dated </FONT>May 14, 2012<FONT STYLE="font-family: Times New Roman, Times, Serif">. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">32.2 </TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Certification of Chief Financial Officer pursuant to 18 U.S.C. &sect;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, dated </FONT>May 14, 2012<FONT STYLE="font-family: Times New Roman, Times, Serif">. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 47; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>2
<FILENAME>v312751_ex3-2.htm
<DESCRIPTION>EXHIBIT 3.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">RESTATED</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">BY LAWS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TG THERAPEUTICS, INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">RESTATED</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">BYLAWS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TG THERAPEUTICS, INC.<BR>
a Delaware Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">ARTICLE I</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; font-variant: normal; text-align: center; text-indent: 0in"><BR>
<U>OFFICES</U></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 1.01&nbsp;&nbsp;REGISTERED OFFICE. The
registered office of TG THERAPEUTICS, INC. (hereinafter called the &ldquo;Corporation&rdquo;) shall be at such place in the State
of Delaware as shall be designated by the Board of Directors (hereinafter called the &ldquo;Board&rdquo;).</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 1.02&nbsp;&nbsp;PRINCIPAL OFFICE. The
principal office for the transaction of the business of the Corporation shall be at such location, within or without the State
of Delaware, as shall be designated by the Board.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 1.03&nbsp;&nbsp;OTHER OFFICES. The Corporation
may also have an office or offices at such other place or places, either within or without the State of Delaware, as the Board
may from time to time determine or as the business of the Corporation may require.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">ARTICLE II</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; font-variant: normal; text-align: center; text-indent: 0in"><BR>
<U>MEETINGS OF STOCKHOLDERS</U></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 2.01&nbsp;&nbsp;ANNUAL MEETINGS. Annual
meetings of the stockholders of the Corporation for the purpose of electing directors and for the transaction of such other proper
business as may come before such meetings may be held at such time, date and place as the Board shall determine by resolution.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 2.02&nbsp;&nbsp;SPECIAL MEETINGS. Special
meetings of the stockholders of the Corporation for any purpose or purposes may be called at any time by the Board, or by a committee
of the Board which, or officer of the corporation who, has been duly designated by the Board and whose powers and authority, as
provided in a resolution of the Board or in the Bylaws, include the power to call such meetings, but such special meetings may
not be called by any other person or persons; provided, however, that if and to the extent that any special meeting of stockholders
may be called by any other person or persons specified in any provisions of the Certificate of Incorporation or any amendment thereto
or any certificate filed under Section 151(g) of the General Corporation Law of the State of Delaware (or its successor statute
as in effect from time to time hereafter), then such special meeting may also be called by the person or persons, in the manner,
at the time and for the purposes so specified.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 2.03&nbsp;&nbsp;PLACE OF MEETINGS. All
meetings of the stockholders shall be held at such places, within or without the State of Delaware, as may from time to time be
designated by the person or persons calling the respective meetings and specified in the respective notices or waivers of notice
thereof.</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; font-variant: normal; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 2.04&nbsp;&nbsp;NOTICE OF MEETINGS. Except
as otherwise required by law, notice of each meeting of the stockholders, whether annual or special, shall be given not less than
ten (10) nor more than sixty (60) days before the date of the meeting to each stockholder of record entitled to vote at such meeting
by delivering a typewritten or printed notice thereof to him personally, or by depositing such notice in the United States mail
or overnight delivery service, in a postage prepaid envelope, or by-hand delivery service, charges prepaid, directed to him at
his address furnished by him to the Secretary of the Corporation for such purpose or, if he shall not have furnished to the Secretary
his address for such purpose, then at his address last known to the Secretary, or by transmitting a notice thereof to him at such
address by telegraph, telecopy, cable or wireless. Except as otherwise expressly required by law, no publication of any notice
of a meeting of the stockholders shall be required. Every notice of a meeting of the stockholders shall state the place, date and
hour of the meeting, and, in the case of a special meeting shall also state the purpose or purposes for which the meeting is called.
Except as otherwise expressly required by law, notice of any adjourned meeting of the stockholders need not be given if the time
and place thereof are announced at the meeting at which the adjournment is taken.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Whenever notice is required to be given to
any stockholder to whom (i) notice of two consecutive annual meetings, and all notices of meetings or of the taking of action by
written consent without a meeting to such person during the period between such two consecutive annual meetings, or (ii) all, and
at least two, payments (if sent by first class mail) of dividends or interest on securities during a twelve month period, have
been mailed addressed to such person at his address as shown on the records of the Corporation and have been returned undeliverable,
the giving of such notice to such person shall not be required. Any action or meeting which shall have been taken or held without
notice to such person shall the same force and effect as if such notice had been duly given. If any such person shall deliver to
the Corporation a written notice setting forth his then current address, the requirement that notice be given to such person shall
be reinstated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">No notice need be given to any person with
whom communication is unlawful, nor shall there be any duty to apply for any permit or license to give notice to any such person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 2.05&nbsp;&nbsp;QUORUM. Except as provided
by law, the holders of record of a majority in voting interest of the shares of stock of the Corporation entitled to be voted,
present in person or by proxy, shall constitute a quorum for the transaction of business at any meeting of the stockholders of
the Corporation or any adjournment thereof. The stockholders present at a duly called or held meeting at which a quorum is present
may continue to do business until adjournment, notwithstanding the withdrawal of enough stockholders to leave less than a quorum.
In the absence of a quorum at any meeting or any adjournment thereof, a majority in voting interest of the stockholders present
in person or by proxy and entitled to vote thereat or, in the absence therefrom of all the stockholders, any officer entitled to
preside at or to act as secretary of such meeting may adjourn such meeting from time to time. At any such adjourned meeting at
which a quorum is present any business may be transacted which might have been transacted at the meeting as originally called.</P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; font-variant: normal; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 2.06&nbsp;&nbsp;VOTING.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)&nbsp;&nbsp;At each meeting of the stockholders,
each stockholder shall be entitled to vote in person or by proxy each share or fractional share of the stock of the Corporation
which has voting rights on the matter in question and which shall have been held by him and registered in his name on the books
of the Corporation:</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(i)&nbsp;&nbsp;on the date fixed pursuant to
Section 2.07 of these Bylaws as the record date for the determination of stockholders entitled to notice of and to vote at such
meeting, or</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(ii)&nbsp;&nbsp;if no such record date shall
have been so fixed, then (A) at the close of business on the day next preceding the day on which notice of the meeting shall be
given or (B) if notice of the meeting shall be waived, at the close of business on the day next preceding the day on which the
meeting shall be held.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)&nbsp;&nbsp;Shares of its own stock belonging
to the Corporation or to another corporation, if a majority of the shares entitled to vote in the election of directors in such
other corporation is held, directly or indirectly, by the Corporation, shall neither be entitled to vote nor be counted for quorum
purposes. Persons holding stock of the Corporation in a fiduciary capacity shall be entitled to vote such stock. Persons whose
stock is pledged shall be entitled to vote, unless in the transfer by the pledgor on the books of the Corporation he shall have
expressly empowered the pledgee to vote thereon, in which case only the pledgee, or his proxy, may represent such stock and vote
thereon. Stock having voting power standing of record in the names of two or more persons, whether fiduciaries, members of a partnership,
joint tenants, tenants in common, tenants by the entirety or otherwise, or with respect to which two or more persons have the same
fiduciary relationship, shall be voted in accordance with the provisions of the General Corporation Law of Delaware.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)&nbsp;&nbsp;Any such voting rights may be exercised
by the stockholder entitled thereto in person or by his proxy appointed by an instrument in writing, subscribed by such stockholder
or by his attorney thereunto authorized and delivered to the secretary of the meeting; provided, however, that no proxy shall be
voted or acted upon after three years from its date unless said proxy shall provide for a longer period. The attendance at any
meeting of a stockholder who may theretofore have given a proxy shall not have the effect of revoking the same unless he shall
in writing so notify the secretary of the meeting prior to the voting of the proxy. At any meeting of the stockholders all matters,
except as otherwise provided in the Certificate of Incorporation, in these Bylaws or by law, shall be decided by the vote of a
majority in voting interest of the stockholders present in person or by proxy and entitled to vote thereat and thereon. The stockholders
present at a duly called or held meeting at which a quorum is present may continue to do business until adjournment, notwithstanding
the withdrawal of enough stockholders to leave less than a quorum. The vote at any meeting of the stockholders on any question
need not be by ballot, unless so directed by the chairman of the meeting. On a vote by ballot, each ballot shall be signed by the
stockholder voting, or by his proxy if there be such proxy, and it shall state the number of shares voted.</P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; font-variant: normal; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 2.07&nbsp;&nbsp;LIST OF STOCKHOLDERS.
The Secretary of the Corporation shall prepare and make, at least ten (10) days before every meeting of stockholders, a complete
list of the stockholders entitled to vote at the meeting, arranged in alphabetical order, and showing the address of each stockholder
and the number of shares registered in the name of each stockholder. Such list shall be open to the examination of any stockholder,
for any purpose germane to the meeting, during ordinary business hours, for a period of at least ten (10) days prior to the meeting,
either at a place within the city where the meeting is to be held, which place shall be specified in the notice of the meeting,
or, if not so specified, at the place where the meeting is to be held. The list shall also be produced and kept at the time and
place of the meeting during the entire duration thereof, and may be inspected by any stockholder who is present.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 2.08&nbsp;&nbsp;STOCK LEDGER. The stock
ledger of the Corporation shall be the only evidence as to who are the stockholders entitled to examine the stock ledger, the list
required by Section 2.07 of this Article II or the books of the Corporation, or to vote in person or by proxy at any meeting of
stockholders.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 2.09&nbsp;&nbsp;INSPECTOR OF ELECTION.
The directors, in advance of any meeting, may, but need not, appoint one or more inspectors of election to act at the meeting or
any adjournment thereof. If an inspector or inspectors are not appointed, the person presiding at the meeting may, but need not,
appoint one or more inspectors. In case any person who may be appointed as an inspector fails to appear or act, the vacancy may
be filled by appointment made by the directors in advance of the meeting or at the meeting by the person presiding thereat. Each
inspector so appointed shall first subscribe an oath faithfully to execute the duties of an inspector at such meeting with strict
impartiality and according to the best of his ability. Such inspectors shall decide upon the qualification of the voters and shall
report the number of shares represented at the meeting and entitled to vote on such question, shall conduct and accept the votes,
and, when the voting is completed, shall ascertain and report the number of shares voted respectively for and against the question.
Reports of the inspectors shall be in writing and subscribed and delivered by them to the Secretary of the Corporation. Inspectors
need not be stockholders of the Corporation, and any officer of the Corporation may be an inspector on any question other than
a vote for or against a proposal in which he shall have a material interest. No director or candidate for the office of director
shall act as an inspector of an election of directors.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 2.10&nbsp;&nbsp;STOCKHOLDER ACTION WITHOUT
MEETINGS. Any action required by the General Corporation Law of the State of Delaware to be taken at any annual or special meeting
of the stockholders, or any action which may be taken at any annual or special meeting of the stockholders, may be taken without
a meeting, without prior notice and without a vote, if a consent in writing setting forth the action so taken shall be signed by
the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take
such action at a meeting at which all shares entitled to vote thereon were present and voted. Prompt notice of the taking of the
corporate action without a meeting by less than unanimous written consent shall be given to those stockholders who have not consented
in writing.</P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; font-variant: normal; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 2.11&nbsp;&nbsp;RECORD DATE. In order
that the Corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment
thereof, or to express consent to corporate action in writing without a meeting, or entitled to receive payment of any dividend
or other distribution or allotment of any rights, or entitled to exercise any rights in respect of any change, conversion or exchange
of stock or for the purpose of any other lawful action, the Board may fix a record date, which record date shall not precede the
date upon which the resolution fixing the record date is adopted by the Board and which record date: (i) in the case of determination
of stockholders entitled to vote at any meeting of stockholders or adjournment thereof, shall, unless otherwise required by law,
not be more than sixty nor less than ten days before the date of such meeting; (ii) in the case of determination of stockholders
entitled to express consent to corporate action in writing without a meeting, shall not be more than ten days from the date upon
which the resolution fixing the record date is adopted by the Board; and (iii) in the case of any other action, shall not be more
than sixty days prior to such other action. If no record date is fixed: (i) the record date for determining stockholders entitled
to notice of or to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which
notice is given, or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held;
(ii) the record date for determining stockholders entitled to express consent to corporate action in writing without ,a meeting
when no prior action of the Board is required by law, shall be the first date on which a signed written consent setting forth the
action taken or proposed to be taken is delivered to the corporation in accordance with applicable law, or, if prior action by
the Board is required by law, shall be at the close of business on the day on which the Board adopts the resolution taking such
prior action; and (iii) the record date for determining stockholders for any other purpose shall be at the close of business on
the day on which the Board of Directors adopts the resolution relating thereto. A determination of stockholders of record entitled
to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however, that the
Board may fix a new record date for the adjourned meeting.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">ARTICLE III</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; font-variant: normal; text-align: center; text-indent: 0in"><BR>
<U>BOARD OF DIRECTORS</U></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 3.01&nbsp;&nbsp;GENERAL POWERS. The property,
business and affairs of the Corporation shall be managed by or under the direction of the Board, which may exercise all of the
powers of the Corporation, except such as are by the Certificate of Incorporation, by these Bylaws or by law conferred upon or
reserved to the stockholders.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 3.02&nbsp;&nbsp;NUMBER AND TERM. The Board
shall consist of one or more members, the number of which shall be one until changed thereafter from time to time by resolution
of the Board. Directors need not be stockholders of the Corporation. Each director shall hold office until a successor is elected
and qualified or until the director resigns or is removed.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 3.03&nbsp;&nbsp;ELECTION OF DIRECTORS.
The directors shall be elected by the stockholders of the Corporation, and at each election the persons receiving the greatest
number of votes, up to the number of directors then to be elected, shall be the persons then elected. The election of directors
is subject to any provisions contained in the Certificate of Incorporation relating thereto, including any provisions for a classified
board.</P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; font-variant: normal; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 3.04&nbsp;&nbsp;RESIGNATION AND REMOVAL.
Any<I> </I>director of the Corporation may resign at any time by giving written notice to the Board or to the Secretary of the
Corporation. Any such resignation shall take effect at the time specified therein, or, if the time is not specified, it shall take
effect immediately upon its receipt; and, unless otherwise specified therein, the acceptance of such resignation shall not be necessary
to make it effective.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Except
as otherwise provided by the Certificate of Incorporation or by law, any director or</FONT> the entire board of directors may be
removed, with or without cause, by the holders of a majority of shares then entitled to vote at an election of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 3.05&nbsp;&nbsp;VACANCIES. Except as otherwise
provided in the Certificate of Incorporation, any vacancy in the Board, whether because of death, resignation, disqualification,
an increase in the number of directors, or any other cause, may be filled by vote of the majority of the remaining directors, although
less than a quorum, or by a sole remaining director. Each director so chosen to fill a vacancy shall hold office until his successor
shall have been elected and shall qualify or until he shall resign or shall have been removed. No reduction of the authorized number
of directors shall have the effect of removing any director prior to the expiration of his term of office.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Upon the resignation of one or more directors
from the Board, effective at a future date, a majority of the directors then in office, including those who have so resigned, shall
have the power to fill such vacancy or vacancies, the vote thereon to take effect when such resignation or resignations shall become
effective, and each director so chosen shall hold office as provided hereinabove in the filling of other vacancies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 3.06&nbsp;&nbsp;PLACE OF MEETING; TELEPHONE
CONFERENCE MEETING. The Board may hold any of its meetings at such place or places within or without the State of Delaware as the
Board may from time to time by resolution designate or as shall be designated by the person or persons calling the meeting or in
the notice or waiver of notice of any such meeting. Directors may participate in any regular or special meeting of the Board by
means of conference telephone or similar communications equipment pursuant to which all persons participating in the meeting of
the Board can hear each other, and such participation shall constitute presence in person at such meeting.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 3.07&nbsp;&nbsp;FIRST MEETING. The Board
shall meet as soon as practicable after each annual election of directors and notice of such first meeting shall not be required.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 3.08&nbsp;&nbsp;REGULAR MEETINGS. Regular
meetings of the Board may be held at such times as the Board<SUP>-</SUP>shall from time to time by resolution determine. If any
day fixed for a meeting shall be a legal holiday at the place where the meeting is to be held, then the meeting shall be held at
the same hour and place on the next succeeding business day which is not a legal holiday. Except as provided by law, notice of
regular meetings need not be given.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 3.09&nbsp;&nbsp;SPECIAL MEETINGS. Special
meetings of the Board may be called at any time by the Chairman of the Board or the President or by any two (2) directors, to be
held at the principal office of the Corporation, or at such other place or places, within or without the State of Delaware, as
the person or persons calling the meeting may designate.</P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; font-variant: normal; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Notice of the time and place of special meetings
shall be given to each director either (i) by depositing such notice in the United States mail or overnight delivery service, in
a postage prepaid envelope, or by-hand delivery service, charges prepaid, addressed to him at his address as it is shown upon the
records of the Corporation, or if it is not so shown on such records or is not readily ascertainable, at the place in which the
meetings of the directors are regularly held, or by transmitting a notice thereof to him at such address by telegraph, telecopy,
cable or wireless, at least seventy-two (72) hours prior to the time of the holding of such meeting; or (ii) by orally communicating
the time and place of the special meeting to him at least forty-eight (48) hours prior to the time of the holding of such meeting.
Either of the notices as above provided shall be due, legal and personal notice to such director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 3.10&nbsp;&nbsp;QUORUM AND ACTION. Except
as otherwise provided in these Bylaws or by law, the presence of a majority of the authorized number of directors shall be required
to constitute a quorum for the transaction of business at any meeting of the Board, and all matters shall be decided at any such
meeting, a quorum being present, by the affirmative votes of a majority of the directors present, subject to Section 3.15. In the
absence of a quorum, a majority of directors present at any meeting may adjourn the same from time to time until a quorum shall
be present. Notice of any adjourned meeting need not be given. The directors shall act only as a Board, and the individual directors
shall have no power as such.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 3.11&nbsp;&nbsp;ACTION BY CONSENT. Any
action required or permitted to be taken at any meeting of the Board or of any committee thereof may be taken without a meeting
if a written consent thereto is signed by all members of the Board or of such committee, as the case may be, and such written consent
is filed with the minutes of proceedings of the Board or such committee. Such action by written consent shall have the same force
and effect as the unanimous vote of such directors.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 3.12&nbsp;&nbsp;COMPENSATION. No stated
salary need be paid to directors, as such, for their services but, as fixed from time to time by resolution of the Board, the directors
may receive directors&rsquo; fees, compensation and reimbursement for expenses for attendance at directors&rsquo; meetings, for
serving on committees and for discharging their duties; provided that nothing herein contained shall be construed to preclude any
director from serving the Corporation in any other capacity and receiving compensation therefor.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 3.13&nbsp;&nbsp;COMMITTEES. The Board
may, by resolution passed by a majority of the whole Board, designate one or more committees, each committee to consist of one
or more of the directors of the Corporation. The Board may designate one or more directors as alternate members of any committee,
who may replace any absent or disqualified member at any meeting of the committee. In the absence or disqualification of a member
of the committee, the member or members thereof present at any meeting and not disqualified from voting, whether or not he or they
constitute a quorum, may unanimously appoint another member of the Board of Directors to act at the meeting in place of any such
absent or disqualified member. Any such committee, to the extent permitted by law and provided in the resolution of the Board,
shall have and may exercise all the powers and authority of the Board in the management of the business and affairs of the Corporation,
and may authorize the seal of the Corporation to be affixed to all papers which may require it.</P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; font-variant: normal; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Unless the Board otherwise provides, each
committee designated by the Board may make, alter and repeal rules for conduct of its business. In the absence of such rules each
committee shall conduct its business in the same manner as the Board conducts its business pursuant to these Bylaws. Any such committee
shall keep written minutes of its meetings and report the same to the Board when required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 3.14&nbsp;&nbsp;OFFICERS OF THE BOARD.
A Chairman of the Board or a Vice Chairman may be appointed from time to time by the Board and shall have such powers and duties
as shall be designated by the Board.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 3.15&nbsp;&nbsp;INTERESTED DIRECTORS.
No contract or transaction between the Corporation and one or more of its directors or officers, or between the Corporation and
any other corporation, partnership, association, or other organization in which one or more of its directors or officers are directors
or officers; or have a financial interest, shall be void or voidable solely for this reason, or solely because the director or
officer is present at or participates in the meeting of the Board of Directors or committee thereof which authorizes the contract
or transaction, or solely because his or their votes are counted for such purpose if (i) the material facts as to his or their
relationship or interest and as to the contract or transaction are disclosed or are known to the Board of Directors or the committee,
and the Board of Directors or committee in good faith authorizes the contract or transaction by the affirmative votes of a majority
of the disinterested directors, even though the disinterested directors be less than a quorum; or (ii) the material facts as to
his or their relationship or interest and as to the contract or transaction are disclosed or are known to the stockholders entitled
to vote thereon, and the contract or transaction is specifically approved in good faith by vote of the disinterested stockholders;
or (iii) the contract or transaction is fair as to the Corporation as of the time it is authorized, approved or ratified, by the
Board of Directors, a committee thereof or the stockholders. Common or interested directors may be counted in determining the presence
of a quorum at a meeting of the Board of Directors or of a committee which authorizes the contract or transaction.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 3.16&nbsp;&nbsp;LIMITED DIRECTOR LIABILITY.
A director of the corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach
of fiduciary duty as a director, except for liability (i) for any breach of the director&rsquo;s duty of loyalty to the Corporation
or its stockholders, (ii) for acts or omissions not in good faith or which involved intentional misconduct or a knowing violation
of law, (iii) under Section 174 of the DGCL for unlawful payment of dividends or improper redemption of stock, or (iv) for any
transaction from which the director derived an improper benefit. If the DGCL is hereafter amended to authorize the further elimination
or limitation of the liability of directors, thus the liability of a director of the Corporation, in addition to the limitation
on personal liability provided herein, shall be limited to the fullest extent permitted by the DGCL, as amended. Any repeal or
modification of this paragraph by the stockholders of the Corporation shall be prospective only, and shall not adversely affect
any limitation on the personal liability of a director of the Corporation existing at the time of such repeal or modification.</P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; font-variant: normal; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">ARTICLE IV</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; font-variant: normal; text-align: center; text-indent: 0in"><BR>
<U>OFFICERS</U></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 4.01&nbsp;&nbsp;OFFICERS. The officers
of the Corporation shall be a President, a Secretary and a Treasurer. The Corporation may also have, at the discretion of the Board,
a Chairman of the Board, a Chief Executive Officer, one or more Vice Presidents, one or more Assistant Vice Presidents, one or
more Assistant Secretaries, one or more Assistant Treasurers and such other officers as may be appointed in accordance with the
provisions of Section 4.03 of these Bylaws. One person may hold two or more offices, except that the Secretary may not also hold
the office of President.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 4.02&nbsp;&nbsp;ELECTION AND TERM. The
officers of the Corporation, except such officers as may be appointed in accordance with the provisions of Section 4.03 or Section
4.05 of these Bylaws, shall be chosen annually by the Board, and each shall hold his office until he shall resign or shall be removed
or otherwise disqualified to serve, or until his successor shall be elected and qualified.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 4.03&nbsp;&nbsp;SUBORDINATE OFFICERS.
The Board may appoint, or may authorize the Chief Executive Officer to appoint, such other officers as the business of the Corporation
may require, each of whom shall have such authority and perform such duties as are provided in these Bylaws or as the Board or
the President from time to time may specify, and shall hold office until he shall resign or shall be removed or otherwise disqualified
to serve.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 4.04&nbsp;&nbsp;REMOVAL AND RESIGNATION.
Any officer may be removed, with or without cause, by a majority of the directors at the time in office, at any regular or special
meeting of the Board, or, except in case of an officer chosen by the Board, by the Chief Executive Officer upon whom such power
of removal may be conferred by the Board.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Any officer may resign at any time by giving
written notice to the Board, the Chairman of the Board, the President or the Secretary of the Corporation. Any such resignation
shall take effect at the date of the receipt of such notice or at any later time specified therein; and unless otherwise specified
therein, the acceptance of such resignation shall not be necessary to make it effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 4.05&nbsp;&nbsp;VACANCIES. A vacancy in
any office because of death, resignation, removal, disqualification or any other cause shall be filled in the manner prescribed
in the Bylaws for the regular appointments to such office.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 4.06&nbsp;&nbsp;PRESIDENT. The President
of the Corporation shall, subject to the control of the Board, have general supervision, direction and control of the business
and affairs of the Corporation. He shall preside at all meetings of stockholders and the Board. He shall have the general powers
and duties of management usually vested in the chief executive officer of a corporation, and shall have such other powers and duties
with respect to the administration of the business and affairs of the Corporation as may from time to time be assigned to him by
the Board or as prescribed by the Bylaws.</P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; font-variant: normal; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 4.07 &nbsp;CHAIRMAN OF THE BOARD.
The Chairman of the Board, if any, shall preside at all meetings of the stockholders and the Board and exercise and perform such
other powers and duties with respect to the administration of the business and affairs of the Corporation as may from time to time
be assigned to him by the Board or as is prescribed by the Bylaws.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 4.08 &nbsp;CHIEF EXECUTIVE OFFICER/CHIEF
OPERATING OFFICER/OFFICE OF THE CHIEF EXECUTIVE. In the event the Board of Directors elects a Chief Executive Officer and/or a
Chief Operating Officer, or establishes an Office of the Chief Executive, the person or persons so elected or the members of such
office shall individually or jointly, as the case may be, have general and active management of the property, business and affairs
of the Corporation, subject to the supervision and control of the Board. The Chief Executive Officer, the Chief Operating Officer,
or members of the Office of the Chief Executive, as the case may be, also shall have such powers and perform such other duties
as prescribed from time to time by the Board of Directors.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 4.09 &nbsp;VICE PRESIDENT. The Vice
President(s), if any, shall exercise and perform such powers and duties with respect to the administration of the business and
affairs of the Corporation as from time to time may be assigned to each of them by the President, by the Chairman of the Board,
if any, by the Board or as is prescribed by the Bylaws. In the absence or disability of the President, the Vice Presidents, in
order of their rank as fixed by the Board, or if not ranked, the Vice President designated by the Board, shall perform all of the
duties of the President and when so acting shall have all of the powers of and be subject to all the restrictions upon the President.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 4.10 &nbsp;SECRETARY. The Secretary
shall keep, or cause to be kept, a book of minutes at the principal office for the transaction of the business of the Corporation,
or such other place as the Board may order, of all meetings of directors and stockholders, with the time and place of holding,
whether regular or special, and if special, how authorized and the notice thereof given, the names of those present at directors&rsquo;
meetings, the number of shares present or represented at stockholders&rsquo; meetings and the proceedings thereof.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">The Secretary shall keep, or cause to be kept,
at the principal office for the transaction of the business of the Corporation or at the office of the Corporation&rsquo;s transfer
agent, a share register, or a duplicate share register, showing the names of the stockholders and their addresses, the number and
classes of shares held by each, the number and date of certificates issued for the same, and the number and date of cancellation
of every certificate surrendered for cancellation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">The Secretary shall give, or cause to be given,
notice of all the meetings of the stockholders and of the Board required by these Bylaws or by law to be given, and he shall keep
the seal of the Corporation in safe custody, and shall have such other powers and perform such other duties as may be prescribed
by the Board or these Bylaws. If for any reason the Secretary shall fail to give notice of any special meeting of the Board called
by one or more of the persons identified in Section 3.09 of these Bylaws, or if he shall fail to give notice of any special meeting
of the stockholders called by one or more of the persons identified in Section 2.02 of these Bylaws, then any such person or persons
may give notice of any such special meeting.</P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 4.11&nbsp;&nbsp;TREASURER. The Treasurer
shall keep and maintain or cause to be kept and maintained, adequate and correct accounts of the properties and business transactions
of the Corporation, including accounts of its assets, liabilities, receipts, disbursements, gains, losses, capital, surplus and
shares. Any surplus, including earned surplus, paid-in surplus and surplus arising from a reduction of capital, shall be classified
according to source and shown in a separate account. The books of account at all reasonable times shall be open to inspection by
any director.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">The Treasurer shall deposit all moneys and
other valuables in the name and to the credit of the Corporation with such depositories as may be designated by the Board. He shall
disburse the funds of the Corporation as may be ordered by the Board, shall render to the President, to the Chief Executive Officer
and to the directors, whenever they request it, an account of all of his transactions as Treasurer and of the financial condition
of the Corporation, and shall have such other powers and perform such other duties as may be prescribed by the Board or these Bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 4.12 &nbsp;ASSISTANT SECRETARIES.
Except as may be otherwise provided in these By-Laws, Assistant Secretaries, if there be any, shall perform such duties and have
such powers as from time to time may be assigned to them by the Board of Directors, the President, any Vice President, if there
be one, or the Secretary, and in the absence of the Secretary or in the event of his disability or refusal to act, shall perform
the duties of the Secretary, and when so acting, shall have all the powers of and be subject to all the restrictions upon the Secretary.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 4.13 &nbsp;ASSISTANT TREASURERS.
Assistant Treasurers, if there be any, shall perform such duties and have such powers as from time to time may be assigned to them
by the Board of Directors, the President, any Vice President, if there be one, or the Treasurer, and in the absence of the Treasurer
or in the event of his disability or refusal to act, shall perform the duties of the Treasurer, and when so acting, shall have
all the powers of and be subject to all the restrictions upon the Treasurer. If required by the Board of Directors, an Assistant
Treasurer shall give the Corporation a bond in such sum and with such surety or sureties as shall be satisfactory to the Board
of Directors for the faithful performance of the duties of his office and for the restoration to the Corporation, in case of his
death, resignation, retirement or removal from office, of all books, papers, vouchers, money and other property of whatever kind
in his possession or under his control belonging to the Corporation.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 4.14 &nbsp;OTHER OFFICERS. Such other
officers as the Board of Directors may choose shall perform such duties and have such powers as from time to time may be assigned
to them by the Board of Directors. The Board of Directors may delegate to any other officer of the Corporation the power to choose
such other officers and to prescribe their respective duties and powers.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 4.15&nbsp; COMPENSATION. The compensation
of the officers of the Corporation, if any, shall be fixed from time to time by the Board.</P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; font-variant: normal; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 4.16&nbsp; VOTING SECURITIES OWNED
BY THE CORPORATION. Powers of attorney, proxies, waivers of notice of meeting, consents and other instruments relating to securities
owned by the Corporation may be executed in the name of and on behalf of the Corporation by the President or any Vice President
and any such officer may, in the name of and on behalf of the Corporation, take all such action as any such officer may deem advisable
to vote in person or by proxy at any meeting of security holders of any corporation in which the Corporation may own securities
and at any such meeting shall possess and may exercise any and all rights and power incident to the ownership of such securities
and which, as the owner thereof, the Corporation might have exercised and possessed if present. The Board of Directors may, by
resolution, from time to time confer like powers upon any other person or persons.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">ARTICLE V</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; font-variant: normal; text-align: center; text-indent: 0in"><BR>
<U>CONTRACTS, CHECKS, DRAFTS, BANK ACCOUNTS, ETC.</U></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 5.01 &nbsp;EXECUTION OF CONTRACTS.
The Board, except as otherwise provided in these Bylaws, may authorize any officer or officers, agent or agents, to enter into
any contract or execute any instrument in the name and on behalf of the Corporation, and such authority may be general or confined
to specific instances; and unless so authorized by the Board or by these Bylaws, no officer, agent or employee shall have any power
or authority to bind the Corporation by any contract or engagement or to pledge its credit or to render it liable for any purpose
or in any amount.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 5.02 &nbsp;CHECKS, DRAFTS, ETC. All
checks, drafts or other orders for payment of money, notes or other evidence of indebtedness, issued in the name of or payable
to the Corporation, shall be signed or endorsed by such person or persons and in such manner as, from time to time, shall be determined
by resolution of the Board. Each such person shall give such bond, if any, as the Board may require.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 5.03&nbsp; DEPOSIT. All funds of
the Corporation not otherwise employed shall be deposited from time to time to the credit of the Corporation in such banks, trust
companies or other depositories as the Board may select, or as may be selected by any officer or officers, assistant or assistants,
agent or agents, attorney or attorneys, of the Corporation to whom such power shall have been delegated by the Board. For the purpose
of deposit and for the purpose of collection for the account of the Corporation, the President, the Chief Executive Officer, any
Vice President or the Treasurer (or any other officer or officers, assistant or assistants, agent or agents, or attorney or-attorneys
of the Corporation who shall be determined by the Board from time to time) may endorse, assign and deliver checks, drafts and other
orders for the payment of money which are payable to the order of the Corporation.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 5.04&nbsp; GENERAL AND SPECIAL BANK
ACCOUNTS. The Board from time to time may authorize the opening and keeping of general and special bank accounts with such banks,
trust companies or other depositories as the Board may select or as may be selected by an officer or officers, assistant or assistants,
agent or agents, or attorney or attorneys of the Corporation to whom such power shall have been delegated by the Board. The Board
may make such special rules and regulations with respect to such bank accounts, not inconsistent with the provisions of these Bylaws,
as it may deem expedient.</P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; font-variant: normal; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 5.05 &nbsp;AUDITS, ACCOUNTS AND REPORTS.
The books of account of the Company shall be audited at least once during each year by a firm of independent certified accountants.
The initial independent auditor of the Company shall be Ernst &amp; Young.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 5.06 &nbsp;ACCESS. All books and
records of the Company shall be kept at the principal place of business of the Company. Each shareholder may at its own expense,
after giving written notice to the Company, audit, investigate and familiarize itself with the operations of the Company using
its own employees or such certified public accounting firm, qualified external auditor or other advisers as it may select. The
shareholders&rsquo; rights under this Section, which shall include the right to make copies of any relevant documents, shall be
exercised such that the actions of the shareholders or their respective agents do not interfere unreasonably with the operation
of the Company in its ordinary course of business.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 5.07 &nbsp;FISCAL YEAR. The fiscal
year of the Company shall end on the last day of each calendar year.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 5.08 &nbsp;ACCOUNTING POLICY. The
Company shall maintain accounting records, accounts and related financial statements in accordance with United States generally
accepted accounting principles applied on a consistent basis.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 5.09 &nbsp;DIVIDENDS. Dividends upon
the capital stock of the Corporation, subject to the provisions of the Certificate of Incorporation, if any, may be declared by
the Board of Directors at any regular or special meeting, and may be paid in cash, in property, or in shares of the capital stock.
Before payment of any dividend, there may be set aside out of any funds of the Corporation available for dividends such sum or
sums as the Board of Directors from time to time, in its absolute discretion, deems proper as a reserve or reserves to meet contingencies,
or for equalizing dividends, or for repairing or maintaining any property of the Corporation, or for any proper purpose, and the
Board of Directors may modify or abolish any such reserve.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">ARTICLE VI</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; font-variant: normal; text-align: center; text-indent: 0in"><BR>
<U>SHARES AND THEIR TRANSFER</U></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 6.01 &nbsp;CERTIFICATES FOR STOCK.
Every owner of stock of the Corporation shall be entitled to have a certificate or certificates, in such form as the Board shall
prescribe, certifying the number and class of shares of the stock of the Corporation owned by him. The certificates representing
shares of such stock shall be numbered in the order in which they shall be issued and shall be signed in the name of the Corporation
by the Chairman of the Board, the President or a Vice President and by the Secretary or an Assistant Secretary or by the Treasurer
or an Assistant Treasurer. Any or all of the signatures on the certificates may be a facsimile. In case any officer, transfer agent
or registrar who has signed or whose facsimile signature has been placed upon any such certificate shall thereafter have ceased
to be such officer, transfer agent or registrar before such certificate is issued, such certificate may nevertheless be issued
by the Corporation with the same effect as though the person who signed such certificate, or whose facsimile signature shall have
been placed thereupon, were such officer, transfer agent or registrar at the date of issue. A record shall be kept of the respective
names of the persons, firms or corporations owning the stock represented by such certificates, the number and class of shares represented
by such certificates, respectively, and the respective dates thereof, and in case of cancellation, the respective dates of cancellation.
Every certificate surrendered to the Corporation for exchange or transfer shall be cancelled, and no new certificate or certificates
shall be issued in exchange for any existing certificate until such existing certificate shall have been so cancelled, except in
cases provided for in Section 6.04 of these Bylaws.</P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; font-variant: normal; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 6.02 &nbsp;TRANSFER OF STOCK. Transfer
of shares of stock of the Corporation shall be made only on the books of the Corporation by the registered holder thereof, or by
his attorney thereunto authorized by power of attorney duly executed and filed with the Secretary, or with a transfer clerk or
a transfer agent appointed as provided in Section 6.03 of these Bylaws, and upon surrender of the certificate or certificates for
such shares properly endorsed and the payment of all taxes thereon. The person in whose name shares of stock stand on the books
of the Corporation shall be deemed the owner thereof for all purposes as regards the Corporation. Whenever any transfer of shares
shall be made for collateral security, and not absolutely, such fact shall be stated expressly in the entry of transfer if, when
the certificate or certificates shall be presented to the Corporation for transfer, both the transferor and the transferee request
the Corporation to do so.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 6.03 &nbsp;REGULATIONS. The Board
may make such rules and regulations as it may deem expedient, not inconsistent with these Bylaws, concerning the issue, transfer
and registration of certificates for shares of the stock of the Corporation. The Board may appoint, or authorize any officer or
officers to appoint, one or more transfer clerks or one or more transfer agents and one or more registrars, and may require all
certificates for stock to bear the signature or signatures of any of them.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 6.04 &nbsp;LOST, STOLEN, DESTROYED
AND MUTILATED CERTIFICATES. In any case of loss, theft, destruction, or mutilation of any certificate of stock, another may be
issued in its place upon proof of such loss, theft, destruction, or mutilation and upon the giving of a bond of indemnity to the
Corporation in such form and in such sums as the Board may direct; provided, however, that a new certificate may be issued without
requiring any bond when, in the judgment of the Board, it is proper to do so.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 6.05 &nbsp;REPRESENTATION OF SHARES
OF OTHER CORPORATIONS. The President or any Vice President and the Secretary or any Assistant Secretary of this Corporation are
authorized to vote, represent and exercise on behalf of this Corporation all rights incident to all shares of any other corporation
or corporations standing in the name of this Corporation. The authority herein granted to said officers to vote or represent on
behalf of this Corporation any and all shares held by this Corporation in any other corporation or corporations may be exercised
either by such officers in person or by any person authorized so to do by proxy or power of attorney duly executed by said officers.</P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; font-variant: normal; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">ARTICLE VII</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; font-variant: normal; text-align: center; text-indent: 0in"><BR>
<U>INDEMNIFICATION</U></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 7.01&nbsp; MANDATORY INDEMNIFICATION.
Each person who at any time is or was a director of the Corporation, and is threatened to be or is made a party to any threatened,
pending or completed action, suit or proceeding, whether civil or criminal, administrative, arbitrative or investigative (a &ldquo;Proceeding&rdquo;),
by reason of the fact that such person is or was a director of the Corporation, or is or was serving at the request of the Corporation
as a director, officer, partner, venturer, proprietor, member, employee, trustee, agent or similar functionary of another domestic
or foreign corporation, partnership, joint venture, sole proprietorship, trust, employee benefit plan or other for-profit or non-profit
enterprise, whether the basis of a Proceeding is alleged action or inaction in such person&rsquo;s official capacity or in another
capacity while holding such office, shall be indemnified and held harmless by the Corporation to the fullest extent authorized
by the DGCL or any other applicable law as may from time to time be in effect (but, in the case of any such amendment or enactment,
only to the extent that such amendment or law permits the Corporation to provide broader indemnification rights than such law prior
to such amendment or enactment permitted the Corporation to provide), against all expense, liability and loss (including, without
limitation, court costs and attorneys&rsquo; fees, judgments, fines, excise taxes or penalties, and amounts paid or to be paid
in settlement) actually and reasonably incurred or suffered by such person in connection with a Proceeding, and such indemnification
shall continue as to a person who has ceased to be director of the Corporation or a director, officer, partner, venturer, proprietor,
member, employee, trustee, agent or similar functionary of another domestic or foreign corporation, partnership, joint venture,
sole proprietorship, trust, employee benefit plan or other for-profit or non-profit enterprise, and shall inure to the benefit
of such person&rsquo;s heirs, executors and administrators. The Corporation&rsquo;s obligations under this Section A include, but
are not limited to, the convening of any meeting, and the consideration of any matter thereby, required by statutes in order to
determine the eligibility of any person for indemnification.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 7.02 &nbsp;PREPAYMENT OF EXPENSES.
Expenses incurred by a director of the Corporation in defending a Proceeding shall be paid by the Corporation in advance of the
final disposition of such Proceeding to the fullest extent permitted by, and only in compliance with, the DGCL or any other applicable
laws as may from time to time be in effect, including, without limitation, any provision of the DGCL which requires, as a condition
precedent to such expense advancement, the delivery to the Corporation of an undertaking, by or on behalf of such director, to
repay all amounts so advanced if it shall ultimately be determined that such director is not entitled to be indemnified under Section
A of this Article B or otherwise. Repayments of all amounts so advanced shall be upon such terms and conditions, if any, as the
Corporation&rsquo;s Board of Directors deems appropriate.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 7.03 &nbsp;VESTING. The Corporation&rsquo;s
obligation to indemnify and to prepay expense under Sections A and B of this Article B shall arise, and all rights granted to the
Corporation&rsquo;s directors hereunder shall vest, at the time of the occurrence of the transaction or event to which a Proceeding
relates, or at the time that the action or conduct to which such Proceeding relates was first taken or engaged in (or omitted to
be taken or engaged in), regardless of when such Proceeding is first threatened, commenced, or completed. Notwithstanding any other
provision of this Certificate of Incorporation or the Bylaws of the Corporation or otherwise, shall diminish or adversely affect
any rights to indemnification or prepayment of expenses granted under Sections A and B of this Article B which shall have become
vested as aforesaid prior to the date that such amendment or other corporate action is effective or taken, whichever is later.</P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; font-variant: normal; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 7.04&nbsp; ENFORCEMENT. If a claim
under Section A or Section B or both Sections A and B of this Article B is not paid in full by the Corporation within 30 days after
a written claim has been received by the Corporation, the claimant may at any time thereafter bring suit in a court of competent
jurisdiction against the Corporation to recover the unpaid amount of the claim and, if successful in whole or in part, the claimant
shall also be entitled to be paid the expense of prosecuting such claim. It shall be a defense to any such suit (other than a suit
brought to enforce a claim for expenses incurred in defending any Proceeding in advance of its final disposition where the required
undertaking, if any is required, has been tendered to the Corporation) that the claimant has not met the standards of conduct which
make it permissible under the DGCL or other applicable law to indemnify the claimant for the amount claimed, but the burden of
proving such defense shall be on the Corporation. The failure of the Corporation (including its Board of Directors, independent
..legal counsel, or stockholders) to have made a determination prior to the commencement of such suit as to whether indemnification
is proper in the circumstances based upon the applicable standard of conduct set forth in the-DGCL or other applicable law shall
neither be a defense to the action nor create a presumption that the claimant has not met the applicable standard of conduct. The
termination of any Proceeding by judgment, order, settlement, conviction, or upon a plea of <I>nolo contendere </I>or its equivalent,
shall not, of itself, create a presumption that the person did not act in good faith and in a manner which such person reasonably
believed to be in or not opposed to the best interests of the Corporation, and, with respect to any criminal Proceeding, had reasonable
cause to believe that his conduct was unlawful.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 7.05&nbsp; NONEXCLUSIVE. The Indemnification
and advancement of expenses provided by or granted pursuant to this Article B shall not be deemed exclusive of any other rights
to which a person seeking indemnification may be entitled under any statute, bylaw, other provisions of this Certificate of Incorporation,
agreement, vote of stockholders or disinterested directors or otherwise, both as to action in such person&rsquo;s official capacity
and as to action in another capacity while holding such office.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 7.06&nbsp; PERMISSIVE INDEMNIFICATION.
The rights to indemnification and prepayment of expenses which are conferred to the Corporation&rsquo;s directors by Sections A
and B of this Article B may be conferred upon any officer, employee or agent of the Corporation if, and to the extent, authorized
by the Board of Directors.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 7.07&nbsp; INSURANCE. The Corporation
shall have power to purchase and maintain insurance, at its expense, on behalf of any person who is or was a director, officer,
employee, or agent of the Corporation, or is or was serving at the request of the Corporation as a director, officer, partner,
venturer, proprietor, member, employee, trustee, agent or similar functionary of another domestic or foreign corporation, partnership,
joint venture, sole proprietorship, trust, employee benefit plan or other for-profit or non-profit enterprise against any expense,
liability or loss asserted against such person and incurred by such person in any such capacity, or arising out of such person&rsquo;s
status as such, whether or not the Corporation would have power to indemnify such person against such expense, liability or loss
under the Corporation&rsquo;s Bylaws, the provisions of this Article B, the DGCL or other applicable law.</P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; font-variant: normal; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">ARTICLE VIII</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; font-variant: normal; text-align: center; text-indent: 0in"><BR>
<U>MISCELLANEOUS</U></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 8.01 &nbsp;SEAL. The Board shall
provide a corporate seal, which shall be in the form of a circle and shall bear the name of the Corporation and words and figures
showing that the Corporation was incorporated in the State of Delaware and showing the year of incorporation.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 8.02 &nbsp;WAIVER OF NOTICES. Whenever
notice is required to be given under any provision of these bylaws, the Certificate of Incorporation or by law, a written waiver,
signed by the person entitled to notice, whether before or after the time stated therein, shall be deemed equivalent to notice.
Attendance of a person at a meeting shall constitute a waiver of notice of such meeting, except when a person attends a meeting
for the express purpose of objecting at the beginning of the meeting, to the transaction of any business because the meeting is
not lawfully called or convened. Neither the business to be transacted at, nor the purpose of, any regular or special meeting of
the stockholders, directors, or members of a committee of directors need be specified in any written waiver of notice unless required
by the Certificate of Incorporation.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 8.03&nbsp; LOANS AND GUARANTIES.
The Corporation may lend money to, or guarantee any obligation of, and otherwise assist any officer or other employee of the Corporation
or of its subsidiaries, including any officer who is a director, whenever, in the judgment of the Board, such loan, guaranty or
assistance may reasonably be expected to benefit the Corporation. The loan, guaranty, or other assistance may be with or without
interest, and may be unsecured or secured in such manner as the Board shall approve, including, without limitation, a pledge of
shares of stock of the Corporation.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 8.04&nbsp; GENDER. All personal pronouns
used in these Bylaws shall include the other genders, whether used in the masculine, feminine or neuter gender, and the singular
shall include the plural, and vice versa, whenever and as often as may be appropriate.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 8.05 &nbsp;AMENDMENTS. These Bylaws,
or any of them, may be rescinded, altered, amended or repealed, and new Bylaws may be made (i) by the Board, by vote of a majority
of the number of directors then in office as directors, acting at any meeting of the Board or (ii) by the stockholders, by the
vote of a majority of the outstanding shares of voting stock of the Corporation, at an annual meeting of stockholders, without
previous notice, or at any special meeting of stockholders, provided that notice of such proposed amendment, modification, repeal
or adoption is given in the notice of special meeting; provided, however, that Section 2.02 of these Bylaws can only be amended
if that Section as amended would not conflict with the Corporation&rsquo;s Certificate of Incorporation. Any Bylaw made or altered
by the stockholders may <I>be </I>altered or repealed by the Board or may be altered or repealed by the stockholders.</P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; font-variant: normal; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CERTIFICATE OF SECRETARY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">The undersigned certifies:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(1) That the undersigned is duly
elected and acting Secretary of TG THERAPEUTICS, INC., a Delaware corporation; and</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(2) That the foregoing Bylaws constitute
the Bylaws of the Corporation as duly adopted by written consent dated the 2nd day of July, 1993 and as restated this 14th day
of May, 2012.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">IN
WITNESS WHEREOF, I have hereunto subscribed my name and affixed the seal of the</FONT> Corporation this 14th day of May, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 55%">&nbsp;</TD>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid">/s Sean A. Power</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Sean A. Power, Secretary</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>[SEAL]</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CERTIFICATE OF AMENDMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">OF THE BY-LAWS OF</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TG THERAPEUTICS, INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 7, 1995,
the By-Laws of this corporation were amended as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Article 2, Section
2.02 of the By-Laws of this corporation was amended in its entirety to read as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Section 2.02
SPECIAL MEETINGS. Special meetings of the stockholders of the Corporation for any purpose or purposes may be called at any time
by the Board, or by a committee of the Board which, or officer of the corporation who, has been duly designated by the Board and
whose powers and authority, as provided in a resolution of the Board or in the Bylaws, include the power to call such meetings
or by one or more stockholders holding shares in the aggregate entitled to cast not less than 50% of the votes at that meeting,
but such special meetings may not be called by any other person or persons; provided, however, that if and to the extent that any
special meeting of stockholders may be called by any other person or persons specified in any provisions of the Certificate of
Incorporation or any amendment thereto or any certificate filed under Section 151(g) of the General Corporation Law of the State
of Delaware (or its successor statute as in effect from time to time hereafter), then such special meeting may also be called by
the person or persons, in the manner, at the time and for the purposes so specified.</P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>v312751_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.1 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF PERIODIC REPORT PURSUANT
TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Michael S. Weiss, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 12pt">1.</TD><TD STYLE="text-align: left">I have reviewed this quarterly report on Form 10-Q of TG Therapeutics, Inc.;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 12pt">2.</TD><TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 12pt">3.</TD><TD STYLE="text-align: left">Based on my knowledge, the financial statements, and other financial information included in this
report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant
as of, and for, the periods presented in this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 12pt">4.</TD><TD STYLE="text-align: left">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial
reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 12pt"></TD><TD STYLE="width: 0.25in">a)</TD><TD STYLE="text-align: left">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures
to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being
prepared;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 12pt"></TD><TD STYLE="width: 0.25in">b)</TD><TD STYLE="text-align: left">Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 12pt"></TD><TD STYLE="width: 0.25in">c)</TD><TD STYLE="text-align: left">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented
in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered
by this report based on such evaluation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 12pt"></TD><TD STYLE="width: 0.25in">d)</TD><TD STYLE="text-align: left">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting
that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case
of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal
control over financial reporting; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 12pt">5.</TD><TD STYLE="text-align: left">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation
of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s
board of directors (or persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 12pt"></TD><TD STYLE="width: 0.25in">a)</TD><TD STYLE="text-align: left">All significant deficiencies and material weaknesses in the design or operation of internal control
over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize
and report financial information; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 12pt"></TD><TD STYLE="width: 0.25in">b)</TD><TD STYLE="text-align: left">Any fraud, whether or not material, that involves management or other employees who have a significant
role in the registrant&rsquo;s internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 43%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Date: </FONT>May 14, 2012<FONT STYLE="font-family: Times New Roman, Times, Serif"> &nbsp;&nbsp; </FONT></TD>
    <TD STYLE="width: 29%; text-align: left; border-bottom: Black 1pt solid">/s/ Michael S. Weiss</TD>
    <TD STYLE="text-align: left; width: 28%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">Michael S. Weiss</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">Executive Chairman, Interim Chief Executive Officer and</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">President &nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">Principal Executive Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>v312751_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.2 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF PERIODIC REPORT PURSUANT
TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">I, Sean A. Power, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 12pt">1.</TD><TD STYLE="text-align: left">I have reviewed this quarterly report on Form 10-Q of TG Therapeutics, Inc.;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: -12pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 12pt">2.</TD><TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: -12pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 12pt">3.</TD><TD STYLE="text-align: left">Based on my knowledge, the financial statements, and other financial information included in this
report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant
as of, and for, the periods presented in this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: -12pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 12pt">4.</TD><TD STYLE="text-align: left">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial
reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: -12pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 12pt"></TD><TD STYLE="width: 0.25in">a)</TD><TD STYLE="text-align: left">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures
to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being
prepared;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: -12pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 12pt"></TD><TD STYLE="width: 0.25in">b)</TD><TD STYLE="text-align: left">Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: -12pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 12pt"></TD><TD STYLE="width: 0.25in">c)</TD><TD STYLE="text-align: left">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented
in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered
by this report based on such evaluation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: -12pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 12pt"></TD><TD STYLE="width: 0.25in">d)</TD><TD STYLE="text-align: left">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting
that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case
of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal
control over financial reporting; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: -12pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 12pt">5.</TD><TD STYLE="text-align: left">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation
of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s
board of directors (or persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: -12pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 12pt"></TD><TD STYLE="width: 0.25in">a)</TD><TD STYLE="text-align: left">All significant deficiencies and material weaknesses in the design or operation of internal control
over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize
and report financial information; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: left; text-indent: -12pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 12pt"></TD><TD STYLE="width: 0.25in">b)</TD><TD STYLE="text-align: left">Any fraud, whether or not material, that involves management or other employees who have a significant
role in the registrant&rsquo;s internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 43%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Date: </FONT>May 14, 2012<FONT STYLE="font-family: Times New Roman, Times, Serif"> &nbsp;&nbsp; </FONT></TD>
    <TD STYLE="width: 29%; text-align: left; border-bottom: Black 1pt solid">/s/ Sean A. Power</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; width: 28%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Sean A. Power</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Chief Financial Officer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Principal Financial and Accounting Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>v312751_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.1 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>STATEMENT OF CHIEF EXECUTIVE OFFICER
OF<BR>
TG THERAPEUTICS, INC.<BR>
PURSUANT TO 18 U.S.C. SECTION 1350,<BR>
AS ADOPTED PURSUANT TO<BR>
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
connection with the quarterly report of TG Therapeutics, Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the period ended March
31, 2012 as filed with the Securities and Exchange Commission (the &ldquo;Report&rdquo;), I, Michael S. Weiss, Chief Executive
Officer of the Company, certify, pursuant to 18 U.S.C. &sect; 1350, as adopted pursuant to &sect; 906 of the Sarbanes-Oxley Act
of 2002, that, based on my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left">1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left">2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 42%; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: </FONT>May 14, 2012<FONT STYLE="font-family: Times New Roman, Times, Serif"> </FONT>&nbsp;</TD>
    <TD STYLE="width: 29%; text-align: left; text-decoration: none; border-bottom: Black 1pt solid">/s/ Michael S. Weiss</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; width: 29%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Michael S. Weiss</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Executive Chairman, Interim Chief Executive
        Officer and</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">President</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Principal Executive Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>v312751_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.2 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>STATEMENT OF CHIEF FINANCIAL OFFICER
OF<BR>
TG THERAPEUTICS, INC.<BR>
PURSUANT TO 18 U.S.C. SECTION 1350,<BR>
AS ADOPTED PURSUANT TO<BR>
SECTION&nbsp;906 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
connection with the quarterly report of TG Therapeutics, Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the period ended March
31, 2012 as filed with the Securities and Exchange Commission (the &ldquo;Report&rdquo;), I, Sean A. Power, Chief Financial Officer
of the Company, certify, pursuant to 18 U.S.C. &sect; 1350, as adopted pursuant to &sect; 906 of the Sarbanes-Oxley Act of 2002,
that, based on my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left">1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left">2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; width: 43%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: </FONT>May 14, 2012<FONT STYLE="font-family: Times New Roman, Times, Serif"> </FONT>&nbsp;</TD>
    <TD STYLE="width: 29%; text-align: left; border-bottom: Black 1pt solid">/s/ Sean A. Power</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; width: 28%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Sean A. Power</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Chief Financial Officer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Principal Financial and Accounting Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>7
<FILENAME>tgtxd-20120331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!-- XBRL document created with Ez-XBRL version 4.0.0.7 [05/13/2012 12:03:55 PM] -->
<!-- Based on XBRL 2.1  -->
<!---->
<!--XBRL Document Modified with Ez-Viewer Version 1.0.4.3 on Tuesday, May 15, 2012 12:02:10 AM -->
<xbrli:xbrl xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:country="http://xbrl.sec.gov/country/2011-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2011-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2011-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2011-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:us-types="http://fasb.org/us-types/2011-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:tgtxd="http://www.tgtherapeuticsinc.com/20120331">
	<link:schemaRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:type="simple" xlink:href="tgtxd-20120331.xsd"/>
	<!-- Context Section  -->
	<xbrli:context id="Context_As_Of_31-Dec-2011">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2011-12-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_3ME_31-Mar-2012">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>
2012-01-01
</xbrli:startDate>
			<xbrli:endDate>
2012-03-31
</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_3ME_31-Mar-2012_StatementEquityComponentsAxis_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>
2012-01-01
</xbrli:startDate>
			<xbrli:endDate>
2012-03-31
</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_3ME_31-Mar-2012_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>
2012-01-01
</xbrli:startDate>
			<xbrli:endDate>
2012-03-31
</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_3ME_31-Mar-2012_StatementEquityComponentsAxis_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>
2012-01-01
</xbrli:startDate>
			<xbrli:endDate>
2012-03-31
</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_3ME_31-Mar-2012_StatementEquityComponentsAxis_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>
2012-01-01
</xbrli:startDate>
			<xbrli:endDate>
2012-03-31
</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_6ME_31-Mar-2012">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2011-04-01</xbrli:startDate>
			<xbrli:endDate>
2012-03-31
</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Mar-2012">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2012-03-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_10-May-2012">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2012-05-10
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2011-12-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Mar-2012_StatementEquityComponentsAxis_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2012-03-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2011-12-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Mar-2012_StatementEquityComponentsAxis_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2012-03-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2011-12-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Mar-2012_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2012-03-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_ContingentlyIssuableSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ContingentlyIssuableSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2011-12-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Mar-2012_StatementEquityComponentsAxis_ContingentlyIssuableSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ContingentlyIssuableSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2012-03-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2011-12-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Mar-2012_StatementEquityComponentsAxis_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2012-03-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2011-12-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Mar-2012_StatementEquityComponentsAxis_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2012-03-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_30-Sep-2011">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2011-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<!-- Unit Section  -->
	<xbrli:unit id="Shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
	<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
	<xbrli:unit id="USDPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
	<!-- Element Section  --><dei:EntityRegistrantName contextRef="Context_3ME_31-Mar-2012">TG THERAPEUTICS, INC.</dei:EntityRegistrantName>
	<dei:EntityCentralIndexKey contextRef="Context_3ME_31-Mar-2012">0001001316</dei:EntityCentralIndexKey>
	<dei:CurrentFiscalYearEndDate contextRef="Context_3ME_31-Mar-2012">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:EntityFilerCategory contextRef="Context_3ME_31-Mar-2012">Smaller Reporting Company</dei:EntityFilerCategory>
	<dei:TradingSymbol contextRef="Context_3ME_31-Mar-2012">tgtxd</dei:TradingSymbol>
	<dei:EntityCommonStockSharesOutstanding contextRef="Context_As_Of_10-May-2012" unitRef="Shares" decimals="0">14917658</dei:EntityCommonStockSharesOutstanding>
	<dei:DocumentType contextRef="Context_3ME_31-Mar-2012">10-Q</dei:DocumentType>
	<dei:AmendmentFlag contextRef="Context_3ME_31-Mar-2012">false</dei:AmendmentFlag>
	<dei:DocumentPeriodEndDate contextRef="Context_3ME_31-Mar-2012">2012-03-31</dei:DocumentPeriodEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="Context_3ME_31-Mar-2012">Q1</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="Context_3ME_31-Mar-2012">2012</dei:DocumentFiscalYearFocus>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="0">9748491</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">20923750</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30-Sep-2011" unitRef="USD" decimals="0">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:OtherAssetsCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="0">87176</us-gaap:OtherAssetsCurrent>
	<us-gaap:OtherAssetsCurrent contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">79030</us-gaap:OtherAssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="0">9835667</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">21002780</us-gaap:AssetsCurrent>
	<tgtxd:InProcessResearchAndDevelopment contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="0">5441839</tgtxd:InProcessResearchAndDevelopment>
	<tgtxd:InProcessResearchAndDevelopment contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">5441839</tgtxd:InProcessResearchAndDevelopment>
	<us-gaap:Goodwill contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="0">629752</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">629752</us-gaap:Goodwill>
	<us-gaap:Assets contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="0">15907258</us-gaap:Assets>
	<us-gaap:Assets contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">27074371</us-gaap:Assets>
	<us-gaap:NotesPayableCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="0">877778</us-gaap:NotesPayableCurrent>
	<us-gaap:NotesPayableCurrent contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">677778</us-gaap:NotesPayableCurrent>
	<us-gaap:OtherAccountsPayableAndAccruedLiabilities contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="0">666640</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
	<us-gaap:OtherAccountsPayableAndAccruedLiabilities contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">467524</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
	<us-gaap:InterestPayableCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="0">61941</us-gaap:InterestPayableCurrent>
	<us-gaap:InterestPayableCurrent contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">76793</us-gaap:InterestPayableCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="0">1606359</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">1222095</us-gaap:LiabilitiesCurrent>
	<us-gaap:LongTermNotesPayable contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="0">4664697</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">4664697</us-gaap:LongTermNotesPayable>
	<us-gaap:Liabilities contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="0">6271056</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">5886792</us-gaap:Liabilities>
	<us-gaap:PreferredStockValue contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="0">413</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">1109</us-gaap:PreferredStockValue>
	<us-gaap:CommonStockValue contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="0">5061</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">5061</us-gaap:CommonStockValue>
	<tgtxd:ContingentlyIssuableShares contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="0">6</tgtxd:ContingentlyIssuableShares>
	<tgtxd:ContingentlyIssuableShares contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">6</tgtxd:ContingentlyIssuableShares>
	<us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="0">10472115</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">22841334</us-gaap:AdditionalPaidInCapital>
	<us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="0">853074</us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage>
	<us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">11109164</us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage>
	<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="0">9624521</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">11738346</us-gaap:StockholdersEquity>
	<us-gaap:MinorityInterest contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="0">11681</us-gaap:MinorityInterest>
	<us-gaap:MinorityInterest contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">9449233</us-gaap:MinorityInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="0">9636202</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">21187579</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_PreferredStockMember" unitRef="USD" decimals="0">413</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31-Mar-2012_StatementEquityComponentsAxis_PreferredStockMember" unitRef="USD" decimals="0">1109</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">5061</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31-Mar-2012_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">5061</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">10472115</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31-Mar-2012_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">22841334</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_ContingentlyIssuableSharesMember" unitRef="USD" decimals="0">6</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31-Mar-2012_StatementEquityComponentsAxis_ContingentlyIssuableSharesMember" unitRef="USD" decimals="0">6</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" decimals="0">11681</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31-Mar-2012_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" decimals="0">9449233</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">-853074</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31-Mar-2012_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">-11109164</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="0">15907258</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">27074371</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_31-Dec-2011" unitRef="USDPerShare" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_31-Mar-2012" unitRef="USDPerShare" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_31-Dec-2011" unitRef="Shares" decimals="0">10000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_31-Mar-2012" unitRef="Shares" decimals="0">10000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_31-Dec-2011" unitRef="Shares" decimals="0">413388</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_31-Mar-2012" unitRef="Shares" decimals="0">1108816</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_31-Dec-2011" unitRef="Shares" decimals="0">413388</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_31-Mar-2012" unitRef="Shares" decimals="0">1108816</us-gaap:PreferredStockSharesOutstanding>
	<tgtxd:PreferredStockLiquidationPreferenceValue contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="0">8267760</tgtxd:PreferredStockLiquidationPreferenceValue>
	<tgtxd:PreferredStockLiquidationPreferenceValue contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="0">22176320</tgtxd:PreferredStockLiquidationPreferenceValue>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31-Dec-2011" unitRef="USDPerShare" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31-Mar-2012" unitRef="USDPerShare" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_31-Dec-2011" unitRef="Shares" decimals="0">500000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_31-Mar-2012" unitRef="Shares" decimals="0">500000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31-Dec-2011" unitRef="Shares" decimals="0">5061399</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31-Mar-2012" unitRef="Shares" decimals="0">5061399</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_31-Dec-2011" unitRef="Shares" decimals="0">5061399</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_31-Mar-2012" unitRef="Shares" decimals="0">5061399</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="0">16741353</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_6ME_31-Mar-2012" unitRef="USD" decimals="0">17068636</us-gaap:ResearchAndDevelopmentExpense>
	<tgtxd:NonCashCompensation contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="0">188509</tgtxd:NonCashCompensation>
	<tgtxd:NonCashCompensation contextRef="Context_6ME_31-Mar-2012" unitRef="USD" decimals="0">275003</tgtxd:NonCashCompensation>
	<us-gaap:OtherGeneralAndAdministrativeExpense contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="0">455492</us-gaap:OtherGeneralAndAdministrativeExpense>
	<us-gaap:OtherGeneralAndAdministrativeExpense contextRef="Context_6ME_31-Mar-2012" unitRef="USD" decimals="0">923689</us-gaap:OtherGeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="0">644001</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_6ME_31-Mar-2012" unitRef="USD" decimals="0">1198692</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:OperatingExpenses contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="0">17385354</us-gaap:OperatingExpenses><us-gaap:OperatingExpenses contextRef="Context_6ME_31-Mar-2012" unitRef="USD" decimals="0">18267328</us-gaap:OperatingExpenses><us-gaap:OperatingIncomeLoss contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="0">-17385354</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="Context_6ME_31-Mar-2012" unitRef="USD" decimals="0">-18267328</us-gaap:OperatingIncomeLoss>
	<us-gaap:InterestExpense contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="0">-220149</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="Context_6ME_31-Mar-2012" unitRef="USD" decimals="0">-227246</us-gaap:InterestExpense>
	<us-gaap:ProfitLoss contextRef="Context_6ME_31-Mar-2012" unitRef="USD" decimals="0">-18285609</us-gaap:ProfitLoss>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="0">-7140448</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="Context_6ME_31-Mar-2012" unitRef="USD" decimals="0">-7176445</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NetIncomeLoss contextRef="Context_6ME_31-Mar-2012" unitRef="USD" decimals="0">-11109164</us-gaap:NetIncomeLoss>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_3ME_31-Mar-2012" unitRef="USDPerShare" decimals="2">-2.03</us-gaap:EarningsPerShareBasicAndDiluted>
	<tgtxd:WeightedAverageNumberOfSharesBasicAndDiluted contextRef="Context_3ME_31-Mar-2012" unitRef="Shares" decimals="0">5061399</tgtxd:WeightedAverageNumberOfSharesBasicAndDiluted>
	<us-gaap:SharesOutstanding contextRef="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_PreferredStockMember" unitRef="Shares" decimals="0">413388</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="Context_As_Of_31-Mar-2012_StatementEquityComponentsAxis_PreferredStockMember" unitRef="Shares" decimals="0">1108816</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="Shares" decimals="0">5061399</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="Context_As_Of_31-Mar-2012_StatementEquityComponentsAxis_CommonStockMember" unitRef="Shares" decimals="0">5061399</us-gaap:SharesOutstanding>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="0">188509</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition><us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition contextRef="Context_3ME_31-Mar-2012_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">188509</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition><us-gaap:ShareBasedCompensation contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="0">188509</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="Context_6ME_31-Mar-2012" unitRef="USD" decimals="0">275003</us-gaap:ShareBasedCompensation>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="0">-8147</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Context_6ME_31-Mar-2012" unitRef="USD" decimals="0">-11740</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="0">-254604</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="Context_6ME_31-Mar-2012" unitRef="USD" decimals="0">153706</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="0">14852</us-gaap:IncreaseDecreaseInInterestPayableNet>
	<us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="Context_6ME_31-Mar-2012" unitRef="USD" decimals="0">21949</us-gaap:IncreaseDecreaseInInterestPayableNet>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="0">-861634</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_6ME_31-Mar-2012" unitRef="USD" decimals="0">-948211</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:CashAcquiredFromAcquisition contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="0">0</us-gaap:CashAcquiredFromAcquisition>
	<us-gaap:CashAcquiredFromAcquisition contextRef="Context_6ME_31-Mar-2012" unitRef="USD" decimals="0">10386</us-gaap:CashAcquiredFromAcquisition>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="0">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_6ME_31-Mar-2012" unitRef="USD" decimals="0">10386</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="0">12036893</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_6ME_31-Mar-2012" unitRef="USD" decimals="0">21861575</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="0">11175259</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_6ME_31-Mar-2012" unitRef="USD" decimals="0">20923750</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<tgtxd:ConversionOfNotesPayableToPreferredStock contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="0">0</tgtxd:ConversionOfNotesPayableToPreferredStock>
	<tgtxd:ConversionOfNotesPayableToPreferredStock contextRef="Context_6ME_31-Mar-2012" unitRef="USD" decimals="0">55271</tgtxd:ConversionOfNotesPayableToPreferredStock>
	<tgtxd:AccruedFinancingCosts contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="0">55487</tgtxd:AccruedFinancingCosts>
	<tgtxd:AccruedFinancingCosts contextRef="Context_6ME_31-Mar-2012" unitRef="USD" decimals="0">116626</tgtxd:AccruedFinancingCosts>
	<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="Context_3ME_31-Mar-2012">&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;NOTE 1 &amp;#8211; ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Description of Business&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;We are a biopharmaceutical company focused on the acquisition, development and commercialization of innovative and medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. We aim to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding their research and development and eventually either out-licensing or bringing the technologies to market. Currently we are developing TGTX-1101 (ublituximab), a novel, third generation monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. We also hold the development rights to AST-726, a nasally delivered product for the treatment of Vitamin B&lt;sub&gt;12&lt;/sub&gt; deficiency, and AST-915, an orally delivered treatment for essential tremor.&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The accompanying unaudited condensed consolidated financial statements were prepared in accordance with U.S. generally accepted accounting principles (&amp;#8220;GAAP&amp;#8221;) for interim financial information and with the instructions to Form 10-Q and Article&amp;#160;10 of Regulation&amp;#160;S-X. Accordingly, they may not include all of the information and footnotes required by GAAP for complete financial statements. All adjustments that are, in the opinion of management, of a normal recurring nature and are necessary for a fair presentation of the consolidated financial statements have been included. Nevertheless, these consolidated financial statements should be read in conjunction with the audited consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2011. The results of operations for the three months ended March 31, 2012 are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period.&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;On December 29, 2011, the Company entered into and consummated an exchange transaction agreement (the &amp;#8220;Exchange Transaction&amp;#8221;) with Opus Point Partners, LLC (&amp;#8220;Opus&amp;#8221;) and TG Biologics, Inc. (formerly known as TG Therapeutics, Inc.) (&amp;#8220;TG Bio&amp;#8221;). The stockholders of TG Bio received the majority of the voting shares of the Company, therefore, the merger was accounted for as a reverse acquisition whereby TG Bio was the accounting acquirer (legal acquiree) and the Company was the accounting acquiree (legal acquirer) under the acquisition method of accounting. TG Bio was incorporated in Delaware in November 2010, but did not commence operations until April 2011, thus the accompanying consolidated financial statements do not include comparative financial information for the three months ended March 31, 2011.&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;On April 30, 2012, the Company filed a Certificate of Amendment to its Certificate of Incorporation to change its name from Manhattan Pharmaceuticals, Inc. (&amp;#8220;Manhattan&amp;#8221;) to TG Therapeutics, Inc. In conjunction with this change, the subsidiary formerly named TG Therapeutics, Inc. filed a Certificate of Amendment changing its name to TG Biologics, Inc.&lt;/p&gt;
&lt;p style="text-align: left; background-color: white; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Liquidity and Capital Resources&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: left; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; background-color: white; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;We have incurred operating losses since our inception and expect to continue to incur operating losses for the foreseeable future and may never become profitable. As of March 31, 2012, we have an accumulated deficit of $11,109,164.&lt;/p&gt;
&lt;p style="text-align: left; background-color: white; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Our primary source of cash has been proceeds from the private placement of equity securities. We have not yet commercialized any of our drug candidates and cannot be sure if we will ever be able to do so. Even if we commercialize one or more of our drug candidates, we may not become profitable. Our ability to achieve profitability depends on a number of factors, including our ability to obtain regulatory approval for our drug candidates, successfully complete any post-approval regulatory obligations and successfully commercialize our drug candidates alone or in partnership. We may continue to incur substantial operating losses even if we begin to generate revenues from our drug candidates.&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;On December 30, 2011, we &lt;font style="color: black;"&gt;completed the first closing of the private placement of our securities, issuing 4,929,523 shares of Company &lt;/font&gt;$0.001 par value common stock&lt;font style="color: black;"&gt; (&amp;#8220;Common Stock &amp;#8220;) at a price per share of $2.25 for total gross proceeds, before placement commissions and expenses, of $11,091,425 (the &amp;#8220;2011 Equity PIPE&amp;#8221;).&amp;#160;Investors also received warrants to purchase 1,232,381 shares of Common Stock. The warrants have an exercise price of $2.25 per share and are exercisable for five years.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: left; text-indent:
 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;In 2012, we completed two additional closings of the 2011 Equity PIPE. These closings were held on January 31, 2012, and February 24, 2012. In these closings, the Company issued 695,428 shares of our Series A preferred stock (&amp;#8220;Company Preferred Stock&amp;#8221;) at a price per share of $20.00, for total gross proceeds, before placement commissions and expenses, of $13,908,560. E&lt;font style="background-color: white;"&gt;ach share of Company Preferred Stock is convertible into 8.89 shares of Common Stock, provided that such conversion rights are subject to sufficient available authorized shares of Common Stock.&lt;/font&gt; Investors also received warrants to purchase 1,545,396 shares of Common Stock. The warrants have an exercise price of $2.25 per share and are exercisable for five years.&amp;#160;&lt;font style="background-color: white;"&gt;The shares of Company Preferred Stock and warrants sold in these closings were offered and sold to accredited investors, including members of management, without registration under the Securities Act, or state securities laws, in reliance on the exemptions provided by Section&amp;#160;4(2) of the Securities Act, and Regulation&amp;#160;D promulgated thereunder and in reliance on similar exemptions under applicable state laws. Accordingly, the securities issued in the Offering have not been registered under the Securities Act, and until so registered, these securities may not be offered or sold in the United States absent registration or availability of an applicable exemption from registration.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Our Common Stock is quoted on &lt;font style="color: black;"&gt;the OTC Bulletin Board&lt;font style="font-family: times new roman, times, serif;"&gt; &lt;/font&gt;&lt;/font&gt;and trades under the symbol &amp;#8220;TGTX.OB.&amp;#8221;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Reverse Stock Split&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font style="background-color: white;"&gt;On April 30, 2012, the Company effected a reverse split of its Common Stock at a ratio of 56.25 for 1, pursuant to a previously obtained stockholder authorization. All share amounts and per share prices in this Quarterly Report on Form 10-Q have been retroactively adjusted to reflect the effect of our reverse stock split, on a fifty six and one quarter (56.25) for one (1) basis, unless otherwise indicated.&amp;#160;&amp;#160;The exercise price for all stock options and warrants and the conversion price for convertible securities in the accompanying condensed consolidated financial statements have been adjusted to reflect the reverse stock split by multiplying the original exercise or conversion price by fifty six and one quarter (56.25).&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;We treat liquid investments with original maturities of less than three months when purchased as cash and cash equivalents.&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Research and Development Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Research and development costs are expensed as incurred. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and amortized over the period that the goods are delivered or the related services are performed, subject to an assessment of recoverability. We make estimates of costs incurred in relation to external clinical research organizations, or CROs, and clinical site costs. We analyze the progress of clinical trials, including levels of patient enrollment, invoices received and contracted costs when evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability. Significant judgments and estimates must be made and used in determining the accrued balance and expense in any accounting period. We review and accrue CRO expenses and clinical trial study expenses based on work performed and rely upon estimates of those costs applicable to the stage of completion of a study. Accrued CRO costs are subject to revisions as such trials progress to completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. With respect to clinical site costs, the financial terms of these agreements are subject to negotiation and vary from contract to contract. Payments under these contracts may be uneven, and depend on factors such as the achievement of certain events, the successful recruitment of patients, the completion of portions of the clinical trial or similar conditions. The objective of our policy is to match the recording of expenses in our financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical site costs are recognized based on our estimate of the degree of completion of the event or events specified in the specific clinical study or trial contract.&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;In-Process Research and Development&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin-top: 0px; text-indent: 0.5in; font: italic 10pt times new roman, times, serif; margin-bottom: 6pt; margin-left: 0in;"&gt;&lt;font style="font-style: normal; font-weight: normal;"&gt;All
 acquired research and development projects are recorded at their fair value as of the date acquisition. The fair values are assessed annually in the fourth quarter to ascertain if there has been any impairment of the recorded value. If there is an impairment, the asset is written down to its current fair value by the recording of an expense. Impairment testing consists of a comparison of the fair value of the in-process research and development with its carrying amount.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, operating losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. If the likelihood of realizing the deferred tax assets or liability is less than &amp;#8220;more likely than not,&amp;#8221; a valuation allowance is then created.&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;We, and our subsidiaries, file income tax returns in the U.S. Federal jurisdiction and in various states. We have tax net operating loss carryforwards that are subject to examination for a number of years beyond the year in which they were generated for tax purposes. Since a portion of these net operating loss carryforwards may be utilized in the future, many of these net operating loss carryforwards will remain subject to examination.&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;We recognize interest and penalties related to uncertain income tax positions in income tax expense.&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;We recognize all share-based payments to employees and to non-employee directors as compensation for service on our board of directors as compensation expense in the consolidated financial statements based on the fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;For share-based payments to consultants and other third-parties, compensation expense is determined at the &amp;#8220;measurement date.&amp;#8221; The expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. We record compensation expense based on the fair value of the award at the reporting date. The awards to consultants and other third-parties are then revalued, or the total compensation is recalculated based on the then current fair value, at each subsequent reporting date.&lt;/p&gt;
&lt;p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Basic and Diluted Net (Loss) Income Per Share of Common Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Basic net income (loss) per share of Common Stock is calculated by dividing net income (loss) applicable to the Common Stock by the weighted-average number of the Common Stock outstanding for the period. Diluted net loss per share of Common Stock is the same as basic net income (loss) per share of Common Stock since potentially dilutive securities from stock options, stock warrants and convertible preferred stock would have an antidilutive effect either because the Company incurred a net loss during the period presented or because such potentially dilutive securities were out of the money and the Company realized net income during the period presented. The amounts of potentially dilutive securities excluded from the calculation were 14,154,452 at March 31, 2012. During the three months ended March 31, 2012, the Company incurred a net loss; therefore, all of the dilutive securities are excluded from the computation of diluted earnings per share.&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Impairment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Long lived assets are reviewed for an impairment loss when circumstances indicate that the carrying value of long-lived tangible and intangible assets with finite lives may not be recoverable. Management&amp;#8217;s policy in determining whether an impairment indicator exists, a triggering event, comprises measurable operating performance criteria as well as qualitative measures. If an analysis is necessitated by the occurrence of a triggering event, we make certain assumptions in
 determining the impairment amount. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized for the difference between the carrying value and the estimated fair value.&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Goodwill is reviewed for impairment annually or when events arise that could indicate that an impairment exists. We test for goodwill impairment using a two-step process. The first step compares the fair value of the reporting unit with the unit's carrying value, including goodwill. When the carrying value of the reporting unit is greater than fair value, the unit&amp;#8217;s goodwill may be impaired, and the second step must be completed to measure the amount of the goodwill impairment charge, if any. In the second step, the implied fair value of the reporting unit&amp;#8217;s goodwill is compared with the carrying amount of the unit&amp;#8217;s goodwill. If the carrying amount is greater than the implied fair value, the carrying value of the goodwill must be written down to its implied fair value. We will continue to perform impairment tests annually at December 31 and whenever events or changes in circumstances suggest that the carrying value of goodwill may not be recoverable.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
	<us-gaap:BusinessCombinationDisclosureTextBlock contextRef="Context_3ME_31-Mar-2012">&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;NOTE 3 - ACQUISITION&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;On December 29, 2011, the Company completed a reverse acquisition of privately held TG Bio, a Delaware Corporation. The acquisition was effected pursuant to an Exchange Transaction Agreement (the &amp;#8220;Agreement&amp;#8221;) dated December 29, 2011 by and among the Company, TG Bio and Opus, the largest shareholder of TG Bio. In accordance with the terms of the Agreement, 95% of the holders of common stock of TG Bio (one (1) minority shareholder of TG Bio holding in aggregate 132,000 shares of common stock of TG Bio did not participate) surrendered their TG Bio common stock. The Agreement caused the Company to issue to TG Bio&amp;#8217;s shareholders 281,250 shares of Company Preferred Stock. &lt;font style="background-color: white; color: black;"&gt;Each share of Company Preferred Stock is convertible into 8.89 shares of the Common Stock provided that such conversion rights are subject to sufficient available authorized shares of Common Stock. &lt;/font&gt;The Company Preferred Stock has the same voting rights (on an as-converted basis), and other attributes as Common Stock. The Company Preferred Stock will automatically be exchanged for Common Stock when sufficient authorized shares are available to allow for such conversion. The Company Preferred Stock issued in connection with the Agreement, provided the former TG Bio shareholders with direct and/or indirect ownership of approximately 95% of the Company&amp;#8217;s outstanding Company Common Stock immediately following the consummation of the transaction.&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company Preferred Stock issued (and the underlying Common Stock once converted) are not registered for resale and, therefore, shall remain subject to the rights and restrictions of Rule 144. All Company Preferred Stock received by the TG Bio shareholders in exchange for their shares of TG Bio common stock will not be registered for resale prior to six (6) months following December 29, 2011 and, therefore, shall remain subject to the rights and restrictions of Rule 144 prior to any such registration.&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company Preferred Stock issued in connection with the agreement provided the former TG Bio shareholders with direct and/or indirect ownership of approximately 95% of the Company&amp;#8217;s outstanding common stock as of December 29, 2011. Based on fair value of the Company&amp;#8217;s Common Stock of $0.04 per share, the purchase price was $295,933, plus the fair value of restricted stock assumed of $82,305. In connection with the Exchange Transaction, the Company incurred $231,580 of acquisition related costs.&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;A summary of the purchase price calculation is as follows:&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 70%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.5in;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; text-indent: -12.6pt; padding-left: 12.6pt; width: 74%;"&gt;Number of shares of Manhattan common stock outstanding at the time of the transaction&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;131,526&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in;"&gt;Multiplied by Manhattan&amp;#8217;s fair value of the Common Stock&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;2.25&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 1pt;"&gt;295,933&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Fair value of restricted stock assumed&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;82,305&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 12.6pt;"&gt;Total purchase price&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;378,238&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The purchase price has been allocated as follows based on the fair values of the assets and liabilities acquired:&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 70%;
 border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.5in;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in; width: 87%;"&gt;Cash and cash equivalents&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;10,386&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in;"&gt;Other assets&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;90,769&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; text-indent: -0.25in; padding-left: 0.25in;"&gt;In-process research and development acquired&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;5,441,840&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; text-indent: -0.25in; padding-left: 0.36in;"&gt;Total identifiable assets&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;5,542,995&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in;"&gt;Accounts payable and accrued expenses&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;197,191&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in;"&gt;Notes payable (ICON and Swiss Pharma)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;939,718&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; text-indent: -0.25in; padding-left: 0.25in;"&gt;5% notes payable and accrued interest&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;4,657,600&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; text-indent: -0.25in; padding-left: 0.36in;"&gt;Total identifiable liabilities&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;5,794,509&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in;"&gt;Net identifiable liabilities&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(251,514&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; text-indent: -0.25in; padding-left: 0.25in;"&gt;Goodwill&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;629,752&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; text-indent: -0.25in; padding-left: 0.36in;"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;378,238&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;A valuation was performed to determine the fair value of certain identifiable intangible assets of Manhattan.&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The fair value of certain identifiable intangible assets was determined using the income approach. This method starts with a forecast of the expected future net cash flows. These cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk of achieving the asset&amp;#8217;s projected cash flows. The present value of the estimated cash flows are then added to the present value equivalent of the residual value of the asset, if any, at the end of the discrete projection period to estimate the fair value.&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The valuations are based on information that is available as of the acquisition date and the expectations and assumptions that have been deemed reasonable by our management. No assurance can be given, however, that the underlying assumptions or events associated with such assets will occur as projected. For these reasons, among others, the actual results may vary from the projected results.&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The following supplemental pro forma information presents the financial results as if the transaction had occurred on January 1, 2011 for the three months ended March 31, 2011.&amp;#160;This supplemental pro forma information has been prepared for comparative purposes and does not purport to be indicative of what would have occurred had the acquisition been made on January 1, 2011, nor are they indicative of future results.&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font:
 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 60%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.5in;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Revenue&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; width: 82%;"&gt;Net income&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right; width: 15%;"&gt;3,832,383&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Basic and diluted income per common share&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1.51&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="Context_3ME_31-Mar-2012">&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;NOTE 4 - STOCKHOLDERS' EQUITY&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Our amended and restated certificate of incorporation authorizes the issuance of up to 10,000,000 shares of preferred stock, $0.001 par value, with rights senior to those of our common stock, &lt;font style="background-color: white; color: black;"&gt;issuable in one or more series. Upon issuance, the Company can determine the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of common stock.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font style="background-color: white; color: black;"&gt;There were 1,108,816 shares of Company Preferred Stock outstanding as of March 31, 2012. &lt;/font&gt;In connection with the Exchange Transaction, the Company filed a Certificate of Designation with respect to its Company Preferred Stock with the Secretary of State of the State of Delaware.&amp;#160;&amp;#160;The Company Preferred Stock ranks senior to the Common Stock with regard to dividend rights, and has a liquidation preference of $20 per share over the Common Stock and any other junior securities.&amp;#160;The Company Preferred Stock is automatically convertible into 8.89 shares of Common Stock provided that, prior to conversion, the Company has sufficient authorized Common Stock to effect such conversion.&amp;#160;&amp;#160;The Company Preferred Stock also automatically converts upon a change of control of the Company or the sale of substantially all of the assets of the Company.&amp;#160;&amp;#160;The Company Preferred Stock votes on an as-converted basis with the Common Stock.&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;In conjunction with the reverse split effected on April 30, 2012 (as discussed in Note 1), our Company Preferred Stock automatically converted to 9,856,259 shares of Common Stock as of that date.&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Common Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Our amended and restated certificate of incorporation authorizes the issuance of up to 500,000,000 shares of $0.001 par value common stock.&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;On December 30, 2011, we &lt;font style="color: black;"&gt;completed the first closing of the private placement of our securities, issuing 4,929,523 shares of Common Stock at a price per share of $2.25 for total gross proceeds, before placement commissions and expenses, of $11,091,425 (the &amp;#8220;2011 Equity PIPE&amp;#8221;).&amp;#160;Investors also received warrants to purchase 1,232,381 shares of Common Stock. The warrants have an exercise price of $2.25 per share and are exercisable for five years.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;In 2012, we completed two additional closings of the 2011 Equity PIPE. These closings were held on January 31, 2012, and February 24, 2012. In these closings, the Company issued 695,428 shares of our Company Preferred Stock at a price per share of $20.00 for total gross proceeds, before placement commissions and expenses, of $13,908,560. E&lt;font style="background-color: white;"&gt;ach share of Company Preferred Stock is convertible into 8.89 shares of Common Stock provided that such conversion rights are subject to sufficient available authorized shares of Common Stock.&lt;/font&gt; Investors also received warrants to purchase 1,545,396 shares of Common Stock. The warrants have an exercise price of $2.25 per share and are exercisable for five years.&amp;#160;&lt;font style="background-color: white;"&gt;The shares of Company Preferred Stock and warrants sold in these closings were offered and sold to accredited investors, including members of management, without registration under the Securities Act, or state securities laws, in reliance on the exemptions provided by Section&amp;#160;4(2) of the Securities Act, and Regulation&amp;#160;D promulgated thereunder and in reliance on similar exemptions under applicable state laws. Accordingly, the securities issued in the offering have not been registered under the Securities Act, and until so registered, these securities may not be offered or sold in the United States absent registration or availability of an applicable exemption from registration. The placement agent received cash commissions equal to 10% of the gross proceeds of the offering, five-year warrants to purchase shares of the Company&amp;#8217;s stock equal to 10% of shares sold in the offering, and a non-accountable expense allowance equal to two percent of the gross proceeds of the offering for their expenses.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font style="background-color: white;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Equity Incentive Plans&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;A summary of the status of the Company&amp;#8217;s stock options as of March 31, 2012 and changes during the period then ended is presented
 below:&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;/p&gt;
&lt;p style="margin: 0px;"&gt;&lt;/p&gt;
&lt;p style="margin: 0px;"&gt;&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;u&gt;Stock Options&lt;/u&gt;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The following table summarizes stock option activity for the three months ended March 31, 2012:&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;of&amp;#160;shares&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;average&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;exercise&amp;#160;price&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;average&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;Term&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;Intrinsic&lt;br /&gt;Value&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2"&gt;(in years)&lt;/td&gt;
&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; width: 48%;"&gt;Outstanding at December 31, 2011&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;3,379&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;1,315.62&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;6.39&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-left: 9pt;"&gt;Granted&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-left: 9pt;"&gt;Exercised&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-left: 9pt;"&gt;Forfeited&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(2,475&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;720.45&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td
 style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt;"&gt;Expired&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 1pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Outstanding at March 31, 2012&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;904&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;2,945.09&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;2.49&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Vested and expected to vest at March 31, 2012&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;904&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;2,945.09&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;2.49&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Exercisable at March 31, 2012&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;898&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;2,963.46&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;2.43&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;As of March 31, 2012, the total compensation cost related to unvested option awards not yet recognized is less than $1,000. The weighted average period over which it is expected to be recognized is approximately 1 year.&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;u&gt;Restricted Stock&lt;/u&gt;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Certain employees have been awarded restricted Company Preferred Stock. The restricted stock vesting consists of milestone and time-based vesting. The following table summarizes restricted share activity for the three months ended March 31, 2012:&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td
 style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid;" colspan="2"&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;Number&amp;#160;of Shares&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;Restricted&amp;#160;Series&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;A Preferred&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;Stock&lt;sup&gt;(1)&lt;/sup&gt;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid;" colspan="2"&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;Weighted&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;Grant&amp;#160;Date&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid;" colspan="2"&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="width: 45%;"&gt;Outstanding at December 31, 2011&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 15%;"&gt;129,375&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 15%;"&gt;20.00&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 15%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="padding-left: 9pt;"&gt;Granted&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="padding-left: 9pt;"&gt;Vested&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 1pt; padding-left: 9pt;"&gt;Forfeited&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 1pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 2.25pt;"&gt;Outstanding at March 31, 2012&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.25pt double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.25pt double; text-align: right;"&gt;129,375&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.25pt double;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.25pt double; text-align: right;"&gt;20.00&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.25pt double;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.25pt double; text-align: right;"&gt;7,762,500&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: left; text-indent: -1pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;&lt;b&gt;&lt;sup&gt;(1) &lt;/sup&gt;&lt;/b&gt;&lt;/font&gt;The restricted Company Preferred Stock listed in the table above was granted in connection with the Exchange Transaction to certain executives as discussed above. Each share of Company Preferred Stock is convertible into 8.89 shares of the Company&amp;#8217;s Common Stock, provided that such conversion right is subject to sufficient available authorized shares of the registrant&amp;#8217;s common stock.&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Total expense associated with restricted stock was $188,509 during the three months ended March 31, 2012.&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;u&gt;Warrants&lt;/u&gt;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The following table summarizes warrant activity for the three months ended March 31, 2012:&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="padding-bottom:
 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid;" colspan="2"&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid;" colspan="2"&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;average&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;exercise price&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"&gt;&lt;b&gt;Aggregate&lt;br /&gt;Intrinsic &lt;br /&gt;Value&lt;/b&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="width: 45%;"&gt;Outstanding at December 31, 2011&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 15%;"&gt;2,118,768&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 15%;"&gt;4.62&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 15%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="padding-left: 9pt;"&gt;Issued&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;2,163,555&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;2.31&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="padding-left: 9pt;"&gt;Exercised&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom; text-decoration: none;"&gt;
&lt;td style="padding-bottom: 1pt; padding-left: 9pt; text-decoration: none;"&gt;Expired&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; text-decoration: none;"&gt;(1,449&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-decoration: none;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-decoration: none;"&gt;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 1pt; text-decoration: none;"&gt;2,812.50&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-decoration: none;"&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-decoration: none;"&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-decoration: none;"&gt;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 1pt; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 2.25pt;"&gt;Outstanding at March 31, 2012&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.25pt double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.25pt double; text-align: right;"&gt;4,280,874&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.25pt double;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.25pt double; text-align: right;"&gt;2.50&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.25pt double;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.25pt double; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;During the three months ended March 31, 2011, as part of the 2011 Equity PIPE, we issued warrants to purchase up to 1,545,396 shares of our Company Common Stock to investors in the 2011 Equity PIPE, none of which have been exercised as of March 31, 2012. The warrants have an exercise price of $2.25 per warrant share. In addition, we issued to the placement agent in the transaction warrants to purchase up to 618,159 shares of our Company Common Stock at an exercise price of $2.48 per warrant share, none of which have been exercised as of March 31, 2012.&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The fair value of stock options granted is estimated at the date of grant using the Black-Scholes pricing model. The expected term of options granted is derived from historical data and the expected vesting period. Expected volatility is based on the historical volatility of our common stock. The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. We have assumed no expected dividend yield, as dividends have never been paid to stock or option holders and will not be paid for the foreseeable future. The Company did not grant any stock options during the three months ended March 31, 2012.&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The following table summarizes stock-based compensation
 expense information about stock options and restricted stock for the three months ended March 31, 2012:&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; text-indent: -14.2pt; padding-left: 14.2pt; width: 87%;"&gt;Stock-based compensation expense associated with restricted stock&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;188,509&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; text-indent: -14.2pt; padding-left: 14.2pt;"&gt;Stock-based compensation expense associated with option grants&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -14.2pt; padding-left: 14.2pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;188,509&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:DebtDisclosureTextBlock contextRef="Context_3ME_31-Mar-2012">&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;NOTE 5 &amp;#8211; NOTES PAYABLE&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The following is a summary of notes payable:&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="10"&gt;March&amp;#160;31,&amp;#160;2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="10"&gt;December&amp;#160;31,&amp;#160;2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Current &lt;br /&gt;portion,&amp;#160;net&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Non- &lt;br /&gt;current &lt;br /&gt;portion,&amp;#160;net&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Current &lt;br /&gt;portion,&amp;#160;net&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Non- &lt;br /&gt;current &lt;br /&gt;portion,&amp;#160;net&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; width: 40%;"&gt;Non-interest Bearing Note Payable, Net&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 7%;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 7%;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 7%;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 7%;"&gt;200,000&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 7%;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 7%;"&gt;200,000&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Convertible 5% Notes Payable&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;4,664,697&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;4,664,697&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;4,664,697&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;4,664,697&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;ICON Convertible Note&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;677,778&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;677,778&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;677,778&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align:
 right;"&gt;677,778&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt;"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;677,778&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;4,664,697&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;5,342,475&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;877,778&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;4,664,697&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;5,542,475&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;We assumed the preceding notes payable as the result of the Exchange Transaction. Accordingly, a valuation was performed and these notes have been presented at their fair value on the date of the transaction.&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Non-Interest Bearing Note Payable&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;In October 2009, Manhattan entered into a Settlement Agreement and Mutual Release with Swiss Pharma Contract LTD (&amp;#8220;Swiss Pharma&amp;#8221;) pursuant to which Manhattan agreed to pay Swiss Pharma $200,000 and issue to Swiss Pharma an interest free promissory note due on October 27, 2011 in the principal amount of $250,000 in full satisfaction of a September 5, 2008 arbitration award. In November 2011, Manhattan renegotiated the $250,000 promissory note due October 27, 2011 in which the amount of the promissory note was reduced to $200,000 and the maturity date was extended to February 15, 2012. This amount was paid on February 14, 2012 in full settlement of this note.&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Convertible 5% Notes Payable&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;On March 8, 2010, Manhattan entered into an Agreement and Plan of Merger (the "Merger Agreement") by and among the Company, Ariston Pharmaceuticals, Inc., a Delaware corporation ("Ariston") and Ariston Merger Corp., a Delaware corporation and wholly-owned subsidiary of the Company (the "Merger Sub").&amp;#160; Pursuant to the terms and conditions set forth in the Merger Agreement, on March 8, 2010, the Merger Sub merged with and into Ariston (the "Merger"), with Ariston being the surviving corporation of the Merger.&amp;#160; As a result of the Merger, Ariston became a wholly-owned subsidiary of the Company.&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The 5% Notes and accrued and unpaid interest thereon are convertible at the option of the holder into Common Stock at the conversion price of $1,125 per share.&amp;#160;&amp;#160;Ariston agreed to make quarterly payments on the 5% Notes equal to 50% of the net product cash flow received from the exploitation or commercialization of Ariston&amp;#8217;s product candidates, AST-726 and AST-915.&amp;#160;&amp;#160;&lt;font style="color: black;"&gt;The Company has no obligations under the 5% Notes aside from a) 50% of the net product cash flows from Ariston&amp;#8217;s product candidates, if any, payable to noteholders; and b) the conversion feature, discussed above.&lt;/font&gt; Interest accrues monthly, is added to principal on an annual basis, every March 8, and is payable at maturity.&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;In connection with the Exchange Transaction in December 2011, the Company performed a valuation of the assets and liabilities of Manhattan immediately prior to the transaction. &lt;font style="color: black;"&gt;The cumulative liability including accrued and unpaid interest of these notes was approximately $16,876,000 immediately prior to the Exchange Transaction, $16,883,000 at December 31, 2011, and $17,089,000 at March 31, 2012. &lt;/font&gt;As these notes payable are tied directly to net product cash flows derived from the preexisting products of the Company, this note and accrued interest was recorded at fair value as of the date of the Exchange Transaction. No payments have been made on these notes as of March 31, 2012. See Note 2 for further details.&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;ICON Convertible Note Payable&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;In connection with the merger with Ariston as discussed above, Ariston satisfied an account payable of $1,275,188 to ICON
 Clinical Research Limited (&amp;#8220;ICON&amp;#8221;) through the payment of $275,188 in cash and the issuance of a three-year 5% note payable (the &amp;#8220;ICON Note&amp;#8221;).&amp;#160;&amp;#160;The principal was to be repaid in 36 monthly installments of $27,778 commencing in April 2010.&amp;#160;&amp;#160;Interest was payable monthly in arrears. &amp;#160;&amp;#160;On March 1, 2011, Ariston entered into an amended and restated convertible promissory note (the &amp;#8220;Amended ICON Note&amp;#8221;) with ICON. The principal terms of the Amended ICON Note are that monthly payments of principal and interest will be waived for the thirteen month period ended December 31, 2011 (the &amp;#8220;Waiver Period&amp;#8221;) in exchange for a single payment of $100,000 on March 31, 2011, an increase in the interest on the Amended ICON Note from 5% to 8% per annum during the Waiver Period and a balloon payment on January 31, 2012. The Amended ICON Note is convertible at the option of the holder into the Company&amp;#8217;s Common Stock at the conversion price of $562.50 per share. During the three months ended March 31, 2012, the Company recorded $14,852 of interest expense on the Amended ICON Note. At March 31, 2012, the principal amount of the Amended ICON Note was $677,778, of which the entire balance has been classified as current, and interest payable on the Amended ICON Note was $76,793, and is reflected as notes payable, current portion, net, and interest payable, current portion, net, respectively, in the accompanying balance sheet as of March 31, 2012. This note is currently in default as the Company did not make the balloon payment due on January 31, 2012, or the monthly installment payments due in February 2012 and March 2012. The Company is currently attempting to negotiate a settlement or alternative arrangement in satisfaction of this note.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
	<tgtxd:LicenseAgreementDisclosureTextBlock contextRef="Context_3ME_31-Mar-2012">&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;NOTE 6 &amp;#8211; LICENSE AGREEMENTS&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;In April 2011, TG Bio, acquired from LFB Biotechnologies, a fully owned subsidiary of France based LFB S.A., an option (the &amp;#8220;License Option&amp;#8221;) for exclusive worldwide rights (except France/Belgium) to develop and market ublituximab (&amp;#8220;TGTX-1101&amp;#8221;), a monoclonal antibody that targets a specific epitope on the B-cell lymphocyte CD20 antigen. In exchange for the License Option, TG Bio issued 132,000 shares of its common stock to LFB.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font style="color: black;"&gt;On January 30, 2012, TG Bio exercised the License Option and &lt;/font&gt;entered into an exclusive license agreement with LFB Biotechnologies, GTC Biotherapeutics and LFB/GTC LLC, all wholly-owned subsidiaries of LFB Group, relating to the development of ublituximab (the &amp;#8220;License Agreement&amp;#8221;)&lt;font style="color: black;"&gt;. &lt;/font&gt;Under the License Agreement, we have acquired the exclusive worldwide rights (exclusive of France/Belgium) for the development and commercialization of TGTX-1101 (ublituximab). To date, we have made no payments to LFB Group and LFB Group is eligible to receive payments of up to an aggregate of approximately $31.0 million upon our successful achievement of certain clinical development, regulatory and sales milestones, in addition to royalty payments on net sales of ublituximab. The license will terminate on a country by country basis upon the expiration of the last licensed patent right or 15 years after the first commercial sale of a product in such country, unless the agreement is earlier terminated.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;In connection with the license agreement, our subsidiary TG Biologics issued 7,368,000 shares of its common stock to LFB, and the Company agreed to contribute $15 million, less applicable fees and expenses associated with the financing, to TG Bio to fund the development of ublituximab under the License Agreement in exchange for 7,500,000 shares of TG Bio common stock. The Company recognized approximately $16,578,000 of non-cash research and development expense during the three months ended March 31, 2012 in connection with the issuance of these shares. In addition, in connection with the issuance of 7,368,000 shares of TG Bio common stock, the Company and TG Bio provided LFB Group the option to,&amp;#160;in its sole discretion, elect to convert all, and not less than all, of the shares of TG Bio common stock into 7,500,000 shares of the Company&amp;#8217;s Common Stock. This option may be exercised by LFB Group at any time before May 14, 2012.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Furthermore, should LFB Group choose to exercise the option for Company Common Stock, the Board of Directors of the Company shall appoint&amp;#160;an individual designated by LFB Group to serve as a director of the Company until the next annual meeting of the stockholders and until his or her successor has been duly elected. Thereafter the Board of Directors of the Company shall nominate a designee named by LFB Group for election at each annual meeting of the stockholders until such time as LFB Group owns less than 10% of the outstanding Company Common Stock.&lt;/p&gt;</tgtxd:LicenseAgreementDisclosureTextBlock>
	<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="Context_3ME_31-Mar-2012">&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;NOTE 7 &amp;#8211; RELATED PARTY TRANSACTIONS&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;On December 30, 2011, OPN Capital Markets (&amp;#8220;OPNCM&amp;#8221;) and its affiliated broker-dealer, National Securities Corporation (&amp;#8220;NSC&amp;#8221; and collectively with OPNCM, &amp;#8220;National&amp;#8221;), both affiliates of National Holdings Corporation (&amp;#8220;National Holdings&amp;#8221;), entered into a Placement Agency Agreement (the &amp;#8220;PAA&amp;#8221;) with the Company in connection with the initial closing of the 2011 Equity PIPE, offering of up to $25 million of stock and warrants of the Company.&amp;#160;&amp;#160;Pursuant to the PAA, National acted as the Company&amp;#8217;s placement agent for 2011 Equity PIPE.&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Until April 2012, Michael S. Weiss was a director and Non-Executive Chairman of the Board of Directors of National Holdings.&amp;#160;&amp;#160;He is also a stockholder of National Holdings and, when combined with his ownership indirectly through Opus and its affiliates, beneficially owns 23.6% of National Holdings, the parent company of NSC.&amp;#160;Mr. Weiss disclaims such beneficiary ownership other than to the extent of his pecuniary interest. In addition, at the time, Opus and NSC were parties to a 50/50 joint venture that shared profits from OPNCM, the investment banking division of NSC that was responsible for managing the Offering. This joint venture was dissolved in April 2012.&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; background-color: white; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;The Company completed the initial closing of the 2011 Equity PIPE on December 30, 2011, &lt;/font&gt;&lt;font style="color: black;"&gt;issuing 4,929,523 shares of Common Stock at a price per share of $2.25 for total gross proceeds, before placement commissions and expenses, of $11,091,425 (the &amp;#8220;2011 Equity PIPE&amp;#8221;).&amp;#160;Investors also received warrants to purchase 1,232,381 shares of Common Stock. The warrants have an exercise price of $2.25 per share and are exercisable for five years&lt;/font&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;. The Company &lt;/font&gt;&lt;font style="color: black;"&gt;completed two additional closings of the 2011 Equity PIPE. These closings were held on January 31, 2012 and February 24, 2012. In these closings, the Company issued 695,428 shares of our Company Preferred Stock (&amp;#8220;Preferred Stock&amp;#8221;) at a price per share of $20.00 for total gross proceeds, before placement commissions and expenses, of $13,908,560. Each share of Company Preferred Stock is convertible into 8.89 shares of Common Stock provided that such conversion rights are subject to sufficient available authorized shares of Common Stock. Investors will also receive warrants to purchase 1,545,396 shares of Common Stock. The warrants have an exercise price of $2.25 per share and are exercisable for five years.&amp;#160; &lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; margin-top: 0px; text-indent: 0.5in; font: 10pt times new roman, times, serif; margin-bottom: 6pt; margin-left: 0in;"&gt;As placement agent, National received cash commissions equal to 10% of the gross proceeds of the 2011 Equity PIPE, five-year warrants to purchase shares of Company Preferred Stock equal to 10% of shares sold in the 2011 Equity PIPE, and a non-accountable expense allowance equal to two percent of the gross proceeds of the 2011 Equity PIPE for National&amp;#8217;s expenses (not including up to $80,000 of National&amp;#8217;s legal expenses and any blue sky fees, both of which the Company also reimbursed).&amp;#160;In addition to acting as placement, National provided advisory services in connection with the Exchange Transaction and received an advisory fee of $150,000 for such services.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
	<us-gaap:SubsequentEventsTextBlock contextRef="Context_3ME_31-Mar-2012">&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;NOTE 8 &amp;#8211; SUBSEQUENT EVENTS&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;On April 30, 2012, the Company filed a Certificate of Amendment to its Certificate of Incorporation to change its name from Manhattan Pharmaceuticals, Inc. to TG Therapeutics, Inc. In conjunction with this change, the subsidiary formerly named TG Therapeutics, Inc. filed a Certificate of Amendment changing its name to TG Biologics, Inc.&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;On April 30, 2012, the Company effected a reverse split of its Common Stock at a ratio of 56.25 for 1, pursuant to a previously obtained shareholder authorization. All share amounts and per share prices in this Quarterly Report on Form 10-Q have been retroactively adjusted to reflect the effect of our reverse stock split, on a fifty six and one quarter (56.25) for one (1) basis, unless otherwise indicated.&amp;#160;&amp;#160;The exercise price for all stock options and warrants and the conversion price for convertible securities in the accompanying condensed consolidated financial statements have been adjusted to reflect the reverse stock split by multiplying the original exercise or conversion price by fifty six and one quarter (56.25).&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
	<us-gaap:FairValueDisclosuresTextBlock contextRef="Context_3ME_31-Mar-2012">&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;NOTE 2 &amp;#8211; FAIR VALUE MEASUREMENTS&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;We measure certain financial assets and liabilities at fair value on a recurring basis in the financial statements. The hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires financial assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="margin-top: 0pt; width: 100%; font: 10pt times new roman, times, serif; margin-bottom: 0pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.5in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;Level 1 &amp;#8211; quoted prices in active markets for identical assets and liabilities;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: left; margin: 0pt 0px 0pt 0.25in; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="margin-top: 0pt; width: 100%; font: 10pt times new roman, times, serif; margin-bottom: 0pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.5in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;Level 2 &amp;#8211; inputs other than Level 1 quoted prices that are directly or indirectly observable; and&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: left; margin: 0pt 0px 0pt 0.25in; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="margin-top: 0pt; width: 100%; font: 10pt times new roman, times, serif; margin-bottom: 0pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.5in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.25in;"&gt;&lt;font style="font-family: symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;Level 3 &amp;#8211; unobservable inputs that are not corroborated by market data.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;As of December 31, 2011 and March 31, 2012, the fair values of cash and cash equivalents, other current assets, notes and interest payable, current portion, accounts payable and accrued expenses, and interest payable, noncurrent approximate their carrying value.&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font style="background-color: white;"&gt;Upon the merger between Manhattan and Ariston Pharmaceuticals, Inc. (&amp;#8220;Ariston&amp;#8221;) in March 2010, Ariston issued $15,452,793 of five-year 5% notes payable (the &amp;#8220;5% Notes&amp;#8221;) in satisfaction of several note payable issuances.&amp;#160;&amp;#160;The 5% Notes and accrued and unpaid interest thereon are convertible at the option of the holder into Common Stock at the conversion price of $1,125 per share.&amp;#160;&amp;#160;Ariston agreed to make quarterly payments on the 5% Notes&amp;#160;equal to 50% of the net product cash flow received from the exploitation or commercialization of Ariston&amp;#8217;s product candidates, AST-726 and AST-915.&amp;#160;&amp;#160;The Company has no obligations under the 5% Notes aside from a) 50% of the net product cash flows from Ariston&amp;#8217;s product candidates, if any, payable to noteholders; and b) the conversion feature, discussed above.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;In connection with the Exchange Transaction in December 2011, the Company performed a valuation of the assets and liabilities of Manhattan immediately prior to the transaction. &lt;font style="background-color: white; color: black;"&gt;The cumulative liability including accrued and unpaid interest of these notes was approximately $16,876,000 immediately prior to the Exchange Transaction, $16,883,000 at December 31, 2011, and $17,089,000 at March 31, 2012. &lt;/font&gt;As these notes payable are tied directly to net product cash flows derived from the preexisting products of the Company, this note and accrued interest was recorded at fair value of $4,664,697 as of the date of the Exchange Transaction. No payments have been made on these notes as of March 31, 2012.&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;We elected the fair value option for valuing our the 5% Notes upon the completion of the reverse merger with TG Bio, as discussed above. The Company elected the fair value option in order to reflect in our financial statements the assumptions that market participants use in evaluating these financial instruments.&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The valuation methods used to estimate the 5% Notes&amp;#8217; fair value was a discounted cash flow model, where the expected cash flows of AST-726 and AST-915 are discounted to the present using a yield that incorporates compensation for the probability of success in clinical development and marketing, among other factors. The discount rate used in this discounted cash flow model approximated 20% at December 31, 2011 and March 31, 2012. The assumptions, assessments and projections of future revenues are subject to uncertainties, are difficult to predict and require significant judgment. The use of different assumptions, applying different judgment to inherently subjective matters and changes in future market conditions could result in significantly different estimates of fair value and the differences could be material to our consolidated financial statements.&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The following table provides the fair value measurements of applicable financial liabilities as of December 31, 2011 and March 31, 2012:&lt;/p&gt;
&lt;p style="text-align:
 left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="14"&gt;Financial&amp;#160;liabilities&amp;#160;at&amp;#160;fair&amp;#160;value&amp;#160;&lt;br /&gt;as&amp;#160;of&amp;#160;December&amp;#160;31,&amp;#160;2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"&gt;Level 1&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"&gt;Level 2&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"&gt;Level 3&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; width: 48%;"&gt;5% Notes&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; width: 10%;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; width: 10%;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; width: 10%;"&gt;4,664,697&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; width: 10%;"&gt;4,664,697&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.12in;"&gt;Totals&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;4,664,697&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;4,664,697&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="14"&gt;Financial&amp;#160;liabilities&amp;#160;at&amp;#160;fair&amp;#160;value&amp;#160;&lt;br /&gt;as&amp;#160;of&amp;#160;March&amp;#160;31,&amp;#160;2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"&gt;Level 1&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"&gt;Level 2&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"&gt;Level 3&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align:
 center; font-weight: bold;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; width: 48%;"&gt;5% Notes&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; width: 10%;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; width: 10%;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; width: 10%;"&gt;4,664,697&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; width: 10%;"&gt;4,664,697&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.12in;"&gt;Totals&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;4,664,697&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;4,664,697&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Level 3 amounts above represent the fair value of the 5% Notes and related accrued interest.&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The following table summarizes the changes in Level 3 instruments during the three months ended March 31, 2012:&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 70%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.5in;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; width: 87%;"&gt;Fair value at December 31, 2011&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;4,664,697&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Interest accrued on face value of 5% Notes&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;205,297&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Change in fair value of Level 3 liabilities&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(205,297&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Fair value at March 31, 2012&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;4,664,697&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The change in the fair value of the Level 3 liabilities is reported in other (income) expense in the accompanying condensed consolidated statement of operations.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
	<us-gaap:RepaymentsOfShortTermDebt contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="0">200000</us-gaap:RepaymentsOfShortTermDebt><us-gaap:RepaymentsOfShortTermDebt contextRef="Context_6ME_31-Mar-2012" unitRef="USD" decimals="0">200000</us-gaap:RepaymentsOfShortTermDebt><us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="0">12257309</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock><us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="Context_6ME_31-Mar-2012" unitRef="USD" decimals="0">12257309</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock><us-gaap:PaymentsOfStockIssuanceCosts contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="0">20416</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="Context_6ME_31-Mar-2012" unitRef="USD" decimals="0">20416</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="0">12181406</us-gaap:StockIssuedDuringPeriodValueNewIssues><us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_3ME_31-Mar-2012_StatementEquityComponentsAxis_PreferredStockMember" unitRef="USD" decimals="0">696</us-gaap:StockIssuedDuringPeriodValueNewIssues><us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_3ME_31-Mar-2012_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">12180710</us-gaap:StockIssuedDuringPeriodValueNewIssues><us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_3ME_31-Mar-2012_StatementEquityComponentsAxis_PreferredStockMember" unitRef="Shares" decimals="0">695428</us-gaap:StockIssuedDuringPeriodSharesNewIssues><tgtxd:SharesIssuedToNonControllingInterestInConnectionWithLicensingAgreement contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="0">16578000</tgtxd:SharesIssuedToNonControllingInterestInConnectionWithLicensingAgreement>
	<tgtxd:SharesIssuedToNonControllingInterestInConnectionWithLicensingAgreement contextRef="Context_3ME_31-Mar-2012_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" decimals="0">16578000</tgtxd:SharesIssuedToNonControllingInterestInConnectionWithLicensingAgreement>
	<tgtxd:PreferredStockIssuedExpenses contextRef="Context_3ME_31-Mar-2012" unitRef="USDPerShare" decimals="2">20.00</tgtxd:PreferredStockIssuedExpenses>
	<tgtxd:NonCashStockExpense contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="0">16578000</tgtxd:NonCashStockExpense>
	<tgtxd:NonCashStockExpense contextRef="Context_6ME_31-Mar-2012" unitRef="USD" decimals="0">16875000</tgtxd:NonCashStockExpense>
	<tgtxd:OtherResearchAndDevelopment contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="0">163353</tgtxd:OtherResearchAndDevelopment>
	<tgtxd:OtherResearchAndDevelopment contextRef="Context_6ME_31-Mar-2012" unitRef="USD" decimals="0">193636</tgtxd:OtherResearchAndDevelopment>
	<us-gaap:InvestmentIncomeNet contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="0">-3668</us-gaap:InvestmentIncomeNet>
	<us-gaap:InvestmentIncomeNet contextRef="Context_6ME_31-Mar-2012" unitRef="USD" decimals="0">-3668</us-gaap:InvestmentIncomeNet>
	<tgtxd:ChangeInFairValueOfNonCurrentNotePayable contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="0">-205297</tgtxd:ChangeInFairValueOfNonCurrentNotePayable>
	<tgtxd:ChangeInFairValueOfNonCurrentNotePayable contextRef="Context_6ME_31-Mar-2012" unitRef="USD" decimals="0">-205297</tgtxd:ChangeInFairValueOfNonCurrentNotePayable>
	<us-gaap:NonoperatingIncomeExpense contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="0">11184</us-gaap:NonoperatingIncomeExpense><us-gaap:NonoperatingIncomeExpense contextRef="Context_6ME_31-Mar-2012" unitRef="USD" decimals="0">18281</us-gaap:NonoperatingIncomeExpense><!-- Footnote Section -->
	<link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
	</link:footnoteLink>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="0">0</us-gaap:ProceedsFromIssuanceOfCommonStock><us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_6ME_31-Mar-2012" unitRef="USD" decimals="0">9824682</us-gaap:ProceedsFromIssuanceOfCommonStock><us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" xsi:nil="true"/>
	<us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" xsi:nil="true"/>
	<us-gaap:ProfitLoss contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="0">-17396538</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="Context_3ME_31-Mar-2012_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" decimals="0">-7140448</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="Context_3ME_31-Mar-2012_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">-10256090</us-gaap:ProfitLoss>
	<us-gaap:NetIncomeLoss contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="0">-10256090</us-gaap:NetIncomeLoss>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>tgtxd-20120331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!---->
<!--XBRL Document Modified with Ez-Viewer Version 1.0.4.1 on Monday, May 14, 2012 12:47:30 AM -->
<!--XBRL Document Modified with Ez-Viewer Version 1.0.4.3 on Monday, May 14, 2012 10:39:44 PM -->
<!--XBRL Document Modified with Ez-Viewer Version 1.0.4.3 on Tuesday, May 15, 2012 12:02:11 AM -->
<schema elementFormDefault="qualified" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:country="http://xbrl.sec.gov/country/2011-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2011-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2011-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2011-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:num="http://www.xbrl.org/dtr/type/numeric" targetNamespace="http://www.tgtherapeuticsinc.com/20120331" xmlns:tgtxd="http://www.tgtherapeuticsinc.com/20120331">
	<annotation><appinfo>
			<link:roleType id="DocumentAndEntityInformation" roleURI="http://www.tgtherapeuticsinc.com/role/DocumentAndEntityInformation">
				<link:definition>001 - Document - Document and Entity Information</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.tgtherapeuticsinc.com/role/CondensedConsolidatedBalanceSheets">
				<link:definition>002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.tgtherapeuticsinc.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
				<link:definition>003 - Statement - Condensed Consolidated Balance Sheets [Parenthetical]</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType id="CondensedConsolidatedStatementsOfOperations" roleURI="http://www.tgtherapeuticsinc.com/role/CondensedConsolidatedStatementsOfOperations">
				<link:definition>004 - Statement - Condensed Consolidated Statements of Operations</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType id="CondensedConsolidatedStatementOfEquity" roleURI="http://www.tgtherapeuticsinc.com/role/CondensedConsolidatedStatementOfEquity">
				<link:definition>005 - Statement - Condensed Consolidated Statement of Equity</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType id="CondensedConsolidatedStatementOfEquityParenthetical" roleURI="http://www.tgtherapeuticsinc.com/role/CondensedConsolidatedStatementOfEquityParenthetical">
				<link:definition>006 - Statement - Condensed Consolidated Statement of Equity [Parenthetical]</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType id="CondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.tgtherapeuticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows">
				<link:definition>007 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType id="OrganizationAndSummaryOfSignificantAccountingPolicies" roleURI="http://www.tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies">
				<link:definition>008 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType id="Acquisition" roleURI="http://www.tgtherapeuticsinc.com/role/Acquisition">
				<link:definition>010 - Disclosure - ACQUISITION</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType id="StockholdersEquity" roleURI="http://www.tgtherapeuticsinc.com/role/StockholdersEquity">
				<link:definition>011 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType id="NOTESPAYABLE" roleURI="http://www.tgtherapeuticsinc.com/role/NOTESPAYABLE">
				<link:definition>012 - Disclosure - NOTES PAYABLE</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType id="LicenseAgreements" roleURI="http://www.tgtherapeuticsinc.com/role/LicenseAgreements">
				<link:definition>013 - Disclosure - LICENSE AGREEMENTS</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType id="RelatedPartyTransactions" roleURI="http://www.tgtherapeuticsinc.com/role/RelatedPartyTransactions">
				<link:definition>014 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType id="SubsequentEvents" roleURI="http://www.tgtherapeuticsinc.com/role/SubsequentEvents">
				<link:definition>015 - Disclosure - SUBSEQUENT EVENTS</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType id="FairValueMeasurements" roleURI="http://www.tgtherapeuticsinc.com/role/FairValueMeasurements">
				<link:definition>009 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:linkbaseRef xlink:type="simple" xlink:href="tgtxd-20120331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="tgtxd-20120331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="tgtxd-20120331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="tgtxd-20120331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
		</appinfo></annotation>
	<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
	<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
	<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
	<import namespace="http://fasb.org/us-gaap/2011-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd"/>
	<import namespace="http://xbrl.sec.gov/invest/2011-01-31" schemaLocation="http://xbrl.sec.gov/invest/2011/invest-2011-01-31.xsd"/>
	<import namespace="http://xbrl.sec.gov/country/2011-01-31" schemaLocation="http://xbrl.sec.gov/country/2011/country-2011-01-31.xsd"/>
	<import namespace="http://xbrl.sec.gov/currency/2011-01-31" schemaLocation="http://xbrl.sec.gov/currency/2011/currency-2011-01-31.xsd"/>
	<import namespace="http://xbrl.sec.gov/exch/2011-01-31" schemaLocation="http://xbrl.sec.gov/exch/2011/exch-2011-01-31.xsd"/>
	<import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
	<import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
	<import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
	<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
	<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
	<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
	<import namespace="http://xbrl.sec.gov/dei/2011-01-31" schemaLocation="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd"/>
	<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
	<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
	<element name="DocumentAndEntityInformationAbstract" id="tgtxd_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="InProcessResearchAndDevelopment" id="tgtxd_InProcessResearchAndDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="ContingentlyIssuableShares" id="tgtxd_ContingentlyIssuableShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="BalanceSheetParentheticalAbstract" id="tgtxd_BalanceSheetParentheticalAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="PreferredStockLiquidationPreferenceValue" id="tgtxd_PreferredStockLiquidationPreferenceValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="NonCashCompensation" id="tgtxd_NonCashCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="WeightedAverageNumberOfSharesBasicAndDiluted" id="tgtxd_WeightedAverageNumberOfSharesBasicAndDiluted" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="NonCashStockExpense" id="tgtxd_NonCashStockExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="OtherResearchAndDevelopment" id="tgtxd_OtherResearchAndDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="SharesIssuedToNonControllingInterestInConnectionWithLicensingAgreement" id="tgtxd_SharesIssuedToNonControllingInterestInConnectionWithLicensingAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" nillable="true"/>
	<element name="ConsolidatedStatementOfEquityParentheticalAbstract" id="tgtxd_ConsolidatedStatementOfEquityParentheticalAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="PreferredStockIssuedExpenses" id="tgtxd_PreferredStockIssuedExpenses" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" abstract="false" nillable="true"/>
	<element name="ConversionOfNotesPayableToPreferredStock" id="tgtxd_ConversionOfNotesPayableToPreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="AccruedFinancingCosts" id="tgtxd_AccruedFinancingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="LicenseAgreementAbstract" id="tgtxd_LicenseAgreementAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="LicenseAgreementDisclosureTextBlock" id="tgtxd_LicenseAgreementDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="InterestPayableNonCurrent" id="tgtxd_InterestPayableNonCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="ChangesDuringPeriodAbstract" id="tgtxd_ChangesDuringPeriodAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" abstract="true" nillable="true"/>
	<element name="ChangeInFairValueOfNonCurrentNotePayable" id="tgtxd_ChangeInFairValueOfNonCurrentNotePayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" nillable="true"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>tgtxd-20120331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Viewer Version 1.0.4.3 on Monday, May 14, 2012 10:39:44 PM -->
<!--XBRL Document Modified with Ez-Viewer Version 1.0.4.3 on Tuesday, May 15, 2012 12:02:11 AM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
	<roleRef xlink:type="simple" xlink:href="tgtxd-20120331.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://www.tgtherapeuticsinc.com/role/CondensedConsolidatedBalanceSheets"/>
	<calculationLink xlink:type="extended" xlink:role="http://www.tgtherapeuticsinc.com/role/CondensedConsolidatedBalanceSheets">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_OtherAssetsCurrent" order="20" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" order="40" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_Goodwill" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_InProcessResearchAndDevelopment" xlink:label="loc_tgtxd_InProcessResearchAndDevelopment"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_tgtxd_InProcessResearchAndDevelopment" order="40" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" order="60" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_NotesPayableCurrent" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities" order="40" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_InterestPayableCurrent" order="60" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LongTermNotesPayable" order="40" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" order="40" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_ContingentlyIssuableShares" xlink:label="loc_tgtxd_ContingentlyIssuableShares"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_tgtxd_ContingentlyIssuableShares" order="60" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapital" order="80" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:label="loc_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" order="100" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_StockholdersEquity" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_MinorityInterest" order="40" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" order="20" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" order="40" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_MinorityInterest" order="60" use="optional" weight="1"/></calculationLink>
	<roleRef xlink:type="simple" xlink:href="tgtxd-20120331.xsd#CondensedConsolidatedStatementsOfOperations" roleURI="http://www.tgtherapeuticsinc.com/role/CondensedConsolidatedStatementsOfOperations"/>
	<calculationLink xlink:type="extended" xlink:role="http://www.tgtherapeuticsinc.com/role/CondensedConsolidatedStatementsOfOperations">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_NonCashStockExpense" xlink:label="loc_tgtxd_NonCashStockExpense"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="loc_tgtxd_NonCashStockExpense" order="20" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_OtherResearchAndDevelopment" xlink:label="loc_tgtxd_OtherResearchAndDevelopment"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="loc_tgtxd_OtherResearchAndDevelopment" order="40" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense"/><loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_NonCashCompensation" xlink:label="loc_tgtxd_NonCashCompensation"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="loc_tgtxd_NonCashCompensation" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="loc_us-gaap_OtherGeneralAndAdministrativeExpense" order="40" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" order="20" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" order="40" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" order="20" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_ProfitLoss" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="40" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaap_InvestmentIncomeNet"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InvestmentIncomeNet" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_ChangeInFairValueOfNonCurrentNotePayable" xlink:label="loc_tgtxd_ChangeInFairValueOfNonCurrentNotePayable"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_tgtxd_ChangeInFairValueOfNonCurrentNotePayable" order="40" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InterestExpense" order="60" use="optional" weight="-1"/></calculationLink>
	<roleRef xlink:type="simple" xlink:href="tgtxd-20120331.xsd#CondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.tgtherapeuticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows"/>
	<calculationLink xlink:type="extended" xlink:role="http://www.tgtherapeuticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ProfitLoss" order="20" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" order="40" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_NonCashStockExpense" xlink:label="loc_tgtxd_NonCashStockExpense"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_tgtxd_NonCashStockExpense" order="60" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="80" use="optional" weight="-1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" order="100" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="loc_us-gaap_IncreaseDecreaseInInterestPayableNet"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInInterestPayableNet" order="120" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt" order="20" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" order="40" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="60" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts" order="80" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" order="20" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" order="40" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" order="60" use="optional" weight="1"/></calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>tgtxd-20120331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Viewer Version 1.0.4.3 on Monday, May 14, 2012 10:39:44 PM -->
<!--XBRL Document Modified with Ez-Viewer Version 1.0.4.3 on Tuesday, May 15, 2012 12:02:11 AM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
	<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
	<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
	<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
	<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
	<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
	<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
	<roleRef xlink:type="simple" xlink:href="tgtxd-20120331.xsd#DocumentAndEntityInformation" roleURI="http://www.tgtherapeuticsinc.com/role/DocumentAndEntityInformation"/>
	<roleRef xlink:type="simple" xlink:href="tgtxd-20120331.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://www.tgtherapeuticsinc.com/role/CondensedConsolidatedBalanceSheets"/>
	<roleRef xlink:type="simple" xlink:href="tgtxd-20120331.xsd#CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.tgtherapeuticsinc.com/role/CondensedConsolidatedBalanceSheetsParenthetical"/>
	<roleRef xlink:type="simple" xlink:href="tgtxd-20120331.xsd#CondensedConsolidatedStatementsOfOperations" roleURI="http://www.tgtherapeuticsinc.com/role/CondensedConsolidatedStatementsOfOperations"/>
	<roleRef xlink:type="simple" xlink:href="tgtxd-20120331.xsd#CondensedConsolidatedStatementOfEquity" roleURI="http://www.tgtherapeuticsinc.com/role/CondensedConsolidatedStatementOfEquity"/>
	<roleRef xlink:type="simple" xlink:href="tgtxd-20120331.xsd#CondensedConsolidatedStatementOfEquityParenthetical" roleURI="http://www.tgtherapeuticsinc.com/role/CondensedConsolidatedStatementOfEquityParenthetical"/>
	<roleRef xlink:type="simple" xlink:href="tgtxd-20120331.xsd#CondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.tgtherapeuticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows"/>
	<definitionLink xlink:type="extended" xlink:role="http://www.tgtherapeuticsinc.com/role/DocumentAndEntityInformation">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_2"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityRegistrantName_2" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_3"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityCentralIndexKey_3" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_4"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_CurrentFiscalYearEndDate_4" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_5"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityFilerCategory_5" order="40" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_6"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_TradingSymbol_6" order="50" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_7"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_7" order="60" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_8"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentType_8" order="70" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_9"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_AmendmentFlag_9" order="80" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_10"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentPeriodEndDate_10" order="90" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_11"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_11" order="100" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_12"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentFiscalYearFocus_12" order="110" use="optional"/>
	</definitionLink>
	<definitionLink xlink:type="extended" xlink:role="http://www.tgtherapeuticsinc.com/role/CondensedConsolidatedBalanceSheets">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_5"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AssetsAbstract_5" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_7"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5" xlink:to="loc_us-gaap_OtherAssetsCurrent_7" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_8"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5" xlink:to="loc_us-gaap_AssetsCurrent_8" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_InProcessResearchAndDevelopment" xlink:label="loc_tgtxd_InProcessResearchAndDevelopment_9"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5" xlink:to="loc_tgtxd_InProcessResearchAndDevelopment_9" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_10"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5" xlink:to="loc_us-gaap_Goodwill_10" order="40" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_11"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5" xlink:to="loc_us-gaap_Assets_11" order="50" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_13"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_NotesPayableCurrent_13" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_14"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_14" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_15"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_InterestPayableCurrent_15" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_16"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_LiabilitiesCurrent_16" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_17"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_LongTermNotesPayable_17" order="40" use="optional"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_InterestPayableNonCurrent" xlink:label="loc_tgtxd_InterestPayableNonCurrent_18"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_tgtxd_InterestPayableNonCurrent_18" order="50" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_19"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_Liabilities_19" order="60" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_20"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_CommitmentsAndContingencies_20" order="70" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_21"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_StockholdersEquityAbstract_21" order="80" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_22"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_21" xlink:to="loc_us-gaap_PreferredStockValue_22" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_23"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_21" xlink:to="loc_us-gaap_CommonStockValue_23" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_ContingentlyIssuableShares" xlink:label="loc_tgtxd_ContingentlyIssuableShares_24"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_21" xlink:to="loc_tgtxd_ContingentlyIssuableShares_24" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_25"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_21" xlink:to="loc_us-gaap_AdditionalPaidInCapital_25" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:label="loc_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_26"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_21" xlink:to="loc_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_26" order="40" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_27"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_21" xlink:to="loc_us-gaap_StockholdersEquity_27" order="50" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_28"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_21" xlink:to="loc_us-gaap_MinorityInterest_28" order="60" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_29"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_21" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_29" order="70" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_30"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_30" order="90" use="optional"/>
	</definitionLink>
	<definitionLink xlink:type="extended" xlink:role="http://www.tgtherapeuticsinc.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_3"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_3" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_4"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesIssued_4" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_5"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_5" order="40" use="optional"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_PreferredStockLiquidationPreferenceValue" xlink:label="loc_tgtxd_PreferredStockLiquidationPreferenceValue_6"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_tgtxd_PreferredStockLiquidationPreferenceValue_6" order="50" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_7"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_7" order="60" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_8"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_8" order="70" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_9"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_9" order="80" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_10"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_10" order="90" use="optional"/>
	</definitionLink>
	<definitionLink xlink:type="extended" xlink:role="http://www.tgtherapeuticsinc.com/role/CondensedConsolidatedStatementsOfOperations">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_2"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_2" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_4"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_4" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_NonCashCompensation" xlink:label="loc_tgtxd_NonCashCompensation_5"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_4" xlink:to="loc_tgtxd_NonCashCompensation_5" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_6"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_4" xlink:to="loc_us-gaap_OtherGeneralAndAdministrativeExpense_6" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_7"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_7" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_8"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_4" xlink:to="loc_us-gaap_OperatingExpenses_8" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_9"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OperatingIncomeLoss_9" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_10"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_InterestExpense_10" order="40" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_11"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ProfitLoss_11" order="50" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_12"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_12" order="60" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_13"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetIncomeLoss_13" order="70" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_14"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_14" order="80" use="optional"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_WeightedAverageNumberOfSharesBasicAndDiluted" xlink:label="loc_tgtxd_WeightedAverageNumberOfSharesBasicAndDiluted_15"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_tgtxd_WeightedAverageNumberOfSharesBasicAndDiluted_15" order="90" use="optional"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_NonCashStockExpense" xlink:label="loc_tgtxd_NonCashStockExpense_16"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_tgtxd_NonCashStockExpense_16" order="100" use="optional"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_OtherResearchAndDevelopment" xlink:label="loc_tgtxd_OtherResearchAndDevelopment_17"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_tgtxd_OtherResearchAndDevelopment_17" order="110" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_18"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_18" order="120" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaap_InvestmentIncomeNet_19"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_18" xlink:to="loc_us-gaap_InvestmentIncomeNet_19" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_ChangeInFairValueOfNonCurrentNotePayable" xlink:label="loc_tgtxd_ChangeInFairValueOfNonCurrentNotePayable_20"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_18" xlink:to="loc_tgtxd_ChangeInFairValueOfNonCurrentNotePayable_20" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_21"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_18" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_21" order="20" use="optional"/>
	</definitionLink>
	<definitionLink xlink:type="extended" xlink:role="http://www.tgtherapeuticsinc.com/role/CondensedConsolidatedStatementOfEquity">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="10" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_9"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_9" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_9_Default"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_9_Default" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_8"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9" xlink:to="loc_us-gaap_RetainedEarningsMember_8" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_7"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9" xlink:to="loc_us-gaap_NoncontrollingInterestMember_7" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ContingentlyIssuableSharesMember" xlink:label="loc_us-gaap_ContingentlyIssuableSharesMember_6"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9" xlink:to="loc_us-gaap_ContingentlyIssuableSharesMember_6" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_5"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_5" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9" xlink:to="loc_us-gaap_CommonStockMember_4" order="40" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_3"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9" xlink:to="loc_us-gaap_PreferredStockMember_3" order="50" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_10"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_10" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_11"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SharesOutstanding_11" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_ChangesDuringPeriodAbstract" xlink:label="loc_tgtxd_ChangesDuringPeriodAbstract_12"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_tgtxd_ChangesDuringPeriodAbstract_12" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_13"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tgtxd_ChangesDuringPeriodAbstract_12" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_13" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_14"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tgtxd_ChangesDuringPeriodAbstract_12" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_14" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_15"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tgtxd_ChangesDuringPeriodAbstract_12" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_15" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_SharesIssuedToNonControllingInterestInConnectionWithLicensingAgreement" xlink:label="loc_tgtxd_SharesIssuedToNonControllingInterestInConnectionWithLicensingAgreement_16"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tgtxd_ChangesDuringPeriodAbstract_12" xlink:to="loc_tgtxd_SharesIssuedToNonControllingInterestInConnectionWithLicensingAgreement_16" order="40" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ProfitLoss" order="90"/>
	</definitionLink>
	<definitionLink xlink:type="extended" xlink:role="http://www.tgtherapeuticsinc.com/role/CondensedConsolidatedStatementOfEquityParenthetical">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_PreferredStockIssuedExpenses" xlink:label="loc_tgtxd_PreferredStockIssuedExpenses_4"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_tgtxd_PreferredStockIssuedExpenses_4" order="10" use="optional"/>
	</definitionLink>
	<definitionLink xlink:type="extended" xlink:role="http://www.tgtherapeuticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_4"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_ProfitLoss_4" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_6"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_ShareBasedCompensation_6" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_NonCashStockExpense" xlink:label="loc_tgtxd_NonCashStockExpense_7"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_tgtxd_NonCashStockExpense_7" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_10"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_10" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_11"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8" xlink:to="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_11" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_12"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_12" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_13"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_13" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_14"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_13" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_14" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_15"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_13" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_15" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_16"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_16" order="40" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_17"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_16" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_17" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_18"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_16" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_18" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_19"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_16" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_19" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_20"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_16" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_20" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_21"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_21" order="50" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_22"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_22" order="60" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonmonetaryTransactionsAbstract" xlink:label="loc_us-gaap_NonmonetaryTransactionsAbstract_23"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NonmonetaryTransactionsAbstract_23" order="70" use="optional"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_ConversionOfNotesPayableToPreferredStock" xlink:label="loc_tgtxd_ConversionOfNotesPayableToPreferredStock_24"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonmonetaryTransactionsAbstract_23" xlink:to="loc_tgtxd_ConversionOfNotesPayableToPreferredStock_24" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_AccruedFinancingCosts" xlink:label="loc_tgtxd_AccruedFinancingCosts_25"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonmonetaryTransactionsAbstract_23" xlink:to="loc_tgtxd_AccruedFinancingCosts_25" order="10" use="optional"/>
	</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>tgtxd-20120331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Viewer Version 1.0.4.3 on Monday, May 14, 2012 10:39:44 PM -->
<!--XBRL Document Modified with Ez-Viewer Version 1.0.4.3 on Tuesday, May 15, 2012 12:02:10 AM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2008-03-31.xsd#negated" roleURI="http://xbrl.us/us-gaap/role/label/negated"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
	<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_DocumentAndEntityInformationAbstract" xlink:label="loc_tgtxd_DocumentAndEntityInformationAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tgtxd_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_tgtxd_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tgtxd_DocumentAndEntityInformationAbstract" xlink:to="lab_tgtxd_DocumentAndEntityInformationAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement Of Financial Position [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, At Carrying Value</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value, Total</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents at beginning of period</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">CASH AND CASH EQUIVALENTS AT END OF PERIOD</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other Assets, Current</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other current assets</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other current assets</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_InProcessResearchAndDevelopment" xlink:label="loc_tgtxd_InProcessResearchAndDevelopment"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tgtxd_InProcessResearchAndDevelopment" xml:lang="en-US">In Process Research and Development</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_tgtxd_InProcessResearchAndDevelopment" xml:lang="en-US">In-process research and development</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tgtxd_InProcessResearchAndDevelopment" xml:lang="en-US">Carrying amount as of the balance sheet date of non current portion of in-process research and development costs.</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tgtxd_InProcessResearchAndDevelopment" xlink:to="lab_tgtxd_InProcessResearchAndDevelopment"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Stockholders Equity [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and equity</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NotesPayableCurrent" xml:lang="en-US">Notes Payable, Current</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NotesPayableCurrent" xml:lang="en-US">Notes payable, current portion</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NotesPayableCurrent" xml:lang="en-US">Notes Payable, Current, Total</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent" xlink:to="lab_us-gaap_NotesPayableCurrent"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Other Accounts Payable and Accrued Liabilities</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Accounts payable and accrued expenses</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPayableCurrent" xml:lang="en-US">Interest Payable, Current</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InterestPayableCurrent" xml:lang="en-US">Interest payable, current portion</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermNotesPayable" xml:lang="en-US">Notes Payable, Noncurrent</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LongTermNotesPayable" xml:lang="en-US">Notes payable, noncurrent portion, at fair value</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LongTermNotesPayable" xml:lang="en-US">Notes Payable, Noncurrent, Total</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermNotesPayable" xlink:to="lab_us-gaap_LongTermNotesPayable"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders Equity Attributable To Parent [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Equity:</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock, $0.001 par value per share (10,000,000 shares authorized, 1,108,816 and 413,388 issued and outstanding as of March 31, 2012 and December 31, 2011, respectively, aggregate liquidation value of $22,176,320 and $8,267,760 at March 31, 2012 and December 31, 2011, respectively)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued, Total</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued, Beginning Balance</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued, Ending Balance</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $0.001 par value per share (500,000,000 shares authorized, 5,061,399 shares issued and outstanding at March 31, 2012 and December 31, 2011)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued, Total</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued, Beginning Balance</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued, Ending Balance</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_ContingentlyIssuableShares" xlink:label="loc_tgtxd_ContingentlyIssuableShares"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tgtxd_ContingentlyIssuableShares" xml:lang="en-US">Contingently Issuable Shares</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_tgtxd_ContingentlyIssuableShares" xml:lang="en-US">Contingently issuable shares</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tgtxd_ContingentlyIssuableShares" xml:lang="en-US">The shares issuable for merger of companies</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tgtxd_ContingentlyIssuableShares" xlink:to="lab_tgtxd_ContingentlyIssuableShares"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Development Stage Enterprise, Deficit Accumulated During Development Stage</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in capital</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in capital</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:label="loc_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xml:lang="en-US">Deficit accumulated in development stage</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xml:lang="en-US">Deficit accumulated in development stage</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:to="lab_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders Equity Attributable To Parent</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total TG Therapeutics, Inc. and subsidiaries equity</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total TG Therapeutics, Inc. and subsidiaries equity</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MinorityInterest" xml:lang="en-US">Stockholders Equity Attributable To Noncontrolling Interest</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MinorityInterest" xml:lang="en-US">Non-controlling interest in subsidiary</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Stockholders Equity, Including Portion Attributable To Noncontrolling Interest</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Total equity</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Total equity</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Balance</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Balance</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Stockholders Equity</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and equity</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and equity</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_BalanceSheetParentheticalAbstract" xlink:label="loc_tgtxd_BalanceSheetParentheticalAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tgtxd_BalanceSheetParentheticalAbstract" xml:lang="en-US">Balance Sheet Parenthetical [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_tgtxd_BalanceSheetParentheticalAbstract" xml:lang="en-US">Balance Sheet Parenthetical [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tgtxd_BalanceSheetParentheticalAbstract" xlink:to="lab_tgtxd_BalanceSheetParentheticalAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par Or Stated Value Per Share</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value (in dollars per share)</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, shares issued</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred stock, shares outstanding</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding, Beginning Balance</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding, Ending Balance</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_PreferredStockLiquidationPreferenceValue" xlink:label="loc_tgtxd_PreferredStockLiquidationPreferenceValue"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tgtxd_PreferredStockLiquidationPreferenceValue" xml:lang="en-US">Preferred Stock Liquidation Preference Value</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_tgtxd_PreferredStockLiquidationPreferenceValue" xml:lang="en-US">Preferred stock, liquidation preference per share (in dollars)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tgtxd_PreferredStockLiquidationPreferenceValue" xml:lang="en-US">The aggregate liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares.</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tgtxd_PreferredStockLiquidationPreferenceValue" xlink:to="lab_tgtxd_PreferredStockLiquidationPreferenceValue"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par Or Stated Value Per Share</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value (in dollars per share)</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares issued</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued, Total</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares outstanding</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding, Beginning Balance</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding, Ending Balance</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xml:lang="en-US">Costs and Expenses [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xml:lang="en-US">Costs and expenses:</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Total research and development</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Total research and development</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract" xml:lang="en-US">General and Administrative Expense [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract" xml:lang="en-US">General and administrative:</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_NonCashCompensation" xlink:label="loc_tgtxd_NonCashCompensation"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tgtxd_NonCashCompensation" xml:lang="en-US">Non Cash Compensation</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_tgtxd_NonCashCompensation" xml:lang="en-US">Non-cash compensation</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tgtxd_NonCashCompensation" xml:lang="en-US">The aggregate compensation expense related to the grants of stock options and restricted stock that is attributable to general and administrative expenses during the reporting period.</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tgtxd_NonCashCompensation" xlink:to="lab_tgtxd_NonCashCompensation"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherGeneralAndAdministrativeExpense" xml:lang="en-US">Other General and Administrative Expense</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherGeneralAndAdministrativeExpense" xml:lang="en-US">Other general and administrative</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_OtherGeneralAndAdministrativeExpense"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">Total general and administrative</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">Total general and administrative</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total costs and expenses</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating loss</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating loss</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest Expense</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest expense</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest Expense, Total</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest expense</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net Income (Loss), Including Portion Attributable To Noncontrolling Interest</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net loss</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net loss</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xml:lang="en-US">Net Income (Loss) Attributable To Noncontrolling Interest</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xml:lang="en-US">Net loss attributable to non-controlling interest</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xml:lang="en-US">Net loss attributable to non-controlling interest</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable To Parent</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss attributable to TG Therapeutics, Inc. and subsidiaries</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss attributable to TG Therapeutics, Inc. and subsidiaries</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Consolidated net loss</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Basic and diluted net loss per common share (in dollars per share)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Basic and diluted (in dollars per share)</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_WeightedAverageNumberOfSharesBasicAndDiluted" xlink:label="loc_tgtxd_WeightedAverageNumberOfSharesBasicAndDiluted"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tgtxd_WeightedAverageNumberOfSharesBasicAndDiluted" xml:lang="en-US">Weighted Average Number Of Shares Basic and Diluted</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_tgtxd_WeightedAverageNumberOfSharesBasicAndDiluted" xml:lang="en-US">Weighted average shares used in computing basic and diluted net loss per common share (in shares)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_tgtxd_WeightedAverageNumberOfSharesBasicAndDiluted" xml:lang="en-US">Basic and diluted (in shares)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tgtxd_WeightedAverageNumberOfSharesBasicAndDiluted" xml:lang="en-US">The average number of shares issued and outstanding that are used in calculating common stock basic and diluted EPS, determined based on the timing of issuance of shares in the period.</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tgtxd_WeightedAverageNumberOfSharesBasicAndDiluted" xlink:to="lab_tgtxd_WeightedAverageNumberOfSharesBasicAndDiluted"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_NonCashStockExpense" xlink:label="loc_tgtxd_NonCashStockExpense"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tgtxd_NonCashStockExpense" xml:lang="en-US">Non Cash Stock Expense</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_tgtxd_NonCashStockExpense" xml:lang="en-US">Non-cash stock expense associated with in-licensing agreement</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tgtxd_NonCashStockExpense" xml:lang="en-US">The aggregate expense related to the issuance of stock in connection with in-licensing agreements during the reporting period.</label>
		<label xlink:type="resource" xlink:label="lab_tgtxd_NonCashStockExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US">Stock issued in connection with in-licensing agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tgtxd_NonCashStockExpense" xlink:to="lab_tgtxd_NonCashStockExpense"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_OtherResearchAndDevelopment" xlink:label="loc_tgtxd_OtherResearchAndDevelopment"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tgtxd_OtherResearchAndDevelopment" xml:lang="en-US">Other Research and Development</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_tgtxd_OtherResearchAndDevelopment" xml:lang="en-US">Other research and development</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tgtxd_OtherResearchAndDevelopment" xml:lang="en-US">Other research and development expense during the period.</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tgtxd_OtherResearchAndDevelopment" xlink:to="lab_tgtxd_OtherResearchAndDevelopment"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Nonoperating Income Expense Abstract</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other (income) expense:</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaap_InvestmentIncomeNet"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentIncomeNet" xml:lang="en-US">Investment Income, Net</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InvestmentIncomeNet" xml:lang="en-US">Interest income</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet" xlink:to="lab_us-gaap_InvestmentIncomeNet"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total other (income) expense</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement Of Stockholders Equity [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Statement, Equity Components [Axis]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Statement, Equity Components [Axis]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockMember" xml:lang="en-US">Preferred Stock [Member]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
		<label xlink:type="resource" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ContingentlyIssuableSharesMember" xlink:label="loc_us-gaap_ContingentlyIssuableSharesMember"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContingentlyIssuableSharesMember" xml:lang="en-US">Contingently Issuable Shares [Member]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentlyIssuableSharesMember" xlink:to="lab_us-gaap_ContingentlyIssuableSharesMember"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xml:lang="en-US">Noncontrolling Interest [Member]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Shares, Outstanding</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance (in shares)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance (in shares)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance (in shares)</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Restricted Stock Units, Requisite Service Period Recognition</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xml:lang="en-US">Compensation in respect of restricted preferred stock granted to employees</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Preferred stock issued at $20.00 per share, net of expenses</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Preferred stock issued at $20.00 per share, net of expenses (in shares)</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_SharesIssuedToNonControllingInterestInConnectionWithLicensingAgreement" xlink:label="loc_tgtxd_SharesIssuedToNonControllingInterestInConnectionWithLicensingAgreement"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tgtxd_SharesIssuedToNonControllingInterestInConnectionWithLicensingAgreement" xml:lang="en-US">Shares Issued To Non Controlling Interest In Connection With Licensing Agreement</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_tgtxd_SharesIssuedToNonControllingInterestInConnectionWithLicensingAgreement" xml:lang="en-US">Shares issued in subsidiary to non-controlling interest in connection with in-licensing agreement</label>
		<label xlink:type="resource" xlink:label="lab_tgtxd_SharesIssuedToNonControllingInterestInConnectionWithLicensingAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US">The value of shares issued to non controlling interest in connection with licensing agreement during the period.</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tgtxd_SharesIssuedToNonControllingInterestInConnectionWithLicensingAgreement" xlink:to="lab_tgtxd_SharesIssuedToNonControllingInterestInConnectionWithLicensingAgreement"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_ConsolidatedStatementOfEquityParentheticalAbstract" xlink:label="loc_tgtxd_ConsolidatedStatementOfEquityParentheticalAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tgtxd_ConsolidatedStatementOfEquityParentheticalAbstract" xml:lang="en-US">Consolidated Statement Of Equity [Parenthetical] [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_tgtxd_ConsolidatedStatementOfEquityParentheticalAbstract" xml:lang="en-US">Consolidated Statement Of Equity [Parenthetical] [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tgtxd_ConsolidatedStatementOfEquityParentheticalAbstract" xlink:to="lab_tgtxd_ConsolidatedStatementOfEquityParentheticalAbstract"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_PreferredStockIssuedExpenses" xlink:label="loc_tgtxd_PreferredStockIssuedExpenses"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tgtxd_PreferredStockIssuedExpenses" xml:lang="en-US">Preferred Stock Issued Expenses</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_tgtxd_PreferredStockIssuedExpenses" xml:lang="en-US">Preferred stock issued net of expenses</label>
		<label xlink:type="resource" xlink:label="lab_tgtxd_PreferredStockIssuedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US">The value of expenses incurred for issuance of preferred stock during the period.</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tgtxd_PreferredStockIssuedExpenses" xlink:to="lab_tgtxd_PreferredStockIssuedExpenses"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement Of Cash Flows [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds From Issuance Of Common Stock</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from sale of common stock, net</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Operating Activities [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments To Reconcile Net Income (Loss) To Cash Provided By (Used In) Operating Activities [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-Based Compensation</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock compensation expense</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Compensation, Total</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) In Operating Capital [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in assets and liabilities, net of effects of acquisition:</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Increase (Decrease) In Prepaid, Deferred Expense and Other Assets</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Decrease in other current assets</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Increase (Decrease) in Prepaid, Deferred Expense and Other Assets, Total</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Decrease in other current assets</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Increase (Decrease) In Other Accounts Payable and Accrued Liabilities</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Increase in accounts payable and accrued expenses</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="loc_us-gaap_IncreaseDecreaseInInterestPayableNet"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInInterestPayableNet" xml:lang="en-US">Increase In Interest Payable, Current Portion</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInInterestPayableNet" xml:lang="en-US">Increase in interest payable</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInInterestPayableNet" xml:lang="en-US">Increase in interest payable</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="lab_us-gaap_IncreaseDecreaseInInterestPayableNet"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided By (Used In) Operating Activities</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operating activities</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operating activities</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Investing Activities [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xml:lang="en-US">Cash Acquired From Acquisition</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xml:lang="en-US">Cash acquired in connection with acquisition</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAcquiredFromAcquisition" xlink:to="lab_us-gaap_CashAcquiredFromAcquisition"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided By (Used In) Investing Activities</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash provided by investing activities</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash provided by investing activities</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Financing Activities [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xml:lang="en-US">Repayments Of Short Term Debt</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xml:lang="en-US">Payments of short-term loans</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_RepaymentsOfShortTermDebt"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xml:lang="en-US">Proceeds From Issuance Of Preferred Stock And Preference Stock</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xml:lang="en-US">Proceeds from sale of preferred stock, net</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payments Of Stock Issuance Costs</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Offering costs paid</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Offering costs paid</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided By (Used In) Financing Activities</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash provided by financing activities</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash provided by financing activities</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">NET INCREASE IN CASH AND CASH EQUIVALENTS</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">NET INCREASE IN CASH AND CASH EQUIVALENTS</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonmonetaryTransactionsAbstract" xlink:label="loc_us-gaap_NonmonetaryTransactionsAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonmonetaryTransactionsAbstract" xml:lang="en-US">Nonmonetary Transactions [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NonmonetaryTransactionsAbstract" xml:lang="en-US">NON-CASH TRANSACTIONS:</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonmonetaryTransactionsAbstract" xlink:to="lab_us-gaap_NonmonetaryTransactionsAbstract"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_ConversionOfNotesPayableToPreferredStock" xlink:label="loc_tgtxd_ConversionOfNotesPayableToPreferredStock"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tgtxd_ConversionOfNotesPayableToPreferredStock" xml:lang="en-US">Conversion Of Notes Payable To Preferred Stock</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_tgtxd_ConversionOfNotesPayableToPreferredStock" xml:lang="en-US">Conversion of notes payable to preferred stock</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tgtxd_ConversionOfNotesPayableToPreferredStock" xml:lang="en-US">Conversion Of Notes Payable To Preferred Stock during the year.</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tgtxd_ConversionOfNotesPayableToPreferredStock" xlink:to="lab_tgtxd_ConversionOfNotesPayableToPreferredStock"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_AccruedFinancingCosts" xlink:label="loc_tgtxd_AccruedFinancingCosts"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tgtxd_AccruedFinancingCosts" xml:lang="en-US">Accrued Financing Costs</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_tgtxd_AccruedFinancingCosts" xml:lang="en-US">Accrued financing costs</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tgtxd_AccruedFinancingCosts" xml:lang="en-US">Accrued Financing Costs during the period.</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tgtxd_AccruedFinancingCosts" xlink:to="lab_tgtxd_AccruedFinancingCosts"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">General Policies [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessAcquisitionDateOfAcquisitionAbstract" xlink:label="loc_us-gaap_BusinessAcquisitionDateOfAcquisitionAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionDateOfAcquisitionAbstract" xml:lang="en-US">Business Acquisition, Date of Acquisition [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionDateOfAcquisitionAbstract" xml:lang="en-US">Business Acquisition, Date of Acquisition [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionDateOfAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessAcquisitionDateOfAcquisitionAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xml:lang="en-US">Business Combination Disclosure [Text Block]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xml:lang="en-US">Business Combination Disclosure [Text Block]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US">Stockholders' Equity Note [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US">Stockholders' Equity Note [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders Equity Note Disclosure [Text Block]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xml:lang="en-US">Debt Disclosure [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xml:lang="en-US">Notes Payable [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Debt Disclosure [Text Block]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Debt Disclosure [Text Block]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_LicenseAgreementAbstract" xlink:label="loc_tgtxd_LicenseAgreementAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tgtxd_LicenseAgreementAbstract" xml:lang="en-US">License Agreement [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_tgtxd_LicenseAgreementAbstract" xml:lang="en-US">License Agreement [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tgtxd_LicenseAgreementAbstract" xml:lang="en-US">License Agreement</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tgtxd_LicenseAgreementAbstract" xlink:to="lab_tgtxd_LicenseAgreementAbstract"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_LicenseAgreementDisclosureTextBlock" xlink:label="loc_tgtxd_LicenseAgreementDisclosureTextBlock"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tgtxd_LicenseAgreementDisclosureTextBlock" xml:lang="en-US">License Agreement Disclosure [Text Block]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_tgtxd_LicenseAgreementDisclosureTextBlock" xml:lang="en-US">License Agreement Disclosure [Text Block]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tgtxd_LicenseAgreementDisclosureTextBlock" xml:lang="en-US">The entire disclosure for research, development, and License Agreement activities, including contracts and arrangements to be performed for others and with federal government.</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tgtxd_LicenseAgreementDisclosureTextBlock" xlink:to="lab_tgtxd_LicenseAgreementDisclosureTextBlock"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share, By Antidilutive Securities [Axis]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_InterestPayableNonCurrent" xlink:label="loc_tgtxd_InterestPayableNonCurrent"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tgtxd_InterestPayableNonCurrent" xml:lang="en-US">Interest Payable Non Current</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_tgtxd_InterestPayableNonCurrent" xml:lang="en-US">Interest payable, noncurrent portion</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_tgtxd_InterestPayableNonCurrent" xml:lang="en-US">Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the non-current portion of the liabilities (due greater than one year).</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tgtxd_InterestPayableNonCurrent" xlink:to="lab_tgtxd_InterestPayableNonCurrent"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and contingencies</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_ChangesDuringPeriodAbstract" xlink:label="loc_tgtxd_ChangesDuringPeriodAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_tgtxd_ChangesDuringPeriodAbstract" xml:lang="en-US">Changes During Period [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_tgtxd_ChangesDuringPeriodAbstract" xml:lang="en-US">Changes during the period:</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tgtxd_ChangesDuringPeriodAbstract" xlink:to="lab_tgtxd_ChangesDuringPeriodAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementScenarioAxis" xml:lang="en-US">Statement, Scenario [Axis]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementScenarioAxis" xlink:to="lab_us-gaap_StatementScenarioAxis"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario, Unspecified [Domain]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain" xlink:to="lab_us-gaap_ScenarioUnspecifiedDomain"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_ChangeInFairValueOfNonCurrentNotePayable" xlink:label="loc_tgtxd_ChangeInFairValueOfNonCurrentNotePayable"/>
		<label xlink:type="resource" xlink:label="lab_tgtxd_ChangeInFairValueOfNonCurrentNotePayable" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Change In Fair Value Of Non Current Note Payable</label>
		<label xlink:type="resource" xlink:label="lab_tgtxd_ChangeInFairValueOfNonCurrentNotePayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Change in fair value of non-current notes payable</label>
		<label xlink:type="resource" xlink:label="lab_tgtxd_ChangeInFairValueOfNonCurrentNotePayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US">The change in the fair value of non current note payable recognized during the period.</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_tgtxd_ChangeInFairValueOfNonCurrentNotePayable" xlink:to="lab_tgtxd_ChangeInFairValueOfNonCurrentNotePayable"/>
	</labelLink></linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>tgtxd-20120331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Viewer Version 1.0.4.3 on Monday, May 14, 2012 10:39:44 PM -->
<!--XBRL Document Modified with Ez-Viewer Version 1.0.4.3 on Tuesday, May 15, 2012 12:02:10 AM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
	<roleRef xlink:type="simple" xlink:href="tgtxd-20120331.xsd#DocumentAndEntityInformation" roleURI="http://www.tgtherapeuticsinc.com/role/DocumentAndEntityInformation"/>
	<roleRef xlink:type="simple" xlink:href="tgtxd-20120331.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://www.tgtherapeuticsinc.com/role/CondensedConsolidatedBalanceSheets"/>
	<roleRef xlink:type="simple" xlink:href="tgtxd-20120331.xsd#CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.tgtherapeuticsinc.com/role/CondensedConsolidatedBalanceSheetsParenthetical"/>
	<roleRef xlink:type="simple" xlink:href="tgtxd-20120331.xsd#CondensedConsolidatedStatementsOfOperations" roleURI="http://www.tgtherapeuticsinc.com/role/CondensedConsolidatedStatementsOfOperations"/>
	<roleRef xlink:type="simple" xlink:href="tgtxd-20120331.xsd#CondensedConsolidatedStatementOfEquity" roleURI="http://www.tgtherapeuticsinc.com/role/CondensedConsolidatedStatementOfEquity"/>
	<roleRef xlink:type="simple" xlink:href="tgtxd-20120331.xsd#CondensedConsolidatedStatementOfEquityParenthetical" roleURI="http://www.tgtherapeuticsinc.com/role/CondensedConsolidatedStatementOfEquityParenthetical"/>
	<roleRef xlink:type="simple" xlink:href="tgtxd-20120331.xsd#CondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.tgtherapeuticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows"/>
	<roleRef xlink:type="simple" xlink:href="tgtxd-20120331.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" roleURI="http://www.tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies"/>
	<roleRef xlink:type="simple" xlink:href="tgtxd-20120331.xsd#Acquisition" roleURI="http://www.tgtherapeuticsinc.com/role/Acquisition"/>
	<roleRef xlink:type="simple" xlink:href="tgtxd-20120331.xsd#StockholdersEquity" roleURI="http://www.tgtherapeuticsinc.com/role/StockholdersEquity"/>
	<roleRef xlink:type="simple" xlink:href="tgtxd-20120331.xsd#NOTESPAYABLE" roleURI="http://www.tgtherapeuticsinc.com/role/NOTESPAYABLE"/>
	<roleRef xlink:type="simple" xlink:href="tgtxd-20120331.xsd#LicenseAgreements" roleURI="http://www.tgtherapeuticsinc.com/role/LicenseAgreements"/>
	<roleRef xlink:type="simple" xlink:href="tgtxd-20120331.xsd#RelatedPartyTransactions" roleURI="http://www.tgtherapeuticsinc.com/role/RelatedPartyTransactions"/>
	<roleRef xlink:type="simple" xlink:href="tgtxd-20120331.xsd#SubsequentEvents" roleURI="http://www.tgtherapeuticsinc.com/role/SubsequentEvents"/>
	<roleRef xlink:type="simple" xlink:href="tgtxd-20120331.xsd#FairValueMeasurements" roleURI="http://www.tgtherapeuticsinc.com/role/FairValueMeasurements"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
	<presentationLink xlink:type="extended" xlink:role="http://www.tgtherapeuticsinc.com/role/DocumentAndEntityInformation">
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_DocumentAndEntityInformationAbstract" xlink:label="loc_tgtxd_DocumentAndEntityInformationAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_3"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_EntityRegistrantName_3" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_4"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_EntityCentralIndexKey_4" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_5"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_CurrentFiscalYearEndDate_5" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_6"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_EntityFilerCategory_6" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_7"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_TradingSymbol_7" order="40" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_8"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_8" order="50" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_9"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_DocumentType_9" order="60" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_10"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_AmendmentFlag_10" order="70" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_11"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_DocumentPeriodEndDate_11" order="80" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_12"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_DocumentFiscalPeriodFocus_12" order="90" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_13"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_DocumentFiscalYearFocus_13" order="100" use="optional"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.tgtherapeuticsinc.com/role/CondensedConsolidatedBalanceSheets">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_5"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_6"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_us-gaap_AssetsAbstract_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_8"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6" xlink:to="loc_us-gaap_OtherAssetsCurrent_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_9"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6" xlink:to="loc_us-gaap_AssetsCurrent_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_InProcessResearchAndDevelopment" xlink:label="loc_tgtxd_InProcessResearchAndDevelopment_10"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6" xlink:to="loc_tgtxd_InProcessResearchAndDevelopment_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_11"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6" xlink:to="loc_us-gaap_Goodwill_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_12"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6" xlink:to="loc_us-gaap_Assets_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_14"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_NotesPayableCurrent_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_15"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_16"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_InterestPayableCurrent_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_17"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_LiabilitiesCurrent_17" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_18"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_LongTermNotesPayable_18" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_InterestPayableNonCurrent" xlink:label="loc_tgtxd_InterestPayableNonCurrent_19"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_tgtxd_InterestPayableNonCurrent_19" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_20"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_Liabilities_20" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_21"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_CommitmentsAndContingencies_21" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_22"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_StockholdersEquityAbstract_22" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_23"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22" xlink:to="loc_us-gaap_PreferredStockValue_23" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_24"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22" xlink:to="loc_us-gaap_CommonStockValue_24" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_ContingentlyIssuableShares" xlink:label="loc_tgtxd_ContingentlyIssuableShares_25"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22" xlink:to="loc_tgtxd_ContingentlyIssuableShares_25" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_26"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22" xlink:to="loc_us-gaap_AdditionalPaidInCapital_26" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:label="loc_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_27"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22" xlink:to="loc_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_27" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_28"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22" xlink:to="loc_us-gaap_StockholdersEquity_28" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_29"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22" xlink:to="loc_us-gaap_MinorityInterest_29" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_30"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_30" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_31"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_31" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.tgtherapeuticsinc.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_BalanceSheetParentheticalAbstract" xlink:label="loc_tgtxd_BalanceSheetParentheticalAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxd_BalanceSheetParentheticalAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_4"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_5"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_PreferredStockSharesIssued_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_6"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_PreferredStockLiquidationPreferenceValue" xlink:label="loc_tgtxd_PreferredStockLiquidationPreferenceValue_7"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_tgtxd_PreferredStockLiquidationPreferenceValue_7" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_8"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_8" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_9"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_9" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_10"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CommonStockSharesIssued_10" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_11"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_11" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.tgtherapeuticsinc.com/role/CondensedConsolidatedStatementsOfOperations">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_3"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_5"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_NonCashCompensation" xlink:label="loc_tgtxd_NonCashCompensation_6"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_5" xlink:to="loc_tgtxd_NonCashCompensation_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_7"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_5" xlink:to="loc_us-gaap_OtherGeneralAndAdministrativeExpense_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_8"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_5" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_9"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_5" xlink:to="loc_us-gaap_OperatingExpenses_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_10"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_OperatingIncomeLoss_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_11"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_19" xlink:to="loc_us-gaap_InterestExpense_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_12"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_ProfitLoss_12" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_13"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_13" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_14"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_NetIncomeLoss_14" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_15"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_15" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_WeightedAverageNumberOfSharesBasicAndDiluted" xlink:label="loc_tgtxd_WeightedAverageNumberOfSharesBasicAndDiluted_16"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_tgtxd_WeightedAverageNumberOfSharesBasicAndDiluted_16" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_NonCashStockExpense" xlink:label="loc_tgtxd_NonCashStockExpense_17"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3" xlink:to="loc_tgtxd_NonCashStockExpense_17" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_OtherResearchAndDevelopment" xlink:label="loc_tgtxd_OtherResearchAndDevelopment_18"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3" xlink:to="loc_tgtxd_OtherResearchAndDevelopment_18" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_19"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_19" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaap_InvestmentIncomeNet_20"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_19" xlink:to="loc_us-gaap_InvestmentIncomeNet_20" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_ChangeInFairValueOfNonCurrentNotePayable" xlink:label="loc_tgtxd_ChangeInFairValueOfNonCurrentNotePayable_21"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_19" xlink:to="loc_tgtxd_ChangeInFairValueOfNonCurrentNotePayable_21" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_22"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_19" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_22" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.tgtherapeuticsinc.com/role/CondensedConsolidatedStatementOfEquity">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_3"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_PreferredStockMember_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_CommonStockMember_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_5"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ContingentlyIssuableSharesMember" xlink:label="loc_us-gaap_ContingentlyIssuableSharesMember_6"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_ContingentlyIssuableSharesMember_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_7"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_NoncontrollingInterestMember_7" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_8"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_RetainedEarningsMember_8" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_9"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_9" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_10"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_11"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_12"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_SharesOutstanding_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_ChangesDuringPeriodAbstract" xlink:label="loc_tgtxd_ChangesDuringPeriodAbstract_13"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_tgtxd_ChangesDuringPeriodAbstract_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_14"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxd_ChangesDuringPeriodAbstract_13" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_15"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxd_ChangesDuringPeriodAbstract_13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_16"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxd_ChangesDuringPeriodAbstract_13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_16" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_SharesIssuedToNonControllingInterestInConnectionWithLicensingAgreement" xlink:label="loc_tgtxd_SharesIssuedToNonControllingInterestInConnectionWithLicensingAgreement_17"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxd_ChangesDuringPeriodAbstract_13" xlink:to="loc_tgtxd_SharesIssuedToNonControllingInterestInConnectionWithLicensingAgreement_17" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_19"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_19" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_20"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_SharesOutstanding_20" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_ProfitLoss" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.tgtherapeuticsinc.com/role/CondensedConsolidatedStatementOfEquityParenthetical">
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_ConsolidatedStatementOfEquityParentheticalAbstract" xlink:label="loc_tgtxd_ConsolidatedStatementOfEquityParentheticalAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxd_ConsolidatedStatementOfEquityParentheticalAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_PreferredStockIssuedExpenses" xlink:label="loc_tgtxd_PreferredStockIssuedExpenses_5"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_tgtxd_PreferredStockIssuedExpenses_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.tgtherapeuticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_5"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_us-gaap_ProfitLoss_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_7"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_us-gaap_ShareBasedCompensation_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_NonCashStockExpense" xlink:label="loc_tgtxd_NonCashStockExpense_8"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_tgtxd_NonCashStockExpense_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_10"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_11"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_12"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9" xlink:to="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_14"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_14" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_15"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_14" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_16"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_14" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_17"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_17" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_18"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_17" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_19"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_17" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_20"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_17" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_21"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_17" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_21" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_22"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_17" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_22" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_23"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_23" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_24"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_24" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_25"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_25" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonmonetaryTransactionsAbstract" xlink:label="loc_us-gaap_NonmonetaryTransactionsAbstract_26"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_NonmonetaryTransactionsAbstract_26" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_ConversionOfNotesPayableToPreferredStock" xlink:label="loc_tgtxd_ConversionOfNotesPayableToPreferredStock_27"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonmonetaryTransactionsAbstract_26" xlink:to="loc_tgtxd_ConversionOfNotesPayableToPreferredStock_27" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_AccruedFinancingCosts" xlink:label="loc_tgtxd_AccruedFinancingCosts_28"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonmonetaryTransactionsAbstract_26" xlink:to="loc_tgtxd_AccruedFinancingCosts_28" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.tgtherapeuticsinc.com/role/Acquisition">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessAcquisitionDateOfAcquisitionAbstract" xlink:label="loc_us-gaap_BusinessAcquisitionDateOfAcquisitionAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionDateOfAcquisitionAbstract_0" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.tgtherapeuticsinc.com/role/StockholdersEquity">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.tgtherapeuticsinc.com/role/NOTESPAYABLE">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.tgtherapeuticsinc.com/role/LicenseAgreements">
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_LicenseAgreementAbstract" xlink:label="loc_tgtxd_LicenseAgreementAbstract_0"/>
		<loc xlink:type="locator" xlink:href="tgtxd-20120331.xsd#tgtxd_LicenseAgreementDisclosureTextBlock" xlink:label="loc_tgtxd_LicenseAgreementDisclosureTextBlock_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxd_LicenseAgreementAbstract_0" xlink:to="loc_tgtxd_LicenseAgreementDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.tgtherapeuticsinc.com/role/RelatedPartyTransactions">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.tgtherapeuticsinc.com/role/SubsequentEvents">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.tgtherapeuticsinc.com/role/FairValueMeasurements">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Disclosures [Text Block]</a></td>
        <td class="text"><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>NOTE 2 &#8211; FAIR VALUE MEASUREMENTS</b></p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">We measure certain financial assets and liabilities at fair value on a recurring basis in the financial statements. The hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires financial assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="margin-top: 0pt; width: 100%; font: 10pt times new roman, times, serif; margin-bottom: 0pt;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: symbol;">&#183;</font></td>
<td style="text-align: left;">Level 1 &#8211; quoted prices in active markets for identical assets and liabilities;</td>
</tr>
</table>
<p style="text-align: left; margin: 0pt 0px 0pt 0.25in; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="margin-top: 0pt; width: 100%; font: 10pt times new roman, times, serif; margin-bottom: 0pt;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: symbol;">&#183;</font></td>
<td style="text-align: left;">Level 2 &#8211; inputs other than Level 1 quoted prices that are directly or indirectly observable; and</td>
</tr>
</table>
<p style="text-align: left; margin: 0pt 0px 0pt 0.25in; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="margin-top: 0pt; width: 100%; font: 10pt times new roman, times, serif; margin-bottom: 0pt;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: symbol;">&#183;</font></td>
<td style="text-align: left;">Level 3 &#8211; unobservable inputs that are not corroborated by market data.</td>
</tr>
</table>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">As of December 31, 2011 and March 31, 2012, the fair values of cash and cash equivalents, other current assets, notes and interest payable, current portion, accounts payable and accrued expenses, and interest payable, noncurrent approximate their carrying value.</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="background-color: white;">Upon the merger between Manhattan and Ariston Pharmaceuticals, Inc. (&#8220;Ariston&#8221;) in March 2010, Ariston issued $15,452,793 of five-year 5% notes payable (the &#8220;5% Notes&#8221;) in satisfaction of several note payable issuances.&#160;&#160;The 5% Notes and accrued and unpaid interest thereon are convertible at the option of the holder into Common Stock at the conversion price of $1,125 per share.&#160;&#160;Ariston agreed to make quarterly payments on the 5% Notes&#160;equal to 50% of the net product cash flow received from the exploitation or commercialization of Ariston&#8217;s product candidates, AST-726 and AST-915.&#160;&#160;The Company has no obligations under the 5% Notes aside from a) 50% of the net product cash flows from Ariston&#8217;s product candidates, if any, payable to noteholders; and b) the conversion feature, discussed above.</font></p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In connection with the Exchange Transaction in December 2011, the Company performed a valuation of the assets and liabilities of Manhattan immediately prior to the transaction. <font style="background-color: white; color: black;">The cumulative liability including accrued and unpaid interest of these notes was approximately $16,876,000 immediately prior to the Exchange Transaction, $16,883,000 at December 31, 2011, and $17,089,000 at March 31, 2012. </font>As these notes payable are tied directly to net product cash flows derived from the preexisting products of the Company, this note and accrued interest was recorded at fair value of $4,664,697 as of the date of the Exchange Transaction. No payments have been made on these notes as of March 31, 2012.</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">We elected the fair value option for valuing our the 5% Notes upon the completion of the reverse merger with TG Bio, as discussed above. The Company elected the fair value option in order to reflect in our financial statements the assumptions that market participants use in evaluating these financial instruments.</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The valuation methods used to estimate the 5% Notes&#8217; fair value was a discounted cash flow model, where the expected cash flows of AST-726 and AST-915 are discounted to the present using a yield that incorporates compensation for the probability of success in clinical development and marketing, among other factors. The discount rate used in this discounted cash flow model approximated 20% at December 31, 2011 and March 31, 2012. The assumptions, assessments and projections of future revenues are subject to uncertainties, are difficult to predict and require significant judgment. The use of different assumptions, applying different judgment to inherently subjective matters and changes in future market conditions could result in significantly different estimates of fair value and the differences could be material to our consolidated financial statements.</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The following table provides the fair value measurements of applicable financial liabilities as of December 31, 2011 and March 31, 2012:</p>
<p style="text-align:
 left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-align: left;">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="14">Financial&#160;liabilities&#160;at&#160;fair&#160;value&#160;<br />as&#160;of&#160;December&#160;31,&#160;2011</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left;">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2">Level 1</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2">Level 2</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2">Level 3</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2">Total</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td>&#160;</td>
<td style="font-weight: bold;">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2">&#160;</td>
<td style="font-weight: bold;">&#160;</td>
<td style="font-weight: bold;">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2">&#160;</td>
<td style="font-weight: bold;">&#160;</td>
<td style="font-weight: bold;">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2">&#160;</td>
<td style="font-weight: bold;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; width: 48%;">5% Notes</td>
<td style="padding-bottom: 1pt; width: 1%;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left; width: 1%;">$</td>
<td style="border-bottom: black 1pt solid; text-align: right; width: 10%;">&#8212;</td>
<td style="text-align: left; padding-bottom: 1pt; width: 1%;">&#160;</td>
<td style="padding-bottom: 1pt; width: 1%;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left; width: 1%;">$</td>
<td style="border-bottom: black 1pt solid; text-align: right; width: 10%;">&#8212;</td>
<td style="text-align: left; padding-bottom: 1pt; width: 1%;">&#160;</td>
<td style="padding-bottom: 1pt; width: 1%;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left; width: 1%;">$</td>
<td style="border-bottom: black 1pt solid; text-align: right; width: 10%;">4,664,697</td>
<td style="text-align: left; padding-bottom: 1pt; width: 1%;">&#160;</td>
<td style="padding-bottom: 1pt; width: 1%;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left; width: 1%;">$</td>
<td style="border-bottom: black 1pt solid; text-align: right; width: 10%;">4,664,697</td>
<td style="text-align: left; padding-bottom: 1pt; width: 1%;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.12in;">Totals</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">&#8212;</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">&#8212;</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">4,664,697</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">4,664,697</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
</table>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-align: left;">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="14">Financial&#160;liabilities&#160;at&#160;fair&#160;value&#160;<br />as&#160;of&#160;March&#160;31,&#160;2012</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left;">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2">Level 1</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2">Level 2</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2">Level 3</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2">Total</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td>&#160;</td>
<td style="font-weight: bold;">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2">&#160;</td>
<td style="font-weight: bold;">&#160;</td>
<td style="font-weight: bold;">&#160;</td>
<td style="text-align:
 center; font-weight: bold;" colspan="2">&#160;</td>
<td style="font-weight: bold;">&#160;</td>
<td style="font-weight: bold;">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2">&#160;</td>
<td style="font-weight: bold;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; width: 48%;">5% Notes</td>
<td style="padding-bottom: 1pt; width: 1%;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left; width: 1%;">$</td>
<td style="border-bottom: black 1pt solid; text-align: right; width: 10%;">&#8212;</td>
<td style="text-align: left; padding-bottom: 1pt; width: 1%;">&#160;</td>
<td style="padding-bottom: 1pt; width: 1%;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left; width: 1%;">$</td>
<td style="border-bottom: black 1pt solid; text-align: right; width: 10%;">&#8212;</td>
<td style="text-align: left; padding-bottom: 1pt; width: 1%;">&#160;</td>
<td style="padding-bottom: 1pt; width: 1%;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left; width: 1%;">$</td>
<td style="border-bottom: black 1pt solid; text-align: right; width: 10%;">4,664,697</td>
<td style="text-align: left; padding-bottom: 1pt; width: 1%;">&#160;</td>
<td style="padding-bottom: 1pt; width: 1%;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left; width: 1%;">$</td>
<td style="border-bottom: black 1pt solid; text-align: right; width: 10%;">4,664,697</td>
<td style="text-align: left; padding-bottom: 1pt; width: 1%;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.12in;">Totals</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">&#8212;</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">&#8212;</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">4,664,697</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">4,664,697</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
</table>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Level 3 amounts above represent the fair value of the 5% Notes and related accrued interest.</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The following table summarizes the changes in Level 3 instruments during the three months ended March 31, 2012:</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="width: 70%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.5in;" cellspacing="0" cellpadding="0">
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; width: 87%;">Fair value at December 31, 2011</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">4,664,697</td>
<td style="text-align: left; width: 1%;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">Interest accrued on face value of 5% Notes</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">205,297</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt;">Change in fair value of Level 3 liabilities</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(205,297</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt;">Fair value at March 31, 2012</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">4,664,697</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
</table>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The change in the fair value of the Level 3 liabilities is reported in other (income) expense in the accompanying condensed consolidated statement of operations.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6925170&amp;loc=d3e19296-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 159<br><br> -Paragraph 17-22, 27, 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6947722&amp;loc=d3e13433-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 107<br><br> -Paragraph 15C, 15D<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6947722&amp;loc=d3e13504-108611<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 107<br><br> -Paragraph 15A<br><br> -Subparagraph a-d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6947722&amp;loc=d3e13537-108611<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 133<br><br> -Paragraph 44A, 44B<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6925170&amp;loc=d3e19207-110258<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 30<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 107<br><br> -Paragraph 3, 10, 14, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 107<br><br> -Paragraph 15B<br><br> -Subparagraph a, b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 157<br><br> -Paragraph 32, 33, 34<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>15
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
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M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N9&5N<V5D7T-O
M;G-O;&ED871E9%]"86QA;F-E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]N9&5N<V5D7T-O;G-O;&ED871E9%]"86QA;F-E,3PO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970P,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;F1E;G-E
M9%]#;VYS;VQI9&%T961?4W1A=&5M93PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-"YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D-O;F1E;G-E9%]#;VYS;VQI9&%T961?4W1A=&5M
M93$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,#4N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#;VYD
M96YS961?0V]N<V]L:61A=&5D7U-T871E;64R/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`V+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^0V]N9&5N<V5D7T-O;G-O;&ED871E9%]3
M=&%T96UE,SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970P-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/D]21T%.25I!5$E/3E]!3D1?4U5-34%265]/1E]323PO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P
M."YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D9!25)?5D%,545?345!4U5214U%
M3E13/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#`Y+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^04-1
M54E3251)3TX\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,3`N:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y35$]#2TA/3$1%4E-?15%52519/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$Q+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^3D]415-?4$%904),13PO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,BYH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/DQ)0T5.4T5?04=2145-14Y44SPO>#I.
M86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E
M=',O4VAE970Q,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@
M("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E)%3$%4141?4$%2
M5%E?5%)!3E-!0U1)3TY3/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$T+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^4U5"4T51545.5%]%5D5.5%,\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,34N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`\+W@Z17AC96Q7;W)K
M<VAE971S/@T*("`\>#I3='EL97-H965T($A2968],T0B5V]R:W-H965T<R]R
M97!O<G0N8W-S(B\^#0H@(#QX.D%C=&EV95-H965T/C`\+W@Z06-T:79E4VAE
M970^#0H@(#QX.E!R;W1E8W13=')U8W1U<F4^1F%L<V4\+W@Z4')O=&5C=%-T
M<G5C='5R93X-"B`@/'@Z4')O=&5C=%=I;F1O=W,^1F%L<V4\+W@Z4')O=&5C
M=%=I;F1O=W,^#0H@/"]X.D5X8V5L5V]R:V)O;VL^#0H\+WAM;#X\(5ME;F1I
M9ETM+3X-"CPO:&5A9#X-"B`@/&)O9'D^#0H@("`\<#Y4:&ES('!A9V4@<VAO
M=6QD(&)E(&]P96YE9"!W:71H($UI8W)O<V]F="!%>&-E;"!84"!O<B!N97=E
M<BX\+W`^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R
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M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P15-!044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1&]C=6UE;G0@86YD
M($5N=&ET>2!);F9O<FUA=&EO;CQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y-87(N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DUA>2`Q,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^16YT:71Y(%)E9VES=')A;G0@3F%M93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^5$<@5$A%4D%0155424-3+"!)3D,N/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%
M;G1I='D@0V5N=')A;"!);F1E>"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/C`P,#$P,#$S,38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-U<G)E;G0@1FES8V%L(%EE87(@16YD
M($1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/BTM,3(M,S$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D5N=&ET>2!&:6QE<B!#871E9V]R>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^4VUA;&QE<B!297!O<G1I;F<@0V]M<&%N>3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5')A9&EN9R!3
M>6UB;VP\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/G1G='AD/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%
M;G1I='D@0V]M;6]N(%-T;V-K+"!3:&%R97,@3W5T<W1A;F1I;F<\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T+#DQ-RPV-3@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT
M(%1Y<&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C$P+5$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M
M96YD;65N="!&;&%G/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#YF
M86QS93QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^1&]C=6UE;G0@4&5R:6]D($5N9"!$871E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#Y-87(@,S$L#0H)"3(P,3(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT($9I
M<V-A;"!097)I;V0@1F]C=7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/E$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y$;V-U;65N="!&:7-C86P@665A<B!&;V-U<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^,C`Q,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?9C!A-C@S8V)?83(W8U\T-#(P7S@R,#)?
M,30Q96(T-V8R8S5D#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V8P
M838X,V-B7V$R-V-?-#0R,%\X,C`R7S$T,65B-#=F,F,U9"]7;W)K<VAE971S
M+U-H965T,#(N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$50-4%%/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\
M<W1R;VYG/D-O;F1E;G-E9"!#;VYS;VQI9&%T960@0F%L86YC92!3:&5E=',@
M*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y-87(N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^07-S971S/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD(&-A<V@@97%U:79A
M;&5N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C`L.3(S
M+#<U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@.2PW-#@L-#DQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y/=&AE<B!C=7)R96YT(&%S<V5T<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-SDL,#,P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#<L,3<V/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@
M8W5R<F5N="!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(Q+#`P,BPW.#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XY+#@S-2PV-C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN+7!R;V-E<W,@<F5S96%R8V@@86YD
M(&1E=F5L;W!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M+#0T,2PX,SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XU+#0T,2PX,SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D=O;V1W:6QL/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XV,CDL-S4R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-C(Y+#<U,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&%S<V5T<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C<L,#<T+#,W,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U+#DP
M-RPR-3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^3&EA8FEL:71I97,@86YD(&5Q=6ET>3PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.;W1E<R!P87EA
M8FQE+"!C=7)R96YT('!O<G1I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C8W-RPW-S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XX-S<L-S<X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!P87EA8FQE(&%N9"!A
M8V-R=65D(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT-C<L-3(T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-C8V+#8T,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^26YT97)E<W0@<&%Y86)L92P@8W5R<F5N="!P
M;W)T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-BPW.3,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV
M,2PY-#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y4;W1A;"!C=7)R96YT(&QI86)I;&ET:65S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#(R,BPP.34\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#8P-BPS-3D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYO=&5S
M('!A>6%B;&4L(&YO;F-U<G)E;G0@<&]R=&EO;BP@870@9F%I<B!V86QU93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PV-C0L-CDW/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PV-C0L
M-CDW/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5&]T86P@;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4L.#@V+#<Y,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C8L,C<Q+#`U-CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6ET;65N=',@86YD
M(&-O;G1I;F=E;F-I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY%<75I='DZ/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E
M<G)E9"!S=&]C:RP@)#`N,#`Q('!A<B!V86QU92!P97(@<VAA<F4@*#$P+#`P
M,"PP,#`@<VAA<F5S(&%U=&AO<FEZ960L(#$L,3`X+#@Q-B!A;F0@-#$S+#,X
M."!I<W-U960@86YD(&]U='-T86YD:6YG(&%S(&]F($UA<F-H(#,Q+"`R,#$R
M(&%N9"!$96-E;6)E<B`S,2P@,C`Q,2P@<F5S<&5C=&EV96QY+"!A9V=R96=A
M=&4@;&EQ=6ED871I;VX@=F%L=64@;V8@)#(R+#$W-BPS,C`@86YD("0X+#(V
M-RPW-C`@870@36%R8V@@,S$L(#(P,3(@86YD($1E8V5M8F5R(#,Q+"`R,#$Q
M+"!R97-P96-T:79E;'DI/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ+#$P.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C0Q,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"`D,"XP,#$@<&%R('9A;'5E('!E
M<B!S:&%R92`H-3`P+#`P,"PP,#`@<VAA<F5S(&%U=&AO<FEZ960L(#4L,#8Q
M+#,Y.2!S:&%R97,@:7-S=65D(&%N9"!O=71S=&%N9&EN9R!A="!-87)C:"`S
M,2P@,C`Q,B!A;F0@1&5C96UB97(@,S$L(#(P,3$I/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XU+#`V,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,#8Q/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYT:6YG96YT;'D@:7-S
M=6%B;&4@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^061D:71I;VYA;"!P86ED+6EN(&-A<&ET86P\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(R+#@T,2PS,S0\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PT-S(L,3$U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969I8VET
M(&%C8W5M=6QA=&5D(&EN(&1E=F5L;W!M96YT('-T86=E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@Q,2PQ,#DL,38T*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#@U,RPP-S0I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T
M86P@5$<@5&AE<F%P975T:6-S+"!);F,N(&%N9"!S=6)S:61I87)I97,@97%U
M:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,2PW,S@L,S0V
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M.2PV,C0L-3(Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y.;VXM8V]N=')O;&QI;F<@:6YT97)E<W0@:6X@<W5B<VED
M:6%R>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2PT-#DL,C,S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3$L-C@Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5&]T86P@97%U:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR,2PQ.#<L-3<Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^.2PV,S8L,C`R/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@;&EA8FEL:71I
M97,@86YD(&5Q=6ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`R-RPP-S0L,S<Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`Q-2PY,#<L,C4X/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
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M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P15=/04,^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS
M=')O;F<^0V]N9&5N<V5D($-O;G-O;&ED871E9"!"86QA;F-E(%-H965T<R!;
M4&%R96YT:&5T:6-A;%T@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C:RP@
M<&%R('9A;'5E("AI;B!D;VQL87)S('!E<B!S:&%R92D\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,#$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@
M<W1O8VLL('-H87)E<R!A=71H;W)I>F5D/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T
M;V-K+"!S:&%R97,@:7-S=65D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#$P."PX,38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XT,3,L,S@X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@<W1O8VLL('-H87)E
M<R!O=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PQ,#@L.#$V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-#$S+#,X.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K+"!L:7%U:61A=&EO
M;B!P<F5F97)E;F-E('!E<B!S:&%R92`H:6X@9&]L;&%R<RD\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C(L,3<V+#,R,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@."PR-C<L-S8P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y#;VUM;VX@<W1O8VLL('!A<B!V86QU92`H:6X@9&]L;&%R<R!P97(@<VAA
M<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`Q/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P
M+C`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V]M;6]N('-T;V-K+"!S:&%R97,@875T:&]R:7IE9#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3`P+#`P,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,#`L,#`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0V]M;6]N('-T;V-K+"!S:&%R97,@:7-S=65D/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XU+#`V,2PS.3D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#`V,2PS.3D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S
M=&]C:RP@<VAA<F5S(&]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU+#`V,2PS.3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XU+#`V,2PS.3D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V8P838X,V-B7V$R-V-?-#0R,%\X
M,C`R7S$T,65B-#=F,F,U9`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B]F,&$V.#-C8E]A,C=C7S0T,C!?.#(P,E\Q-#%E8C0W9C)C-60O5V]R:W-H
M965T<R]3:&5E=#`T+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%-E1!13X-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY#;VYD96YS960@0V]N<V]L:61A=&5D(%-T871E;65N=',@
M;V8@3W!E<F%T:6]N<R`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,3(\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,CQB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;W-T<R!A
M;F0@97AP96YS97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DYO;BUC87-H('-T;V-K(&5X<&5N<V4@87-S;V-I871E9"!W
M:71H(&EN+6QI8V5N<VEN9R!A9W)E96UE;G0\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,38L-3<X+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,38L.#<U+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W1H97(@
M<F5S96%R8V@@86YD(&1E=F5L;W!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ-C,L,S4S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3DS+#8S-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(')E<V5A<F-H(&%N
M9"!D979E;&]P;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,38L-S0Q+#,U,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$W+#`V."PV,S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1V5N97)A;"!A;F0@861M
M:6YI<W1R871I=F4Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DYO;BUC87-H(&-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3@X+#4P.3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(W-2PP,#,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R(&=E;F5R
M86P@86YD(&%D;6EN:7-T<F%T:79E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XT-34L-#DR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^.3(S+#8X.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&=E;F5R86P@86YD(&%D
M;6EN:7-T<F%T:79E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV
M-#0L,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,2PQ.3@L-CDR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5&]T86P@8V]S=',@86YD(&5X<&5N<V5S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-RPS.#4L,S4T/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@L,C8W
M+#,R.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D]P97)A=&EN9R!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@Q-RPS.#4L,S4T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#$X+#(V-RPS,C@I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]T:&5R
M("AI;F-O;64I(&5X<&5N<V4Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DEN=&5R97-T(&EN8V]M93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,RPV-C@I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,RPV-C@I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1E<F5S="!E>'!E
M;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,C`L,30Y/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C(W
M+#(T-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0VAA;F=E(&EN(&9A:7(@=F%L=64@;V8@;F]N+6-U<G)E;G0@;F]T
M97,@<&%Y86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C`U
M+#(Y-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@R,#4L,CDW*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&]T:&5R("AI;F-O;64I(&5X<&5N<V4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q+#$X-#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X+#(X,3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3F5T(&QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$W+#,Y
M-BPU,S@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,3@L,C@U+#8P.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S(&%T=')I8G5T86)L92!T;R!N
M;VXM8V]N=')O;&QI;F<@:6YT97)E<W0\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#<L,30P+#0T."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@W+#$W-BPT-#4I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,@871T
M<FEB=71A8FQE('1O(%1'(%1H97)A<&5U=&EC<RP@26YC+B!A;F0@<W5B<VED
M:6%R:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#$P+#(U
M-BPP.3`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XD("@Q,2PQ,#DL,38T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0F%S:6,@86YD(&1I;'5T960@;F5T(&QO
M<W,@<&5R(&-O;6UO;B!S:&%R92`H:6X@9&]L;&%R<R!P97(@<VAA<F4I/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#(N,#,I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E
M9"!A=F5R86=E('-H87)E<R!U<V5D(&EN(&-O;7!U=&EN9R!B87-I8R!A;F0@
M9&EL=71E9"!N970@;&]S<R!P97(@8V]M;6]N('-H87)E("AI;B!S:&%R97,I
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#`V,2PS.3D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V8P838X,V-B
M7V$R-V-?-#0R,%\X,C`R7S$T,65B-#=F,F,U9`T*0V]N=&5N="U,;V-A=&EO
M;CH@9FEL93HO+R]#.B]F,&$V.#-C8E]A,C=C7S0T,C!?.#(P,E\Q-#%E8C0W
M9C)C-60O5V]R:W-H965T<R]3:&5E=#`U+FAT;6P-"D-O;G1E;G0M5')A;G-F
M97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@
M=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH
M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%1#%!1SX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY#;VYD96YS960@0V]N<V]L:61A=&5D
M(%-T871E;65N="!O9B!%<75I='D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y0<F5F97)R960@4W1O8VL@6TUE
M;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^0V]M;6]N
M(%-T;V-K(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D%D9&ET:6]N86P@4&%I9"UI;B!#87!I=&%L(%M-96UB97)=/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D-O;G1I;F=E;G1L>2!)<W-U
M86)L92!3:&%R97,@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^3F]N8V]N=')O;&QI;F<@26YT97)E<W0@6TUE;6)E<ET\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4F5T86EN960@16%R;FEN
M9W,@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M5&]T86P\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A
M;&%N8V4@870@1&5C+B`S,2P@,C`Q,3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`T,3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#4L,#8Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,"PT-S(L,3$U/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,2PV.#$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@
M*#@U,RPP-S0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`Y+#8S-BPR,#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A;&%N8V4@*&EN('-H87)E<RD@870@
M1&5C+B`S,2P@,C`Q,3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-#$S+#,X.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C4L,#8Q+#,Y.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#:&%N9V5S(&1U<FEN9R!T:&4@
M<&5R:6]D.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#;VUP96YS871I;VX@:6X@<F5S<&5C="!O9B!R97-T<FEC=&5D('!R
M969E<G)E9"!S=&]C:R!G<F%N=&5D('1O(&5M<&QO>65E<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3@X+#4P.3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X."PU,#D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E
M9"!S=&]C:R!I<W-U960@870@)#(P+C`P('!E<B!S:&%R92P@;F5T(&]F(&5X
M<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV.38\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BPQ
M.#`L-S$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3(L,3@Q+#0P-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K(&ES<W5E9"!A="`D
M,C`N,#`@<&5R('-H87)E+"!N970@;V8@97AP96YS97,@*&EN('-H87)E<RD\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8Y-2PT,C@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E
M<R!I<W-U960@:6X@<W5B<VED:6%R>2!T;R!N;VXM8V]N=')O;&QI;F<@:6YT
M97)E<W0@:6X@8V]N;F5C=&EO;B!W:71H(&EN+6QI8V5N<VEN9R!A9W)E96UE
M;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$V+#4W."PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M-BPU-S@L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y.970@;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH-RPQ-#`L-#0X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#$P+#(U-BPP.3`I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3<L,SDV+#4S."D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A;&%N
M8V4@870@36%R+B`S,2P@,C`Q,CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`Q+#$P.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@-2PP-C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#(R+#@T,2PS,S0\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#DL-#0Y+#(S
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M)"`H,3$L,3`Y+#$V-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#(Q+#$X-RPU-SD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A;&%N8V4@*&EN('-H87)E
M<RD@870@36%R+B`S,2P@,C`Q,CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,2PQ,#@L.#$V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-2PP-C$L,SDY/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
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M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P15%$/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/D-O;F1E;G-E9"!#;VYS;VQI9&%T960@4W1A=&5M96YT(&]F($5Q=6ET
M>2!;4&%R96YT:&5T:6-A;%T@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@<W1O8VL@:7-S=65D(&YE
M="!O9B!E>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`R,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M9C!A-C@S8V)?83(W8U\T-#(P7S@R,#)?,30Q96(T-V8R8S5D#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V8P838X,V-B7V$R-V-?-#0R,%\X,C`R
M7S$T,65B-#=F,F,U9"]7;W)K<VAE971S+U-H965T,#<N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$4V,T%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-O;F1E;G-E9"!#;VYS
M;VQI9&%T960@4W1A=&5M96YT<R!O9B!#87-H($9L;W=S("A54T0@)"D\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R
M+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-
M87(N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D-!4T@@1DQ/5U,@1E)/32!/4$52051)3D<@04-4259)
M5$E%4SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3F5T(&QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H
M,3<L,SDV+#4S."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B0@*#$X+#(X-2PV,#DI/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%D:G5S=&UE;G1S
M('1O(')E8V]N8VEL92!N970@;&]S<R!T;R!N970@8V%S:"!U<V5D(&EN(&]P
M97)A=&EN9R!A8W1I=FET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y3=&]C:R!C;VUP96YS871I;VX@97AP96YS93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@X+#4P.3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(W-2PP,#,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-T;V-K(&ES<W5E9"!I;B!C;VYN96-T:6]N('=I=&@@:6XM;&EC96YS:6YG
M(&%G<F5E;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38L
M-3<X+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$V+#@W-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0VAA;F=E<R!I;B!A<W-E=',@
M86YD(&QI86)I;&ET:65S+"!N970@;V8@969F96-T<R!O9B!A8W%U:7-I=&EO
M;CH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1&5C<F5A<V4@:6X@;W1H97(@8W5R<F5N="!A<W-E=',\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C@L,30W/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$L-S0P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);F-R96%S92!I;B!A
M8V-O=6YT<R!P87EA8FQE(&%N9"!A8V-R=65D(&5X<&5N<V5S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@R-30L-C`T*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U,RPW,#8\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN8W)E
M87-E(&EN(&EN=&5R97-T('!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$T+#@U,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(Q+#DT.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!C87-H('5S960@:6X@;W!E
M<F%T:6YG(&%C=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#@V,2PV,S0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH.30X+#(Q,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0T%32"!&3$]74R!&4D]-
M($E.5D535$E.1R!!0U1)5DE42453.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%C<75I<F5D(&EN(&-O;FYE8W1I
M;VX@=VET:"!A8W%U:7-I=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$P+#,X-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DYE="!C87-H('!R;W9I9&5D(&)Y(&EN=F5S=&EN
M9R!A8W1I=FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3`L,S@V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D-!4T@@1DQ/5U,@1E)/32!&24Y!3D-)3D<@04-4
M259)5$E%4SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4&%Y;65N=',@;V8@<VAO<G0M=&5R;2!L;V%N<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,C`P+#`P,"D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R,#`L,#`P*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E
M9',@9G)O;2!S86QE(&]F(&-O;6UO;B!S=&]C:RP@;F5T/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^.2PX,C0L-C@R/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M
M('-A;&4@;V8@<')E9F5R<F5D('-T;V-K+"!N970\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$R+#(U-RPS,#D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BPR-3<L,S`Y/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/9F9E<FEN
M9R!C;W-T<R!P86ED/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R
M,"PT,38I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,C`L-#$V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DYE="!C87-H('!R;W9I9&5D(&)Y(&9I;F%N8VEN
M9R!A8W1I=FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,BPP,S8L.#DS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C$L.#8Q+#4W-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DY%5"!)3D-214%312!)3B!#05-(($%.
M1"!#05-(($5154E604Q%3E13/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ,2PQ-S4L,C4Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,C`L.3(S+#<U,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!A;F0@8V%S:"!E<75I
M=F%L96YT<R!A="!B96=I;FYI;F<@;V8@<&5R:6]D/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XY+#<T."PT.3$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#05-(($%.1"!#05-(($51
M54E604Q%3E13($%4($5.1"!/1B!015))3T0\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(P+#DR,RPW-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,"PY,C,L-S4P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DY/
M3BU#05-((%1204Y304-424].4SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V]N=F5R<VEO;B!O9B!N;W1E<R!P87EA8FQE
M('1O('!R969E<G)E9"!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C4U+#(W,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^06-C<G5E9"!F:6YA;F-I;F<@8V]S=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-34L-#@W/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,38L-C(V/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
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M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D]21T%.25I!5$E/3B!!3D0@4U5-34%2
M62!/1B!324=.249)0T%.5"!!0T-/54Y424Y'(%!/3$E#2453/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,3(\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06-C;W5N
M=&EN9R!0;VQI8VEE<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-I9VYI9FEC86YT($%C8V]U;G1I;F<@
M4&]L:6-I97,@6U1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!M87)G:6XZ
M(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@
M<V5R:68[)SX\8CY.3U1%(#$@)B,X,C$Q.R!/4D=!3DE:051)3TX@04Y$(%-5
M34U!4ED@3T8@4TE'3DE&24-!3E0@04-#3U5.5$E.1R!03TQ)0TE%4SPO8CX\
M+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!M87)G:6XZ(#!P
M="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
M+"!T:6UE<RP@<V5R:68[)SX\8CX\:3Y$97-C<FEP=&EO;B!O9B!"=7-I;F5S
M<SPO:3X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P
M<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^
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M:6YG(%1'5%@M,3$P,2`H=6)L:71U>&EM86(I+"!A(&YO=F5L+"!T:&ER9"!G
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M96UO<BX\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT
M+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T
M:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P.SPO<#X-"CQP
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P+C5I
M;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
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M9"!W:71H('1H92!I;G-T<G5C=&EO;G,@=&\@1F]R;2`Q,"U1(&%N9"!!<G1I
M8VQE)B,Q-C`[,3`@;V8@4F5G=6QA=&EO;B8C,38P.U,M6"X@06-C;W)D:6YG
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M;W5R($%N;G5A;"!297!O<G0@;VX@1F]R;2`Q,"U+(&9O<B!T:&4@>65A<B!E
M;F1E9"!$96-E;6)E<B`S,2P@,C`Q,2X@5&AE(')E<W5L=',@;V8@;W!E<F%T
M:6]N<R!F;W(@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C:"`S,2P@,C`Q
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M/B8C,38P.SPO:3X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SY/;B!$
M96-E;6)E<B`R.2P@,C`Q,2P@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&%N
M9"!C;VYS=6UM871E9"!A;B!E>&-H86YG92!T<F%N<V%C=&EO;B!A9W)E96UE
M;G0@*'1H92`F(S@R,C`[17AC:&%N9V4@5')A;G-A8W1I;VXF(S@R,C$[*2!W
M:71H($]P=7,@4&]I;G0@4&%R=&YE<G,L($Q,0R`H)B,X,C(P.T]P=7,F(S@R
M,C$[*2!A;F0@5$<@0FEO;&]G:6-S+"!);F,N("AF;W)M97)L>2!K;F]W;B!A
M<R!41R!4:&5R87!E=71I8W,L($EN8RXI("@F(S@R,C`[5$<@0FEO)B,X,C(Q
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M;W9E;6)E<B`R,#$P+"!B=70@9&ED(&YO="!C;VUM96YC92!O<&5R871I;VYS
M('5N=&EL($%P<FEL(#(P,3$L('1H=7,@=&AE(&%C8V]M<&%N>6EN9R!C;VYS
M;VQI9&%T960@9FEN86YC:6%L('-T871E;65N=',@9&\@;F]T(&EN8VQU9&4@
M8V]M<&%R871I=F4@9FEN86YC:6%L(&EN9F]R;6%T:6]N(&9O<B!T:&4@=&AR
M964@;6]N=&AS(&5N9&5D($UA<F-H(#,Q+"`R,#$Q+CPO<#X-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P+C5I;CL@;6%R
M9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM
M97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[
M(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SY/
M;B!!<')I;"`S,"P@,C`Q,BP@=&AE($-O;7!A;GD@9FEL960@82!#97)T:69I
M8V%T92!O9B!!;65N9&UE;G0@=&\@:71S($-E<G1I9FEC871E(&]F($EN8V]R
M<&]R871I;VX@=&\@8VAA;F=E(&ET<R!N86UE(&9R;VT@36%N:&%T=&%N(%!H
M87)M86-E=71I8V%L<RP@26YC+B`H)B,X,C(P.TUA;FAA='1A;B8C.#(R,3LI
M('1O(%1'(%1H97)A<&5U=&EC<RP@26YC+B!);B!C;VYJ=6YC=&EO;B!W:71H
M('1H:7,@8VAA;F=E+"!T:&4@<W5B<VED:6%R>2!F;W)M97)L>2!N86UE9"!4
M1R!4:&5R87!E=71I8W,L($EN8RX@9FEL960@82!#97)T:69I8V%T92!O9B!!
M;65N9&UE;G0@8VAA;F=I;F<@:71S(&YA;64@=&\@5$<@0FEO;&]G:6-S+"!)
M;F,N/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@8F%C:V=R
M;W5N9"UC;VQO<CH@=VAI=&4[('1E>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN
M.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L
M('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[(&UA<F=I;CH@,'!T(#!P
M>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG
M/CQB/CQI/DQI<75I9&ET>2!A;F0@0V%P:71A;"!297-O=7)C97,\+VD^/"]B
M/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG<F]U
M;F0M8V]L;W(Z('=H:71E.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@
M=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!B86-K9W)O=6YD+6-O;&]R
M.B!W:&ET93L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[
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M,3(L('=E(&AA=F4@86X@86-C=6UU;&%T960@9&5F:6-I="!O9B`D,3$L,3`Y
M+#$V-"X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!B86-K
M9W)O=6YD+6-O;&]R.B!W:&ET93L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G
M:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
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M(&]U<B!D<G5G(&-A;F1I9&%T97,N/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P
M<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T
M97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P
M="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/D]N($1E8V5M8F5R
M(#,P+"`R,#$Q+"!W92`\9F]N="!S='EL93TS1"=C;VQO<CH@8FQA8VL[)SYC
M;VUP;&5T960@=&AE(&9I<G-T(&-L;W-I;F<@;V8@=&AE('!R:79A=&4@<&QA
M8V5M96YT(&]F(&]U<B!S96-U<FET:65S+"!I<W-U:6YG(#0L.3(Y+#4R,R!S
M:&%R97,@;V8@0V]M<&%N>2`\+V9O;G0^)#`N,#`Q('!A<B!V86QU92!C;VUM
M;VX@<W1O8VL\9F]N="!S='EL93TS1"=C;VQO<CH@8FQA8VL[)SX@*"8C.#(R
M,#M#;VUM;VX@4W1O8VL@)B,X,C(P.RD@870@82!P<FEC92!P97(@<VAA<F4@
M;V8@)#(N,C4@9F]R('1O=&%L(&=R;W-S('!R;V-E961S+"!B969O<F4@<&QA
M8V5M96YT(&-O;6UI<W-I;VYS(&%N9"!E>'!E;G-E<RP@;V8@)#$Q+#`Y,2PT
M,C4@*'1H92`F(S@R,C`[,C`Q,2!%<75I='D@4$E0128C.#(R,3LI+B8C,38P
M.TEN=F5S=&]R<R!A;'-O(')E8V5I=F5D('=A<G)A;G1S('1O('!U<F-H87-E
M(#$L,C,R+#,X,2!S:&%R97,@;V8@0V]M;6]N(%-T;V-K+B!4:&4@=V%R<F%N
M=',@:&%V92!A;B!E>&5R8VES92!P<FEC92!O9B`D,BXR-2!P97(@<VAA<F4@
M86YD(&%R92!E>&5R8VES86)L92!F;W(@9FEV92!Y96%R<RX\+V9O;G0^/"]P
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z
M#0H@,"XU:6X[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N
M97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P.SPO<#X-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P+C5I;CL@;6%R
M9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM
M97,L('-E<FEF.R<^26X@,C`Q,BP@=V4@8V]M<&QE=&5D('1W;R!A9&1I=&EO
M;F%L(&-L;W-I;F=S(&]F('1H92`R,#$Q($5Q=6ET>2!025!%+B!4:&5S92!C
M;&]S:6YG<R!W97)E(&AE;&0@;VX@2F%N=6%R>2`S,2P@,C`Q,BP@86YD($9E
M8G)U87)Y(#(T+"`R,#$R+B!);B!T:&5S92!C;&]S:6YG<RP@=&AE($-O;7!A
M;GD@:7-S=65D(#8Y-2PT,C@@<VAA<F5S(&]F(&]U<B!397)I97,@02!P<F5F
M97)R960@<W1O8VL@*"8C.#(R,#M#;VUP86YY(%!R969E<G)E9"!3=&]C:R8C
M.#(R,3LI(&%T(&$@<')I8V4@<&5R('-H87)E(&]F("0R,"XP,"P@9F]R('1O
M=&%L(&=R;W-S('!R;V-E961S+"!B969O<F4@<&QA8V5M96YT(&-O;6UI<W-I
M;VYS(&%N9"!E>'!E;G-E<RP@;V8@)#$S+#DP."PU-C`N($4\9F]N="!S='EL
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M=V%R<F%N=',@:&%V92!A;B!E>&5R8VES92!P<FEC92!O9B`D,BXR-2!P97(@
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M>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN
M.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L
M('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SY/=7(@
M0V]M;6]N(%-T;V-K(&ES('%U;W1E9"!O;B`\9F]N="!S='EL93TS1"=C;VQO
M<CH@8FQA8VL[)SYT:&4@3U1#($)U;&QE=&EN($)O87)D/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
M.R<^(#PO9F]N=#X\+V9O;G0^86YD('1R861E<R!U;F1E<B!T:&4@<WEM8F]L
M("8C.#(R,#M41U18+D]"+B8C.#(R,3L\+W`^#0H\<"!S='EL93TS1"=T97AT
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M(&QE9G0[('1E>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O
M;G0@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SY/;B!!<')I
M;"`S,"P@,C`Q,BP@=&AE($-O;7!A;GD@969F96-T960@82!R979E<G-E('-P
M;&ET(&]F(&ET<R!#;VUM;VX@4W1O8VL@870@82!R871I;R!O9B`U-BXR-2!F
M;W(@,2P@<'5R<W5A;G0@=&\@82!P<F5V:6]U<VQY(&]B=&%I;F5D('-T;V-K
M:&]L9&5R(&%U=&AO<FEZ871I;VXN($%L;"!S:&%R92!A;6]U;G1S(&%N9"!P
M97(@<VAA<F4@<')I8V5S(&EN('1H:7,@475A<G1E<FQY(%)E<&]R="!O;B!&
M;W)M(#$P+5$@:&%V92!B965N(')E=')O86-T:79E;'D@861J=7-T960@=&\@
M<F5F;&5C="!T:&4@969F96-T(&]F(&]U<B!R979E<G-E('-T;V-K('-P;&ET
M+"!O;B!A(&9I9G1Y('-I>"!A;F0@;VYE('%U87)T97(@*#4V+C(U*2!F;W(@
M;VYE("@Q*2!B87-I<RP@=6YL97-S(&]T:&5R=VES92!I;F1I8V%T960N)B,Q
M-C`[)B,Q-C`[5&AE(&5X97)C:7-E('!R:6-E(&9O<B!A;&P@<W1O8VL@;W!T
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M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X
M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^
M)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@;6%R
M9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM
M97,L('-E<FEF.R<^/&(^/&D^0V%S:"!A;F0@0V%S:"!%<75I=F%L96YT<SPO
M:3X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X
M="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@
M=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\
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M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P+C5I;CL@
M;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&(^/&D^4F5S96%R8V@@86YD
M($1E=F5L;W!M96YT($-O<W1S/"]I/CPO8CX\+W`^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@
M,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S
M97)I9CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[('1E>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT
M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^4F5S96%R
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M9'D@;W(@=')I86P@8V]N=')A8W0N/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P
M<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!M
M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T
M:6UE<RP@<V5R:68[)SX\8CX\:3Y);BU0<F]C97-S(%)E<V5A<F-H(&%N9"!$
M979E;&]P;65N=#PO:3X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&(^/&D^)B,Q-C`[/"]I/CPO8CX\
M+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XM
M=&]P.B`P<'@[('1E>'0M:6YD96YT.B`P+C5I;CL@9F]N=#H@:71A;&EC(#$P
M<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;BUB;W1T
M;VTZ(#9P=#L@;6%R9VEN+6QE9G0Z(#!I;CLG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG/D%L;`T*
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M=VET:"!I=',@8V%R<GEI;F<@86UO=6YT+CPO9F]N=#X\+W`^#0H\<"!S='EL
M93TS1"=T97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!T(#!P>#L@9F]N
M=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P
M.SPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&UA<F=I;CH@
M,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S
M97)I9CLG/CQB/CQI/DEN8V]M92!487AE<SPO:3X\+V(^/"]P/@T*/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT
M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&(^/&D^
M)B,Q-C`[/"]I/CPO8CX\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!L
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M+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N
M=#H@,"XU:6X[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N
M97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P.SPO<#X-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P+C5I;CL@;6%R
M9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM
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M96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M
M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T
M:6UE<RP@<V5R:68[)SY792!R96-O9VYI>F4@:6YT97)E<W0@86YD('!E;F%L
M=&EE<R!R96QA=&5D('1O('5N8V5R=&%I;B!I;F-O;64@=&%X('!O<VET:6]N
M<R!I;B!I;F-O;64@=&%X(&5X<&5N<V4N/"]P/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&(^/&D^)B,Q-C`[/"]I
M/CPO8CX\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!M87)G
M:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[)SX\8CX\:3Y3=&]C:RU"87-E9"!#;VUP96YS871I;VX\+VD^
M/"]B/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M
M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN
M.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
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M+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N
M=#H@,"XU:6X[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N
M97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P.SPO<#X-"CQP('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT
M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^1F]R('-H
M87)E+6)A<V5D('!A>6UE;G1S('1O(&-O;G-U;'1A;G1S(&%N9"!O=&AE<B!T
M:&ER9"UP87)T:65S+"!C;VUP96YS871I;VX@97AP96YS92!I<R!D971E<FUI
M;F5D(&%T('1H92`F(S@R,C`[;65A<W5R96UE;G0@9&%T92XF(S@R,C$[(%1H
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M86-H('-U8G-E<75E;G0@<F5P;W)T:6YG(&1A=&4N/"]P/@T*/'`@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z
M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\
M+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!M87)G:6XZ(#!P
M="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[)SX\8CX\:3Y"87-I8R!A;F0@1&EL=71E9"!.970@*$QO<W,I($EN8V]M
M92!097(@4VAA<F4@;V8@0V]M;6]N(%-T;V-K/"]I/CPO8CX\+W`^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!M87)G:6XZ(#!P="`P<'@[(&9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\8CX\
M:3XF(S$V,#L\+VD^/"]B/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('1E>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^0F%S
M:6,@;F5T(&EN8V]M92`H;&]S<RD@<&5R('-H87)E(&]F($-O;6UO;B!3=&]C
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M:&4@8V%L8W5L871I;VX@=V5R92`Q-"PQ-30L-#4R(&%T($UA<F-H(#,Q+"`R
M,#$R+B!$=7)I;F<@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C:"`S,2P@
M,C`Q,BP@=&AE($-O;7!A;GD@:6YC=7)R960@82!N970@;&]S<SL@=&AE<F5F
M;W)E+"!A;&P@;V8@=&AE(&1I;'5T:79E('-E8W5R:71I97,@87)E(&5X8VQU
M9&5D(&9R;VT@=&AE(&-O;7!U=&%T:6]N(&]F(&1I;'5T960@96%R;FEN9W,@
M<&5R('-H87)E+CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL
M('1I;65S+"!S97)I9CLG/CQB/CQI/B8C,38P.SPO:3X\+V(^/"]P/@T*/'`@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@;6%R9VEN.B`P<'0@,'!X.R!F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&(^
M/&D^26UP86ER;65N=#PO:3X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M
M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T
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M+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N
M=#H@,"XU:6X[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N
M97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P.SPO<#X-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P+C5I;CL@;6%R
M9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM
M97,L('-E<FEF.R<^1V]O9'=I;&P@:7,@<F5V:65W960@9F]R(&EM<&%I<FUE
M;G0@86YN=6%L;'D@;W(@=VAE;B!E=F5N=',@87)I<V4@=&AA="!C;W5L9"!I
M;F1I8V%T92!T:&%T(&%N(&EM<&%I<FUE;G0@97AI<W1S+B!792!T97-T(&9O
M<B!G;V]D=VEL;"!I;7!A:7)M96YT('5S:6YG(&$@='=O+7-T97`@<')O8V5S
M<RX@5&AE(&9I<G-T('-T97`@8V]M<&%R97,@=&AE(&9A:7(@=F%L=64@;V8@
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M86)L92X\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
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M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D9!25(@5D%,544@
M345!4U5214U%3E13/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DUA<BX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^1F%I<B!686QU92!$:7-C;&]S=7)E<R!;06)S=')A
M8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D9A:7(@5F%L=64@1&ES8VQO<W5R97,@6U1E>'0@0FQO8VM=/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=M87)G:6XZ(#!P
M="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[)SX\8CY.3U1%(#(@)B,X,C$Q.R!&04E2(%9!3%5%($U%05-54D5-14Y4
M4SPO8CX\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT
M+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T
M:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P.SPO<#X-"CQP
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P+C5I
M;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
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M92!F;VQL;W=I;F<@=&AR964@8V%T96=O<FEE<SH\+W`^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I
M;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S
M+"!S97)I9CLG/B8C,38P.SPO<#X-"CQT86)L92!S='EL93TS1"=M87)G:6XM
M=&]P.B`P<'0[('=I9'1H.B`Q,#`E.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XM8F]T=&]M.B`P<'0[)R!C96QL
M<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!T;W`[)SX-"CQT9"!S='EL93TS1"=W:61T:#H@,"XU
M:6X[)SX\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`P+C(U:6X[)SX\9F]N
M=#XF(S$X,SL\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^3&5V96P@,2`F(S@R,3$[('%U;W1E9"!P<FEC97,@:6X@86-T
M:79E(&UA<FME=',@9F]R(&ED96YT:6-A;"!A<W-E=',@86YD(&QI86)I;&ET
M:65S.SPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[(&UA<F=I;CH@,'!T(#!P>"`P<'0@,"XR-6EN.R!F;VYT
M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[
M/"]P/@T*/'1A8FQE('-T>6QE/3-$)VUA<F=I;BUT;W`Z(#!P=#L@=VED=&@Z
M(#$P,"4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[(&UA<F=I;BUB;W1T;VTZ(#!P=#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O
M<#LG/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`P+C5I;CLG/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G=VED=&@Z(#`N,C5I;CLG/CQF;VYT/B8C,3@S.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SY,979E;"`R
M("8C.#(Q,3L@:6YP=71S(&]T:&5R('1H86X@3&5V96P@,2!Q=6]T960@<')I
M8V5S('1H870@87)E(&1I<F5C=&QY(&]R(&EN9&ER96-T;'D@;V)S97)V86)L
M93L@86YD/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@;6%R9VEN.B`P<'0@,'!X(#!P="`P+C(U:6X[(&9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V
M,#L\+W`^#0H\=&%B;&4@<W1Y;&4],T0G;6%R9VEN+71O<#H@,'!T.R!W:61T
M:#H@,3`P)3L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S
M97)I9CL@;6%R9VEN+6)O='1O;3H@,'!T.R<@8V5L;'-P86-I;F<],T0P(&-E
M;&QP861D:6YG/3-$,#X-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M=&]P.R<^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#`N-6EN.R<^/"]T9#X-"CQT
M9"!S='EL93TS1"=W:61T:#H@,"XR-6EN.R<^/&9O;G0^)B,Q.#,[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/DQE=F5L
M(#,@)B,X,C$Q.R!U;F]B<V5R=F%B;&4@:6YP=71S('1H870@87)E(&YO="!C
M;W)R;V)O<F%T960@8GD@;6%R:V5T(&1A=&$N/"]T9#X-"CPO='(^#0H\+W1A
M8FQE/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@;6%R9VEN.B`P
M<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E
M<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z
M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SY!<R!O9B!$
M96-E;6)E<B`S,2P@,C`Q,2!A;F0@36%R8V@@,S$L(#(P,3(L('1H92!F86ER
M('9A;'5E<R!O9B!C87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S+"!O=&AE<B!C
M=7)R96YT(&%S<V5T<RP@;F]T97,@86YD(&EN=&5R97-T('!A>6%B;&4L(&-U
M<G)E;G0@<&]R=&EO;BP@86-C;W5N=',@<&%Y86)L92!A;F0@86-C<G5E9"!E
M>'!E;G-E<RP@86YD(&EN=&5R97-T('!A>6%B;&4L(&YO;F-U<G)E;G0@87!P
M<F]X:6UA=&4@=&AE:7(@8V%R<GEI;F<@=F%L=64N/"]P/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G
M:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!T97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!T(#!P>#L@
M9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQF
M;VYT('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R<^57!O;B!T
M:&4@;65R9V5R(&)E='=E96X@36%N:&%T=&%N(&%N9"!!<FES=&]N(%!H87)M
M86-E=71I8V%L<RP@26YC+B`H)B,X,C(P.T%R:7-T;VXF(S@R,C$[*2!I;B!-
M87)C:"`R,#$P+"!!<FES=&]N(&ES<W5E9"`D,34L-#4R+#<Y,R!O9B!F:79E
M+7EE87(@-24@;F]T97,@<&%Y86)L92`H=&AE("8C.#(R,#LU)2!.;W1E<R8C
M.#(R,3LI(&EN('-A=&ES9F%C=&EO;B!O9B!S979E<F%L(&YO=&4@<&%Y86)L
M92!I<W-U86YC97,N)B,Q-C`[)B,Q-C`[5&AE(#4E($YO=&5S(&%N9"!A8V-R
M=65D(&%N9"!U;G!A:60@:6YT97)E<W0@=&AE<F5O;B!A<F4@8V]N=F5R=&EB
M;&4@870@=&AE(&]P=&EO;B!O9B!T:&4@:&]L9&5R(&EN=&\@0V]M;6]N(%-T
M;V-K(&%T('1H92!C;VYV97)S:6]N('!R:6-E(&]F("0Q+#$R-2!P97(@<VAA
M<F4N)B,Q-C`[)B,Q-C`[07)I<W1O;B!A9W)E960@=&\@;6%K92!Q=6%R=&5R
M;'D@<&%Y;65N=',@;VX@=&AE(#4E($YO=&5S)B,Q-C`[97%U86P@=&\@-3`E
M(&]F('1H92!N970@<')O9'5C="!C87-H(&9L;W<@<F5C96EV960@9G)O;2!T
M:&4@97AP;&]I=&%T:6]N(&]R(&-O;6UE<F-I86QI>F%T:6]N(&]F($%R:7-T
M;VXF(S@R,3<[<R!P<F]D=6-T(&-A;F1I9&%T97,L($%35"TW,C8@86YD($%3
M5"TY,34N)B,Q-C`[)B,Q-C`[5&AE($-O;7!A;GD@:&%S(&YO(&]B;&EG871I
M;VYS('5N9&5R('1H92`U)2!.;W1E<R!A<VED92!F<F]M(&$I(#4P)2!O9B!T
M:&4@;F5T('!R;V1U8W0@8V%S:"!F;&]W<R!F<F]M($%R:7-T;VXF(S@R,3<[
M<R!P<F]D=6-T(&-A;F1I9&%T97,L(&EF(&%N>2P@<&%Y86)L92!T;R!N;W1E
M:&]L9&5R<SL@86YD(&(I('1H92!C;VYV97)S:6]N(&9E871U<F4L(&1I<V-U
M<W-E9"!A8F]V92X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[
M(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF
M(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT
M+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T
M:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/DEN(&-O;FYE8W1I;VX@
M=VET:"!T:&4@17AC:&%N9V4@5')A;G-A8W1I;VX@:6X@1&5C96UB97(@,C`Q
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M9"!I;G1E<F5S="!O9B!T:&5S92!N;W1E<R!W87,@87!P<F]X:6UA=&5L>2`D
M,38L.#<V+#`P,"!I;6UE9&EA=&5L>2!P<FEO<B!T;R!T:&4@17AC:&%N9V4@
M5')A;G-A8W1I;VXL("0Q-BPX.#,L,#`P(&%T($1E8V5M8F5R(#,Q+"`R,#$Q
M+"!A;F0@)#$W+#`X.2PP,#`@870@36%R8V@@,S$L(#(P,3(N(#PO9F]N=#Y!
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M92!N;W1E<R!A<R!O9B!-87)C:"`S,2P@,C`Q,BX\+W`^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I
M;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S
M+"!S97)I9CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('1E>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^5V4@
M96QE8W1E9"!T:&4@9F%I<B!V86QU92!O<'1I;VX@9F]R('9A;'5I;F<@;W5R
M('1H92`U)2!.;W1E<R!U<&]N('1H92!C;VUP;&5T:6]N(&]F('1H92!R979E
M<G-E(&UE<F=E<B!W:71H(%1'($)I;RP@87,@9&ES8W5S<V5D(&%B;W9E+B!4
M:&4@0V]M<&%N>2!E;&5C=&5D('1H92!F86ER('9A;'5E(&]P=&EO;B!I;B!O
M<F1E<B!T;R!R969L96-T(&EN(&]U<B!F:6YA;F-I86P@<W1A=&5M96YT<R!T
M:&4@87-S=6UP=&EO;G,@=&AA="!M87)K970@<&%R=&EC:7!A;G1S('5S92!I
M;B!E=F%L=6%T:6YG('1H97-E(&9I;F%N8VEA;"!I;G-T<G5M96YT<RX\+W`^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@
M,"XU:6X[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@
M<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN
M.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L
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M)2!A="!$96-E;6)E<B`S,2P@,C`Q,2!A;F0@36%R8V@@,S$L(#(P,3(N(%1H
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M960@9FEN86YC:6%L('-T871E;65N=',N/"]P/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P
M="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!T97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@
M,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/E1H92!F;VQL
M;W=I;F<@=&%B;&4@<')O=FED97,@=&AE(&9A:7(@=F%L=64@;65A<W5R96UE
M;G1S(&]F(&%P<&QI8V%B;&4@9FEN86YC:6%L(&QI86)I;&ET:65S(&%S(&]F
M($1E8V5M8F5R(#,Q+"`R,#$Q(&%N9"!-87)C:"`S,2P@,C`Q,CH\+W`^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.@T*(&QE9G0[('1E>'0M:6YD96YT.B`P
M+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'1A8FQE('-T>6QE
M/3-$)W=I9'1H.B`Q,#`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<@8V5L
M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O;&0[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI
M9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+7=E:6=H=#H@8F]L9#LG(&-O
M;'-P86X],T0Q-#Y&:6YA;F-I86PF(S$V,#ML:6%B:6QI=&EE<R8C,38P.V%T
M)B,Q-C`[9F%I<B8C,38P.W9A;'5E)B,Q-C`[/&)R("\^87,F(S$V,#MO9B8C
M,38P.T1E8V5M8F5R)B,Q-C`[,S$L)B,Q-C`[,C`Q,3PO=&0^#0H\=&0@<W1Y
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M/DQE=F5L(#$\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
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M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[
M(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ
M(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,CY,979E
M;"`S/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F
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M;VT[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CLG(&-O;'-P86X],T0R/B8C,38P.SPO=&0^#0H\=&0^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F
M;VYT+7=E:6=H=#H@8F]L9#LG(&-O;'-P86X],T0R/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M=V5I9VAT
M.B!B;VQD.R<@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=F;VYT+7=E:6=H=#H@8F]L9#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G9F]N="UW96EG:'0Z(&)O;&0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[)R!C
M;VQS<&%N/3-$,CXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M=V5I
M9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G
M8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I
M;F<M8F]T=&]M.B`Q<'0[('=I9'1H.B`T."4[)SXU)2!.;W1E<SPO=&0^#0H\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@=VED=&@Z(#$E.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B0\
M+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S
M;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q,"4[)SXF(S@R,3([
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG
M+6)O='1O;3H@,7!T.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('=I9'1H.B`Q)3LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T
M('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXD/"]T9#X-
M"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[
M('1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,3`E.R<^)B,X,C$R.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T
M;VTZ(#%P=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
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M(#%P=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P
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M=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4]
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M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R
M+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R<^)#PO
M=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@
M9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#LG/B8C.#(Q,CL\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R
M+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[
M)SXD/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R
M+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^-"PV-C0L-CDW/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O
M='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N
M.B!L969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#LG/C0L-C8T
M+#8Y-SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D
M9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\+W1A
M8FQE/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E
M;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@
M;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\=&%B;&4@
M<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P
M<V4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T
M('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&9O;G0M=V5I9VAT.B!B;VQD
M.R<@8V]L<W!A;CTS1#$T/D9I;F%N8VEA;"8C,38P.VQI86)I;&ET:65S)B,Q
M-C`[870F(S$V,#MF86ER)B,Q-C`[=F%L=64F(S$V,#L\8G(@+SYA<R8C,38P
M.V]F)B,Q-C`[36%R8V@F(S$V,#LS,2PF(S$V,#LR,#$R/"]T9#X-"CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7=E:6=H=#H@8F]L
M9#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
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M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG
M:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,CY,979E;"`R/"]T9#X-"CQT9"!S='EL
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M=F5L(#,\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[
M(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&9O;G0M=V5I9VAT.B!B
M;VQD.R<@8V]L<W!A;CTS1#(^5&]T86P\+W1D/@T*/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[
M/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V
M,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X-"CQT9#XF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([
M(&9O;G0M=V5I9VAT.B!B;VQD.R<@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X-
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M>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M=V5I9VAT.B!B;VQD
M.R<@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+7=E:6=H=#H@8F]L9#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE
M/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-C8V9F8V,[('9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P
M861D:6YG+6)O='1O;3H@,7!T.R!W:61T:#H@-#@E.R<^-24@3F]T97,\+W1D
M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('=I9'1H.B`Q
M)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[
M)SXD/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q
M<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,3`E.R<^)B,X
M,C$R.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D
M9&EN9RUB;W1T;VTZ(#%P=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT
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M8F]T=&]M.B`Q<'0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@=VED=&@Z(#$E.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@
M<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B0\+W1D/@T*
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@
M=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q,"4[)SXT+#8V-"PV.3<\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T
M=&]M.B`Q<'0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L
M:60[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B0\+W1D/@T*/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X
M="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q,"4[)SXT+#8V-"PV.3<\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M
M.B`Q<'0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T
M>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R!V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!P861D:6YG+6QE9G0Z(#`N,3)I;CLG
M/E1O=&%L<SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N
M-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T
M9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D
M;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^)B,X,C$R.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N
M-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
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M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L
M969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#LG/C0L-C8T+#8Y
M-SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN
M9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA
M;&EG;CH@;&5F=#LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[)SXT
M+#8V-"PV.3<\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*
M/"]T86)L93X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M
M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN
M.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
M+"!T:6UE<RP@<V5R:68[)SY4:&4@3&5V96P@,R!A;6]U;G1S(&%B;W9E(')E
M<')E<V5N="!T:&4@9F%I<B!V86QU92!O9B!T:&4@-24@3F]T97,@86YD(')E
M;&%T960@86-C<G5E9"!I;G1E<F5S="X\+W`^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!T
M(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I
M9CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('1E>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q
M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^5&AE(&9O;&QO
M=VEN9R!T86)L92!S=6UM87)I>F5S('1H92!C:&%N9V5S(&EN($QE=F5L(#,@
M:6YS=')U;65N=',@9'5R:6YG('1H92!T:')E92!M;VYT:',@96YD960@36%R
M8V@@,S$L(#(P,3(Z/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z
M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\
M+W`^#0H\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#<P)3L@8F]R9&5R+6-O;&QA
M<'-E.B!C;VQL87!S93L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I
M;65S+"!S97)I9CL@;6%R9VEN+6QE9G0Z(#`N-6EN.R<@8V5L;'-P86-I;F<]
M,T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD
M+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#@W)3LG/D9A
M:7(@=F%L=64@870@1&5C96UB97(@,S$L(#(P,3$\+W1D/@T*/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)#PO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q,"4[)SXT+#8V-"PV.3<\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q
M)3LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U
M;F0M8V]L;W(Z('=H:71E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/DEN=&5R97-T(&%C8W)U
M960@;VX@9F%C92!V86QU92!O9B`U)2!.;W1E<SPO=&0^#0H\=&0^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C(P-2PR
M.3<\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V
M,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R
M.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#%P=#LG
M/D-H86YG92!I;B!F86ER('9A;'5E(&]F($QE=F5L(#,@;&EA8FEL:71I97,\
M+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V
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M86QU92!A="!-87)C:"`S,2P@,C`Q,CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI
M9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^-"PV
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M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P+C5I;CL@
M;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R<^5&AE(&-H86YG92!I;B!T:&4@9F%I<B!V86QU92!O
M9B!T:&4@3&5V96P@,R!L:6%B:6QI=&EE<R!I<R!R97!O<G1E9"!I;B!O=&AE
M<B`H:6YC;VUE*2!E>'!E;G-E(&EN('1H92!A8V-O;7!A;GEI;F<@8V]N9&5N
M<V5D(&-O;G-O;&ED871E9"!S=&%T96UE;G0@;V8@;W!E<F%T:6]N<RX\+W`^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
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M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D%#455)4TE424]./&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,3(\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0G5S:6YE
M<W,@06-Q=6ES:71I;VXL($1A=&4@;V8@06-Q=6ES:71I;VX@6T%B<W1R86-T
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"
M=7-I;F5S<R!#;VUB:6YA=&EO;B!$:7-C;&]S=7)E(%M497AT($)L;V-K73PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'`@<W1Y;&4],T0G;6%R
M9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM
M97,L('-E<FEF.R<^/&(^3D]412`S("T@04-154E3251)3TX\+V(^/"]P/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N
M-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@
M,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S
M97)I9CLG/D]N($1E8V5M8F5R(#(Y+"`R,#$Q+"!T:&4@0V]M<&%N>2!C;VUP
M;&5T960@82!R979E<G-E(&%C<75I<VET:6]N(&]F('!R:79A=&5L>2!H96QD
M(%1'($)I;RP@82!$96QA=V%R92!#;W)P;W)A=&EO;BX@5&AE(&%C<75I<VET
M:6]N('=A<R!E9F9E8W1E9"!P=7)S=6%N="!T;R!A;B!%>&-H86YG92!4<F%N
M<V%C=&EO;B!!9W)E96UE;G0@*'1H92`F(S@R,C`[06=R965M96YT)B,X,C(Q
M.RD@9&%T960@1&5C96UB97(@,CDL(#(P,3$@8GD@86YD(&%M;VYG('1H92!#
M;VUP86YY+"!41R!":6\@86YD($]P=7,L('1H92!L87)G97-T('-H87)E:&]L
M9&5R(&]F(%1'($)I;RX@26X@86-C;W)D86YC92!W:71H('1H92!T97)M<R!O
M9B!T:&4@06=R965M96YT+"`Y-24@;V8@=&AE(&AO;&1E<G,@;V8@8V]M;6]N
M('-T;V-K(&]F(%1'($)I;R`H;VYE("@Q*2!M:6YO<FET>2!S:&%R96AO;&1E
M<B!O9B!41R!":6\@:&]L9&EN9R!I;B!A9V=R96=A=&4@,3,R+#`P,"!S:&%R
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M(%-T;V-K+B`\+V9O;G0^5&AE($-O;7!A;GD@4')E9F5R<F5D(%-T;V-K(&AA
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M9&ER96-T(&%N9"]O<B!I;F1I<F5C="!O=VYE<G-H:7`@;V8@87!P<F]X:6UA
M=&5L>2`Y-24@;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!O=71S=&%N9&EN9R!#
M;VUP86YY($-O;6UO;B!3=&]C:R!I;6UE9&EA=&5L>2!F;VQL;W=I;F<@=&AE
M(&-O;G-U;6UA=&EO;B!O9B!T:&4@=')A;G-A8W1I;VXN/"]P/@T*/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT
M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[
M/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E
M;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@
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M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N
M-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T
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M;F1I<F5C="!O=VYE<G-H:7`@;V8@87!P<F]X:6UA=&5L>2`Y-24@;V8@=&AE
M($-O;7!A;GDF(S@R,3<[<R!O=71S=&%N9&EN9R!C;VUM;VX@<W1O8VL@87,@
M;V8@1&5C96UB97(@,CDL(#(P,3$N($)A<V5D(&]N(&9A:7(@=F%L=64@;V8@
M=&AE($-O;7!A;GDF(S@R,3<[<R!#;VUM;VX@4W1O8VL@;V8@)#`N,#0@<&5R
M('-H87)E+"!T:&4@<'5R8VAA<V4@<')I8V4@=V%S("0R.34L.3,S+"!P;'5S
M('1H92!F86ER('9A;'5E(&]F(')E<W1R:6-T960@<W1O8VL@87-S=6UE9"!O
M9B`D.#(L,S`U+B!);B!C;VYN96-T:6]N('=I=&@@=&AE($5X8VAA;F=E(%1R
M86YS86-T:6]N+"!T:&4@0V]M<&%N>2!I;F-U<G)E9"`D,C,Q+#4X,"!O9B!A
M8W%U:7-I=&EO;B!R96QA=&5D(&-O<W1S+CPO<#X-"CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P
M<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E
M<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z
M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SY!('-U;6UA
M<GD@;V8@=&AE('!U<F-H87-E('!R:6-E(&-A;&-U;&%T:6]N(&ES(&%S(&9O
M;&QO=W,Z/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@;6%R
M9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM
M97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'1A8FQE('-T>6QE/3-$)W=I9'1H
M.B`W,"4[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[(&9O;G0Z(#$P<'0@
M=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;BUL969T.B`P
M+C5I;CLG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(@
M<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[('1E>'0M:6YD96YT.B`M,3(N-G!T.R!P861D:6YG+6QE9G0Z(#$R+C9P
M=#L@=VED=&@Z(#<T)3LG/DYU;6)E<B!O9B!S:&%R97,@;V8@36%N:&%T=&%N
M(&-O;6UO;B!S=&]C:R!O=71S=&%N9&EN9R!A="!T:&4@=&EM92!O9B!T:&4@
M=')A;G-A8W1I;VX\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED
M=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#L@=VED=&@Z(#$P)3LG/C$S,2PU,C8\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@
M,3`E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL
M93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET93L@=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A
M9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M:6YD96YT.B`M,"XQ:6X[('!A9&1I
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M9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXD
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@<&%D9&EN
M9RUB;W1T;VTZ(#%P=#LG/C(Y-2PY,S,\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\
M+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C
M8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/D9A
M:7(@=F%L=64@;V8@<F5S=')I8W1E9"!S=&]C:R!A<W-U;65D/"]T9#X-"CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O
M;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
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M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q
M<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R<^.#(L,S`U/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@
M,7!T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R
M;W5N9"UC;VQO<CH@=VAI=&4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O
M;3H@,BXU<'0[('!A9&1I;F<M;&5F=#H@,3(N-G!T.R<^5&]T86P@<'5R8VAA
M<V4@<')I8V4\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R
M+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@<&%D9&EN9RUB;W1T;VTZ
M(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@
M9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L
M:6=N.B!R:6=H=#LG/C,W."PR,S@\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO
M=&0^#0H\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@
M<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN
M.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L
M('-E<FEF.R<^5&AE('!U<F-H87-E('!R:6-E(&AA<R!B965N(&%L;&]C871E
M9"!A<R!F;VQL;W=S(&)A<V5D(&]N('1H92!F86ER('9A;'5E<R!O9B!T:&4@
M87-S971S(&%N9"!L:6%B:6QI=&EE<R!A8W%U:7)E9#H\+W`^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z
M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\
M+W`^#0H\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#<P)3L-"B!B;W)D97(M8V]L
M;&%P<V4Z(&-O;&QA<'-E.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R!M87)G:6XM;&5F=#H@,"XU:6X[)R!C96QL<W!A8VEN
M9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U
M;F0M8V]L;W(Z("-C8V9F8V,[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@
M+3`N,C5I;CL@<&%D9&EN9RUL969T.B`P+C(U:6X[('=I9'1H.B`X-R4[)SY#
M87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S/"]T9#X-"CQT9"!S='EL93TS1"=W
M:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,3`E.R<^,3`L,S@V/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXF(S$V
M,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R
M.B!W:&ET93L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M,"XR-6EN.R!P
M861D:6YG+6QE9G0Z(#`N,C5I;CLG/D]T:&5R(&%S<V5T<SPO=&0^#0H\=&0^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG
M/CDP+#<V.3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG
M/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M
M8V]L;W(Z("-C8V9F8V,[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@
M,7!T.R!T97AT+6EN9&5N=#H@+3`N,C5I;CL@<&%D9&EN9RUL969T.B`P+C(U
M:6X[)SY);BUP<F]C97-S(')E<V5A<F-H(&%N9"!D979E;&]P;65N="!A8W%U
M:7)E9#PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[
M('1E>'0M86QI9VXZ(')I9VAT.R<^-2PT-#$L.#0P/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T.R<^
M)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC
M;VQO<CH@=VAI=&4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T
M.R!T97AT+6EN9&5N=#H@+3`N,C5I;CL@<&%D9&EN9RUL969T.B`P+C,V:6X[
M)SY4;W1A;"!I9&5N=&EF:6%B;&4@87-S971S/"]T9#X-"CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI
M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[)SXU
M+#4T,BPY.34\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT
M<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@=&5X="UI;F1E;G0Z("TP+C(U:6X[('!A9&1I;F<M;&5F=#H@,"XR
M-6EN.R<^06-C;W5N=',@<&%Y86)L92!A;F0@86-C<G5E9"!E>'!E;G-E<SPO
M=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#LG/C$Y-RPQ.3$\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B
M86-K9W)O=6YD+6-O;&]R.B!W:&ET93L@=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD
M96YT.B`M,"XR-6EN.R!P861D:6YG+6QE9G0Z(#`N,C5I;CLG/DYO=&5S('!A
M>6%B;&4@*$E#3TX@86YD(%-W:7-S(%!H87)M82D\+W1D/@T*/'1D/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXY,SDL
M-S$X/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO
M<CH@(V-C9F9C8SL@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[
M('1E>'0M:6YD96YT.B`M,"XR-6EN.R!P861D:6YG+6QE9G0Z(#`N,C5I;CLG
M/C4E(&YO=&5S('!A>6%B;&4@86YD(&%C8W)U960@:6YT97)E<W0\+W1D/@T*
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D
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M:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE
M9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[)SXU+#<Y-"PU
M,#D\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I
M;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL
M93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M=&5X="UI;F1E;G0Z("TP+C(U:6X[('!A9&1I;F<M;&5F=#H@,"XR-6EN.R<^
M3F5T(&ED96YT:69I86)L92!L:6%B:6QI=&EE<SPO=&0^#0H\=&0^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
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M;&P\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T
M97AT+6%L:6=N.B!R:6=H=#LG/C8R.2PW-3(\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V
M,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R
M.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#%P=#L@
M=&5X="UI;F1E;G0Z("TP+C(U:6X[('!A9&1I;F<M;&5F=#H@,"XS-FEN.R<^
M5&]T86P\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P
M=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R<^)#PO=&0^
M#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U
M8FQE.R!T97AT+6%L:6=N.B!R:6=H=#LG/C,W."PR,S@\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P
M=#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN
M.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L
M('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SY!('9A
M;'5A=&EO;B!W87,@<&5R9F]R;65D('1O(&1E=&5R;6EN92!T:&4@9F%I<B!V
M86QU92!O9B!C97)T86EN(&ED96YT:69I86)L92!I;G1A;F=I8FQE(&%S<V5T
M<R!O9B!-86YH871T86XN/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V
M,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN
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M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N
M-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T
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M"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P
M+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ
M(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@
M<V5R:68[)SY4:&4@9F]L;&]W:6YG('-U<'!L96UE;G1A;"!P<F\@9F]R;6$@
M:6YF;W)M871I;VX@<')E<V5N=',@=&AE(&9I;F%N8VEA;"!R97-U;'1S(&%S
M(&EF('1H92!T<F%N<V%C=&EO;B!H860@;V-C=7)R960@;VX@2F%N=6%R>2`Q
M+"`R,#$Q(&9O<B!T:&4@=&AR964@;6]N=&AS(&5N9&5D($UA<F-H(#,Q+"`R
M,#$Q+B8C,38P.U1H:7,@<W5P<&QE;65N=&%L('!R;R!F;W)M82!I;F9O<FUA
M=&EO;B!H87,@8F5E;B!P<F5P87)E9"!F;W(@8V]M<&%R871I=F4@<'5R<&]S
M97,@86YD(&1O97,@;F]T('!U<G!O<G0@=&\@8F4@:6YD:6-A=&EV92!O9B!W
M:&%T('=O=6QD(&AA=F4@;V-C=7)R960@:&%D('1H92!A8W%U:7-I=&EO;B!B
M965N(&UA9&4@;VX@2F%N=6%R>2`Q+"`R,#$Q+"!N;W(@87)E('1H97D@:6YD
M:6-A=&EV92!O9B!F=71U<F4@<F5S=6QT<RX\+W`^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@
M,'!T(#!P>#L@9F]N=#H-"B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L
M('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'1A8FQE('-T>6QE/3-$)W=I9'1H.B`V
M,"4[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[(&9O;G0Z(#$P<'0@=&EM
M97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;BUL969T.B`P+C5I
M;CLG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(@<W1Y
M;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/E)E=F5N=64\+W1D/@T*/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE
M.R!T97AT+6%L:6=N.B!L969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R
M:6=H=#LG/B8C.#(Q,CL\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\
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M1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D
M9&EN9RUB;W1T;VTZ(#(N-7!T.R<^0F%S:6,@86YD(&1I;'5T960@:6YC;VUE
M('!E<B!C;VUM;VX@<VAA<F4\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L
M969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#LG/C$N-3$\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T
M=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/"]T86)L93X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V8P838X,V-B
M7V$R-V-?-#0R,%\X,C`R7S$T,65B-#=F,F,U9`T*0V]N=&5N="U,;V-A=&EO
M;CH@9FEL93HO+R]#.B]F,&$V.#-C8E]A,C=C7S0T,C!?.#(P,E\Q-#%E8C0W
M9C)C-60O5V]R:W-H965T<R]3:&5E=#$Q+FAT;6P-"D-O;G1E;G0M5')A;G-F
M97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@
M=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH
M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0R/CQS=')O;F<^4U1/0TM(3TQ$15)3)R!%455)5%D\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,CQB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3
M=&]C:VAO;&1E<G,G($5Q=6ET>2!.;W1E(%M!8G-T<F%C=%T\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VMH;VQD97)S
M)R!%<75I='D@3F]T92!$:7-C;&]S=7)E(%M497AT($)L;V-K73PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&(^3D]412`T("T@4U1/0TM(3TQ$
M15)3)R!%455)5%D\+V(^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T
M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&(^/&D^4')E9F5R
M<F5D(%-T;V-K/"]I/CPO8CX\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I
M;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S
M+"!S97)I9CLG/D]U<B!A;65N9&5D(&%N9"!R97-T871E9"!C97)T:69I8V%T
M92!O9B!I;F-O<G!O<F%T:6]N(&%U=&AO<FEZ97,@=&AE(&ES<W5A;F-E(&]F
M('5P('1O(#$P+#`P,"PP,#`@<VAA<F5S(&]F('!R969E<G)E9"!S=&]C:RP@
M)#`N,#`Q('!A<B!V86QU92P@=VET:"!R:6=H=',@<V5N:6]R('1O('1H;W-E
M(&]F(&]U<B!C;VUM;VX@<W1O8VLL(#QF;VYT('-T>6QE/3-$)V)A8VMG<F]U
M;F0M8V]L;W(Z('=H:71E.R!C;VQO<CH@8FQA8VL[)SYI<W-U86)L92!I;B!O
M;F4@;W(@;6]R92!S97)I97,N(%5P;VX@:7-S=6%N8V4L('1H92!#;VUP86YY
M(&-A;B!D971E<FUI;F4@=&AE(')I9VAT<RP@<')E9F5R96YC97,L('!R:79I
M;&5G97,@86YD(')E<W1R:6-T:6]N<R!T:&5R96]F+B!4:&5S92!R:6=H=',L
M('!R969E<F5N8V5S(&%N9"!P<FEV:6QE9V5S(&-O=6QD(&EN8VQU9&4@9&EV
M:61E;F0@<FEG:'1S+"!C;VYV97)S:6]N(')I9VAT<RP@=F]T:6YG(')I9VAT
M<RP@=&5R;7,@;V8@<F5D96UP=&EO;BP@;&EQ=6ED871I;VX@<')E9F5R96YC
M97,L('-I;FMI;F<@9G5N9"!T97)M<R!A;F0@=&AE(&YU;6)E<B!O9B!S:&%R
M97,@8V]N<W1I='5T:6YG(&%N>2!S97)I97,@;W(@=&AE(&1E<VEG;F%T:6]N
M(&]F('-U8V@@<V5R:65S+"!A;GD@;W(@86QL(&]F('=H:6-H(&UA>2!B92!G
M<F5A=&5R('1H86X@=&AE(')I9VAT<R!O9B!C;VUM;VX@<W1O8VLN/"]F;VYT
M/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD
M96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M
M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T
M:6UE<RP@<V5R:68[)SX\9F]N="!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R
M.B!W:&ET93L@8V]L;W(Z(&)L86-K.R<^5&AE<F4@=V5R92`Q+#$P."PX,38@
M<VAA<F5S(&]F($-O;7!A;GD@4')E9F5R<F5D(%-T;V-K(&]U='-T86YD:6YG
M(&%S(&]F($UA<F-H(#,Q+"`R,#$R+B`\+V9O;G0^26X@8V]N;F5C=&EO;B!W
M:71H('1H92!%>&-H86YG92!4<F%N<V%C=&EO;BP@=&AE($-O;7!A;GD@9FEL
M960@82!#97)T:69I8V%T92!O9B!$97-I9VYA=&EO;B!W:71H(')E<W!E8W0@
M=&\@:71S($-O;7!A;GD@4')E9F5R<F5D(%-T;V-K('=I=&@@=&AE(%-E8W)E
M=&%R>2!O9B!3=&%T92!O9B!T:&4@4W1A=&4@;V8@1&5L87=A<F4N)B,Q-C`[
M)B,Q-C`[5&AE($-O;7!A;GD@4')E9F5R<F5D(%-T;V-K(')A;FMS('-E;FEO
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M-C`[)B,Q-C`[5&AE($-O;7!A;GD@4')E9F5R<F5D(%-T;V-K('9O=&5S(&]N
M(&%N(&%S+6-O;G9E<G1E9"!B87-I<R!W:71H('1H92!#;VUM;VX@4W1O8VLN
M/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E
M;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@
M;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,"XU:6X[(&UA
M<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I
M;65S+"!S97)I9CLG/DEN(&-O;FIU;F-T:6]N('=I=&@@=&AE(')E=F5R<V4@
M<W!L:70@969F96-T960@;VX@07!R:6P@,S`L(#(P,3(@*&%S(&1I<V-U<W-E
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M/CQB/CQI/D-O;6UO;B!3=&]C:SPO:3X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ
M(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@
M<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!T97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!T(#!P>#L@9F]N
M=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/D]U<B!A
M;65N9&5D(&%N9"!R97-T871E9"!C97)T:69I8V%T92!O9B!I;F-O<G!O<F%T
M:6]N(&%U=&AO<FEZ97,@=&AE(&ES<W5A;F-E(&]F('5P('1O(#4P,"PP,#`L
M,#`P('-H87)E<R!O9B`D,"XP,#$@<&%R('9A;'5E(&-O;6UO;B!S=&]C:RX\
M+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N
M=#H@,"XU:6X[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N
M97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P.SPO<#X-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P+C5I;CL@;6%R
M9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM
M97,L('-E<FEF.R<^3VX@1&5C96UB97(@,S`L(#(P,3$L('=E(#QF;VYT('-T
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M>'!E;G-E<RP@;V8@)#$Q+#`Y,2PT,C4@*'1H92`F(S@R,C`[,C`Q,2!%<75I
M='D@4$E0128C.#(R,3LI+B8C,38P.TEN=F5S=&]R<R!A;'-O(')E8V5I=F5D
M('=A<G)A;G1S('1O('!U<F-H87-E(#$L,C,R+#,X,2!S:&%R97,@;V8@0V]M
M;6]N(%-T;V-K+B!4:&4@=V%R<F%N=',@:&%V92!A;B!E>&5R8VES92!P<FEC
M92!O9B`D,BXR-2!P97(@<VAA<F4@86YD(&%R92!E>&5R8VES86)L92!F;W(@
M9FEV92!Y96%R<RX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[
M(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF
M(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT
M+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T
M:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/DEN(#(P,3(L('=E(&-O
M;7!L971E9"!T=V\@861D:71I;VYA;"!C;&]S:6YG<R!O9B!T:&4@,C`Q,2!%
M<75I='D@4$E012X@5&AE<V4@8VQO<VEN9W,@=V5R92!H96QD(&]N($IA;G5A
M<GD@,S$L(#(P,3(L(&%N9"!&96)R=6%R>2`R-"P@,C`Q,BX@26X@=&AE<V4@
M8VQO<VEN9W,L('1H92!#;VUP86YY(&ES<W5E9"`V.34L-#(X('-H87)E<R!O
M9B!O=7(@0V]M<&%N>2!0<F5F97)R960@4W1O8VL@870@82!P<FEC92!P97(@
M<VAA<F4@;V8@)#(P+C`P(&9O<B!T;W1A;"!G<F]S<R!P<F]C965D<RP@8F5F
M;W)E('!L86-E;65N="!C;VUM:7-S:6]N<R!A;F0@97AP96YS97,L(&]F("0Q
M,RPY,#@L-38P+B!%/&9O;G0@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@
M=VAI=&4[)SYA8V@@<VAA<F4@;V8@0V]M<&%N>2!0<F5F97)R960@4W1O8VL@
M:7,@8V]N=F5R=&EB;&4@:6YT;R`X+C@Y('-H87)E<R!O9B!#;VUM;VX@4W1O
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M92!P<FEC92!O9B`D,BXR-2!P97(@<VAA<F4@86YD(&%R92!E>&5R8VES86)L
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M;"!T;R`Q,"4@;V8@=&AE(&=R;W-S('!R;V-E961S(&]F('1H92!O9F9E<FEN
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M>'!E;G-E<RXF(S$V,#LF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ
M(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@
M<V5R:68[)SX\9F]N="!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET
M93LG/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\8CX\:3Y%<75I='D@26YC96YT:79E
M(%!L86YS/"]I/CPO8CX\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N+"!T:6UE<RP@<V5R:68[)SX\8CX\:3XF(S$V,#L\+VD^/"]B/CPO<#X-
M"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P
M+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R<^02!S=6UM87)Y(&]F('1H92!S=&%T=7,@
M;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!S=&]C:R!O<'1I;VYS(&%S(&]F($UA
M<F-H(#,Q+"`R,#$R(&%N9"!C:&%N9V5S(&1U<FEN9R!T:&4@<&5R:6]D('1H
M96X@96YD960@:7,@<')E<V5N=&5D#0H@8F5L;W<Z/"]P/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q
M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@;6%R9VEN.B`P<'0@
M,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
M.R<^/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'@[)SX\+W`^#0H\<"!S
M='EL93TS1"=M87)G:6XZ(#!P>#LG/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE
M<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQU/E-T;V-K($]P=&EO;G,\
M+W4^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI
M;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM
M97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,"XU:6X[
M(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL
M('1I;65S+"!S97)I9CLG/E1H92!F;VQL;W=I;F<@=&%B;&4@<W5M;6%R:7IE
M<R!S=&]C:R!O<'1I;VX@86-T:79I='D@9F]R('1H92!T:')E92!M;VYT:',@
M96YD960@36%R8V@@,S$L(#(P,3(Z/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'1A8FQE
M('-T>6QE/3-$)W=I9'1H.B`Q,#`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA
M<'-E.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
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M=&5R.R!F;VYT+7=E:6=H=#H@8F]L9#LG(&-O;'-P86X],T0R/@T*/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!M87)G:6XZ(#!P="`P<'@[(&9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\8CXF
M(S$V,#L\+V(^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
M+"!T:6UE<RP@<V5R:68[)SX\8CY.=6UB97(\+V(^/"]P/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z
M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\8CYO9B8C
M,38P.W-H87)E<SPO8CX\+W`^#0H\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T
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M=&5D+3PO8CX\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([
M(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL
M('1I;65S+"!S97)I9CLG/CQB/F%V97)A9V4\+V(^/"]P/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z
M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\8CYE>&5R
M8VES928C,38P.W!R:6-E/"]B/CPO<#X-"CPO=&0^#0H\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O;&0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O
M;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E
M;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,CX-"CQP('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;6%R9VEN.B`P<'0@,'!X.R!F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&(^
M5V5I9VAT960M/"]B/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R<^/&(^879E<F%G93PO8CX\+W`^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&UA<F=I;CH@,'!T(#!P>#L@
M9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQB
M/D-O;G1R86-T=6%L/"]B/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&-E;G1E<CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&(^5&5R;3PO8CX\+W`^#0H\+W1D
M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I
M9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG
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M;65S+"!S97)I9CLG/CQB/B8C,38P.SPO8CX\+W`^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.B!C96YT97([(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P
M="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQB/D%G9W)E9V%T
M93PO8CX\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&UA
M<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I
M;65S+"!S97)I9CLG/CQB/DEN=')I;G-I8SQB<B`O/E9A;'5E/"]B/CPO<#X-
M"CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N
M="UW96EG:'0Z(&)O;&0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG(&-O;'-P86X]
M,T0R/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<@8V]L<W!A
M;CTS1#(^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M=V5I9VAT.B!B;VQD.R<@
M8V]L<W!A;CTS1#(^*&EN('EE87)S*3PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="UW96EG:'0Z(&)O;&0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O
M;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!C96YT97([(&9O;G0M=V5I9VAT.B!B;VQD.R<@8V]L<W!A
M;CTS1#(^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@
M8F]L9#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG
M<F]U;F0M8V]L;W(Z("-C8V9F8V,[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@-#@E
M.R<^3W5T<W1A;F1I;F<@870@1&5C96UB97(@,S$L(#(P,3$\+W1D/@T*/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#$P)3LG
M/C,L,S<Y/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W
M:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@=VED=&@Z(#$E.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[('=I9'1H.B`Q,"4[)SXQ+#,Q-2XV,CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H
M.B`Q,"4[)SXV+C,Y/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#$P)3LG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^
M)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC
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M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,X,C$R
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P
M.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT
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M=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#LG/B8C.#(Q,CL\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXF(S@R,3([/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT
M9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@
M<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[('9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!P861D:6YG+6QE9G0Z(#EP=#LG/D9O<F9E:71E9#PO=&0^#0H\=&0^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/B@R
M+#0W-3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/BD\
M+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[)SXW,C`N-#4\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
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M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@
M=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R
M:6=H=#LG/B8C.#(Q,CL\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M
M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
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M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M
M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R!P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@
M,7!T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R
M;W5N9"UC;VQO<CH@=VAI=&4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O
M;3H@,BXU<'0[)SY/=71S=&%N9&EN9R!A="!-87)C:"`S,2P@,C`Q,CPO=&0^
M#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P
M="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@
M=&5X="UA;&EG;CH@<FEG:'0[)SXY,#0\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[
M('1E>'0M86QI9VXZ(')I9VAT.R<^,BPY-#4N,#D\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N
M-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N
M-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[)SXR+C0Y/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@
M,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T
M.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#LG/B8C.#(Q,CL\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T
M=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$
M)V)A8VMG<F]U;F0M8V]L;W(Z("-C8V9F8V,[('9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-
M"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\
M='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0[)SY697-T960@86YD(&5X<&5C
M=&5D('1O('9E<W0@870@36%R8V@@,S$L(#(P,3(\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ
M(')I9VAT.R<^.3`T/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U
M8FQE.R!T97AT+6%L:6=N.B!L969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N
M.B!R:6=H=#LG/C(L.30U+C`Y/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU
M<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[
M('1E>'0M86QI9VXZ(')I9VAT.R<^,BXT.3PO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[
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M+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ
M(#(N-7!T.R<^17AE<F-I<V%B;&4@870@36%R8V@@,S$L(#(P,3(\+W1D/@T*
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@
M9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E
M>'0M86QI9VXZ(')I9VAT.R<^.#DX/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C
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M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P
M=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P
M="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^,BXT,SPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N
M-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
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M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!M87)G:6XZ(#!P="`P<'@[(&9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V
M,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN
M9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE
M<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/D%S(&]F($UA<F-H(#,Q+"`R
M,#$R+"!T:&4@=&]T86P@8V]M<&5N<V%T:6]N(&-O<W0@<F5L871E9"!T;R!U
M;G9E<W1E9"!O<'1I;VX@87=A<F1S(&YO="!Y970@<F5C;V=N:7IE9"!I<R!L
M97-S('1H86X@)#$L,#`P+B!4:&4@=V5I9VAT960@879E<F%G92!P97)I;V0@
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M<W1R:6-T960@4W1O8VL\+W4^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[
M(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF
M(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT
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M+"`R,#$R.CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&UA
M<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I
M;65S+"!S97)I9CLG/B8C,38P.SPO<#X-"CQT86)L92!S='EL93TS1"=W:61T
M:#H@.#`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!F;VYT.B`Q,'!T
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M86XL('1I;65S+"!S97)I9CLG/CQB/B8C,38P.SPO8CX\+W`^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.B!C96YT97([(&UA<F=I;CH@,'!T(#!P>#L@9F]N
M=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQB/DYU
M;6)E<B8C,38P.V]F(%-H87)E<SPO8CX\+W`^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97([(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T
M:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQB/E)E<W1R:6-T960F
M(S$V,#M397)I97,F(S$V,#L\+V(^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@8V5N=&5R.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM
M97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\8CY!(%!R969E<G)E9#PO
M8CX\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&UA<F=I
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M9#LG(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N
M=&5R.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N+"!T:6UE<RP@<V5R:68[)SX\8CY796EG:'1E9"8C,38P.SPO8CX\+W`^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&UA<F=I;CH@,'!T
M(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I
M9CLG/CQB/D%V97)A9V4\+V(^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@
M;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\8CY'<F%N="8C,38P.T1A=&4F
M(S$V,#L\+V(^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
M+"!T:6UE<RP@<V5R:68[)SX\8CY&86ER(%9A;'5E/"]B/CPO<#X-"CPO=&0^
M#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG
M:'0Z(&)O;&0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[
M)R!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E
M<CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
M;BP@=&EM97,L('-E<FEF.R<^/&(^06=G<F5G871E/"]B/CPO<#X-"CQP('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;6%R9VEN.B`P<'0@,'!X.R!F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&(^
M26YT<FEN<VEC/"]B/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
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M.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@
M,34E.R<^,3(Y+#,W-3PO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B0\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,34E.R<^,C`N,#`\
M+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,34E.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT
M<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET93L@=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@
M.7!T.R<^1W)A;G1E9#PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V
M,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[)SXF(S@R,3([/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*
M/'1D/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#LG/B8C.#(Q,CL\+W1D/@T*/'1D/B8C,38P
M.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT
M9#XF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD
M+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.B`Y<'0[)SY697-T960\+W1D/@T*
M/'1D/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,X,C$R
M.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M)SXF(S@R,3([/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO
M=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CPO='(^
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M('-O;&ED.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R<^)B,X
M,C$R.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P
M=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#%P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S@R,3([/"]T9#X-"CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[
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M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R
M+C(U<'0@9&]U8FQE.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R
M:6=H=#LG/C$R.2PS-S4\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R<^)#PO=&0^#0H\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L
M93L@=&5X="UA;&EG;CH@<FEG:'0[)SXR,"XP,#PO=&0^#0H\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B
M;&4[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#LG/C<L-S8R+#4P
M,#PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^
M)B,Q-C`[/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z("TQ<'0[(&UA<F=I;CH@,'!T
M(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I
M9CLG/CQB/B8C,38P.SPO8CX\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!T97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!T(#!P>#L@
M9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL('1I
M;65S+"!S97)I9CLG/CQB/CQS=7`^*#$I(#PO<W5P/CPO8CX\+V9O;G0^5&AE
M(')E<W1R:6-T960@0V]M<&%N>2!0<F5F97)R960@4W1O8VL@;&ES=&5D(&EN
M('1H92!T86)L92!A8F]V92!W87,@9W)A;G1E9"!I;B!C;VYN96-T:6]N('=I
M=&@@=&AE($5X8VAA;F=E(%1R86YS86-T:6]N('1O(&-E<G1A:6X@97AE8W5T
M:79E<R!A<R!D:7-C=7-S960@86)O=F4N($5A8V@@<VAA<F4@;V8@0V]M<&%N
M>2!0<F5F97)R960@4W1O8VL@:7,@8V]N=F5R=&EB;&4@:6YT;R`X+C@Y('-H
M87)E<R!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS($-O;6UO;B!3=&]C:RP@<')O
M=FED960@=&AA="!S=6-H(&-O;G9E<G-I;VX@<FEG:'0@:7,@<W5B:F5C="!T
M;R!S=69F:6-I96YT(&%V86EL86)L92!A=71H;W)I>F5D('-H87)E<R!O9B!T
M:&4@<F5G:7-T<F%N="8C.#(Q-SMS(&-O;6UO;B!S=&]C:RX\+W`^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,"XU:6X[
M(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL
M('1I;65S+"!S97)I9CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@
M,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
M.R<^5&]T86P@97AP96YS92!A<W-O8VEA=&5D('=I=&@@<F5S=')I8W1E9"!S
M=&]C:R!W87,@)#$X."PU,#D@9'5R:6YG('1H92!T:')E92!M;VYT:',@96YD
M960@36%R8V@@,S$L(#(P,3(N/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q
M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/'4^5V%R<F%N
M=',\+W4^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X
M="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@
M=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,"XU
M:6X[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M
M86XL('1I;65S+"!S97)I9CLG/E1H92!F;VQL;W=I;F<@=&%B;&4@<W5M;6%R
M:7IE<R!W87)R86YT(&%C=&EV:71Y(&9O<B!T:&4@=&AR964@;6]N=&AS(&5N
M9&5D($UA<F-H(#,Q+"`R,#$R.CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N
M97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P.SPO<#X-"CQT86)L92!S
M='EL93TS1"=W:61T:#H@.#`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E
M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<@
M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ#0H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
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M+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&UA<F=I;CH@
M,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S
M97)I9CLG/CQB/E=A<G)A;G1S/"]B/CPO<#X-"CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O;&0[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[
M(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[)R!C;VQS<&%N/3-$
M,CX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;6%R9VEN.B`P
M<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E
M<FEF.R<^/&(^5V5I9VAT960M/"]B/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&-E;G1E<CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&(^879E<F%G93PO8CX\
M+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&UA<F=I;CH@
M,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S
M97)I9CLG/CQB/F5X97)C:7-E('!R:6-E/"]B/CPO<#X-"CPO=&0^#0H\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O
M;&0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M
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M)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W
M:61T:#H@,34E.R<^,BPQ,3@L-S8X/"]T9#X-"CQT9"!S='EL93TS1"=W:61T
M:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R<^)#PO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q-24[
M)SXT+C8R/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#$U)3LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CPO
M='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[('9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=P861D:6YG
M+6QE9G0Z(#EP=#LG/DES<W5E9#PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT
M9#XF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[)SXR+#$V,RPU-34\+W1D/@T*/'1D/B8C,38P
M.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,BXS,3PO=&0^#0H\=&0^
M)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXF(S$V,#L\+W1D
M/@T*/'1D/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG
M<F]U;F0M8V]L;W(Z("-C8V9F8V,[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M)SX-"CQT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#EP=#LG/D5X97)C:7-E
M9#PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M)SXF(S@R,3([/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO
M=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#LG/B8C.#(Q,CL\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0^
M)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D
M/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET
M93L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=&5X="UD96-O<F%T:6]N.B!N
M;VYE.R<^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@<&%D
M9&EN9RUL969T.B`Y<'0[('1E>'0M9&5C;W)A=&EO;CH@;F]N93LG/D5X<&ER
M960\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E
M>'0M9&5C;W)A=&EO;CH@;F]N93LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@=&5X="UD96-O<F%T:6]N.B!N;VYE
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q<'0@<V]L:60[('1E>'0M9&5C;W)A=&EO;CH@;F]N93LG/B8C,38P
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M=&]M.B`Q<'0[('1E>'0M9&5C;W)A=&EO;CH@;F]N93LG/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('!A9&1I;F<M8F]T=&]M.B`Q
M<'0[('1E>'0M9&5C;W)A=&EO;CH@;F]N93LG/C(L.#$R+C4P/"]T9#X-"CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!T97AT+61E8V]R871I
M;VXZ(&YO;F4[)SX\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q<'0[('1E>'0M9&5C;W)A=&EO;CH@;F]N93LG/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@=&5X="UD96-O<F%T:6]N.B!N
M;VYE.R<^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@
M<&%D9&EN9RUB;W1T;VTZ(#%P=#L@=&5X="UD96-O<F%T:6]N.B!N;VYE.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T
M.R!T97AT+61E8V]R871I;VXZ(&YO;F4[)SXF(S$V,#L\+W1D/@T*/"]T<CX-
M"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#(N,C5P=#LG/D]U='-T86YD:6YG(&%T($UA<F-H(#,Q+"`R,#$R
M/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P
M=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,BXR-7!T(&1O=6)L93LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@=&5X="UA
M;&EG;CH@<FEG:'0[)SXT+#(X,"PX-S0\+W1D/@T*/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R<^
M)#PO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR
M-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[)SXR+C4P/"]T9#X-"CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR
M-7!T(&1O=6)L93LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^
M)B,X,C$R.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N
M-7!T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q
M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&(^/&D^)B,Q
M-C`[/"]I/CPO8CX\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!T97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@
M,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQB/CQI/CPO
M:3X\+V(^1'5R:6YG('1H92!T:')E92!M;VYT:',@96YD960@36%R8V@@,S$L
M(#(P,3$L(&%S('!A<G0@;V8@=&AE(#(P,3$@17%U:71Y(%!)4$4L('=E(&ES
M<W5E9"!W87)R86YT<R!T;R!P=7)C:&%S92!U<"!T;R`Q+#4T-2PS.38@<VAA
M<F5S(&]F(&]U<B!#;VUP86YY($-O;6UO;B!3=&]C:R!T;R!I;G9E<W1O<G,@
M:6X@=&AE(#(P,3$@17%U:71Y(%!)4$4L(&YO;F4@;V8@=VAI8V@@:&%V92!B
M965N(&5X97)C:7-E9"!A<R!O9B!-87)C:"`S,2P@,C`Q,BX@5&AE('=A<G)A
M;G1S(&AA=F4@86X@97AE<F-I<V4@<')I8V4@;V8@)#(N,C4@<&5R('=A<G)A
M;G0@<VAA<F4N($EN(&%D9&ET:6]N+"!W92!I<W-U960@=&\@=&AE('!L86-E
M;65N="!A9V5N="!I;B!T:&4@=')A;G-A8W1I;VX@=V%R<F%N=',@=&\@<'5R
M8VAA<V4@=7`@=&\@-C$X+#$U.2!S:&%R97,@;V8@;W5R($-O;7!A;GD@0V]M
M;6]N(%-T;V-K(&%T(&%N(&5X97)C:7-E('!R:6-E(&]F("0R+C0X('!E<B!W
M87)R86YT('-H87)E+"!N;VYE(&]F('=H:6-H(&AA=F4@8F5E;B!E>&5R8VES
M960@87,@;V8@36%R8V@@,S$L(#(P,3(N/"]P/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P
M="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
M+"!T:6UE<RP@<V5R:68[)SX\8CX\:3Y3=&]C:RU"87-E9"!#;VUP96YS871I
M;VX\+VD^/"]B/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('1E>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q
M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z
M(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W
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M(&1U<FEN9R!T:&4@=&AR964@;6]N=&AS(&5N9&5D($UA<F-H(#,Q+"`R,#$R
M+CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD
M96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M
M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T
M:6UE<RP@<V5R:68[)SY4:&4@9F]L;&]W:6YG('1A8FQE('-U;6UA<FEZ97,@
M<W1O8VLM8F%S960@8V]M<&5N<V%T:6]N#0H@97AP96YS92!I;F9O<FUA=&EO
M;B!A8F]U="!S=&]C:R!O<'1I;VYS(&%N9"!R97-T<FEC=&5D('-T;V-K(&9O
M<B!T:&4@=&AR964@;6]N=&AS(&5N9&5D($UA<F-H(#,Q+"`R,#$R.CPO<#X-
M"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P
M+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'1A8FQE('-T>6QE
M/3-$)W=I9'1H.B`X,"4[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[(&9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)R!C96QL
M<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R('-T>6QE/3-$)V)A
M8VMG<F]U;F0M8V]L;W(Z("-C8V9F8V,[('9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN
M9&5N=#H@+3$T+C)P=#L@<&%D9&EN9RUL969T.B`Q-"XR<'0[('=I9'1H.B`X
M-R4[)SY3=&]C:RUB87-E9"!C;VUP96YS871I;VX@97AP96YS92!A<W-O8VEA
M=&5D('=I=&@@<F5S=')I8W1E9"!S=&]C:SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!W:61T:#H@,24[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#$P)3LG/C$X."PU,#D\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C
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M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#LG/B8C.#(Q,CL\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T
M=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B
M86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN
M9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6EN9&5N=#H@+3$T+C)P=#L@<&%D9&EN
M9RUL969T.B`Q-"XR<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L
M:6=N.B!L969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#LG/C$X
M."PU,#D\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A
M9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/"]T
M86)L93X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
M7V8P838X,V-B7V$R-V-?-#0R,%\X,C`R7S$T,65B-#=F,F,U9`T*0V]N=&5N
M="U,;V-A=&EO;CH@9FEL93HO+R]#.B]F,&$V.#-C8E]A,C=C7S0T,C!?.#(P
M,E\Q-#%E8C0W9C)C-60O5V]R:W-H965T<R]3:&5E=#$R+FAT;6P-"D-O;G1E
M;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E
M;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT
M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^3D]415,@4$%904),13QB
M<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$R
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/D1E8G0@1&ES8VQO<W5R92!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E8G0@1&ES8VQO<W5R92!;5&5X
M="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQP('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&UA<F=I;CH@,'!T(#!P>#L@9F]N
M=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQB/DY/
M5$4@-2`F(S@R,3$[($Y/5$53(%!!64%"3$4\+V(^/"]P/@T*/'`@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z
M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\
M+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N
M=#H@,"XU:6X[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N
M97<@<F]M86XL('1I;65S+"!S97)I9CLG/E1H92!F;VQL;W=I;F<@:7,@82!S
M=6UM87)Y(&]F(&YO=&5S('!A>6%B;&4Z/"]P/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'1A
M8FQE('-T>6QE/3-$)W=I9'1H.B`Q,#`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O
M;&QA<'-E.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E
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M+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M
M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,7!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O
M;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&9O;G0M=V5I9VAT.B!B;VQD.R<@
M8V]L<W!A;CTS1#$P/D1E8V5M8F5R)B,Q-C`[,S$L)B,Q-C`[,C`Q,3PO=&0^
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M;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#Y#=7)R96YT(#QB<B`O/G!O<G1I
M;VXL)B,Q-C`[;F5T/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,7!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG(&YO=W)A<#TS1&YO=W)A<#XF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[
M(&9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O
M;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&9O;G0M=V5I9VAT.B!B;VQD.R<@
M8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/DYO;BT@/&)R("\^8W5R<F5N
M="`\8G(@+SYP;W)T:6]N+"8C,38P.VYE=#PO=&0^#0H\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R
M87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,7!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG(&YO=W)A<#TS1&YO
M=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+7=E
M:6=H=#H@8F]L9#LG(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#Y4;W1A
M;#PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N
M="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7=E:6=H
M=#H@8F]L9#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA
M;&EG;CH@8V5N=&5R.R!F;VYT+7=E:6=H=#H@8F]L9#LG(&-O;'-P86X],T0R
M(&YO=W)A<#TS1&YO=W)A<#Y#=7)R96YT(#QB<B`O/G!O<G1I;VXL)B,Q-C`[
M;F5T/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F
M;VYT+7=E:6=H=#H@8F]L9#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I
M9VAT.B!B;VQD.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT
M+6%L:6=N.B!C96YT97([(&9O;G0M=V5I9VAT.B!B;VQD.R<@8V]L<W!A;CTS
M1#(@;F]W<F%P/3-$;F]W<F%P/DYO;BT@/&)R("\^8W5R<F5N="`\8G(@+SYP
M;W)T:6]N+"8C,38P.VYE=#PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R
M87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,7!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P
M="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+7=E:6=H=#H@8F]L
M9#LG(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#Y4;W1A;#PO=&0^#0H\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z
M(&)O;&0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K
M9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#0P
M)3LG/DYO;BUI;G1E<F5S="!"96%R:6YG($YO=&4@4&%Y86)L92P@3F5T/"]T
M9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B0\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@-R4[
M)SXF(S@R,3([/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@=VED=&@Z(#$E.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[('=I9'1H.B`W)3LG/B8C.#(Q,CL\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXD/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#<E
M.R<^)B,X,C$R.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T
M:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('=I9'1H.B`Q)3LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R!W:61T:#H@-R4[)SXR,#`L,#`P/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)#PO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`W
M)3LG/B8C.#(Q,CL\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!W:61T:#H@,24[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#<E.R<^,C`P+#`P,#PO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q-C`[
M/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@
M=VAI=&4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^0V]N=F5R=&EB;&4@-24@3F]T97,@4&%Y
M86)L93PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
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M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-
M"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R<^-"PV-C0L-CDW/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^-"PV-C0L-CDW/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO
M='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SY)0T].($-O;G9E
M<G1I8FQE($YO=&4\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T
M('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#LG/C8W-RPW-S@\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q
M<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
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M;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@
M<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R<^-C<W+#<W.#PO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#%P
M=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#%P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@
M<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R<^-C<W+#<W.#PO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#%P
M=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#%P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@
M<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S
M;VQI9#L@=&5X="UA;&EG;CH-"B!R:6=H=#LG/C8W-RPW-S@\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q
M<'0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O
M=6YD+6-O;&]R.B!W:&ET93L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M
M.B`R+C5P=#L@<&%D9&EN9RUL969T.B`Y<'0[)SY4;W1A;#PO=&0^#0H\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B
M;&4[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ
M(')I9VAT.R<^-C<W+#<W.#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-
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M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[
M('1E>'0M86QI9VXZ(')I9VAT.R<^-2PS-#(L-#<U/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R
M+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R<^)#PO
M=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@
M9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#LG/C@W-RPW-S@\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R
M+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[
M)SXD/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R
M+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^-"PV-C0L-CDW/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O
M='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N
M.B!L969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#LG/C4L-30R
M+#0W-3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D
M9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\+W1A
M8FQE/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@;6%R9VEN.B`P
M<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E
M<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z
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M92!O9B!T:&4@=')A;G-A8W1I;VXN/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT
M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&(^/&D^
M3F]N+4EN=&5R97-T($)E87)I;F<@3F]T92!087EA8FQE/"]I/CPO8CX\+W`^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!M87)G:6XZ(#!P="`P
M<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T
M97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P
M="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/DEN($]C=&]B97(@
M,C`P.2P@36%N:&%T=&%N(&5N=&5R960@:6YT;R!A(%-E='1L96UE;G0@06=R
M965M96YT(&%N9"!-=71U86P@4F5L96%S92!W:71H(%-W:7-S(%!H87)M82!#
M;VYT<F%C="!,5$0@*"8C.#(R,#M3=VES<R!0:&%R;6$F(S@R,C$[*2!P=7)S
M=6%N="!T;R!W:&EC:"!-86YH871T86X@86=R965D('1O('!A>2!3=VES<R!0
M:&%R;6$@)#(P,"PP,#`@86YD(&ES<W5E('1O(%-W:7-S(%!H87)M82!A;B!I
M;G1E<F5S="!F<F5E('!R;VUI<W-O<GD@;F]T92!D=64@;VX@3V-T;V)E<B`R
M-RP@,C`Q,2!I;B!T:&4@<')I;F-I<&%L(&%M;W5N="!O9B`D,C4P+#`P,"!I
M;B!F=6QL('-A=&ES9F%C=&EO;B!O9B!A(%-E<'1E;6)E<B`U+"`R,#`X(&%R
M8FET<F%T:6]N(&%W87)D+B!);B!.;W9E;6)E<B`R,#$Q+"!-86YH871T86X@
M<F5N96=O=&EA=&5D('1H92`D,C4P+#`P,"!P<F]M:7-S;W)Y(&YO=&4@9'5E
M($]C=&]B97(@,C<L(#(P,3$@:6X@=VAI8V@@=&AE(&%M;W5N="!O9B!T:&4@
M<')O;6ES<V]R>2!N;W1E('=A<R!R961U8V5D('1O("0R,#`L,#`P(&%N9"!T
M:&4@;6%T=7)I='D@9&%T92!W87,@97AT96YD960@=&\@1F5B<G5A<GD@,34L
M(#(P,3(N(%1H:7,@86UO=6YT('=A<R!P86ED(&]N($9E8G)U87)Y(#$T+"`R
M,#$R(&EN(&9U;&P@<V5T=&QE;65N="!O9B!T:&ES(&YO=&4N/"]P/@T*/'`@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@;6%R9VEN.B`P<'0@,'!X(#!P
M="`P+C5I;CL@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S
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M)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN
M.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L
M('-E<FEF.R<^3VX@36%R8V@@."P@,C`Q,"P@36%N:&%T=&%N(&5N=&5R960@
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M9&EA<GD@;V8@=&AE($-O;7!A;GD@*'1H92`B365R9V5R(%-U8B(I+B8C,38P
M.R!0=7)S=6%N="!T;R!T:&4@=&5R;7,@86YD(&-O;F1I=&EO;G,@<V5T(&9O
M<G1H(&EN('1H92!-97)G97(@06=R965M96YT+"!O;B!-87)C:"`X+"`R,#$P
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M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^5&AE(#4E($YO=&5S(&%N
M9"!A8V-R=65D(&%N9"!U;G!A:60@:6YT97)E<W0@=&AE<F5O;B!A<F4@8V]N
M=F5R=&EB;&4@870@=&AE(&]P=&EO;B!O9B!T:&4@:&]L9&5R(&EN=&\@0V]M
M;6]N(%-T;V-K(&%T('1H92!C;VYV97)S:6]N('!R:6-E(&]F("0Q+#$R-2!P
M97(@<VAA<F4N)B,Q-C`[)B,Q-C`[07)I<W1O;B!A9W)E960@=&\@;6%K92!Q
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M-24@3F]T97,@87-I9&4@9G)O;2!A*2`U,"4@;V8@=&AE(&YE="!P<F]D=6-T
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M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P+C5I
M;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
M;BP@=&EM97,L('-E<FEF.R<^26X@8V]N;F5C=&EO;B!W:71H('1H92!%>&-H
M86YG92!4<F%N<V%C=&EO;B!I;B!$96-E;6)E<B`R,#$Q+"!T:&4@0V]M<&%N
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M871E;'D@)#$V+#@W-BPP,#`@:6UM961I871E;'D@<')I;W(@=&\@=&AE($5X
M8VAA;F=E(%1R86YS86-T:6]N+"`D,38L.#@S+#`P,"!A="!$96-E;6)E<B`S
M,2P@,C`Q,2P@86YD("0Q-RPP.#DL,#`P(&%T($UA<F-H(#,Q+"`R,#$R+B`\
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M(&%S(&]F($UA<F-H(#,Q+"`R,#$R+B!3964@3F]T92`R(&9O<B!F=7)T:&5R
M(&1E=&%I;',N/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P
M<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!M87)G:6XZ(#!P="`P
M<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M)SX\8CX\:3Y)0T].($-O;G9E<G1I8FQE($YO=&4@4&%Y86)L93PO:3X\+V(^
M/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E
M;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@
M;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,"XU:6X[(&UA
M<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I
M;65S+"!S97)I9CLG/DEN(&-O;FYE8W1I;VX@=VET:"!T:&4@;65R9V5R('=I
M=&@@07)I<W1O;B!A<R!D:7-C=7-S960@86)O=F4L($%R:7-T;VX@<V%T:7-F
M:65D(&%N(&%C8V]U;G0@<&%Y86)L92!O9B`D,2PR-S4L,3@X('1O($E#3TX-
M"B!#;&EN:6-A;"!297-E87)C:"!,:6UI=&5D("@F(S@R,C`[24-/3B8C.#(R
M,3LI('1H<F]U9V@@=&AE('!A>6UE;G0@;V8@)#(W-2PQ.#@@:6X@8V%S:"!A
M;F0@=&AE(&ES<W5A;F-E(&]F(&$@=&AR964M>65A<B`U)2!N;W1E('!A>6%B
M;&4@*'1H92`F(S@R,C`[24-/3B!.;W1E)B,X,C(Q.RDN)B,Q-C`[)B,Q-C`[
M5&AE('!R:6YC:7!A;"!W87,@=&\@8F4@<F5P86ED(&EN(#,V(&UO;G1H;'D@
M:6YS=&%L;&UE;G1S(&]F("0R-RPW-S@@8V]M;65N8VEN9R!I;B!!<')I;"`R
M,#$P+B8C,38P.R8C,38P.TEN=&5R97-T('=A<R!P87EA8FQE(&UO;G1H;'D@
M:6X@87)R96%R<RX@)B,Q-C`[)B,Q-C`[3VX@36%R8V@@,2P@,C`Q,2P@07)I
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M96UB97(@,S$L(#(P,3$@*'1H92`F(S@R,C`[5V%I=F5R(%!E<FEO9"8C.#(R
M,3LI(&EN(&5X8VAA;F=E(&9O<B!A('-I;F=L92!P87EM96YT(&]F("0Q,#`L
M,#`P(&]N($UA<F-H(#,Q+"`R,#$Q+"!A;B!I;F-R96%S92!I;B!T:&4@:6YT
M97)E<W0@;VX@=&AE($%M96YD960@24-/3B!.;W1E(&9R;VT@-24@=&\@."4@
M<&5R(&%N;G5M(&1U<FEN9R!T:&4@5V%I=F5R(%!E<FEO9"!A;F0@82!B86QL
M;V]N('!A>6UE;G0@;VX@2F%N=6%R>2`S,2P@,C`Q,BX@5&AE($%M96YD960@
M24-/3B!.;W1E(&ES(&-O;G9E<G1I8FQE(&%T('1H92!O<'1I;VX@;V8@=&AE
M(&AO;&1E<B!I;G1O('1H92!#;VUP86YY)B,X,C$W.W,@0V]M;6]N(%-T;V-K
M(&%T('1H92!C;VYV97)S:6]N('!R:6-E(&]F("0U-C(N-3`@<&5R('-H87)E
M+B!$=7)I;F<@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C:"`S,2P@,C`Q
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M;GEI;F<@8F%L86YC92!S:&5E="!A<R!O9B!-87)C:"`S,2P@,C`Q,BX@5&AI
M<R!N;W1E(&ES(&-U<G)E;G1L>2!I;B!D969A=6QT(&%S('1H92!#;VUP86YY
M(&1I9"!N;W0@;6%K92!T:&4@8F%L;&]O;B!P87EM96YT(&1U92!O;B!*86YU
M87)Y(#,Q+"`R,#$R+"!O<B!T:&4@;6]N=&AL>2!I;G-T86QL;65N="!P87EM
M96YT<R!D=64@:6X@1F5B<G5A<GD@,C`Q,B!A;F0@36%R8V@@,C`Q,BX@5&AE
M($-O;7!A;GD@:7,@8W5R<F5N=&QY(&%T=&5M<'1I;F<@=&\@;F5G;W1I871E
M(&$@<V5T=&QE;65N="!O<B!A;'1E<FYA=&EV92!A<G)A;F=E;65N="!I;B!S
M871I<V9A8W1I;VX@;V8@=&AI<R!N;W1E+CPO<#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V8P838X,V-B7V$R-V-?-#0R,%\X
M,C`R7S$T,65B-#=F,F,U9`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B]F,&$V.#-C8E]A,C=C7S0T,C!?.#(P,E\Q-#%E8C0W9C)C-60O5V]R:W-H
M965T<R]3:&5E=#$S+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^3$E#14Y312!!1U)%14U%3E13/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3&EC96YS92!!9W)E96UE
M;G0@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y,:6-E;G-E($%G<F5E;65N="!$:7-C;&]S=7)E(%M497AT
M($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT
M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&(^3D]4
M12`V("8C.#(Q,3L@3$E#14Y312!!1U)%14U%3E13/"]B/CPO<#X-"CQP('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&UA<F=I;CH@,'!T(#!P>#L@9F]N
M=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P
M.SPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD
M96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^26X@07!R:6P@,C`Q,2P@5$<@
M0FEO+"!A8W%U:7)E9"!F<F]M($Q&0B!":6]T96-H;F]L;V=I97,L(&$@9G5L
M;'D@;W=N960@<W5B<VED:6%R>2!O9B!&<F%N8V4@8F%S960@3$9"(%,N02XL
M(&%N(&]P=&EO;B`H=&AE("8C.#(R,#M,:6-E;G-E($]P=&EO;B8C.#(R,3LI
M(&9O<B!E>&-L=7-I=F4@=V]R;&1W:61E(')I9VAT<R`H97AC97!T($9R86YC
M92]"96QG:75M*2!T;R!D979E;&]P(&%N9"!M87)K970@=6)L:71U>&EM86(@
M*"8C.#(R,#M41U18+3$Q,#$F(S@R,C$[*2P@82!M;VYO8VQO;F%L(&%N=&EB
M;V1Y('1H870@=&%R9V5T<R!A('-P96-I9FEC(&5P:71O<&4@;VX@=&AE($(M
M8V5L;"!L>6UP:&]C>71E($-$,C`@86YT:6=E;BX@26X@97AC:&%N9V4@9F]R
M('1H92!,:6-E;G-E($]P=&EO;BP@5$<@0FEO(&ES<W5E9"`Q,S(L,#`P('-H
M87)E<R!O9B!I=',@8V]M;6]N('-T;V-K('1O($Q&0BX\+W`^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6X[
M(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL
M('1I;65S+"!S97)I9CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@
M,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
M.R<^/&9O;G0@<W1Y;&4],T0G8V]L;W(Z(&)L86-K.R<^3VX@2F%N=6%R>2`S
M,"P@,C`Q,BP@5$<@0FEO(&5X97)C:7-E9"!T:&4@3&EC96YS92!/<'1I;VX@
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M;G0@86YD(&-O;6UE<F-I86QI>F%T:6]N(&]F(%1'5%@M,3$P,2`H=6)L:71U
M>&EM86(I+B!4;R!D871E+"!W92!H879E(&UA9&4@;F\@<&%Y;65N=',@=&\@
M3$9"($=R;W5P(&%N9"!,1D(@1W)O=7`@:7,@96QI9VEB;&4@=&\@<F5C96EV
M92!P87EM96YT<R!O9B!U<"!T;R!A;B!A9V=R96=A=&4@;V8@87!P<F]X:6UA
M=&5L>2`D,S$N,"!M:6QL:6]N('5P;VX@;W5R('-U8V-E<W-F=6P@86-H:65V
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M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN
M.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
M+"!T:6UE<RP@<V5R:68[)SY);B!C;VYN96-T:6]N('=I=&@@=&AE(&QI8V5N
M<V4@86=R965M96YT+"!O=7(@<W5B<VED:6%R>2!41R!":6]L;V=I8W,@:7-S
M=65D(#<L,S8X+#`P,"!S:&%R97,@;V8@:71S(&-O;6UO;B!S=&]C:R!T;R!,
M1D(L(&%N9"!T:&4@0V]M<&%N>2!A9W)E960@=&\@8V]N=')I8G5T92`D,34@
M;6EL;&EO;BP@;&5S<R!A<'!L:6-A8FQE(&9E97,@86YD(&5X<&5N<V5S(&%S
M<V]C:6%T960@=VET:"!T:&4@9FEN86YC:6YG+"!T;R!41R!":6\@=&\@9G5N
M9"!T:&4@9&5V96QO<&UE;G0@;V8@=6)L:71U>&EM86(@=6YD97(@=&AE($QI
M8V5N<V4@06=R965M96YT(&EN(&5X8VAA;F=E(&9O<B`W+#4P,"PP,#`@<VAA
M<F5S(&]F(%1'($)I;R!C;VUM;VX@<W1O8VLN(%1H92!#;VUP86YY(')E8V]G
M;FEZ960@87!P<F]X:6UA=&5L>2`D,38L-3<X+#`P,"!O9B!N;VXM8V%S:"!R
M97-E87)C:"!A;F0@9&5V96QO<&UE;G0@97AP96YS92!D=7)I;F<@=&AE('1H
M<F5E(&UO;G1H<R!E;F1E9"!-87)C:"`S,2P@,C`Q,B!I;B!C;VYN96-T:6]N
M('=I=&@@=&AE(&ES<W5A;F-E(&]F('1H97-E('-H87)E<RX@26X@861D:71I
M;VXL(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@:7-S=6%N8V4@;V8@-RPS-C@L
M,#`P('-H87)E<R!O9B!41R!":6\@8V]M;6]N('-T;V-K+"!T:&4@0V]M<&%N
M>2!A;F0@5$<@0FEO('!R;W9I9&5D($Q&0B!'<F]U<"!T:&4@;W!T:6]N('1O
M+"8C,38P.VEN(&ET<R!S;VQE(&1I<V-R971I;VXL(&5L96-T('1O(&-O;G9E
M<G0@86QL+"!A;F0@;F]T(&QE<W,@=&AA;B!A;&PL(&]F('1H92!S:&%R97,@
M;V8@5$<@0FEO(&-O;6UO;B!S=&]C:R!I;G1O(#<L-3`P+#`P,"!S:&%R97,@
M;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!#;VUM;VX@4W1O8VLN(%1H:7,@;W!T
M:6]N(&UA>2!B92!E>&5R8VES960@8GD@3$9"($=R;W5P(&%T(&%N>2!T:6UE
M(&)E9F]R92!-87D@,30L(#(P,3(N/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN
M.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
M+"!T:6UE<RP@<V5R:68[)SY&=7)T:&5R;6]R92P@<VAO=6QD($Q&0B!'<F]U
M<"!C:&]O<V4@=&\@97AE<F-I<V4@=&AE(&]P=&EO;B!F;W(@0V]M<&%N>2!#
M;VUM;VX@4W1O8VLL('1H92!";V%R9"!O9B!$:7)E8W1O<G,@;V8@=&AE($-O
M;7!A;GD@<VAA;&P@87!P;VEN="8C,38P.V%N(&EN9&EV:61U86P@9&5S:6=N
M871E9"!B>2!,1D(@1W)O=7`@=&\@<V5R=F4@87,@82!D:7)E8W1O<B!O9B!T
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M('-U8V@@=&EM92!A<R!,1D(@1W)O=7`@;W=N<R!L97-S('1H86X@,3`E(&]F
M('1H92!O=71S=&%N9&EN9R!#;VUP86YY($-O;6UO;B!3=&]C:RX\+W`^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
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M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E)%3$%4140@4$%25%D@5%)!3E-!0U1)
M3TY3/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L
M(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^4F5L871E9"!087)T>2!4<F%N<V%C=&EO;G,@6T%B<W1R86-T73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296QA
M=&5D(%!A<G1Y(%1R86YS86-T:6]N<R!$:7-C;&]S=7)E(%M497AT($)L;V-K
M73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T
M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&(^3D]412`W("8C
M.#(Q,3L@4D5,051%1"!005)462!44D%.4T%#5$E/3E,\+V(^/"]P/@T*/'`@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@;6%R9VEN.B`P<'0@,'!X.R!F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&(^
M)B,Q-C`[/"]B/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('1E>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q
M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^3VX@1&5C96UB
M97(@,S`L(#(P,3$L($]03B!#87!I=&%L($UA<FME=',@*"8C.#(R,#M/4$Y#
M328C.#(R,3LI(&%N9"!I=',@869F:6QI871E9"!B<F]K97(M9&5A;&5R+"!.
M871I;VYA;"!396-U<FET:65S($-O<G!O<F%T:6]N("@F(S@R,C`[3E-#)B,X
M,C(Q.R!A;F0@8V]L;&5C=&EV96QY('=I=&@@3U!.0TTL("8C.#(R,#M.871I
M;VYA;"8C.#(R,3LI+"!B;W1H(&%F9FEL:6%T97,@;V8@3F%T:6]N86P@2&]L
M9&EN9W,@0V]R<&]R871I;VX@*"8C.#(R,#M.871I;VYA;"!(;VQD:6YG<R8C
M.#(R,3LI+"!E;G1E<F5D(&EN=&\@82!0;&%C96UE;G0@06=E;F-Y($%G<F5E
M;65N="`H=&AE("8C.#(R,#M004$F(S@R,C$[*2!W:71H('1H92!#;VUP86YY
M(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@:6YI=&EA;"!C;&]S:6YG(&]F('1H
M92`R,#$Q($5Q=6ET>2!025!%+"!O9F9E<FEN9R!O9B!U<"!T;R`D,C4@;6EL
M;&EO;B!O9B!S=&]C:R!A;F0@=V%R<F%N=',@;V8@=&AE($-O;7!A;GDN)B,Q
M-C`[)B,Q-C`[4'5R<W5A;G0@=&\@=&AE(%!!02P@3F%T:6]N86P@86-T960@
M87,@=&AE($-O;7!A;GDF(S@R,3<[<R!P;&%C96UE;G0@86=E;G0@9F]R(#(P
M,3$@17%U:71Y(%!)4$4N/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ
M(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@
M<V5R:68[)SY5;G1I;"!!<')I;"`R,#$R+"!-:6-H865L(%,N(%=E:7-S('=A
M<R!A(&1I<F5C=&]R(&%N9"!.;VXM17AE8W5T:79E($-H86ER;6%N(&]F('1H
M92!";V%R9"!O9B!$:7)E8W1O<G,@;V8@3F%T:6]N86P@2&]L9&EN9W,N)B,Q
M-C`[)B,Q-C`[2&4@:7,@86QS;R!A('-T;V-K:&]L9&5R(&]F($YA=&EO;F%L
M($AO;&1I;F=S(&%N9"P@=VAE;B!C;VUB:6YE9"!W:71H(&AI<R!O=VYE<G-H
M:7`@:6YD:7)E8W1L>2!T:')O=6=H($]P=7,@86YD(&ET<R!A9F9I;&EA=&5S
M+"!B96YE9FEC:6%L;'D@;W=N<R`R,RXV)2!O9B!.871I;VYA;"!(;VQD:6YG
M<RP@=&AE('!A<F5N="!C;VUP86YY(&]F($Y30RXF(S$V,#M-<BX@5V5I<W,@
M9&ES8VQA:6US('-U8V@@8F5N969I8VEA<GD@;W=N97)S:&EP(&]T:&5R('1H
M86X@=&\@=&AE(&5X=&5N="!O9B!H:7,@<&5C=6YI87)Y(&EN=&5R97-T+B!)
M;B!A9&1I=&EO;BP@870@=&AE('1I;64L($]P=7,@86YD($Y30R!W97)E('!A
M<G1I97,@=&\@82`U,"\U,"!J;VEN="!V96YT=7)E('1H870@<VAA<F5D('!R
M;V9I=',@9G)O;2!/4$Y#32P@=&AE(&EN=F5S=&UE;G0@8F%N:VEN9R!D:79I
M<VEO;B!O9B!.4T,@=&AA="!W87,@<F5S<&]N<VEB;&4@9F]R(&UA;F%G:6YG
M('1H92!/9F9E<FEN9RX@5&AI<R!J;VEN="!V96YT=7)E('=A<R!D:7-S;VQV
M960@:6X@07!R:6P@,C`Q,BX\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93L@
M=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P
M<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[)SY4:&4@0V]M<&%N>2!C;VUP;&5T960@=&AE(&EN:71I86P@8VQO<VEN
M9R!O9B!T:&4@,C`Q,2!%<75I='D@4$E012!O;B!$96-E;6)E<B`S,"P@,C`Q
M,2P@/"]F;VYT/CQF;VYT('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/FES<W5I
M;F<@-"PY,CDL-3(S('-H87)E<R!O9B!#;VUM;VX@4W1O8VL@870@82!P<FEC
M92!P97(@<VAA<F4@;V8@)#(N,C4@9F]R('1O=&%L(&=R;W-S('!R;V-E961S
M+"!B969O<F4@<&QA8V5M96YT(&-O;6UI<W-I;VYS(&%N9"!E>'!E;G-E<RP@
M;V8@)#$Q+#`Y,2PT,C4@*'1H92`F(S@R,C`[,C`Q,2!%<75I='D@4$E0128C
M.#(R,3LI+B8C,38P.TEN=F5S=&]R<R!A;'-O(')E8V5I=F5D('=A<G)A;G1S
M('1O('!U<F-H87-E(#$L,C,R+#,X,2!S:&%R97,@;V8@0V]M;6]N(%-T;V-K
M+B!4:&4@=V%R<F%N=',@:&%V92!A;B!E>&5R8VES92!P<FEC92!O9B`D,BXR
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M97-E(&-L;W-I;F=S('=E<F4@:&5L9"!O;B!*86YU87)Y(#,Q+"`R,#$R(&%N
M9"!&96)R=6%R>2`R-"P@,C`Q,BX@26X@=&AE<V4@8VQO<VEN9W,L('1H92!#
M;VUP86YY(&ES<W5E9"`V.34L-#(X('-H87)E<R!O9B!O=7(@0V]M<&%N>2!0
M<F5F97)R960@4W1O8VL@*"8C.#(R,#M0<F5F97)R960@4W1O8VLF(S@R,C$[
M*2!A="!A('!R:6-E('!E<B!S:&%R92!O9B`D,C`N,#`@9F]R('1O=&%L(&=R
M;W-S('!R;V-E961S+"!B969O<F4@<&QA8V5M96YT(&-O;6UI<W-I;VYS(&%N
M9"!E>'!E;G-E<RP@;V8@)#$S+#DP."PU-C`N($5A8V@@<VAA<F4@;V8@0V]M
M<&%N>2!0<F5F97)R960@4W1O8VL@:7,@8V]N=F5R=&EB;&4@:6YT;R`X+C@Y
M('-H87)E<R!O9B!#;VUM;VX@4W1O8VL@<')O=FED960@=&AA="!S=6-H(&-O
M;G9E<G-I;VX@<FEG:'1S(&%R92!S=6)J96-T('1O('-U9F9I8VEE;G0@879A
M:6QA8FQE(&%U=&AO<FEZ960@<VAA<F5S(&]F($-O;6UO;B!3=&]C:RX@26YV
M97-T;W)S('=I;&P@86QS;R!R96-E:79E('=A<G)A;G1S('1O('!U<F-H87-E
M(#$L-30U+#,Y-B!S:&%R97,@;V8@0V]M;6]N(%-T;V-K+B!4:&4@=V%R<F%N
M=',@:&%V92!A;B!E>&5R8VES92!P<FEC92!O9B`D,BXR-2!P97(@<VAA<F4@
M86YD(&%R92!E>&5R8VES86)L92!F;W(@9FEV92!Y96%R<RXF(S$V,#L@/"]F
M;VYT/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&UA<F=I
M;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S
M+"!S97)I9CLG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[(&UA<F=I;BUT;W`Z(#!P>#L@=&5X="UI;F1E;G0Z(#`N-6EN.R!F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G
M:6XM8F]T=&]M.B`V<'0[(&UA<F=I;BUL969T.B`P:6X[)SY!<R!P;&%C96UE
M;G0@86=E;G0L($YA=&EO;F%L(')E8V5I=F5D(&-A<V@@8V]M;6ES<VEO;G,@
M97%U86P@=&\@,3`E(&]F('1H92!G<F]S<R!P<F]C965D<R!O9B!T:&4@,C`Q
M,2!%<75I='D@4$E012P@9FEV92UY96%R('=A<G)A;G1S('1O('!U<F-H87-E
M('-H87)E<R!O9B!#;VUP86YY(%!R969E<G)E9"!3=&]C:R!E<75A;"!T;R`Q
M,"4@;V8@<VAA<F5S('-O;&0@:6X@=&AE(#(P,3$@17%U:71Y(%!)4$4L(&%N
M9"!A(&YO;BUA8V-O=6YT86)L92!E>'!E;G-E(&%L;&]W86YC92!E<75A;"!T
M;R!T=V\@<&5R8V5N="!O9B!T:&4@9W)O<W,@<')O8V5E9',@;V8@=&AE(#(P
M,3$@17%U:71Y(%!)4$4@9F]R($YA=&EO;F%L)B,X,C$W.W,@97AP96YS97,@
M*&YO="!I;F-L=61I;F<@=7`@=&\@)#@P+#`P,"!O9B!.871I;VYA;"8C.#(Q
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M=FES;W)Y(&9E92!O9B`D,34P+#`P,"!F;W(@<W5C:"!S97)V:6-E<RX\+W`^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
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M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-50E-%455%3E0@159%3E13/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,3(\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M4W5B<V5Q=65N="!%=F5N=',@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=6)S97%U96YT($5V96YT<R!;
M5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQP
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&UA<F=I;CH@,'!T(#!P>#L@
M9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQB
M/DY/5$4@."`F(S@R,3$[(%-50E-%455%3E0@159%3E13/"]B/CPO<#X-"CQP
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&UA<F=I;CH@,'!T(#!P>#L@
M9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C
M,38P.SPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M
M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^3VX@07!R:6P@,S`L(#(P
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M8W,L($EN8RX\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T
M97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P
M="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P.SPO<#X-
M"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P
M+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R<^3VX@07!R:6P@,S`L(#(P,3(L('1H92!#
M;VUP86YY(&5F9F5C=&5D(&$@<F5V97)S92!S<&QI="!O9B!I=',@0V]M;6]N
M(%-T;V-K(&%T(&$@<F%T:6\@;V8@-38N,C4@9F]R(#$L('!U<G-U86YT('1O
M(&$@<')E=FEO=7-L>2!O8G1A:6YE9"!S:&%R96AO;&1E<B!A=71H;W)I>F%T
M:6]N+B!!;&P@<VAA<F4@86UO=6YT<R!A;F0@<&5R('-H87)E('!R:6-E<R!I
M;B!T:&ES(%%U87)T97)L>2!297!O<G0@;VX@1F]R;2`Q,"U1(&AA=F4@8F5E
M;B!R971R;V%C=&EV96QY(&%D:G5S=&5D('1O(')E9FQE8W0@=&AE(&5F9F5C
M="!O9B!O=7(@<F5V97)S92!S=&]C:R!S<&QI="P@;VX@82!F:69T>2!S:7@@
M86YD(&]N92!Q=6%R=&5R("@U-BXR-2D@9F]R(&]N92`H,2D@8F%S:7,L('5N
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M8V4@8GD@9FEF='D@<VEX(&%N9"!O;F4@<75A<G1E<B`H-38N,C4I+CPO<#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V8P838X
M,V-B7V$R-V-?-#0R,%\X,C`R7S$T,65B-#=F,F,U9`T*0V]N=&5N="U,;V-A
M=&EO;CH@9FEL93HO+R]#.B]F,&$V.#-C8E]A,C=C7S0T,C!?.#(P,E\Q-#%E
M8C0W9C)C-60O5V]R:W-H965T<R]F:6QE;&ES="YX;6P-"D-O;G1E;G0M5')A
M;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP
M93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/'AM;"!X;6QN
M<SIO/3-$(G5R;CIS8VAE;6%S+6UI8W)O<V]F="UC;VTZ;V9F:6-E.F]F9FEC
M92(^#0H@/&\Z36%I;D9I;&4@2%)E9CTS1"(N+B]7;W)K8F]O:RYH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#$N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#`R+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970P,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#0N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`U+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970P-BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,#<N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`X+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P.2YH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,3`N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#$Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q,BYH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3,N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#$T+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970Q-2YH=&UL(B\^#0H\+WAM;#X-"BTM+2TM+3U?3F5X=%!A<G1?9C!A
E-C@S8V)?83(W8U\T-#(P7S@R,#)?,30Q96(T-V8R8S5D+2T-"@``
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
        <td class="text"><p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>NOTE 1 &#8211; ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Description of Business</i></b></p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">We are a biopharmaceutical company focused on the acquisition, development and commercialization of innovative and medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. We aim to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding their research and development and eventually either out-licensing or bringing the technologies to market. Currently we are developing TGTX-1101 (ublituximab), a novel, third generation monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. We also hold the development rights to AST-726, a nasally delivered product for the treatment of Vitamin B<sub>12</sub> deficiency, and AST-915, an orally delivered treatment for essential tremor.</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The accompanying unaudited condensed consolidated financial statements were prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q and Article&#160;10 of Regulation&#160;S-X. Accordingly, they may not include all of the information and footnotes required by GAAP for complete financial statements. All adjustments that are, in the opinion of management, of a normal recurring nature and are necessary for a fair presentation of the consolidated financial statements have been included. Nevertheless, these consolidated financial statements should be read in conjunction with the audited consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2011. The results of operations for the three months ended March 31, 2012 are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period.</p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>&#160;</i></b></p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On December 29, 2011, the Company entered into and consummated an exchange transaction agreement (the &#8220;Exchange Transaction&#8221;) with Opus Point Partners, LLC (&#8220;Opus&#8221;) and TG Biologics, Inc. (formerly known as TG Therapeutics, Inc.) (&#8220;TG Bio&#8221;). The stockholders of TG Bio received the majority of the voting shares of the Company, therefore, the merger was accounted for as a reverse acquisition whereby TG Bio was the accounting acquirer (legal acquiree) and the Company was the accounting acquiree (legal acquirer) under the acquisition method of accounting. TG Bio was incorporated in Delaware in November 2010, but did not commence operations until April 2011, thus the accompanying consolidated financial statements do not include comparative financial information for the three months ended March 31, 2011.</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On April 30, 2012, the Company filed a Certificate of Amendment to its Certificate of Incorporation to change its name from Manhattan Pharmaceuticals, Inc. (&#8220;Manhattan&#8221;) to TG Therapeutics, Inc. In conjunction with this change, the subsidiary formerly named TG Therapeutics, Inc. filed a Certificate of Amendment changing its name to TG Biologics, Inc.</p>
<p style="text-align: left; background-color: white; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Liquidity and Capital Resources</i></b></p>
<p style="text-align: left; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; background-color: white; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">We have incurred operating losses since our inception and expect to continue to incur operating losses for the foreseeable future and may never become profitable. As of March 31, 2012, we have an accumulated deficit of $11,109,164.</p>
<p style="text-align: left; background-color: white; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Our primary source of cash has been proceeds from the private placement of equity securities. We have not yet commercialized any of our drug candidates and cannot be sure if we will ever be able to do so. Even if we commercialize one or more of our drug candidates, we may not become profitable. Our ability to achieve profitability depends on a number of factors, including our ability to obtain regulatory approval for our drug candidates, successfully complete any post-approval regulatory obligations and successfully commercialize our drug candidates alone or in partnership. We may continue to incur substantial operating losses even if we begin to generate revenues from our drug candidates.</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On December 30, 2011, we <font style="color: black;">completed the first closing of the private placement of our securities, issuing 4,929,523 shares of Company </font>$0.001 par value common stock<font style="color: black;"> (&#8220;Common Stock &#8220;) at a price per share of $2.25 for total gross proceeds, before placement commissions and expenses, of $11,091,425 (the &#8220;2011 Equity PIPE&#8221;).&#160;Investors also received warrants to purchase 1,232,381 shares of Common Stock. The warrants have an exercise price of $2.25 per share and are exercisable for five years.</font></p>
<p style="text-align: left; text-indent:
 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In 2012, we completed two additional closings of the 2011 Equity PIPE. These closings were held on January 31, 2012, and February 24, 2012. In these closings, the Company issued 695,428 shares of our Series A preferred stock (&#8220;Company Preferred Stock&#8221;) at a price per share of $20.00, for total gross proceeds, before placement commissions and expenses, of $13,908,560. E<font style="background-color: white;">ach share of Company Preferred Stock is convertible into 8.89 shares of Common Stock, provided that such conversion rights are subject to sufficient available authorized shares of Common Stock.</font> Investors also received warrants to purchase 1,545,396 shares of Common Stock. The warrants have an exercise price of $2.25 per share and are exercisable for five years.&#160;<font style="background-color: white;">The shares of Company Preferred Stock and warrants sold in these closings were offered and sold to accredited investors, including members of management, without registration under the Securities Act, or state securities laws, in reliance on the exemptions provided by Section&#160;4(2) of the Securities Act, and Regulation&#160;D promulgated thereunder and in reliance on similar exemptions under applicable state laws. Accordingly, the securities issued in the Offering have not been registered under the Securities Act, and until so registered, these securities may not be offered or sold in the United States absent registration or availability of an applicable exemption from registration.</font></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Our Common Stock is quoted on <font style="color: black;">the OTC Bulletin Board<font style="font-family: times new roman, times, serif;"> </font></font>and trades under the symbol &#8220;TGTX.OB.&#8221;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Reverse Stock Split</i></b></p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="background-color: white;">On April 30, 2012, the Company effected a reverse split of its Common Stock at a ratio of 56.25 for 1, pursuant to a previously obtained stockholder authorization. All share amounts and per share prices in this Quarterly Report on Form 10-Q have been retroactively adjusted to reflect the effect of our reverse stock split, on a fifty six and one quarter (56.25) for one (1) basis, unless otherwise indicated.&#160;&#160;The exercise price for all stock options and warrants and the conversion price for convertible securities in the accompanying condensed consolidated financial statements have been adjusted to reflect the reverse stock split by multiplying the original exercise or conversion price by fifty six and one quarter (56.25).</font></p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Cash and Cash Equivalents</i></b></p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">We treat liquid investments with original maturities of less than three months when purchased as cash and cash equivalents.</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Research and Development Costs</i></b></p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Research and development costs are expensed as incurred. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and amortized over the period that the goods are delivered or the related services are performed, subject to an assessment of recoverability. We make estimates of costs incurred in relation to external clinical research organizations, or CROs, and clinical site costs. We analyze the progress of clinical trials, including levels of patient enrollment, invoices received and contracted costs when evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability. Significant judgments and estimates must be made and used in determining the accrued balance and expense in any accounting period. We review and accrue CRO expenses and clinical trial study expenses based on work performed and rely upon estimates of those costs applicable to the stage of completion of a study. Accrued CRO costs are subject to revisions as such trials progress to completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. With respect to clinical site costs, the financial terms of these agreements are subject to negotiation and vary from contract to contract. Payments under these contracts may be uneven, and depend on factors such as the achievement of certain events, the successful recruitment of patients, the completion of portions of the clinical trial or similar conditions. The objective of our policy is to match the recording of expenses in our financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical site costs are recognized based on our estimate of the degree of completion of the event or events specified in the specific clinical study or trial contract.</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>In-Process Research and Development</i></b></p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>&#160;</i></b></p>
<p style="text-align: justify; margin-top: 0px; text-indent: 0.5in; font: italic 10pt times new roman, times, serif; margin-bottom: 6pt; margin-left: 0in;"><font style="font-style: normal; font-weight: normal;">All
 acquired research and development projects are recorded at their fair value as of the date acquisition. The fair values are assessed annually in the fourth quarter to ascertain if there has been any impairment of the recorded value. If there is an impairment, the asset is written down to its current fair value by the recording of an expense. Impairment testing consists of a comparison of the fair value of the in-process research and development with its carrying amount.</font></p>
<p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Income Taxes</i></b></p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>&#160;</i></b></p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, operating losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. If the likelihood of realizing the deferred tax assets or liability is less than &#8220;more likely than not,&#8221; a valuation allowance is then created.</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">We, and our subsidiaries, file income tax returns in the U.S. Federal jurisdiction and in various states. We have tax net operating loss carryforwards that are subject to examination for a number of years beyond the year in which they were generated for tax purposes. Since a portion of these net operating loss carryforwards may be utilized in the future, many of these net operating loss carryforwards will remain subject to examination.</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">We recognize interest and penalties related to uncertain income tax positions in income tax expense.</p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>&#160;</i></b></p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Stock-Based Compensation</i></b></p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">We recognize all share-based payments to employees and to non-employee directors as compensation for service on our board of directors as compensation expense in the consolidated financial statements based on the fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">For share-based payments to consultants and other third-parties, compensation expense is determined at the &#8220;measurement date.&#8221; The expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. We record compensation expense based on the fair value of the award at the reporting date. The awards to consultants and other third-parties are then revalued, or the total compensation is recalculated based on the then current fair value, at each subsequent reporting date.</p>
<p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Basic and Diluted Net (Loss) Income Per Share of Common Stock</i></b></p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>&#160;</i></b></p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Basic net income (loss) per share of Common Stock is calculated by dividing net income (loss) applicable to the Common Stock by the weighted-average number of the Common Stock outstanding for the period. Diluted net loss per share of Common Stock is the same as basic net income (loss) per share of Common Stock since potentially dilutive securities from stock options, stock warrants and convertible preferred stock would have an antidilutive effect either because the Company incurred a net loss during the period presented or because such potentially dilutive securities were out of the money and the Company realized net income during the period presented. The amounts of potentially dilutive securities excluded from the calculation were 14,154,452 at March 31, 2012. During the three months ended March 31, 2012, the Company incurred a net loss; therefore, all of the dilutive securities are excluded from the computation of diluted earnings per share.</p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>&#160;</i></b></p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Impairment</i></b></p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Long lived assets are reviewed for an impairment loss when circumstances indicate that the carrying value of long-lived tangible and intangible assets with finite lives may not be recoverable. Management&#8217;s policy in determining whether an impairment indicator exists, a triggering event, comprises measurable operating performance criteria as well as qualitative measures. If an analysis is necessitated by the occurrence of a triggering event, we make certain assumptions in
 determining the impairment amount. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized for the difference between the carrying value and the estimated fair value.</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Goodwill is reviewed for impairment annually or when events arise that could indicate that an impairment exists. We test for goodwill impairment using a two-step process. The first step compares the fair value of the reporting unit with the unit's carrying value, including goodwill. When the carrying value of the reporting unit is greater than fair value, the unit&#8217;s goodwill may be impaired, and the second step must be completed to measure the amount of the goodwill impairment charge, if any. In the second step, the implied fair value of the reporting unit&#8217;s goodwill is compared with the carrying amount of the unit&#8217;s goodwill. If the carrying amount is greater than the implied fair value, the carrying value of the goodwill must be written down to its implied fair value. We will continue to perform impairment tests annually at December 31 and whenever events or changes in circumstances suggest that the carrying value of goodwill may not be recoverable.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18743-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18854-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 22<br><br> -Paragraph 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18861-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EP5AE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 20,923,750<span></span></td>
        <td class="nump">$ 9,748,491<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
        <td class="nump">79,030<span></span></td>
        <td class="nump">87,176<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump">21,002,780<span></span></td>
        <td class="nump">9,835,667<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtxd_InProcessResearchAndDevelopment', window );">In-process research and development</a></td>
        <td class="nump">5,441,839<span></span></td>
        <td class="nump">5,441,839<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
        <td class="nump">629,752<span></span></td>
        <td class="nump">629,752<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump">27,074,371<span></span></td>
        <td class="nump">15,907,258<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and equity</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable, current portion</a></td>
        <td class="nump">677,778<span></span></td>
        <td class="nump">877,778<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
        <td class="nump">467,524<span></span></td>
        <td class="nump">666,640<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest payable, current portion</a></td>
        <td class="nump">76,793<span></span></td>
        <td class="nump">61,941<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump">1,222,095<span></span></td>
        <td class="nump">1,606,359<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable, noncurrent portion, at fair value</a></td>
        <td class="nump">4,664,697<span></span></td>
        <td class="nump">4,664,697<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
        <td class="nump">5,886,792<span></span></td>
        <td class="nump">6,271,056<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Equity:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value per share (10,000,000 shares authorized, 1,108,816 and 413,388 issued and outstanding as of March 31, 2012 and December 31, 2011, respectively, aggregate liquidation value of $22,176,320 and $8,267,760 at March 31, 2012 and December 31, 2011, respectively)</a></td>
        <td class="nump">1,109<span></span></td>
        <td class="nump">413<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value per share (500,000,000 shares authorized, 5,061,399 shares issued and outstanding at March 31, 2012 and December 31, 2011)</a></td>
        <td class="nump">5,061<span></span></td>
        <td class="nump">5,061<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtxd_ContingentlyIssuableShares', window );">Contingently issuable shares</a></td>
        <td class="nump">6<span></span></td>
        <td class="nump">6<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
        <td class="nump">22,841,334<span></span></td>
        <td class="nump">10,472,115<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage', window );">Deficit accumulated in development stage</a></td>
        <td class="num">(11,109,164)<span></span></td>
        <td class="num">(853,074)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total TG Therapeutics, Inc. and subsidiaries equity</a></td>
        <td class="nump">11,738,346<span></span></td>
        <td class="nump">9,624,521<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest in subsidiary</a></td>
        <td class="nump">9,449,233<span></span></td>
        <td class="nump">11,681<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
        <td class="nump">21,187,579<span></span></td>
        <td class="nump">9,636,202<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
        <td class="nump">$ 27,074,371<span></span></td>
        <td class="nump">$ 15,907,258<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtxd_ContingentlyIssuableShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The shares issuable for merger of companies</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tgtxd_ContingentlyIssuableShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tgtxd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtxd_InProcessResearchAndDevelopment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date of non current portion of in-process research and development costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tgtxd_InProcessResearchAndDevelopment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tgtxd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br> -Section S99<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Publisher FASB<br><br><br><br> -Paragraph 1<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Concepts (CON)<br><br><br><br> -Number 6<br><br><br><br> -Paragraph 25<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Section 45<br><br><br><br> -SubTopic 10<br><br><br><br> -Topic 210<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Paragraph 1<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7<br><br><br><br> -Footnote 1<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 8, 9<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7, 26<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6952336&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 5<br><br><br><br> -Paragraph 8, 9<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingencies</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cumulative net losses reported during the development stage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 7<br><br><br><br> -Paragraph 11<br><br><br><br> -Subparagraph a<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 915<br><br><br><br> -SubTopic 210<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472335&amp;loc=d3e37729-110921<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date, which is the cumulative amount paid and (if applicable) the fair value of any noncontrolling interest in the acquiree, adjusted for any amortization recognized prior to the adoption of any changes in generally accepted accounting principles (as applicable) and for any impairment charges, in excess of the fair value of net assets acquired in one or more business combination transactions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 142<br><br><br><br> -Paragraph 45<br><br><br><br> -Subparagraph e<br><br><br><br> -Clause 1<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 142<br><br><br><br> -Paragraph 43<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 141R<br><br><br><br> -Paragraph 68<br><br><br><br> -Subparagraph l<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 142<br><br><br><br> -Paragraph 45<br><br><br><br> -Subparagraph e<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 141R<br><br><br><br> -Paragraph 34<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6905597&amp;loc=d3e13816-109267<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 141R<br><br><br><br> -Paragraph 72<br><br><br><br> -Subparagraph d<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Goodwill</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Chapter 3<br><br><br><br> -Section A<br><br><br><br> -Paragraph 7<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e7018-107765<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph A3<br><br><br><br> -Appendix A<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 27<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph 38<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 20<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Publisher AICPA<br><br><br><br> -Number 51<br><br><br><br> -Paragraph 26<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_MinorityInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19, 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NotesPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations, including trade payables, incurred through that date and due within one year (or in the operating cycle if longer) arising from transactions not otherwise specified in the taxonomy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Audit and Accounting Guide (AAG)<br><br><br><br> -Number AAG-BRD<br><br><br><br> -Chapter 4<br><br><br><br> -Paragraph 80<br><br><br><br> -Subparagraph Exhibit 4-9<br><br><br><br> -IssueDate 2006-05-01<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAccountsPayableAndAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 129<br><br><br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 5<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph A3<br><br><br><br> -Appendix A<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of Stockholders' Equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity including portions attributable to both the parent and noncontrolling interests (previously referred to as minority interest), if any. The entity including portions attributable to the parent and noncontrolling interests is sometimes referred to as the economic entity. This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 16<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6921628&amp;loc=SL4568740-111683<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 4I<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6922042&amp;loc=SL4590271-111686<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Publisher AICPA<br><br><br><br> -Number 51<br><br><br><br> -Paragraph 26<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph A3<br><br><br><br> -Appendix A<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph 25<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6921628&amp;loc=SL4568447-111683<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001144204-12-028735-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001144204-12-028735-xbrl.zip
M4$L#!!0````(`+*)KD!4Y4/OI58``":]`@`2`!P`=&=T>&0M,C`Q,C`S,S$N
M>&UL550)``-_=;%/?W6Q3W5X"P`!!"4.```$.0$``.P]:W/;1I*?DZK\ASG=
M5LJIX@,`"9"4;6W1>OATL1XKR=GL75VE0&!(3@P"6`P@B?GUUST#@``)4@`)
MR9(M)W%(8*:[I]\]+[[[^_W,(;<TX,QSW^^I+66/4-?R;.9.WN]]OCEI]O?^
M?O#3C^_^H]DDOW^X^D1LSXIFU`V)%5`SI#:Y8^&4'/_5%&]C2*3;4N"?'OE?
M16^KG;:FJ!I1M7VELZ_KY/+L_TBSF4#]8'*``GT$`*VEDL7+](-X=Y2@/@/Z
MQBR#^S=&[VA`?HNQPS!:W58'@=Y$E-OFO$'.S#E1]09)2='V584,SV)D]Z/`
M8?OX-P&.N'S?8>Z7]WO3,/3WV^V[N[L6OFMYP00&HW3:^'H$E._%S?&MS=(.
MV<9&6[Y,FZZ`ONN(MNI@,&B+MVE3SHH:`E"U_?O9IVMK2F=FD[D\-%TK1PO;
M0/MR>\:]KJ;V-O60+9(.KN>ZT:RXO1T&[7#NTS8T:D(K&C`K[?=PIWP'F_H!
MM5#-UA(W:)N!%7@.;8]-*VS2>]\Q73/T@OD)?$\`!72\%H+1AK<IB33<@$K@
M@28YJ8>%4M>EU-.FEA>Y83#/M^74:DV\VW;\$NU$;2IJLZ.FW:(@`(-<UR]^
M6]#1IJRX#[PH:$[OK6EQ>WQ3T(&YMY2'Q5WDNX).KLDL7MQ'O"KHPIE5W`%>
M%#4/_6!->WA3T"'BS8EI^FF?L<E'0H;QB_5=FF88KN\&+P,VBD+*,]U0QWEA
M'_&F`->]L\$L?_^4\17A)+S/FPD\F=+`]&D4`F^9:[4L;R9\L=(!#.#V?GB'
MWF:?"S]R1<=$>)_]V*(V^ZBV'W@^#4(&=&>\H0"`HWF_Q]G,=])G4V&#@LIF
M0D/KGMM[;4$(AH)#SPWI?4BNJ16B'Y>^^8?8.5OQ6P:CC%O^,>1_7(S_Z*C-
M(VHA5#FJI`?$"A;.Q9/D$;/Q(02/@(A1YP>9Z,KAZ:][!PIX6?BWHQKOVLN=
M)9;V"IH8"_"%>78>L7"Z(3P30E8U$#+$G?;RVP78!9#D2<R!!WC2.3M&CIR9
M@>#SL^4(C#@(C\"Y2YYHJ/A*AB?9]S]D1F#G^G1R?%R\K9V/?UR'`!GSC^-_
M1S"Z0V_F>RY\Y<-[QO^X!/6FX(WMZ]"SOIS1V8@&3\GZE*MT@C3*9_*A#<@A
M+#*+A9(N8C-H(U.^V%_M;QS=WD'2K&B8[]J%6&*RVJMT?<=J,K1MAK[-="Y-
M9I^ZAZ;/0M/Y9O5EXWA?%:>\XIQ[+@*!N`S1='(*(`+(L;Y9O=DTW%>U*:\V
M5S0TF4OM8S-P@9'\FU68XH%^WZIBO+A,4!9`7>#B<^%A6F$\>R[F*HP5GM19
M84B>J`KP9/ZR>*(W5>4Q>9*I1%_KA:]3+SQ=H;WB&EY%_@Q$_@2>K[R5P]>9
MYW[;\EX9X_=JWZ_"_HXL^W4BY\DF<IZOQ;\JP==1@F?E";`?<R?PW9F?<AZ9
M(X=>3\V`?KN3+0\-^7OU!Z^J\#55X5EYA=?Y^B>:KW^^WN!5!;Z&"CPK+_"Z
M_/)=6OZKV+\E:U>:U]1_&;O+Y/H9<F1[?N!.O,\N6[<-+\)7R"69Y>T=Q,]G
MU.110`]BZ8J7"?CD7?(=812!_'Q]M`(OWGN\#^^V`'=)`T%G"M9FM\#H@TS3
M<]QSC#N&M\2\TA\?'E'7FS&W"&Q9!N5`M//4+P\<97;L"(/-B>V=3=G^L="@
M*SIA/`Q`%\[-&26QQ*]P4^;:G8,W'\G-?QU?#2^//]^<'EXWR.GY8>M=>QU0
M0<KBY2%0$YC.J6O3^U_IO!S*K%VL!94B.A0;H,,3QBW3^1<U@V.Y]%L.5U/&
M#(EH':BE09TPAP:'\'SB!26'=#TS'>A$KJCO!5@L$72GICO/CC`'-\5Y$YAX
M%.-Z/AMY3CEL8H>MA)SKO2R<Q42N-.2+*$1/@1T*$:TN^A)4/]$F=@7$IA:#
MP?+W>\K>@=H=J#U#[^?DN`%K2F!RSN-F[I<4)%#U#XDFVS<%.(0G-CX]<<SB
MP:U`',,HJ`29Z[U"Y*7PI974;A&V\C3G0*T@DHHIVYS`,UX.V3^6D*R`68,(
M+:`"&OR["%$*1J!))PU,/AVZ-OX/\XM;TQ&I17AH!L$<5.$WTXF*F;FZX7NA
MA1@]\BHXZ'7[H(7OVI40UTUJRJ5-I&K*0.OT=.6KTIK)=#;1NA.1%W@H8<@Y
M#7GL<FL0=+\'KF9!U2J.G4@H)<#>0.DHI4FHFP&#?D<WC-X"?RVHRVDNQ&NM
MUU<VX19!:?_4O0P\BW)^13GX!0LUYXC>4L?S9_6P0>]VU7YG\*Y="F%=I)5B
MTQ:D)?S\Z'GV'7.*$X!J##*T04_7%J)*0&^!K]2H2^&3^E+#Z%1]H/0T3#GR
MH"MC*Z?X/:77[?34C=C.O9#R2W..\^)U^COXDQEF`9;=J"@GW(I42)]HB=..
M23M0>W@21-3^Q,P1<Q@>**M#T>%/=\4?E\#]&!27XF;7`$OI[DIQ,N]:N\H9
MZJ";4?5B/#N34B[4&KU!IQ(I&6[5QQ'54(R./E@0LHIE)R)*\4+5-$@=]?)$
M>.[DA@:SK*W6P(LN6)LQR.0?17AV)*2D%54FI%Z_H_5413<*Y;$=VG+91;\/
M1J$]C#:_.[.N0JNK9NRQ`,5N))0S!%49E*<A,Q%1%P]TQ<A6FDL(=L!>3@$>
MQBX3S_4+]G5H?Y+>KL=2`RGEDI.2I#RPMZF..*%T>YJJ9GST&ER[TU,N;]7Z
M8*^=;C5Z,L7)=6A.Z#%&73]@G![1,2[R0&(2S2(';^LXB@+@^'*/.O)>O0,Y
M]X+PW8EZTC&6=&3@R53C\48IW,+4<VP:<+F\5\<$A*%U=2WC@E:Q[$1$2=;U
M.OU.URA-Q1ESO0`>)BED'=:N&OT,&Y8Q[("^%`L&W>Y`ZW1*$K#*GE/7<B*<
MCK_$M0K/'<;WF*#7O/&*]WC4HCX=0U.T38+;AK(G'VS)&3.UW]-[@Q<_VEW.
MNI5.)U\H;W8Y%%8^SWVAS-GZ^%3Y%/B%<F;KLT;?/&=J.9A3+4]_H9RJY?1*
MM0KBA7*JKB,>#Q2B+YQ+=9U^^+:Y5,?!@`J%Q0OE4AU[YRO5/R^43[MM,-_$
MH>;R),H+Y=!N>[$W<FAU"N81>)29H1^Z]J-,RJRNAS^$M$8*MUQ#KT1AOGJZ
M-(.+0&B#+6:]D\V_VW`RW3B<H;>S=Z"T%$5=M\RP#G_M)!>S]HE(EB%]&(53
M+V!_4;LR=XMWBRKRSSI"E['61F`!+Y^&0$R1ZN(>9N/]_F;2)+Y:R"K-,U7I
M]U6C%KK*[4^NF6?+VY-K(;!6[BU3*->\\BT_,?"<MHE12KZ@KD7K6O;L:T:O
M9RC):EM9S+436W+I2^T9'6T[:@L65Y\^XI1`7B^QN\2:'8A]G"BC*RM>?`/.
M>F@K:^YUTE9G;,')P\Y@L(&J`@^^%47E.54'1;4'E(?)6A=.MJ>M/I:MHZUX
M?_+QO4]=7N[`R^8]=#V(PWJF7M^(;T?*EB]$W4A93S'Z1L>H0ID,*E#[X7D(
MK$/AC0@GN_.IW]>5=/-X`88M\%?AAM8#]]1Y"']NZ^I'ZM+`='#+JCUCKC@G
M&+);6I?J='6]F]WQ5@9I/5168=Q`ZQC]P0Y4/C8;C6XW%[,?F[9*-J@.^D96
MQI7$Z^.Q7'!G\<MR)]DVNX1.7^_HV3W:RS@.*J*OQ`U,M3M:OQKZ4]?R9O23
MQW<??W,#`Q9HBH7P`!E5^-#<P(@U9"03<'4935.#)MV,62\AJ(R\TO@UK:=E
M-SEM0GX9>&,6UL;WOF[DM]DFT//'36BX$,36,[V5!-)3NTJWFSV,4I6&1QA!
M)>[B$<9N5W^4$=0@^Y4I\1R"'.IDJCVI\3Z8G%F8-3$G"M<4`1N%751MXOE]
MK:5D,L<'T&8RI']2-IG"H^$MN(T)/8]P2>!B+!/AW:C=G'U71Y]?5MFN<-EM
M"U*IR;/--<261<TCT+TRIU8KX35L:RI7O7T-=C\VU4/[SXB'B)[?>&OVIB1V
M3>UL[0&%&3A'*XPU`2^OX5<4QL!92*]I<,LL*F\\N**6-W%9K2795Z+_X#DS
M[O'V:#T7IA<#K5VIBM&L6GLY2K:I^"M0`NE`0$T\E2#_CV?<J0^B.(H==9R@
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M->_.:4B`="U[I485]/7278G;)2]OVT!W>E;]E@9X%>_%.'MAQ8V7G^RHPV-4
MPU@7D578JNL:[@S=FM`XY4I5_-#C-90;NM[M]Q*J"E%L14*U=3'#T(R':4AK
M-P;UZYA9IAO&B:G8MXQW,U-^`]@_.&65ZN!G)WSK$Q[.'?I^#YLT30?`[Q.'
MCL.W9&8&$P;?%#^$_^[?DC$`VB<J?@_9#%R;2^\(A$W3;<@'#<+!+,9O]WZ>
MA&\1^@@_G%_<'!.5_&S._+?_B1G+6W)Q]7%X?OH_PYO3BW,R/#\BUY_/SH97
M_R(7)^3Z]./YZ<GIX?#\A@P/#R\^G]^<GG\DEQ>?3@]/CZ\1;'N4(&C[^.FG
M'Q]Y*()TU5">$F?"/OS`\,,1Y5;`?)$(>6/R(>+,I9P+DEC*D*JL$4^8BS=6
M`ZTMG;E?AUV/0,<_*<$]<289,<^?FL',M&@4@NW@U1OBVEX`:$40/`FP%&H]
M8BX2P`;8Z>+20-/%U8/9C`86`[+_,A,I,-?U;L7"M6@SHS;"=^:$S?"*8#!3
MLH3:#SP[LL!UC+U`(`TA=(AY+X0'AFW10,#RL/H$WX$;YFEP"U3B`],7@&#D
MU.8M@F-D,Q)ZDG88;H`K$AR?0'.(B"&UIJ[G>!-,1D9S`JX"KXAW)P3P"QQW
MC,=#QPLG`#?Q[EQ`.F4^C$]6:`TRCN0$-/1@`0GB'32"TF5.P5<WC`0;*!.C
M\**PF4,\0E0QN#R)0#C(_0L-6R2^]0K`W$E1QHBPW\W'F]^;JJJHY$TT@BH\
MN@>G.OJE`>(&B5`'%&+*`IM,Q#X#(:Z9YWJ6@Y.*0&7(1IX]AT8FZ!+H&<[Z
MF(3[X)S!O8IA@-O^=T0)]5GH^331D<,C31']`3+(,'*%]LS,,`("/S2=^<R?
M>M8<PIJ4CL,]@L<>1.<LIQ:"&E[?-'N:(6@WN>";31W0*8B$B;X4J\MO+#1G
MS"4?T+IX)(Q?U839Q=\`$EXL0EUKWA"C0F0#56\(.0=+R!;`$1UX%[RS'O@%
MSV=>T'KU*XCS1GB*V(6@+D:N&=DL7F&T<1Y/?.(0EFW<)DO&,J`#(WDRF\Y!
MIT%A?)P&1,Z#$!%F8*,#('=@-N1SZ[H5ZR]*"5Y3'Z&9:>"'[@S@^@Z0_"8)
ML)KR]N-P>)E^5=_^(J0I3!E\Q8(8YL+SF30.5`V!%74,?VH@B,3E\T)!3Z`9
MP:NYI08%X(`<NA"'JJ`N7M$)7EP#?19OKIN_M\A0C`O(=>9HE70.`IB#E8:`
M!T]>H9$X"$&BSM,T]KS0Q2017(ZLU-&)X0#%H%`*#@UI(8L!-0`V%PL+TMR!
MWPWD-Z)#9Q*[<I"V.1$=&_@5_0@0X@!>"_P0<MN51HYDH3=R*=[Z:@9S08E)
MQB8X1A\]HQNF`0*1/*P+4Q,"R(B"1XE98K?(.?B*`+J#<'DC=N8/0^)3+P)G
M,X)`0$VA5M#GS\B5OR202CBCL`\`Q%12'+M#6%X4D*'K@F^/[\!'WY=HQZ^I
MCYI#;"`43,$F4!K)GR;IJ`V"*ZHM@O8#7(H<@`X<\OS806="XC2@%/UU..4Q
MG#,1;6(@FN0_:%`B`X8AU\7@*V)QS/@$BQ`[*AVPA=Z#CQ>CC9&ABPM0@?"6
M<TDZBA.R`QF!$[N1O[51Q0?6G@(N><!GE?5=N`M9:P,IZX:,F'&R144N@7J$
MZ8HKE2^:S83N032B]];4="<8XDR7FU)CS0FH@HA(;Q!6QLD=)\UO%LUS3D\H
M^X4?<7+I`4YR:08AYC4-\NG38<Y?8J-<5Z3NYB/YP$168D$7*/5;Y`WZ)AJ`
MKGUQ(4<B)L=6-XNT+&[X2PZZ!)2%+VV`9TY$HL;*=NAO*(O3/1#*G^+.IT2C
M;SWA]^5OCB0/8P8+;D,%[:%_$YTIY#4!N0,RXY@1JST^`#Q8A>>27G*'`,"_
MQJ1@SS".=G'$B=/,@+QQZ`0S*?F=2IYEQ;V^,UWJ'/PBT]SE'!P&$$X]6WCC
M%$@K2QQX2R\`/R14B*$&.N8=^@;X?`YIH-1&154:9!2%Q&:V\!HBE<<XF_$]
M"-TA0XBH3JJ[T6($:;!_V&/:7BZXB;YR<^N:V%O6[:FO"5CB:J2<.HH,!WD_
M,V8..A1R".%3S)6$(B"DO_Z!&0T#.2V]/TUU"64";6+W@DU=_*&=,1`$`G$A
MF$!A1RYS=5WJ(C*&G[;-^1:`7.@TX*^B6,UX3(@<)*3UG-DLSCJD,T+J[#5`
M'V2&`(Z*G8Y3$KCD^RI(?&1:7R8!5D9-"V`$^^!6(-EX/BJYEL#:`[8\AXC^
M&[UC<O'G%>602$'BLF,4?[1QU,K4QYG9$1DSN%B<(K`3/PY:['@<=^AS)MQ[
MA.D;EDU).2&S/V'='H:32*B[@+,*)/'+&%$YI>)>ZW&4U@"BBL$@"FDE[I[%
M4GW,Q+Y>J#Q$=,YGK0V<QQ"$FZ+:2V[ZC&MT4='_#2*/J@P:JM']IFSN,<)`
MA.46FZ$OE`8E9]#X%)C,93GEXT]S4)M+YXW"A!ZWZ`1]!WQW,H]"Y2T8'$L]
ML7(FYFZ$J#"4SVF8F_X3^:K(R5##["":X,2=+9("+E-;T\6.(W38F(Z,4?3B
MESABA2%"FT#W(%O@7HL<WV+Q)YKE,$&!1;$>F8$.KD$HU"HIJ0M4$?DDMZK,
MY43AE`$1:1/YPJ8^1`2.]1Q4OF(?,Z(;0U[M8<K,DDM2!`49<-X(RT/()D7U
MCS^E9OH`^A;\'-I/(;T\LK!L&T<XKY&6\,A2W^.@.`F`#%!O!-H4IVK(X&40
M68X5R<2)^0BD^G$=,&6^$#.R;M4;8*#%^5M,UE8\`UU(:T0G3*0+\4PC%8DU
M@(IUKH":US1NI6*,,SE5Z#*2@J`2:F*/-@*+_2*[)CHC*XXQ"_#8!LA&Z.=X
MO9VC,!9&#EK->81]NHT!U*RZULE45DDZ*9B$Y"#BOXES\:A"Y#:^R0#W4LM:
M[F&Z<^FAW(9-Y`IKYCF44B$8(0P`/)J/OT`JSO9C<-!:FB[#DH>)!'A\SE,?
M!S6.*/XR0T;J8(RIU=#X=%DC"37*0&UT`>9R<8VR(/'=0)>GE\>YZG6A0')O
M!S@(.<^=EJY0@^%/28K)0Q\\\Q37YM6&UM$:G;Z:9W+*`UD5IUV30$GOT;0Y
MC1F2LF'!F61"+FXIXS0P:8PE%T[HQ!:7"'%+M?_IQV_,`*'@2-.2C$7=08Q(
M]U\G9I5.-BQKAI`:3DTF[<2\]I0Z8EWDOTTWPOB\2(%06"=T%(C'6E<^%L5/
MF(.3K^F8O'3`&.B@KOV,`J%%7\.0X-L0)U_E_@%IC\O6)B"E>PRDTN6G?=;:
M'9I]HT;+ZS0&2K^A&PI$_F6WL2Z7$S*#Z+V@:\V8"!/3MCA]S-`6Q(1;O]4?
MK#&\!@Y$["62,Z406Z<Q`!Q`LE*%2"$J_ADGT#P:RY4E8-JMR1QA=N;B*HTU
M1IZS1%+1@>A=O=$9&%_#@>1LMK2XQ#S?2DA9EI=8?$G(YKA8R);-09J5-QZ+
M*521`8E%1<SG+'C$Y`Q8S,ULOC83$98O+W'@]((7A9ACQ8>O@8V+:;CK-$J2
MH84K(H&<XLJ$3^*8=P(3P'"86+>*UTB!CS-?YFJI9HWFR>\9+UC9?:/]?WO?
MUMPVDJ3[?!SA_X#CM6/E"(CF1:0H]TQ'R++<HSVVY;;DZ9VG"9`L2FB#`!L7
MRYQ??_)2-X`@15*D"$G<F)VQ)`!5E965E=<O7RNY4AP0EU@64GJ/GP3#Z<J3
MUW\L>-;X0F$NB3\"OHSM^<AGQ]C.G/:95X5+F8Y4V8N5$DC&C<YQ(Y"ZVD8@
M<X.)25LTFY0<6T9O(W&\>D/%>*PQC5*O=Q[WP3`(M?<F-F(MMY=09-G>4G3W
M\O%DE1V=J:%-`$T<UE?MEU>X-C'6Y@\GCUMQA3LGI[R!O/TKBU).)+E="R0&
MNCQQWH'Q(E(,WT=>/"B^A__>'WK`P9.WB\S*F=XL]0.YYF-O(!*++1-N19T+
M5%S^;^W\7<VZ$Q^@I;)V)]Y7&2CAO;Z`@Y/>T7'W2,[!4C?A+4Y[`?*-PK(F
M,)4@I2G)"IWU]GDC/8U$%/ZYW5%6$2B9H"PDF<=.?M3EQ`\_RI)@(OT42C7D
ML)M65UC:4;J`U`A&5/1#LMKH":1`)"Q[X<S_#CIL2A[XZ6#X[U9,/Q9I'&&`
M\H?`/`[*1Q!T=X,>$)`ZA9<F44#IM)H(M&`BA<O.F:$_1%>5_Y.SQ$(!LH?F
MX>P1)3C;`W^_UWCM]+S$AUW+0DPCL/*]9+!<#&S-1O_K\EH4U2:*&R)]:$+1
MV+ABM.:B(H"6ZFC>M152^UH-2T-L"V?1&"K/HFL))5$9`14B]<?!1"6A`1O`
M68"/ZW7K25LKZ4UNI_]:C,U')4$Q>5Y&0.`?5AI]]=(8%B78V@,:E'KG!!0P
MDHJ\S!/#.*#F3DHTY*,#DH(.-=AL83YV?'.-KF]I-@TPW-]7.T#_$&8''J(O
M<@,WO)7-:C<+IP3\A\NDFY['UUE9P'TJCF"3>LRBG+,U*%Q7<SY'(8AH4!38
M:3#X01;;V)LPR^-]<15%&(Y`?RU5\,LL+HJA@#W$:=MX3Z)"*_-:9'!N=G*R
M*<OB=&)IA9/]/T+T=W1<1#^DALP97S)'&'[F*?&;*F-6A@C!ZJ0[2D^6U`41
M4XQ^X-I^$[2^,(B0**=T+/HXI#309$CB.Y`.+*D1V748UB**ZH`G&[HZ50&V
M5L3LK?-#2C/7-(CB*R^4&DY"=OS)U_.$K5#]-"(E\!"<M`R?FOQ'2#]Z=!63
M[C`TSZ>Q3RD/QLL0()GIH3$,A2L3(8(:L;,!Y%E$9-$.'IG_!59)G_,0<7DD
MMP0ZUCG:0IK!`*25U]<94*R967PEE0ZU`V,NK"<:<SJZQU4U(%LUB:TR&K!8
M!U?,=N2GTT0?@3:!G#;R!NPA(I8#P@\$$!LQZ]0,Y?=[7D!L;+G[**TWG.12
M=CF-$,F,RBD<+S-'W!KM*<SO$%$<#G<VF)@G>IXL7KB)XN^&W>C-&'7-;`Q_
MS/$1Z+N)4.?3.`&X7``5JRN.HK([6":Q>CPP.4AHJ3A/<\8MYL8E2:=GPGY$
M9A7#1A1Z5Q^O@>:L7T#\XFM,Q1\P2VL*6F?1QQPUO\])K!B<E&+A"CUUV$=3
MK41-1`5$*6$/J(Z7*<Q#9P%,GP!7QI24LHF;K;S?F"ZG$A*GUAZ*JRCU3>KR
M#TK209^*8G25=X#_KCE?E+C3-KDL8(QI73)?-<,4@]"5L@R#M+CA,B[+)-:)
M=A38U:4DH&UC9):J,1*5/:2BIG@2X\S7E03RU,KG\ML_YKX8.@108$J4T=+1
MAIH[!0X2]L5&1!R9D8MFS1A+U="=SW4>J=Q)%('Q0$;O-'O+A.-2O5]N,Y`!
MDY&UV,W)%["H8.8)?Y!RJH^98J[F+CIWR)]*?)3S!&UUS.@Q_Z&C+@\>SD^=
M+T6>@4`6F3Y%9.3]('K'<E=4P8EQ+.H*%#,+.O-XSQ"U-?\\0!5D[8K;6;C_
M!6,P(%=FZ7!;=M5L(H=;^UAY<OMI-'[+DRO;:)XP)IX!5RTP;_757I2FT>BM
MTQEK,NPC3>##\-E2!Q"Y+.G?;V7U!`^_?T,X>?J7]/)Q$#Q_IE*`![.5-K@Y
M4(B8,QAC.(%5,C_FJ@N.Q7M:0J'#P,XD9FED'N6/L1I&PB+D<C5Y"(=PK.&>
M4'8]*FV)$J?^D(,.)L>(XI,C4#IB)4R-2!,#'K#FG*GW?+S9K1=8XK*Z`G^[
M`>LNA:\.,,%<9JKVN1#.7FMO,BTX*=9%<@V&,Q-*&7Z!G"E^PD47GDQ+]A,C
MFZROZV*<_;$\7C.WA\Q3FJ07Q^1-80UM&2_(XQ1-I'=<>C_OG.=911FTP:0$
MHEN*=.-3FBM=L`H%M(*O%7M9,%!S%*P6?H8?3')/*@O0NM)ULB?;D/@B'A@P
M/K!2`!ZW8%M)^Q!8X8LJWL`?R@XC*!#2&Y0)>152ZRW%0Y*PON/S`9TU4;9P
MN.IV+/4IG!]J(6C2%;/3Z`6</\6%>4Q8WHT78\GPHK09"0]S%]'NP6^+D"TU
M?"LF:T)74J%\!%."T@'ASQ[G'-`V2H%*,71;>8^H,KF,@LIIH+[<$\I`EM%/
MD:8!ZG*7EL\\-+;\G%6QW)-9_:&U$C^Q.0'53E,7DK<_R-B0E1V)+!\#NM#>
MXJ6CY#R,^UT$_G7$Y2NQP-1$93"6S1569M@8YF,\>U:`CI)`Z<L3_EL8I:X5
MK8/E2>,939`@B&[((/5IIB'R`WO\'Y[FN!&?*QM5D4SVI*H*R@K$F@G%P,0D
M`D2"806JR_T@!EB7"[H8W*$#OZ^M/G@(##\,.O&QMU*)\5LAR*S\@<V?3UVB
M:EN6XB=6>9MB(3M#EX]63TPBZ0BA"D;;3IYP[HC*3Y6B#N8RSN(Q',0$_2'D
MN%"6GK%V;YVNLE)3/U"'QTA1%S-.)DM\C;Q[L1BAHE6^_AWSJH"!EE@:I$%&
M*T,O('%GF;19J-57P]:P][Z6<=;OE0[Y*#24M<^,(M#[!)_JV/BIU=.D*LFK
MG@JQ[[,/1?O\\9B/QD$T$4J#P3+*<%_]$I0$^`JG"B9DO6B`W*&)$BB?3`\S
M:E#PS'ZKX&"\/=2LG3YIP9:$8<@/I]92XS0%N<+202UU0V!*IW)O%D;)66.6
M<"ZAH.-9]P=\!\/;Z)4*)CEU"N.*SB"+E2ZBW-$?HG@H?!3:4@633BUE:=.^
MXM!7&.N7'N8??H+!#3")-18"Y0/B=4J*<RJ_G^`STE<WM$9BQ4\5YZ!2J)W5
M#T30KW?4#U$\\W10M7R0ZDP+1B<@E)M]+&DAU:6<PQ,=LS#[::N5K.D;)=96
M*3D51'_(8EP=)Y/XCHJ)5:`&^;'F?*-,1RY'SP_#GP/NE[F/,K5:!GBD^[3D
MY*!VD)@K3892T`]2_L:,<YN;IZ)*3(D\N!C6YB_5`XMN`1T>TK9C"F3AVE1Y
M-RTO-T4FJ!?T92%@;JJLLT^Y?ER<*PD-ZY@5YOWTW"W4;(-]O[+;!R(8[V%'
MD]>.]"E\@<VZL'+G=4)9U72,*OMGF-"HR4N5<2\@&N<*)HK9L3:+H[G_PR>?
MY?17ID.2N4])K^>-;+NR[W'?%<L<FGHELIIG*!^/NO04J^`\R!J9NP@*SV"!
MO$>W]))4X(KD<90RI!;";N'HZ,NQTN'H)LREV+GRQUR6G9U,5RQZN2$`(%UF
M#*/I@:2[1(*R]4#R9(G(U]FH!`//$&5*6U`@1^R049]A%>B6]7$50Z:]Y$`?
M,9F"#F%WB=P82>`YLY!BVGC4;IN%^,D@2Z8J6#$H`2_@'!L';J-]X!ZTFRAN
M\W7<P#AF,K=B%;FW$?@7#@PP;HL%A54V<_:.3<T>/IX9S*F!9&LAVR@9KMS9
M=.6^>ATLV25VXY@?(W3/<!Q=NE)CE:ZB((3L$!;+"<K>Z?MQ/QNAQ.5,:<XR
M-CE4V@&N=;``!MOGP5*$(J&,,'*DF1]Y$A1J`M,,P_+X0JY`1F=18<G[)UWH
MI&%G#W])=/9!/H<'YDWR,+\D.74,U:-_'C.F,`)_=<5U/Q2_9WT;TTX2J=W2
MS65<7#(EA[RP?3C"\*Z'U\>-0&`ZK!J!K4P9&TBJQPFYD$ER>\$D\<D[S>:5
MGZH;E!*6^ZP;<DE;V>1N9"*9\OT`&3-5!^6'SY]-93)9RY=!/.7.+L0M5!41
MA6!`'A'$`@8!C=DHXRB4;SH,HAM*.;-'X%R?@DVA;F@3$<B%5`K<H^X-:U2M
M)C\0^W'3\_@MB@;D524Z6P?8WFL5_H9?RQ0\F=]$"55X=/ND5.2/<WX[^920
M,88!9YW#R8.;YSB:Y&&9\7Z2BK$C(\PR1$^E_/1[#E#+*,NTV68L'H37-LB&
M^--_)P5.L3,5U:1@JM?E;%4^`A#PB@(H,<=>;(M,#9R3-GKUTD?.1$"#4/$M
M7.SHM:?EJG1#JQ`[4C+!3GR4DRLC+9\H\L>`JJ%JJNU17'7,`S]W6,J77+X:
M/U%;8R&&ELB'N329*5B*5"Z?KSMGVPS9)47+,BJF/TF<2^_96"!2@-M41NY.
MS)F!@V!A7')!#/`5P;S(<X2%)!1U)$][_H9,,A#:23KO@LSQ4<EM9P2,U>-K
M(9SX'+2\`A0'3;4G@RWO_03KCX$#[P(MOU8@^9:S[QR?_/[M[.(,T>.K8A57
M1=S?CL)IY$LY!"2:3PR=`LQ-,`X,!H?ZCX97/#%(>=+XLD$D0;'1Y7RY>KS0
M*0/M=(YG8GSJO^1@&MA'/[5.5(QD)K_49S0PIH2,Q+\BUB=3)$!IB;<-6D:R
M(%##<)+T+"(RD[UGI0.;F;O.4?N5^JV%Z6G#PU@8GWNJ/`^4+\;W+)T$?8FP
M^1`(%<;"HG>GT6JZ]7K=PA68,8J"NR379-\?P\NO$8]*UTQP5HE\VOX(;ZK9
M%[+P\S8Z"E(LB3=P@3E!;ZTG<9K=AMMLUV]'0JA-54_/!#:;+JL^71<VQI0/
MZ1[A,?)5W)<6P8L+N?8LEY3$A953V:-<!%#/]^52V;7L)Z]=RV^M,IH$Q<:F
M@31F#4QW$:PD0OA2[G9`N,I\LEF[S)&/=$J;'E-4H#PO3244%9B\PH&]/+7G
M3\V`-,`;H2B`7ENGU=I1(8$TU3G(<2Z]RS%$I-P;0A"3/YLN"6@-(6;93Q5Q
MLX2!G&KN<-@^2;64O+=QA)TD^%O#"&FA3#2-F6PEE5MXR??IX*G(E;<`/^PI
MA9NR![GF-^\D)@-=G977&E[<PO,84K%9XK%W(H>U#!Q3FK9"&K44#A0OY3ZU
MJI3B:Q:@G_&`Z\YG+4%7-$BSOXQ+?0L\6UK0?FQ)F!()SZ=8:Y-ERP0U@/".
MJ-9YK_-:.3D-0TY?P6LFC9D#DH9$P30^R9-7^E:7B`9=O3H",<>EG-(_Q6<U
MYYV*E$X;L64#Y$_[T$$<OP/C%V>%4`--<:T_ZK$OFT=M]ZC5@ALCR,I<$8IS
M=?B%G&R"HN`ONTVW56\K9.<IZI<IPS.B!2^;K8;;[M89"]WHVBK'BVLW=\>!
M"DL<NB%C73):V%<[UN.3[L,2+7E;A<LSE:A4-.Z-/TBOWSJ']5>_.#TL)XE1
M"PZ\<2+>.NI?2XQ=J.,A<K]P^B((DK&''>>P*1W]/$8(0/[9FEL\6RW_KWY_
M..SW?W%(M08:*WIQ'=$O]F<&"_+#?J-9H_(C.1LY;_5;19V#5_SUSSH*;*X^
M@]>>-Y(L@5-(<"IH5+0_Z:!L]G+\QJO2/2U_9WK%=_T*7:/F,W7YG08*C&9G
MXU.I-!$V/ILW:;S8\9!6Z]T.ASH&JC2O,9XZ,?5:`T5H_L#P+VF03PQ[X[-"
M.=6A@"[+TBLUGRQ33LFR^2V^#U+`J9?)LL=/.)27*1=JTX,^_7)-7V0.HD\B
M.N12_'*W==_M[25F,X]4)8=IYG>D3K1Q$BU\N-9T]\R<XX>%5+XJ;/&J@K-:
M$]R&'%G[IRV!PG9`=<[+1BZC9JT]4U5C,Y7R7_/*^!),P-]?)U/>Y8LSSLWV
M)WG7]TM9G#[B#*(,;).U7<2S/VH=G=9AUVVVNO=`PMSI>4-FV%-SHQ8,98-P
M`.9QGXM!M+$\MQPFO18S2XLEX$.EC>WGSYZDN5T'Q;?,>N#?2OIT#Z59=#(+
M4_"^K<4E]=HI2[GNMKJ;,I3O]TY>8CLY78`#@7122PBP^A;=Y5*E=X_J[F'G
M:)U#5L&:6'J#SA9`8%$2]0DIU&WWX*#A=@_JCURG7H)G6AW%,ZQG^_B\/_0]
MDT#]I!BD?=!TCXXJ9'3=_XW-T1!._TNPEM13N?4*LE)![55+]C>.#MW&46,K
MPG\KU_!G:G"O-FCO[.3\,VW3Q8T/@I\;S;ZNUAX=M8[<P\92=EG53M):+NCV
M*TRB$.7'2P%S/"'!>^!VVH=NI[Z[F1>[F2W3^`EQ2=L]/#IPV_6E%/Q'>3UC
ME?H2#+%%B;_7;#?<=N-@Z4&G;ZX'<W3-/JDZJB=T2#M-N.+;S4=W1-<GRI=@
MAIT;?L-N^$>=T&90'3$IT0#]8_]PA>Q3DIRH0=_L"V:ZKMI.D]KE$.IHR$JT
MQ/VQP):XVI6*&!G&@M)BO?XUUC'XB02LA:5YL2IP]S#]5O2]1%=1:OPN65.-
MP!&FKEHWX-6_,1A$=D\L"9=A\*,)LY42X$*>UCC&D@-GX"?D,B!P5"YYD?VT
M$IFWG7SG/%3L-Z"[8.#Z\]7V#-PM!L7)%J:B5JF+N,M7,N!EI%/OF\B#*6--
M_`%BC>6!GG"&JCK656E_U%!!`6XD_1@[T<N94]LOB?L:&9C__#G;'1A]8+24
MXGW3`4(_)!`$;E8CX>FLFB@3,;02FQG!7=7WTP%0GPX'.20#^J)I`S?`A':L
M*/"2**0!@-41$M`TO\7^0_2)F($9/.P20BU$8&G7T0U61;JF(M<J&K''-4T<
MX+=1WR?6I1,LFW)(S`H$=$&H!ERH/A($N(=?)T0SG"KB(U#A(A5GR1)%"9D'
M_)P%LB6(Z2K")T&=,?G,CAV-_-9U*DD&HHZV'A-0XH@*'+P<7TJ1(E/\-?RC
MHKR72.!_.S48N&Z@8#ARW<X;LAI&H5G<AA'4L)HPTK6PP(1U<)X:'JG2':[,
M9T`1!>_+`:,(28;%H/C;.)70VA+1079HN:$.6P8_2J\-%UH\H30X-4>:7KF+
MG1Z4\)X41C%=NC;'L,^?;2@[H/-T4O'GZ._8$C?,-IF]53'[1RLVS?O(YJI$
M(I]*]VBJZ@J-Q;;TMJ^4WK\*!RR3&;(2,^@!VG*$EMMM-=U6]V[9T$N3:=L^
M$XN/#?*FPIV3I@Y6UZFB&ZS'>3K2HE%K+Q6]7*^KQ*#`+`;IDD.!N3#=L1-L
MU)M.,#BY'B"8]2?V!38TS(&S[UQ<GI_\OW^<?WQ_^O7BOYW3W[^=7?Z+J--3
MSV\[Y?`^<0T+Q<`TE2</;GB.IMB(M7!5>\YN!Y200P8XPZ[S(,4TRHW!K&`+
M`<NJ/0F]EXU1F6[4$92E`,Q2P&9UJ>ZXWD!$%@5D11:C+(4'"T26NS,8NFR:
M:%<NNG=!2*%9L]^*&I?#6-12!JF#P(/?QE02RTLKP`9Y8<'5R'-VY1JI>8]+
MT$%^(*Y$25T_P0)$0^6O*GF?&UB83RC4.<([9=A@=->H-Z<P6-P\#HIKP'I@
M"P0;[J[LL:W-/C-Y$);?"28X0[\#O:H\$&&QM!1Q.%(_S;AQ$X(3$`T5UO=`
M),#%&J6#/`+\A$M/HW7$2*_<ID5"Q$U!GTG&*&#\//@.\YN8Q^K'XI+Z\C'L
MK]NH=]UNHW,[5E&^AEAZT?,PP;EM6AD$`-L1(5K725X^O;=8[*;0UA8A[F;#
M]\B1+P1Z.V6=_$5J=3#5/RC`+\L_87LJ9L-.P%J^Y^59`5))SO@*L?<QBE$\
MVWCPT,7AS3BNA*_0K-N`VZH=06X<\A;B@:-,YS\SFI`!5*XMMAQT6.8`CVZ#
MD)H-'^4:3!,CO_(;?DV]D\O@DG*?19\T`WH7,9*6W2TO2*+R!2;<0EJW32-!
M%*9QI%&JU3>EX"/D&))X/3P<$H3;0K4V,2?K[:5G_(-RKF;!7!D>SZ%:[02E
MD4-P$@J"2($!)N/`3PV`'^+S`<<&3JO.8LW9PQ`7&`19(ANBHX7@-%Z[I*S,
MY+$R]N*0SI';;7?<9GOF`5(A`B]=I+W%UI76M>OQ:^Q5\8@9>T.*?;M>IMD7
M%?D2_6RW(188J90>#4(E+^IJTRJ9A8*L4:'1`R$['7/HBU!*G3&\I9O>4S-'
M?;N[M)WXSH%[U#QRV\W63!&38OM#*GO,]?!XB6`0',BAY$U0*9.$,:O%``;H
M$="9-0GD`QA5ARI5BKU+7P,"U(\:[@%\LXAU2A$C=KDX7\Z^G-J0I];]>!9B
MNR5J:(:WMH:'T_U!,-2OZC@;;I.\DXV9<)-XR>I75=,0\5/$?5_7@6HR&,J0
M6D6]*.A),BJ12$.,\5!+RIV-4GKU<D>0FQS.]TV$Z0T45<,&4<SF6D4J\H7.
M]U#/D>%"2+U6(,YT'\&M^B!Z,?VZ>:!L$P8'M[Y30!YCW+C.41N8M6NQS]P[
M?N8A0FFYQE/4<H_`3&MWZC7G=%'#CW9@71"QVX*'S1TJ9TE9T#YHNZVCSC9D
M0>X`+KQ;.*';[7""7%?33J)`-:&=.B,1]91@Y8">0US)/G?))DU64M/N%C"B
MZXO&-PDD[+7#-D8V&J75F_S"=.PY[J?4`8YT$;N5#UC6-!)B^/FL<H0RVT6H
M'!/-6;T)?I/PR#0I#_::K[7%7A@0E_A57$F8._/.>_SD*`NN/'FWQH)G+5L7
MVW-)_!'P96S/1SYKFG3QJG`I->>8T+*!:,'$58T'U*0,#"7^@38"J4M,QB"D
MU#%/PY#.)B5.-*.>@L3QZ@U7[K@UI@67KW8>]\$PB/,MI(TG=P><H5["K?2L
M+44_'1]/[LPM^YX8`FCB<$Y.#IV4<]VT3`/FH<_+0TI9;K:<$]@-AEW)&BPS
M+RC5;Q7]7#IC^]3QN?3,3V%:3P%C,H)1<6CYGDTK,R:==^K-ZG%MH20$=ULT
M;<?U1_&"`W'1MS+TYJ_+`K%5@K_40U`E%6,9N7;W%:S=Q)0*QEF(NX2"^TO@
MA<F6(T93LZQR8\0IV%&4C=D"AT\V^BOU(3.^AFP>,MT"CU)CV>+U$],0#^%+
M!!S#2F"L;)8_2D<RW_VYMB<W,OL,_\%:S#ES`8V?;9^;JV(RY1,Y948>G3-R
MV=@G"+-E_1\HQ1;-NVQ6XH"4I1DVZNO*,UPIIW!#.(HK@__1<O>Y[2O.)AAL
MJ/P-;S\1EXZ'Q`<RAG]_T7QQ"\.HKZSM_LLO<_'+;MT3883E+4\B&AIZL*(Z
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M4!6@X\:$>J=5.UBN]?R#I>'FA?HZ,-@?`"$?G5!?HLO;(ZEJ/BXI]6?,%,9'
M0G`H$2:,0=*/$H0-"3QI4V2$4X-H)K+L^<:+!]S<92((8"2Z"@E$R$]@"4G"
M<,(O&PAA)U%^9(63(TN,%)X`8:@R(K%/;9IL6Z8G"M^FIF$_J2E6,'$:E%K^
M!+`9J3K_JT2VSF&K[^KV]3Q.9+L\,1H'T42(Q&K110PK##HX`]N683LQMUK/
M<;T_\C^&11"$VT\837;D!XC>%,JN83"A?6Y`)A_F3\V!$K!'85RKQP,GT'TP
M:`+;B'":K(W[KNW;%>U=:5`!/1U$([^EK/]>YF5$O)G;!6'X5X9TQT9@;GDF
M^A),,AIZK\&9=?+'V;-;XB0_J++=*A2P5X=/*U')3C4IAB;OL4ZX*A3Z@`UE
MMUHA_#2/2B4KQK<XCRH6J:_)U:M*;-O;*;'=1B'CC*:%C>:1VYJ;++^E!:Y8
M8JO613#3U5O5NK9MS6-O,G:^_JK0NS^P4(+"+`?H;GYW2O#8JN"?P8R<LE%A
M6E9]KZL^OPWSXAW$XB)%-_/J[+;I+5M4J5_7A^X6L-HFA:I6?O.4:+&!Z=S/
M)67BJ,VMEX)L*,3=M,+1:_W8S'[<M]H[#X52*\3^%R'0;8;3$R?/H7O8:;KM
M#9!HU3R(7,1VG]2(K<>%[JVW!CF6AM[(#R9OE^XC8>(3W)ZW/$"A6G(4PL^S
M6A`%?I*:]C8<@?5ZT0_LIY0X5VSUXI\7[0!,[6%5"/VGZ&?8DX-:1)C.FS1`
MS3E=5T^K65TJ["91[B+-KG"PE5I=<1M2[J"C//5R$KOVBM.M$2A52/?=29*H
M[U..D.H&G4^:0$Y\V>AV08X=V:U$;LUJ>"HI/7_(#DHT]"Z59]$6'++QU"Y=
MI@+I,L^?;=VH>ZR!PLI$BG-B:A<GWO4$V,(L\DU!GQXGKHK)KPF82SM0`/$Z
M!\"Q?UL6D=]%X1]!.+?I-AI=][`SKX;J8<;A#^;#7#_P?7OX8?@SZL9;,OM;
MEW?W!VZ)W,&AZ+3<=KO,65N!V=5:90)I^Q-[<,'W.T$&WQ,YJQ[?KOK\MAI_
M9Q5M(/H1=^-^BQVKQ9W"\O,^N1I$YKPOKJ[XWO6C"RF_F_Y^_@Z>,^1>PSV8
MB^>P+(WF-<>IQB8NI;XL^_6FVVTT:^UE8EUWF'`U/[4&,M[W\=UE)SS4[(0#
MM]FMN]W#>0!)#X56F\I/6$X>/3'JK);]56V@AL`*V?LE<_2U!*](@D)AMB5S
M?+]XS!7^VTO@RHE3%1;'7SJG?V488/MR]N74=6Z$XY,=KR)P"0;;QQE\QDN$
MDXWQQX;;/FB[K:..%66/LEBG"=BQ?7S>)VR)*$Y4+L/TN'@;X6<8)L)4]2N?
M\`"G/H5N(7$GU$SI-<^\Q(YD?.TE\CSB4>C`(LV\YIR%#G(P7HGVXF'2.,\Q
MG!<QHAR#*_QOE8IAI53,(5.GT74;[:-%B`0WW*QY'W2GY[TRO;;,T5L*Q.=/
M$5%\_QW!.)Q8D"@5E`!5BM5C*>D/C!H@6W'R!T/%6*E((':2E*!;!LC2>%8&
M\`.^0<\X6:*$U3N\BO8O^M=1`,,CP^-?1M%`!'RJ#4B,B$=T>*9'@[O-_P'_
M',+4G6L?90SJGCBHQX@=]H<4P`?#TM2<4_V'*``."%`:P4<9X"/BHVY]U'I*
M'N5<^A"#BOC)]_TABF$?PS>(TQDC`8J?_5:[@!=BX259/'$FO@@&E.'@*<P<
M"4*"0D>G=$U1!'\IX7HPHVLXQ-PH27?<1?4,4:SF_"&DA`09-X+/A)'YY,#'
M_"N@&,W%Y9PP_I64JZ%`&!\2,F//)Q$IN2!6DX"]A!U)B/(W?A`0>E!/\/,J
M@0/^5R1"4(+$,$LSE,*7)DD,AAW0>\PP^)L\LVTJR>BQG]_9N39$7XEK8V-$
M/7^F\\#\$+9MQ,A17B_*TL*FX(Y/Y89M)&7G7K>I>FD\&P.H+.3^'M2:T^Y*
M]5M%B4,9A[J8P4`+IQ'.,3`JV727\QWO,H,MA>YN1]HSSJ+%F&$U!I`7QI7)
M.=I$)MG3[@!5#8C;I7EIF[Z5;<%DKB)0UNIY^=N;+-F_\KSQ6SK*4I%C"_US
ME(KW?M(/(E!6Q25,Y%T`S_SZ_-G_^9MZZ[WHI27/H!J+,_\JAG]_<<+__G?K
MT^F_6XU]4`'V\?)_\>L]&8"?SR]/G;:CCV#C%P=_=>%\.?[7\;N/IXM:?4]!
M1T0<3JDBDK4#"CE::=X$&::R&=:-^H-)L;[#U5/]M,0&TX>4?#,#T/;-#TM&
M<9Y`+J<DFDI5G$VW><F+FTW6W#&XSKL%B7@3>^._O^#_I;F<9'&,#ANZ<62>
M[3B*R;=LYAF*=`UK+QM_K<1=>8![(O;G*-S/4;J_H_[]49^J!'>$W,F,!T7L
MG<QX##*C8FX/57JBG(/(9#KX\TYX%*U`&]KYPN:3ZWR>RU`5\G@>YN:PO-MJ
M&_45N^7OEK_6Y3?K=>QQ\A27OMOY#>[\O<9Y6-FTL%K:K^A22M2M5++(U;=A
MM1V\>YSD]G&WN*8#M].!_S\ZW*VHLBO:\=V37=&VPZ4ZI'MV<O[9L44URNDE
M[::''"/O'!ZZAX=WZP%:(<C:K649+*T[[8BX8\,=!:M$P=U!7O'3SY]M@Q&W
MF[DG\ZUF0",LZWU]X!E5Z]CRBA3\;8N$*VG9.R+FB=AV6P=-]V`N3/B.B+<0
ML;L[S+O#7`$BMMWVO1WF)][+_@]3ID:%N+'H"\*"R&6B8ID:PWLG6:"KFLN@
MSVO.<;\/&P^?"":NXU$IHR<K>!.LNL,")RQ;Y*K!1,B13&GM&.O60E/:Z,>Y
MHL@P5^Y8*!-^`FC7/?4/*J'%*/C9O"@X36[U:MM'PN9GH7/>3R.$IFS6ZT>N
M\\D+K[TTQ6)PHMZ`0?4]YT*D:<"UZ,=7L9!5Z<"LG[(T\P+GJP@$EIY3><W%
MC9\DSI=K+QYYZ$H$3NRGSL?+]\Z>\G`WZ[_83^E?-WYYC77L28;5ES`R%YB;
M:7DX.%5_PAG,#_12QLMH6E1(CX_E'O%"4QA+9;)C(`W\/8HG=-Z<`1\E391#
M1BY0E?=CX*.^/X;U>B,PJ%*ND6_SL/#,,`L"!VN/DJ&LSX<'D'CCE`%`V_B]
M>M?QXIZ?QK*@\<:+!P0%\#GZP8\Q6H)9=2Q"<16E7,&$$]&#EBV@;/9,1WS5
MS)Q7E'\?I1%L>]9G(N=HBL^/O#2+L0:9)`T^#5S)197P^`?1BS/,V6^T#4("
M)O/SF"3JL!@75FT>/>!'#?T,J]$DX7V<VAUD&/\OGYB'*,UN#9P^>4%V'LJ:
MWBXQ4WVV)`L+\NM+X-$I_23B*S@S>\CD+^0/^LD7KYW>A!X'3I;5W[)@W'6.
M8RS2#Z6,Z8N,G"HPO[.P7\.[_KT(\(P+!S2`L03`<O9>R/?@V_AA]14Y]`D\
M.OMEJG"_CH)@LA_=A%C&FO42?^#+<AEK>OD%762]%Z]K9M.<+Y:H)9U!Q",N
MI^Y'(>.2)'@@L9@:!+L4@T7RN'B@"_2WGH-1G1'^4U9?DGS&S5!KMN?XXK7+
M3ZD_]H2JMT^R^(?_`W^R:2'7RV_;:SO&(J*\:L8/N=:W^]X(1.*"Q*QM11Q4
MY(AAA986/G04^OTXDRIK%I)<UY<K$"T6R*C$N$9Z270(67\KJ<OE?LP215@:
M_+O5BL<@TS3<AH3482@=BTSZ7VJ;C=(P\KX+YR^X=V">P01U".3?1*G/>GWB
M+U1JX(5V_96:9@C'`*Y+N!M3I^\EU\XPB(!>8!D8$!")DQ%$?BJYDV$Z$!4'
M-N@_FF7EU'3`']L!F8_#T</[%3;@^.)R_[#981$!_SYJM$N7BOQ@MY.2GEZR
M+LW^*:%P[>&=ZD0]X!F/#WD6XA[DB.#!*1"\+N_UK91(^,E%%^8/'9*>RI0"
M6N,M+TL_?Z$%]UX7]W\H4/\0[E3'*#H;JL&5HU5_YM&$T1_0\D)E9""U%:/-
MD4B%_X2XZSU8-TP0\48F1JJQ4FDLOU2K0E4WKC9C-RS<]`ON#(U_SWJM?3U9
MEJ]E$TL^`Q-<I"QL`M_K(?B-+R2NE+K=?3A<`U2,\3C'/F)^1%/FK[/8\>AG
MHPQ!=L#D5N--8/[](&,<R#D"CV>LS7;4=+TQ\/U/@B."N;UL=-SN88<MA5ES
M+B.@RZ]V6ZR'EW038.9\V3ATZ]TC]501J2QW0(Z3W&PU4\<(W$-P/"#64I@=
MGLKRPY[#/I(^$O'3EQ!'_'RQ`YMKM/G<#:*IR-8'.DK8S6$Y.#S],=O'4>YK
M^1P9R6X<*"-OH/PD>N7EJ&X7@K->G":!R`RS&.\S6'+J^4'R$%%]UFZ2E&8)
MK<DFJ0K1[D]PCEA1SNF]TVT1C=[*+@:?9!&>(K*NU2EF[:AYV'8;W2Z>8-RK
MY\^<D\`/"4GL*_`_<?Q'?X2]N'->&7PXYXU)K^,HN^)YRE/%;@\Y`#:`1+&@
M/`3H>?%"UM(\!E_:G\!XJ%?0R5?S)*V_,#(GFUG#ERH[ESE7#`H-6&4/_;!2
M*#NMCKKRX:<D]8)`ZGDT<8SFL%H6$NP;O'`,WPO(="D=\<R64&H!9@20G#$L
M,:DY92]KXU3+:[6/1=,4C!%RI2@\*_+WV/IST5U3I.&Q_$`I+9F_\$\,>69(
MR&:?E*E3W^![`3MCJA4;O7EH^\1"6Y0C`%L/741\36@P+A]T;Y3&^"D%-\<#
M3EUL4\O[`S\6.U_HK=S2J*6HO`L8R0ZA_H(\RS:D,TM;J_8-BA=]3#Y,:>6:
MNSV<01>Z^X"ML>WH*[)%4(4<V1AQN1GSI0<*9A!$:,RHJ87._W@A.</RR*+3
M(Q8ZGMYJ3BW2_G2NF=7N($RQ96<Y2R"^-O.ZGK[97S8.W&Z[B0-H(BNHIEG$
MKCG'1:7&G>F3+=\N:A8J,S-<@UY*-EN8@LJ#.T.B"^TCTAGZ`>B@/DM:(#W7
M:[IY3M=R=Q:;T+B@^AT>M;0=$8MAP-"'7I+7PEPUC*-*05$%*Q]SUK/P#`(K
M`NN1S<,3PWN"-@*W3ZTTN1:@W\T"MU7*FJ_7SN)N((8>NE5D_*N(G4A6-OZA
MR.G2O5[D=M>1TJ%$9AM9@R_[EN.8G,84@J!YFV.CII.;-5@+8C0F[9246NE.
M1T%A^9OA!`=`XI"-`,*\O>(_^>&48[_,-6V0C&9@$A%N47J5_AR\_0B'#%A>
MN]$>!()1)X=@]/'LY/3SQ:ES_-O7T]-/IY\O+YZR%_K,TB.`M2]_<][Y$9S<
M_E\9]E'A^^+CAW?XZU3TKT.P0J]\_(A'H8^)4^:`_!#3265X.WS[HG9<HQM+
MROWB+2GYRCFG/^>N2;P:X9X,L@3Y^R:*@\$-.GDHRR!Q]N!O`M;*0[YY)X(K
M/QN]QA,S$"!,HC$=."#3=Y`:60\,Y`PMW%Y.A;S\[?)_]QN->L,>&M<(QSL"
M#@])5X`;+!I,6*](@>YDZ3LHMT#>]ATQ]M-HK*7JNWU$0'*"R6A\'?4G<'!/
MWC?K])DK$5+T+'?_XSMY.JC]4!C;C5:3E`$#C^VG^9;<N&R@]V+VWI\9F+[#
MR:.V7F[WHIQ;PKVNA+NDN\$&G]X<8JN<BZ*H&ANN#>2;GH[CD%Y;>JY^NSRA
M7X+Y[HTI,L/N)'CX#?[MX\<38$Q@K/(`@/0VX:=_`RMHC#<K.HCX$B%G!!\+
MI6+FCL2,8ZGEO7T\;B=MP87S3?MKI[Y+2/(,M:PD#_NEYYY[^3<M<,SI5^?)
M7BN'B$H<V_KP.WL6,5[#S1R1Y\9,COPQH>6JX>/&E%:[)']":&]@;E]ZBJ73
M/6>',.@]I0C(-J1D@>:=<*U&K>Z,P#3!V69CG'(&FFW6[XLD`1$,%+OV89EJ
M/_N@:7MHX2K;V:(!,L,5^@O1&L/I)AYBB</7L=M`2$YN`^]/TXXFH%[DPP[H
M7N,7\^S#JHSB=;*FT$KS0UH8?-<AJQ^&[DW,/]%US>N2D0@_'R4#=395'QW`
M/`CAFY@`=9]&VT%+'8[(,)7,-?1C>,/L-,V537OE%$3-*`,%3$["=;(0EL.:
MH3FCN(->'/CX7;6.P4ZTWN(8FI)UKF18K2"P<$5Y!Z)-7FV';JO37>QR<[7?
M1FG-)EB&NF?L]S)@N)?`&O+8N`[M+APLF!S#J`L9$90V7#*%M\N<%'KD;G'Q
MV_).@'\-,SF!.:(TFRWLIBS_0[<MS7RS>#G:-&"^;9I>A?Y_T!Z;<MNW#YF8
M!$09[I.W*U8^-%RW/7-EQRZ#$T\^M)+=MUUI[+7F)17ZABSP=AE'E!`E;Z_C
MTN1#0!)$X[=%LN5X2",+K@AF@[R61,`9Z,",!<]2H+TKV0H=&'CM,O>AR2@E
M!HIO_+445W,GRZI!V78OXO60YJU<P<B;H+/*J"@@5*V[B!L!4$^#GL`.`K"!
M)G-I22GV2"36!XZ*C"(,QR;741;8W-&_CJ*$[FK=5<9B&#RG98UHF/_>15X\
MP'U\3V$H;-Q32&J!K8;[$$YJY"LU"@E"3CSJ&Y'159T`!4@(Y783.T>(F!I1
MP"TVD&,4AX"[#`PYCG;_3%5L>"0$:7^*/RVT8AD6Q+>(L6('8T92M<"?E$]I
MD(%<$>S](2D4"W/?+KKV,)*J@"?7"1(F]$;%M9*]%TC)`&PL/!)9MZZ%UT'7
M.G$]S-U\%)3DQ#JP#9,8$%E=\\KV-^<H6=@)DH-Z_HH*N!A\\>)T8@7]D@?A
M/#G,.4^^GGX\OCQ][WPY_GKY+^?RZ_'GB^.3R[/SS]MQHN@87U[`5"!Z=VZE
M$$BS$F[.\R^?G1-O[*?`RY_((Y'DW!#P]Y-/.>\'N5#1S3`<^@&K)[TX^B[B
M_8$`M39VG<^D+<,'+T0?DSO0`#RQL_:L[W^^.+&^+BVB(%!^5[Z(:1*N;0:J
M(?+.D5Z$B7%J7G3H]5S^`8<23M2<F12?S'^[D,K]17<5.[X287]BZ5)%D_7+
M\?%T`,D61K-4CQ!(!_/!$VF)F.F^:]%P*&+Y!(OFETVM:9I.3Y3OJ#J=S<[)
MT_\JIC7".JR]]93??9:>4.R[AE*T./<GF/7SC2X%[>%LNLXG'Q1O`:<%NSMA
MGOU-_D[%?<-2C-.?<)S(I7YR[?GQR-,&:?E]-\70I;O\#PI,>$&"7&U=7^6'
M!^;B.C?7&-2)1CT_5+8)7=8W(=QZU_Z8]`>5^R(#W^?C+)D6'4":G@C%T$>K
MF#VWB=-LU3JO2H>7L2J/@C4R#D,/7IQ8:_L4*T*BYAQX_BCA2U@/%4^LR9)?
MBR]AR>B4C$_F$RYK#%0/Z1T5."I8#E:S+M>L$^;DW,#CU*L1)2")C7;]3;ON
M_(D:E_,#!LE44)CT[@&:"$.D$#FYI=AC68"-S^@T];SP.QYV5-$2><!Q,/H,
MY_XD8^P\1E8E\`\PBG>ES*AS*2NDYIZ?R0VG2X#5\8,DG<6F53^I,^OS[\&#
M2_BF0P\$[N3MHDG`2O8C%P="5:0L*/+1=55RE^=<F[?[0M&TQ4$.W*/FD=MN
MMBSC;ZJQI8QFZQ"V:<A)CDT$)G"`_@GEJ?:%&-#1)BO/7`1H>,*HNMN8<G6X
MG%C0<.M'#?<`OEF\0HL$F)'<<J9[E)(\TUG%I?T]&VZSU71;W<:,9:_0EY0I
M0_D)L;:#/74.ARBZR34X=Z.6Y::\#V9)'K#8[R;2,LUP8#*+!6E4H()^CF3=
M-?9`+(E-$TU,S%F9_"A'T]QG\KX3Z8GK'+6!*[HS>K!^B06(-!2>S*VV3E?X
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MF@1Y:<%UZ\I=7OIV(*Y@9B96@`L"ZO0PRSOY/J%P@C2(<SE:VBW-!]<?]<#*
M$X/\+9J+MZ%K"//V+=ZPN$++'F\`ZB@&\=`M"$<VF676EM8W<*ZF9##T7ZNO
MP3I8BLI2720G23@U3&G:T!+^K9Q?["+K);#GL,13U(F3"GO!NCDOV,6W=Q>G
MOW\[_7SIG/[SJ6<0G2O#Q61/V*P/MB=5RIS@!0N7H`QR4\HA23[L=@]RJ/#W
ML]`NF,00#+,Q/HI.8[;93$U-:26KC-I=6JD4\@\<N_PS"W/'!54!&L:5Q9LZ
M9$D%/UA^QP[K\H_>NE3Z.&5OJU7HL")'0_E#N[J#!?B*>W<3O6.L>\/K:QSX
MJ0H<3]M4Q$OXYW9'65*@,-O(#:BABA]^E"7H'>EA&H52SJ2;1NELGD1(P=I_
MUH\HD9>O!J,UD3J5\,T(S/6[KN+\*C#[E4`%@+.`)ON_6V4_L4CCR%-.66^`
M<3B.;\L<7':<</=RJ:!K(M""B10N)UT,_2%<CXG_DR87A;J:U-DC2G"V#/Y^
MK_%:E1+*A`ARU]SXE&$^((X>S"QO*"B1E-*.])EJ>ZUU#Q7'GTKC'E(-JE'*
M$^/:+LL,QL)O3@_!)O`(;4B.<AF^QPP0+$LH%E?-HFL))3%"-<J"U!\'$^7;
M`38`]B:U0*Y;3]I:26]R._U++]69EV/N"OW@^?$_L=C,W+5WND;7>FDV<Y?F
MA^.SK\X_CS]^.W4^G1Y??/MZA^3;1RSV_L#2*@\W4F=R&3Z>45V:+SND0Q_C
MB8DY;1X3K.2Q*3L2;!->^W"?@1TP`3D9?N=``^KCJ%JSOFCJ2ZD(8IRE"67!
M$^H4'V^0&XG0EL!`J+0IZ3BU:R/IDY3JE]R^P#Y(#'^JOI(KJ.QZ!TQLX8/`
ML\##)DT%TZF5<UM0EEU%F"ZY3'/6>V6\7,/6O)EJMUC'#JXKVZ?XJ;6T;H6)
ME<.PRGDRL;24F-_2I`YBT7YZIL<NF8QZ49`C9+?UR[3[81G$^X^8&N4T<L+K
MKRQ**6"@[G.^G65:>4(7EH]<01F7Y5R\,<0ZB1747"M8T([YMLA\^9N39:T=
M.E,LFF=+<DBBVJGC@<B5)CH8]=",]PBO$7ASQXX[=ER,'5LY=LQ"PTB*-S7K
MH7<-+/<XZJ'MSKE=LO8&E'*OMBFF>ZCJWC'Y,J?+B$V18+YTU*@_]*(N8Z=_
MH#X%?T.ESI7B0A5;\I7D*@R)Q0HSI;O60MNP$#!,W*7\:V$4ZL%-?C(N`E:`
M"AU94K24G<>C]'3/BK)S9HNJF)!`##V1WJ!5:^%.6A!MY>XQ.WA7`$%2%>JZ
M4+5N(`!DH/!EH^T>M)M8(TS*O8XM2-2$9"9L@H)K*@Y6K%9-T!+W@CP&@\H1
M+T^PN;Q^.I!?YA,/#OO+#J(_<F2OG6R;4RST<."W9J8\[7"YT@>&RX6"6:/[
MWR=*UTX42`^G+"4I:+1VJ0W^@G+RLL(]H"M%93*5=?B5X]Z&IM*`!E/05/E,
MKODS0E=B3%>2"17X7(A;&F20HDBY1=D\DF809:@B^@L^F#%VCY""C$,+B>VG
M15R1.&-'[8Y_E'@U@G\DTNMHD+#C&6NW0&PH0\,I*IJ@`-B[JU*_$S)S5+(-
MZ4FC:"`"2KZ.A5*3F$,LP86*T;3"(UTP^J-2(,MF"#!1N@"<B8_I>\09O@YV
M"ZIX1</*TT>!7XYZEO==EF@Y,\J\+<0+*EYE!&@V"%&]CF+I]%>SQ-BHL'SW
M?C*'*O9M-`#!]JKT)BFQ8'G,7+@`[^LDX4-#H=,X^I-U!*+N,*-,:3S8(5J\
MA;2Z+)0ADI0128CNF&F'0#^$E@IW8S^U@PT.%IY1<!Y6_6<VN,*Q>6)X%F%,
M_()0-K,UT[&,_9F_J]<IA2&\%A*V1TZ0W<-IJNKL^#Y)&#.>EB4%@@5;W:>2
M1`D`C0:1F6PPL4963)Z41%7H)I-/]H7Z9H\F`X>([0247+?&2G?R1LL;*WKD
M25`[3,1*BO>%#-UIA`>[Y%Q3.!>Z6]C_LU"8ZOFSK0>J<KY8V3D(B\R\<2+>
M.NI?RPR^#I?L\JW?"\M=O/,CK6S_1F`F,`X<#);XX#+-(/M4)5<Z'M(9*!;^
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MS_T#(^*#\-S??Q&$`@/16(=81N?$0E4V%6OGAH4*;D81HW*38KGFKM1$4[E8
M:I)D(_BJ_Q]9;&*5$:G]L$H$E^KA]S"`SZ02=KBNF%0!C9NA>%:)4VW,72!7
MW#V4>N<'J\"KI-)NCD!<1;^_D_Z^,?V\HJHX/76F:LZ55,/"3:\OC!R<X]M9
M?5]6VU+K2FW6VVYSN7UX")XU>O5$PD6'A1M)R4P[@KJ<T;Q!2WDSG[9V?&^%
M+9]-X]>5-(-+1&;^VMOIS#N=^=ZTN;Z60^7:<8D\PHXT,>&#2Q!;JMO?0Y"`
MD7BM^V8L`82M2[H)+'PL&%6_O)G#7$3I0EM3A85R/KRXANE>BGCT7O32A7"G
MG2ST^8EO%^]?.`/1]T=>D*"R]6NSCO]G-YB8,=*O*TZFL]G)?)%M2CX`:YQ)
MN++SH>ZE0K!AQ^&`?X%5^@PD=E>R-9K-]F&K?F3FNMI$-K*094B^@868+<,_
MJ$^<1`GUF+\KNQXT.M9<YXR5.T!+3VHYMEUM4OK/8O">;,DO(-"B`8F$S^*&
M_G)WDC6:C6[CH&Y-<*%Q?UW_-/]]H80C]Q%"0*`H1%(=__23?^=9[!-97G-7
MUCFJ_J*.=>>Y+YX_.`ME2^(%5H?[5C]LU->]Q`OJ(W6/&\<#3NU=^Z#9O75M
MA<G^^C=N"\Z_YL<OH\]1B!./HR"`%Y6)>(:_E"AX?_CI-;<2AP=,0^,['ZU.
M^[!+-]8ZIT4RXK[7><L6P]#]Z:$7X>)-DRC/?/SA4]4];.D-!JZC&=JK:**$
MKYDES!O1FABNS4NNZ2'YY[4S7,D8*\Q@*7VATSUL+SR#<]2GOXI$H%4(2L-[
M"SCK[K1HM=HM-8\Y(]UA/DM1YJC5:746G8^2>V>Z__$9&1V?Q=TIL]_J="S1
M6C+$2E-8AA@+3H%IQ0ZDLU#;0^=#9"M&M$9GWA>)='EGPC3K[>;1H=JC1<==
MUU27(N`=IJJH#D]("Q1E*])];7*HT>@>F.V=.="O*\YEJ7/7;78;"\WE_^[O
M.Q^B*"4DTPN)C[N_3S2#^^?[VZ'\XT?XP?E)OTHG8_'W%P(;IP_$X(7\+5Q8
M\-OK-!V_??/FYN:F]K,7![4HOGH#)FSK#?[Y#3[X@K[]9NKC>=NDU.!BW.OU
M6*OUVZP[:[#;+-+;YK7,UAUUFP>=;G.EV>$O?1(I"8A7'!TV',Q1?\:U?YS\
M^WPX;V8_$_]MZ`=_?Y'&F7CQ)K=%*P_V7O1QL,8R@P$1AG[Z$9NPWEG@-0Y;
M1YUVJYLCL?SZ'0;=E+:X?PB6ZL'!/4_WJ^#V@Z=>'&*O[D4FVJ@WVYWZ4?W6
MF<)5QV)H31LZ-6YN`!CZ;V]0&/EO\;_AQ_\/4$L#!!0````(`+*)KD!E'FY^
M4`<``"E7```6`!P`=&=T>&0M,C`Q,C`S,S%?8V%L+GAM;%54"0`#?W6Q3W]U
ML4]U>`L``00E#@``!#D!``#=7-USVC@0?^[-W/_@HZ\U8)*[:9CD.H0D'69(
MPR1IIV\=80O0U):H)`>XO_XD8Y<OV3(?L>4\A;J[J]W]K=:[^O#EIWG@6R^0
M,D3P5<VI-VL6Q"[Q$!Y?U;X^W]D?:Y_^_?./R[]L^_OU8]^Z(6X80,RM>T$S
M0M"S9HA/K-O_[&\(SB"UOBUE64)4_;Q^9HF?]P1[8/'!N@<+RSG_8+6:3LMR
MFNVSB_;YN36XMVS[V"&>0\A68_R=C-%J-UMMQ[$ZR1@^PC^'@$%+F(W956W"
M^;3=:,QFL_I\2/TZH>-&J]D\:R2$M25E>\[0!O7L+*%U&M_O^T_N!`;`1IAQ
M@-T5EQ2CXG,N+BX:T?\*4H;:+.+O$Q?P"`BM7E8JA?R7G9#9\I'MM.PSISYG
M7DWXX-TE)3Y\A",K&K_-%U-X56,HF/I2[^C9A,+158V/^=RSI2>;9TO^]UT!
M)<0,>N('(S[R`(?>-?"ET4\3"#FK65+\U\?>AA%"U`12,(4A1RY#V*V[)&A(
MRD8.D8U(;1?X;NA'#NH+)3?4AW,.A1@O,4!*/J$"<OQWESYQ-P;U)5R$;CHM
M'C/"9`38,`(F9/88@*D`R'$:T.<L>2*]Z]A-)\;G??SX1X<Q,6XWI%1,A&0`
M'PRA'PW[0TW7*%S/!^G5O,HJB&.-UZ#MT$WE`743D>+G#JZ;L1]3-%@8!)$T
M&W$8)/PC2H(L]R7C$JW:%J$>I%>UEDB7(1,:D:D<#?@U:P;1>,)%*BT!C2Y@
MDP[VY)_;7R%Z`;Y0EG5X%U"Z$!G]&_!#F`%0/OXJ8);3$S&,YV;!N+10.^N%
M9D5J]9D0;X9\/T.OWR1"LW+#(RTN5D;DF\'Y'*QX44:/?O3P@!(7,O8(&126
MR)B\@2_0)]-`G2OS\1GGWYSFYIMOAMF6DGAB6_XY10"=9H;V$1@B'W$$<[R,
M%<3%:ON%<,@&8`&&/M2KJZ(N,5+27;T=-4HS3YE\3EG(N2X)Q7LR5E?,7O&$
MAM!;,U=;W^6140GD]G!)SKQ6()X]S"&%C.>>8"D,E4`JS5BC4W2^W&P(`&F>
M5V%D7G+K$SQ^AC18S\59[E>1&XZ#TD+STM(3)^[/"?&%7DPV9GR1@8."N%AM
M!T(6%%'M19KHNF<5=8E1D^[J[>!1FFG>+.Z2("`X%Q0[I)7`8=?`4T[@U":U
M2S!'>"QRM[_H,1;*W/$T`53YBM*R&.UIO<'FE0P=ST-+'08`>3W<!5/$0=8R
M3!J'T=!HS8V1^6@.,FM+&T\<C.&M+$.G%#%X`T?(15RT"F$@W0V]FY"*D-OF
MR`#Q!,(K@?<IG!B'AM-,CPV[_$JGAUT_E!NK`T(C0#BG:!ARF7Z>R1>"79&7
MA)>%*N.DH]FK.CIH`*."Y!@7;0>6*@3-*VKN$28TLEP+^`[IFX5NURGF=3)K
M35D'>WOU-5I6,WK-3+,R%@)R3[.JV9B144S=T3C4U-09J"N,&UNG-%[EP(EX
M[0NKY8[NP^AA"FDTVHE.GJ3(+N$(2HHFA6]'JS?S;N=3J7%&FLOFVV=;/;5U
M%:\5N<4?Q76Z0NFT)1]ER.79S=Y5:?&I3Z.D^CO:$MES+SN+IWK^S_2`F<=)
M/D,LDH<OMZZ\`&'$N$PE+U`_@W6<1R\]Q='<)8$4&$&FF[\;M"6^67-Z53E[
M-^TUKRF)@OSPL,G%7AWH]O.*>9U*7#O@<:QCYA;^#FV).*4JOHV,)H\;WH[D
M-K/*L=<3_7\`^X3EBKXU:A.`V55^)S?L8JB/NL+7)+]`G@N'3;JB]US)"'&-
M@FM$)<:'TIV[FZLK>\Q[TV^8<.2"]/ZR3,?N`._H4W#QLYY@LIG)]"5<.D_1
MQ]A>A%OEVWRIA4`D\PS;+G69,:9S_.XY-H6UA1Q4[TX`'L,>O@.(1F</'D:R
M5UD>Z9*'BM)/3>TIH`IX[.L3\^JN)"'I9_HV917P2;52OTAME[-*+;O^.Y_,
M7F&1>B6ZY#7JE2*%+W&)1"E'%[76"Q+F72^^"CU[^'=5WG%%GZ0[=;N'D.(7
M\?8OBTM=6=T?D./KYJ(AB8Z,78-H1F2N7VH8*@]5FB-.O1S^5K>!#D=`OR>D
MV:\M>LZ(USJ%0)[M6OZ5-P;A%"#O)CZ"'.O?P=[:M>O,\N4@@95%_%A'ZD]1
MVF;$Q2DNI!TC]0U&R/X7VK).5)H1)EM7OW3K`SG8WR#P*B<E"!M65*68OUP9
M.;*25PDI^`J+_"R%^RM$(D'?">BCWPQIZL8LKG*74/>$2OF5CC1W&+E8KC+X
M#F&`W2-C4R6D6.L>1?FPB%OYIPFA7-XGO('#K(2:SF->7&;`M+N?G.H*`W?U
MHF]N0(_)&11=9\(N?!BM72;+7C'0\%8:R!RN,6_M5JWTYB5-4;8M'T#YD;*#
M0-8*?(/(ZYUHWOV_P2H521438[J$93;&F6S5AC;3(3D;W/(_RS:`%!%ONUC7
ME8%YQ92(\"'F*G;><W=!AA_O>D5W*$MMPV^DO*([E#GD\'LKE[\_MBK^\3]0
M2P,$%`````@`LHFN0)A_I!FX#@``\M8``!8`'`!T9W1X9"TR,#$R,#,S,5]D
M968N>&UL550)``-_=;%/?W6Q3W5X"P`!!"4.```$.0$``.U=67/C-A)^SE;M
M?]`ZKY%ER3/)C&MF4QH?*=7Z*MLSR3ZQ*!*2L*$`!P!]Y-<O0(HZ<9&B!'#*
M+QE%!L#^^@/`[D:C]>G7EVG2>@*$0HP^'W0/CPY:`$4XAFC\^>#KPT7[P\&O
M__[G/S[]J]W^X\O=9>L,1^D4(-:ZXFU&$,2M9\@FK?._V]\@>`:D]2T?J\6'
M.GQW>-SB'Z\PBL/7GUI7X6NK^^ZG5N^HVVMUCTZ./YZ\>]>ZO6JUV]L^XB$%
M=/&,]\4S>B='O9-NM]4OGI%`].<PI*#%82/Z^6#"V.-)I_/\_'SX,B3)(2;C
M3N_HZ+A3-#S(6YZ\4+C2^OFX:-OM_'%U>1]-P#1L0T19B*)%+S&,K%_WX\>/
MG>ROO"F%)S3K?XFCD&5$&.5J*5N(_VL7S=KBJW:WUS[N'K[0>"X7;Q.S^6.6
M!WC?R?]XP-7UPZ>01`0GX`Z,6K./7^\&F_T@8IT83CNS-ITP2?BCA!`G[/41
M?#Z@</J8@.*["0$C)<9"`"'Z>R'TCV*TSC;B\,\`B2G3CL$H3!-6HW";8]<E
M*IZ&$.U&TGSH[03-QFA/P70(2)U2KHR[E8@3+@V)TB%HSZ'7**AL]*W$19CU
M:UTWLP%SH0J)3*.S,7N)VV+[/#K.-XT?BPVYC^)SQ"![':`1)M-LJSIHK>,3
M<O%!)H"$CR!E,*(018<1GG8RE-K!MA;UE+]J.!<@YA\H3F`<,A!_"1.Q*=]/
M`&"TM,`60^Y![-N0<*5-`!<O3':`877\W0"Z9_R_@GMZ,[KABR?CO"9"%&/O
M&,C-Z/ROE,_AFC',A]V3^#N87(9G['Z"G89T<I'@YQW,K\70.0S^XH<(B@EW
MR65>00->&."CQ04>\8!:=DKQX!\^)3A:>5PB#$A,I.^+[%TQ"NDP>V&DM#T.
MPT?^XNAV.R!AM/A&J+G;/NK.+,8?9U\'<P5PC&#`/]+B*4DX!$GV[$#=.#C*
ME>5&YH=PN)A3.GFSAD&WD'7!;)^L2LU?VL5XL_=W*:MX1/#40F7%([%!W!8F
M,2"?#WB/E'))\*.06:SEW"8XB3!B?"Z>)UDWOLK`6'Q8_#W!?,+SE4924)DH
M"J+#,7[JQ`#F'/$/Z]3PKX)\-M^!,:2,A(A=AU,9.:JF06\W]$@MVFI$:40O
MJ.IN<+4?M9]RR4F8#/BN]/(?\*K5^UK;X+A!BM^4O=!\;^^:/TV)>/E=0,K?
M??\%(3E'\1D'HU"^JGGPKA'ZUXA?4'#L:/)?P`204R[+&!/]U%]I&;QOA.+E
MDA<Z?[=WG3^04,01[U^G0YPHM+W2)OBY$7I>E[G0\'M76SJ>3C&Z9SCZ\W["
MS6QZDS(1AQ1"ZO=W3<?@ET9P806D(.CGO1-4V/`/?%@%%<M-@@^-4/J:R(5Z
M?]F[>OM<BEA(<I&$JJF^TB;XV`@%K\M<:/B#LPE\"PC$L=YND;8-ND>-4+E2
M^$+W'YWI/K>D<L$N^'<RSUO;/NCNR*/=$0=2``O'R3$1PJ2UIV'>.N@VPV_5
MB#^G0.&\?NJLAL)V&1VS",N_Q<C>8F2^Q<BJ$]6GE$_J_E!$DR*F(6JU80-\
M5Z7@]<?*JJM?!/W[*!;_B`.-IS`1AP%]=AH2\LK=C&]ADNJ6CU5_QP[P)@%R
MHFRQ*)?<_NF[$2^2'-\L/J7A:K.Q8V_8EABIX#ZM(EL&5C&X]8IME;\N<SWQ
M9LG99_95,$"W!$>`TCM`N9$6B15Y!IY`@A^G<N5:]7/L(9N4;8NA_DAS]4G_
M&\;Q,TQD(=#U)JZ]9=NYOBQO_0'F;?<7X\;BVB$NMZ4L>[_UQ9BK*_D2AD.8
M<)T!RM==%G6=X(2+1_-4#PL;U7:()CC-53#5?Q99G<YKS`"]#5^%GV1^,TM:
M!UVW!\.E%"_G3H'*.P,VBG"*6"$I1\N_X>YHO*0"HUUK,4;0=7O47`.CI;#Z
M9"(/$`,$4&:](N4=@JY;Q[\&"M7`?-H^EX":N=IL''3=^OPU\"0'Y9,%?HG1
M^`&0Z?(VKV-)TCSHN@T!U,&3`E8]!KS&45U9QM<8J=>)H4?0=1L*V(($"V2>
MVOAVVUG0=1LXJ'<?$VCJSQK9(OJ,IU/(LOQS$7C%B$$T!BC2TZ/I%?3<!AIJ
MH,N`KOZLE&T.V2KXR!JE]-R&+VH@3P^N_GR7ZMS=\K$`WZ-SG*9C'DGKH.<Z
MAJ%5M9P?!0Z/'.*EG#_CV=M:TZ#G.I.]`B,R$/7XK4K+;;ZGLN1U0&DJ3)8\
MOU)INJF[!#W7Z>LEE&X#QB<GM!_','_X;0CC`3H-'R$+=2<.BAY!SW6^0(6E
MH<'BDQ>Z=$)US\(Q.!?.P".!%)QQ54>0]:,HG::)R&0Z2PF?>>L]-'QN/WC0
M<YU^7X'Z>F#[=(2UJ892-F+0<YVX7X%%.0R?_.$KB##)[N#F#KR&D_6F0<]U
M5G\%1F0@?'*(-T$-4)2DXL+'+2:9AADC<)@R\=)^P-<8B?P^KC<NRMB"Q7H>
M$/1<7SBH9356A>Z3#VYR6K<XK0Z.&Q],L8%HN`GA5_;W:KV)MU3PMU3P[R<5
M?#4XPV?Z#<DPQEE@X!:0S$FUCE*I!FA`H872@'PZZ5\5.@\L]%,VX8;7WXMM
MT4C?>L<&E&FP!N)3C$4FK(@*E:8J[]2`:@Y6('R*L,@$U5^&M^S9H%LT9B0[
M/N]?%>`2<OLQSHI6Y7\`W$13!>S+#="`<A&E`?D4\U@Z<:A@8UCT;D"-B7)H
M?(J0;-3$L#(M-+T:4)S"#H5/48D-28T6A:)'`RI;F!'X=.Y?LJJ.33?7MWNV
M(FD-A^_!($5!V+=`T%L@Z/L)!)UBFB6_G;\\B@5@4QU`U:5!P1X-!)_"._*[
MJ3.A-0QI^SD.[NA4+R?+A,:CC++?`.+OB43<$HJG7+<"&H-/8":LQ>*R'*%!
MH1][1#N^[BY2Y4,ZX6:)>/#LMP<4`01)6\<!G!)JE`40Y(`\6CK9;3L#2,VZ
ML>GN.-I3F<&2&'UZ@U4GU(33;>!G:R[-\'PZN)BY/VA<O+5U*W&]K>.HS_;+
M3@+(IR.+N7P#Q!U:<(FI%3V+U@T*_,BE]XF-(GG)O,.MM6Q2:$<BND\)L+<$
MCR`S+(1%(]>U7,J=S2U+[=-9SS5@BT6Y9>IDZ;&:5.6E$CB?SH56`-BRZ+K$
M2V6&EJNX^'#><QX2Q"<'+0X-OX041B(V`I.4:<]]##U=EVPIPY`%E'I.@I31
MA-\!'$_XH_I/W"(9@^M4@+L9Y2<=9D[*#^*Z'(M]LD)95/741S?%?;*#*+55
MIFSKNKR*O=X5PM=4]ERIWRPL4;*$I*:/ZS(I]OHV@##5.M]SB3:$5WTG^YBT
ML:_KHBJEWNTV8.;4^1!\&:`G;@0*>+F\W#K1>I4;K5T75K%3N<K3E,*I)7"M
MOK4^"=$8#-!%"$F6H'4S6M39$;6/U`6@R@W@NH9*%6;*(_0I(*U$7&7_<UU%
M99N%I05EB#W[DYHS_YWCMZR<MZR<S:R<S1VG(6DY<T3Y]!;'MAAE=:I>H-5$
MD_7;58+.A/<D43H$;?XM7ZM+!^L:7N=<&3A5(/'HZ'I-PK-L\];%863M=W8(
M4U#2CE?DTC"CTK@B%*-`\_T1%)R!49@F;.=$S1ZS)Z;FL#QB[`XP+AN(BSC?
MU8HE)$UYDW5P?/2L7!IR?I08/")&?D)AI$?7S7$J1TF2#$A\\G74Q<>,?)FZ
M.DZE*LF9!1J?LFT4Q<B,I&G[.4Y?+,F8"8I/&1]+]UPLUM5:6\>)O*47TJ;X
M?B5^+%^3-;(A:^XX/;XD(0H$/N6%-*7.5H/2K^I#[--KK\P=2<F%PN;D<$F%
MK^>-9CC2H'D!R_QWL34G?\8^3<BWL@+AD6O5C_^7YD==]`$K#*`BV46$PQ<W
M.>[X:B8P8K/7P%=.![T#?&.@D(%[0)Y@!'+H=R#"XYPMK2&Y5TE<I8;931"5
M@;IW%?GD6F:BYY?NEQ67G01>@^?L+_HXM45_5PEIV\P+:V!>O7GE0N?OJ2WH
M7!O`50;;#OB4(-OQ"WRYSD5FT9UN6G0#\24"D7CN[Y!-+OE6@BAOT!\3`+0)
M6?4,[RI7K@K#=>/VRP\N=0'">U-.AFN1-.II3L);_=BW!`53@L+^\Q,LB^[E
M.Z+FNJ>Y4P-J%%B!,-C=_FP\]&8D\K\O$OS\5J;H;;_Q8[^IS:")`(CI!5=+
M=H*'(L!G^^(X0F_GZ/LVJ'"1#1:?X@37@(DMB8O]!/F>]^7U*Y]%`S2_QMWG
M1O53_IL!%O<02@_6H$+6E<#Y%$0H>^G:K7503=TFKV3)6O"`D948I0@FH@@F
M8.5RZP.N;WGNXG&.LQ;JG"4[4H]/N[T\X&TZQMOHX#BY:%=$:0X#92K8[16G
M;2_%NLW9VP]%.O0^+3L.FH!0_%YA_N\2S-E)E,7N;3^(XZ3:_2[/4FKQR1S;
M%/R6@,<0QF>S8$=Q50S%V3WF/J6`Z4RW:@,ZKBU5CC[;*6`)W"-34**'3-0H
MPBD2/W667=84-=*BB'OX\=*/N97;,VQ'=9UNM9N)40J^WZ^0XO!KAL)TZ=S<
MW76&UFX8E^/TZ45@[\/4$GIQG1E6I\M6#G4#2,^K*=04=],,UK!B7Q70>74!
M@8O?C_Y*(;=%1&`X^TQ-27Z:7JXK@56D1,ZO`:='1IH][%H6J^N"8K6R7`ZV
M3Z:70O(+B$+NV=:S56L&:T)YL^W0^928=<<=Q]?96?W]!!/V`,CT#`QUG"K[
MN*Z45I$..;=:E!YMTO(3V-44$N[R+7Z7L=KQM&E`UR77:N6^N@I\VLAO%_.W
MR",20+(?O-'QK^GFO');K2P;@#;`?Y(`K^5E[+P.7)T\EX/MG2.%8O&/2.%]
M"A,Q7_-,\O70C\FSLAS&=0FY4K^:5A*73[>0Y;+W^4PEY)5/2M7O29?J'_2:
MDTEF#<BKRO,833$"+"2O#R1$-,SN9%@Y1OJ>0:]!`2LSE'KJU:LO$V/N5A-1
MJTI4_62@..IXP*LVFS*CP':`H.<X$&6A:EG.0!E\N\WSF!T]S5^^*FM4TSKH
M.8X3521!":9\0O^GCAA_R-]K_'_^#U!+`P04````"`"RB:Y`V]OHPZLB```*
MW`$`%@`<`'1G='AD+3(P,3(P,S,Q7VQA8BYX;6Q55`D``W]UL4]_=;%/=7@+
M``$$)0X```0Y`0``U5WK;]M(DO]\!]S_T)<;8!-`CNUD9C8)9G:A^#$K7&)[
M;26[A\%B0)$MF[L4J24I)YZ__OI!4B3[39'=G0\SD:6N9E7S5]6O>OSTYZ^;
M!#S"O(BS].=GIR]/G@&8AED4I_<_/_NTO#QZ\^S/?_JO__SIOX^._O[^]@,X
MS\+=!J8E^(C:K&,8@2]Q^0`N?C_Z',,O,`>?:5\`=?7R^Y>O`?KX,4NCX&D&
M/@9/X/3[&7AU<OH*G)Z\>_WVW???@YN/X.CHT$<L=[#8/^.'^AFOWIV\>G=Z
M`N;U,Y(X_=<J*"!`8J?%S\\>RG+[[OCXRY<O+[^N\N1EEM\?OSHY>7U<-WQ&
M6[[[6L2=UE]>UVU/C__^\<-=^``WP5&<%F60AGLJW`V/[O3MV[?'Y%?4M(C?
M%83^0Q8&)7D12KZ`L`7^ZZAN=H2_.CI]=?3Z].77(GJ&QN`_?LJS!-["-2#/
M?U<^;>'/SXIXLTTPW^2[AQRN^4PD>7Z,Z8]3>!^4,,(/>'.$GD$?\#_5U\\`
M;O3I=M'T0GK8%<>[XN@^"+:TDR18P:3NZMGQ)-R]Q>*?_MCF[@-^+,MB?RS?
M=OJB1-9XO(%YG$47Z3!F>]26N;XK@[P\@.\6O37.EUD9)(-X;E%:X_8*#AO?
MAL[>N")C#8>-ZYYR5&Y+EE/CP>R,(K%B']#S.YS!KR5,(VP*Z;>84F+8J3W$
M$P+N$W6:A9WN$CPW9'E7TO*^_(H'_O35R>O*`).O?JOGT'F*C$`9ET^+=)WE
M&S*[S%=%F0=A67=%V"</^,V`^+AB$Q-W&,UAD>WR$!K)38>_RT^P,N$'S[B(
M%"];8'KTZ>[9GYIU1)!&@!*"%B7XM:;]QT^4@3$E0DNJ5=8`WQ_!YGD75D$>
MUNRACPK)JA;'88;6.-ORJ//:UGFV,491S4MF/"S'!FK27H*L@V)%)*H7(DA[
M3H]A4C9+$ZQ/IT<GI_62IOKZ-S0KE1#SM0Q6>Y/3TAY!0RN:(F2R#YZF`?B5
M-'$`_C%YM8%G.0!J["K>O@.<HBD)+M#'0@>K^\9N\-IF5H(#W`R0=CX`=PRF
MG2"8@880Q2PN3)%<P/#E??9X',&8@AA]Z&,7??4;M?6W\#[&)CXMKX(-S\H*
MFUK!K831/@"JF7G?#N"&]E$[`<LV,*N"1(U8)1ZFQ>L9TI$\2!9HJ?_U?^&3
M%+#]MI81R[(J>/]50T!:`M34)6C'Y-HN;@708($KPL54R#W;Y3EZY&5<A$'R
M?S#(+]+H'-E[`7B%S:WA5\)P'PQ54T#;`MP8[9$B@)N[@?%DS-M"LPHN;4`K
ML3*M-;Z,$YB?H>?=9[G<%G=;6K;$?38%%HTT`W4[ET9X)(;MVE\N&%CKRT?"
M5#A=Y@&^7+M[VJPR9LPK]KMMK&&SSUK_)5>_`]K`#1P/Y=$6`KFON8T]_CN>
M>*V:;399>E=FX;_N'@+TAJYW);ZPQ(S(%ZXR0MNK6+D0HL4AH0*$;`8H(6A1
M.EWA6I+(\NI7`VR<I;`.TJ;2DOK@>8FZ%>A#IXDUY/<8$UX(X-_=(/DP#FTA
MD_>"VQCDOMVIT#9'3XKPTRZ30&1^NVVLX:W/6O]U-K\#W,`-X@[ET1;FN*^Y
M#3K^.Y[:QC4>(I*-/[^M=:O79U5H7&A#Q]O]\;FV;1VYT."923XNID8N/5N@
MS[Y$W_&NM^3MK2.8Q[(0#]7A3P4+TMPMDL?GWC:BA9#AH5J,%SO(QJ=F^KC>
MMW:$ZC:[*E20`TUO$#T6YV[0S,!$C&46(PZ\$:[7EW$:I&&,="LK8H4GFA&Y
M&X\%N4!B=X#K-6@(04WIU!MM--$R8]&<>#]H0%'H#Z&#0WO:-2\*6!8:>M1K
M:%5C&":9K1IIX(4*:/+J%LC\M]Z'K."5VP/G65`\S-,(_W/Q[UW\&"1(?XIY
M>1;D^5.<WG\.DIW,CU*/WBJ4=45B+G81`7'7)1]:I#,P+T%-#0BY._`?+%V(
M/\`]Z02BE*TX#9NO*>B_IAD@@1\3B+AE@FCLO3$LYPK>QVF*!47S.65F,BGW
M`4[CRSB_^PN87YT#\N'BKY\6G^<?+JZ6=V"^!!?H^^M+<'-QN[@^=VO-C<QD
MW\B;V4A[MO^Z?(`YG8$JEQ")H><TMFK5N<SVX40:`=IJ!JIV[FRU`<]AY544
M")8N=FSRB`S;U$XQD/NJ*$&Q[0V!6N4<:IL*`]ZHF(I1,O][HEWC\&I_$Z/0
MJ>'J)`R-7*0W>1;"HKB%!40\X^GS'#[")-MN^#JC1V<Q(%(M0O_U+U)0D8":
MABS_6E2N@B"'"'.TK83)V\)$DPH354>J)`QQ1&F:746PR79$-_&R&\TE8!4D
M.)D$*!X@+$$4E!#_DF9IH\?;+"<G;.CK6#TH(,R*LGCI,BA44_FZ\:"ZFF=O
MEOTERZ(O<<+SWV2:6)U;6XSU<5;_Y&X^'<2<S2FI_UK[LQ'S3FVOZY0+.A<K
M.8-#4KLK-^$RR(>EFC%S]M=F\D69`R7X$`>K.(G+&!9H"B!.H@]9$L&\P&<?
MY9/&/8AV%U85R4"P/FA:I&2^;Q,#2NW%Q<J((D)"X%9#3*'8UR%C'-K3LJNL
MA,5-\(33%Z@/$GBMK>H.G]T^AD@K4#7SX&S!A.MMS75OV>]J`CMDQ(6W)C:5
M5X+POI[*X&W[-#T,\0:QY@:9#?1-OH-1RY8H#]EU^G!P]JXGFN!(OB*NL4;F
MB(H>M#IP?58_3,9&NFU+NJ"2#G[=PK3@B6;_B-P`G?R3<Q-HVE.]15I"!(U2
M>T(4$%A5*B'3[%$:;>C1S&C.N_[\:%,KY,#IJX`"-4[V6&JL<QJ[VC>)<=)J
MY`&\M5CNWM8DD\YA6DN^L;EVM%53**$$SA85,$OOES#?M%>>,A7D-;>KA'R&
M%?N!*_3RG.NB">?-+),VG-<3#?$.6P=Q#AXG<N#34](#7X07>S,9_!E]E6'?
MR92I-U<ZFR3ELZ,7DZ)P7O%K%AS&IJ-I3V.^<Q(9-.#\WI<3>Z,#;-Z9_+PL
M\WBU*\F>?IDA>TQF%!^.ZHUDHPW>N8[L,3U_]^K$_0;U!=$43.\!5&$1O-96
ML<]GMP^,IE6=HJ;RFE\4Q0Y.X5"NB6Y3[@O*_7<G+T].3M$JL%KD8<=X4.`4
M->#YZ<GLY(3\1[\I0+`K'[(\_AU&,W`Z.SUY,WMS^B,YNOO^]/7L]9LW(";#
M0+[*]BEN*N^?C\1]Y_5I5<>&>FJ%<+-"SZR^1?]'#]K"L(P?8?*$EJ#W]SDI
MG("F(`3HB.:"I[RB+K][]6IV^L<?9Z]?G9#^OGLS>_7C'V=__/$$+U[-'_C"
MU20\!OJ\B-T81Y#W3;#&>^HNYC)48QR1+J@J".6Q.;-(3'-_2I'998M!=_L$
M6LKXNGY3NZ%T+*.,:V0GQ9DG\X<^WQHSQP\GTJGCA]G)CZ>SUV_?UC^*9@T]
M"^[,9A_VKKVPUH>*X)6=/E08GRRTR.`QD7(B:W=0-,%9EI9H*-#6+7G"HX.W
M<S1Q(<?P*DDLQA!(&6?!L&\,ZM95SDE7<0/#!8AK`8JI!-"+%3"28/D`VY,`
MX7^=Y6`#\WMDXM$*/\PVVR!U=NZDJP]=WWX-9;#H9!U%)*%'D-P$<;1(SX)M
MC"8>R1)*1&'7#5O(-I/5J!4,@F:]>XC+A\%\F\<%LN[G<!V'<8E]9W:;78)K
M\('S78XM/4/HT+=;6]I]2[3XBJ.C.`4A;3PF][PJH;:YM^H;+E<2QEE<H2'V
MM+N%80+A/?0KX+=P3V'?IY`8@A$ZMVHS1AF,/F1O81G$*;(:%T&.E[H%>-ZQ
M);3G*78AFK9C$JEKLQFT1$7*V@Z\*\8VF69&QS.Q;5JK\92^;]A&U'B7=VY&
M=VVN[]@.NEOSZ4)->'V\_`6@E7X>;.&NC,,";;G3\"4YS2EVJR*.XB#'83"B
M$!@[QSGVY'%[B:A_>>A`E3_&:9:3XKC4<U2BR$Q3JVK,872($F,_);191(],
M\(ZD[LV=5FO(A7@^:C,=UR[+:*)L\.\8]B(<]4$O!)'+V0M9DV2'SR)OJ"=>
M&S3+K`L9#449Z0&.9\F!@Z*AE,1\T[Y!U;G_>CK9`-$9SK>I^-L0SN#F93(1
M/;B(L2^;VQ75(?9:O0H[R%C[D\9`,D$I2;U*6\#!I4:Z`B_<D'7E89Q^I1D*
M[,P)DXOA4Z(%D770UI2#KG\K,WN',W314X8'B/:Y02)Q9=:EM'@9K".&8(8!
MA`ATJ)QZ,=N7R-[MJC;<NI>L^EASY?.,N+K.28V%B#AGW,"<W`)+ID+-#AQZ
M1DN$4KI$(EIPG0-*3=UO<$TEZG/AB_/T(`$KK[B].]QS?&N`%F4!6@$TKG&<
M2R)W;I\J=,H]0970=*5TU,]BWO@;:BL;0^A0R3A"*)6K*I:[)_)%H8R$J12)
M<1OU27-$$)-KC!!?;C6%>C\::DE%Y%Q#&N9UM<.UG_5`(;I:$0N$<*T172CI
M:$,/1VXU05XW7I?2N4[(ZZR+%,-IU?@QQ.FJ2#:I.(/CH49Z0YXYWD\DHT_^
M^)KV0L?F\8S%0<<UW8=\V,=)TA\@$E`4-&78@<7#&P.A%.`"+6*PIW95EFQ$
M\2J3UXZ,W>[E:P5D[?>B4[@IZL4%'"`QCA+@!P*WQ'V>Y3B4M\SC$/]4O*C*
M"J`G0K@A][C;[L@1DOYWK>8%$BYYPF%HN&Y!MJV+$N"_R!(L?X$^HY\?`K13
M:?."QCM.'[-DAP8E?^IPC.Q-$4<P1T]XPNW@5U+=H.H6GQ\@I@IZ0-*$.9=-
MF(33.@>FAJ9[7F=L99R$EPXXL].A=A6$:G"8U8V-\_2H[B#1OHE#.@,L2H(!
M/3J>:W%E<#8GHW*E3!H'65TE\NA(;I`8?A[&:0!*HAD>',,QW"C/X$04;C5!
M>'#%TP*O<ASH\:]WZG8P^Z;)!@X8?"^2(2K@K]1=9X>&#"=Z)X92,K<:+#^E
MX2/)BY/"89)X>D8X]FOQ['AP?/%\.AG4,0I*DS;T3'"L:@!AMH%DMX#/<302
M5HHH+-<#$+'-)M7'+4'3U(N$E!.Q;[<:@!0X;#D`.6ILSN1%B3TH+ZI2(QJ0
M%Y)8GL&%C+-V%#4E'J]U8R]@/TB"NB2,XXRL*MBP=EZ!&7N(O^56F:T8D\!>
M3F<5^RH1V,0-_)K0M3ZXTP%32:@C>VZO++36EG1J*6QJMI9Z]-5;3S<L%G"&
M*<R#!!>9BC9Q&F-C@_/:5AQI3'*Z/=@M_ZPM%E.`F5+2VFD=VMH&>#$ECB-@
MT*%U/%,:0I&I26V(PX/\)ZZR]"PH'M"F#'?.O<5NKD!Y;2UZ1?!9Y03H`]P,
MM-NY\G309ODHQ"R'T[*LYZN@QW/7+:'->+U>19,=32%49N0._SX/<-'#;%TY
M&U"?`KK$K7T7&D\$XEH0HQ_;H>BHHWNASC?+9!#1!'?XF3DD]7S07_3`QJD'
M@435NLX",CVS7*%488LDLZD6N?VZI&J!^"5)U;.IXV*D0P43:Y0')4@UX<>M
M/JJ+/6^6J,.7IEXM20<M1;U=?PJW<B9Z8V=+:D,2CY;1`Y?/+F92M/@(\"JD
M/@J339M,6[MS)(=59MZHVS1GJZX0K\-M5<*4.4UU/+N)(,%,94(\.,`OO</X
MD!5:"&ZU=H/A#KMB%%<W3,]Q0X>9;$W93E`#YXIW$*].%([%L%#E.`"V7Z5>
MO3CLMW12EUZ\R&B*NCM?ZAGP"B?C54N_S$=U@HHZ9AFIQQA<N]?W7/UBK^WY
MRF4S6C=;QZ5BTFTULAR#VV*..=>$97=R_2:332I%=#D1#V3.;O1H'[]LH"@#
M7GOJA09I/\\?F&S6O"^KRCI$5*5.^Z_`8XF-58FYD$@%^:#=3<2>B&O3Q`S6
MX;XE&J[`C@R6KC%R:&@&&9')ZCN@UV9H,>S.^D-LFHD"ZU5O<+6<^?;$BN`Z
M3DDYK%]P2'<:,CMU`_'.LK3($AP9#B.0>K%ZXUH;J=ET8!+KXE1UH._[H(A#
M[)@6)[M2&ENHHK1J-M5B]`'35.5JHM-G@%!1MT]*Y\Y*F0NT9SZB;1HU(#'J
M817*U,_L(0U@MV.ZQI#5QY!\3=WJFP1=Q3K(>>UO,+Y_0+W-$1Z#>WBUP[6Q
MK]<TK$AM!`9T8M'=S5"X/KIJ<E#1`]H!N%[7D?D>&(IQ)0TJ2:L0QUU!Z]=A
MY[0=N898&5H7VI%UDS+*J/"MRW02Z3D7'B@4\3JLWG)*\8S]"=LQZD3D5G0K
M=27$;[3!0Y"$N(@?_C%LQ<9RX'%Q<S<#$42;A@VI@HE:H/\C`NQ<6,8;W`5B
M@)1OQKF/6LS0-AZX'0XQDEU_Q$$6<@RO9!(D*KX`$[>U[Y7<8U7HE4RSLCF[
M"C/DF;HE4^VHW7J#HLC"F&Q1OL3E`T+Z41*'Z">L#,%]#N%$<3E&[LL*V;KN
MRP*/Y8Y:DS$@LTF:0I)E32:^J1>R='`T91QV!L*M$5;;4FUY]Q(Y\JKFC077
MJYIK)PXR5L3;E!\.)31:,AJ+QDO..M]A6!19Z,J8#9'!8C2AGM4:4XC&G+5,
MD`?K$`TUZ2JLCHY8/';/TJSK&*0?6:BFM7L\KR$*9S&0]3WFZC#"FLSA<?@`
MB:@2H4T1;OZB5AK'H8/:*&..8+4A9M.%[1$6)=97RM$5E*=585M;=F7CL<MZ
M,=6M*C68`=30I5.;'M=-F6+<R+7KE1`7K/N5&!0>V/XA-M\36Z]IXY]7S9V=
MJYL(0'W],ZYA]]2N&]MS)T6ZJZ1%UVNVZJ+&\D>/WG*);3V1V-UQG88*GZ-S
M:MS[D%+A<.&RKG!_T)'.ICH9(9*M,FP"1P=J1CG!X=]9BL^2YE]CF:./G,Z-
M6@E$$")N5B-L3X+`AHA\4*,IA7&B-3*`";5%BBY7Q:L^0GP7(5$.;G.'9:H:
MAE6%6WZE+1U#1C;:\GH_O:%VDJA8B0ZVK:N4Q$)<M#/">@(*X0A+4KTZ@\,\
MBHA[7I#<!'&T2,^";8QV"4IHR.FLPD0E0A\R^_8`$QS%^.Z1D$@`I'L#932N
M`V;C482QJ0U:`]'7##UTV32:*=YIHGD]><(IYK%?+;W?U["A"E++)E4I",?K
MMB$!-4WM).4'QG1?#VN`-=^-U;,T3AR%$F52,MLG:C(!.(=JO'`H3X"E\S8X
M1U/J5V$SN6\98.>LVN-4"24!@>5TO@*FV3R^M"%H7+W]`(Y\U-EDL=(AMWC&
M8E"ZQ'&]$IUR$5Z5)=%AN*I:,;$OJD'Y$=^8UB@I,AK+5L^>=,N#^%`39![]
M<T=O'8ME)EBJUU$-,&KGZ;QM$IF27>^G-"Z+6_CO75S$);R#^6,<XG*$Z$7?
MPC"[IY%CTEVH74XL[VMM#S.[N6PXP$Z?O;TFV.\UJUH\1]0!O,W*#.R9J4YI
M"#OX^XHA4'$$*$N@Q9,[:^U^\-M]XJ%&PFYA2"Z?\OV0]FL4DS3"U$<7;K9)
M]@1=YW)S9"W8(P4WIL+F!1GBCA;`.R>NC90I4N/U"GXAO\@ORG3H+5^8Z8G$
M]]*FA(!25M9E1NL58Z^D+[2!PS#UH>+URKPWH3TE^.[5R<N3DWUTY(R$<"&3
MX4=>1R.(LE=M)OATKG=TI7:`XO4[\$'S6*%,5*_>CWFL>VH!#U`^C_8;1IC5
MU$018`\*'VG7=25I9L[8P[4%_K(*P_E;7#Y\J"-PYG4`#D?[1NW>8E#*:`/"
M/RVI59>FJ@)GO,/9!?F^CGO"#P#-$\!\PA@WK8B7J0=H'_S5)$]YDB5_&A(F
M-BSP;5Q=&1*^PPLD?,03-!N(3$<,Z(X89[@\B^`9=_2[P3XCFZF#+'([#4_+
M69`Z0-',5`^PC,,@D3B_#N[*HJ4=)*@T:5''/[9V&NWT]`^G+K*^RFU/B8>#
MNZNP!R#[(.7L>IE1@R&IJZ!!9%'A%,RK?`*KE<N$91>TU&>P%)W]A'+?;K8T
MT,'%Z!-^L^^)TW!'1%QG>2=O0/_XTJ\976?0NFJOI4E.0E-P</]EDGW1J6<M
M)7,5B,(30!I_0A**$`K?PD[,1,FT17$48R*$EB2T1(PKJZGC0PBCXA()MZB,
M$N)L[Y4K41$UK>U$\TI1V(F'T@!,!&HJHCDMIVJGF>6'RX0!"XH@(;-,.XT5
M.91S'36@B3M.)GA-T%G-MXQU&;'V&$<P>O_TJ8#1(FVJQ,S1?O0Q+F.H,_$,
MZ,QVYF9S87E9>HE!K[L![Y_`<]P36*0OP+XLT+XW+R:P480_F]_]!5Q^N/[;
M';B\O?X(KF\N;N?+Q=4O8'ZV7'Q>+!<7=ZZ33`Q&-"?Q[U`X._+FP3?8:1@G
ML).S>)F-I^*3/,Z=7\YX`R9SOEEFH'D08-/#HY^_18/B8"#+#.3-0#;93?%1
M-/I,LOG5:3#WJ1Z"YB&.#=.4FBIUEQE;32T[-#,>/;*M+Y_`OFLSCVGNA=31
M>\;ISK&3LQ;KY+@G;/NX.2XJ9SCJ/%='08TYZX[$0L!SO8G%:+>9"RO,(>+C
M'-)_6W:D\LW36%H8=&(Y<Y:!<&QJ*DH$GM?D+_#]^WY2;\(]/9C1#Y+T[`']
M17-#!T4!JX+$21RLXH3,(WM_FO4:ANAW]#$(J2,F@JWCV=D<PFPV+V/\NM30
MFQQN@S@ZKTZ\ZX1Z:412!\[)*S325JT.'6NNIM":6ESU-@-U?TW22`Q]FH*1
M]NF33@\<@[H#LKHFHI%+H;2LU-U=-=D)7W)L\I(]J%+K[%V[-=4FMDQMMHT,
MF=-%%N$G#+,=VN?=!$\X`!ZQB;[)=P@M^ZG7;-6EW:OK99B!^+KK,JK.59^@
MZI1H>M4M:/7KDU4?93#PVJV6?=N2/:AD]R,,801%T%B[&6N!2TM0.Q%6C*IR
M$6N0.]9MKD!"W"+-;;R;*XH9.*NFK*H6MT_*:B9=G.Y=:RNM]&>Q-8$H;FV)
M6)741D.B1SY>Z8YRE>OK%>XX5[??PGVM0%+E?8C#.KC6)?/S!OKPFV=_[`M-
M9C^2RXBL,Q_LC5Q80[O3=.;;#>\HPO==1A97GR_NO@F7$0U$:RJN#IPMID-$
M',[QP7L.(^R+-M\?PDLT549E-PFBE'T&?ECOZN;45[)%X$ZW!D@1U%)PXNL"
MF4Q6DSFJP<7D<=1`EH_3VRC3FJ_3V3C3V+<P=\D6F=M:TM43TKI:/F^7T)-+
MY^>L?/AL[(^=N8S3(`U'6D;+.O/![LB%-;0_36??R#+:3/C^,OIR<36_.OL6
MEM$:B-947!TXVTS-NPV>B(LEKA:>Y>42YIMSN)+IJ9C&<H)>,>MLCMZZ+:D*
MA5L#W!S@]N[NNDU$N*D%(%DL4-LC7/,>)%F0.I[CE!AB<PVK`.0Z`*\;0SM/
M(_H%1#\.B\I3=NA!J)Z&T/KQ>_W`>-0=V/?G9US?(0/0"?;KA91[&^^G"W.]
M($!MC%O4[KV=J8/A,:]G62'U"Y22V=54N0#"2:*N?;C724+B4./,!+E>(^3@
M97"(&P#LRN1NFIZ"=ZO*KZ$%C(KKJ("/&\U1-IB^;BS'V5!^"[M(W2.?=2.?
MMP=:DTOGY_[X\'VQJVNE-,+_X#Q9CVA!AUWG2!Z@OJN,ZIY)MQO[%T_Z`O+O
M<-!:GGQH]3"K4^=SG%(=7U`-E_;J8@D65V>W%_.["_0!D/.K^=4Y_7#QUT^+
MS_,/%U?+.U<6QYU\UJ_C#)62>S]GJI%6:ZYM,K1+#/*G91ZD14"N1;5.S164
MMBNO*<3@%%^K*4";Q(]#;W-QKJ^.B/(L;^=7=_A4^_K*^9&V'K8X1>2T@'5H
M(E?T+@K4\?7Z*BMA[:6^S+JG"1P%,.S`;M)67:$X*4LK4KR%)\1-`,<RZY^J
M.<S..H*`V1JD1,`Z2J/,^B=G$PC8SQ[I^!6VTTT^P2!WFFS25!N9?+-FJGB0
MY:B"6)IM@^A,3];:HDT0L<MDBJFBE/;[=D<'=\/8WF]8PXG8UM/?`X?;LR2P
M4JQWE5`.=(LIO6C4&2[,D25QJ)F82TQD-[V6C'D.A*K&H&[MQ>+52(A?8`IS
M7%1/1P*K":>4.&+21JE!9#'Y4WR?QNLX#-*2Y6L)OY;O$_EULF8'=I-#Z0K%
MI"W:$P*NVF!B0*A=9DEV(Y[5%$U&L&12-IEATIZVO=\5<0J+HN5\?1Z4\'K=
M^D)C&C+JQJKF&0K(U!RNR-O1`S.`>\";L=:77DQ@7@AK4RN'P+>OFX.P:U]#
MS[+-"BU1"7MQ$299L<NASGRHV8$3K50*)81HBQ+L23V9#QV)YT+S]&`ITCE-
M3%HN"_J0)1',"UKV!Y_+:%7?D!+:+P,J$X*;U[,B^$-=Z@G3>#&K61+'>B5/
M)<RX%3S5&'.M+6;3DWX?'NB0GA5OTW;@Y]U$-9:4?Q@FIGN5,YBSS(%J3Q%Q
M*,">$XWI2D!@5<6$3+-Y"5=E!U0>3$K:S'>OLWR9@.2`Z4-?@197.->97D04
M#I$N,ZH,U+V8)J;BWQWBE=9>A9N#;F)ID5_8E/A5EMP5$EB\CY4PW4=!U71?
M5=R#^KC^LJ]W/WL(_RYO8E58[U[&*H$^JM[I327ZM`ZU4<\\L\CV9J[Y5L4:
MIKUZ<N&ZO*AQC*2(]@+A<KR(4XC4\&$&(O@(DVR+.YT1/W-V,/:1$#-<U#?9
M1=3=)"6J12LV!'F."SDT!9=6Q(T#/6I3%0`F"<%I6Y)Z:`TC<O]]GZ$7FV(Z
MIPX?!JHMMSA^;.AN88+C[&Z"O#1U;U:26LXYH!2$33U`2`"A\<_%V9Y$=E,2
MZ`&.S4R@B3;WNF.V<33IQ0N-TIM2)%#T9BG@CZ0^:*#!IG4(9BW>%NQ6!?SW
M#LVQ%X]XF:%SJR8BL7L7(&:<.11OF@+:UHLI:S(!K![@*^##G->KL.,.^5KW
M8D(:I]B7W@BQV/%B'IE2!I<:H+ZR4F+(G@Y<!G'^.4AVK1LSG1E`2F95$Q0"
M](&$FP/2OK7<\&,ZF%X2FUJA`ZR^8FBARJUNZ,P1<CKGVB&SLR)0>3%A6!'&
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MI][EO8D@9T&>/^'K]4>R'0A(]G&<%&$5)"2K;/$`80FB*JCNUZK&[C^8`ID`
MO<`@2?#=^X9T$L%5V;Z_1YO5"-:MD3DH'X(2/*`'KB#$]3;)Z$7DPCXNP"[%
M655?`I+FLLP`TI@$AB5A#0WU46^L:ZZ3?<5;\#Q"`MWG$+&>XZ>A1BE-P?+"
MZ=6_4KV[%_YJW;:8/#';;.*2.%W@5&L9B0N&:2C/RBJCLIL:4<H^F^:G:4T3
M(K;;.\QX>)`0H5P(JTG_U&!B<OQI(.FP;&4/V*NH."?)86CN0*6SJXS&9DXR
M*>L,+FAK0)O7J3W=N[T.DX))YN,H(9\VB'IYM3009,_(TV`AO(-$\V5:*C=A
M_/96#;N(Y3Y>JJBOIJ$'.ZP)6+=IQ*5@Z9MO.5)LQH&B-2&>1>Y"F`9(W11G
MJOSVEN,[^2RS48Y5NQFH6WIQ2B8=<C9T43;>%G%2/?Y36FQA&*]C&"FMH9C&
M+EXDK#.8J=K.0*NU)_9%^0H8["C'?X0%XB)M+IMP)LQZ1X9C)ZMMFF*UJ-&!
M-EP$:RA]'DWPQE^!@44*6I>*)"MJ<YY#@ZRK9QI.M%9DZ\W4`A'C%*RQB/2@
MA*2VW1]#=-+<^BAC_^2(%[H1-H+BA30C+&@+VQS[Y##,[M/X=V0Q_$JI:3J*
MO"6YKII6<GY`_?P)?4;_K(("HE_^'U!+`P04````"`"RB:Y`GXW'0"82``#>
M(`$`%@`<`'1G='AD+3(P,3(P,S,Q7W!R92YX;6Q55`D``W]UL4]_=;%/=7@+
M``$$)0X```0Y`0``[5U;<^*X$G[>4W7^`R?[NB2!S.QN4C-GB]RV4IL$*F'V
M\N021H#.&IN1["3,KS^2C0&#)4NVH8TW+SNSC%KTUU_KUFHUGWYYFSJ-%TP9
M\=S/1ZWCTZ,&=FUO2-SQYZ,O_=OFST>__/??__KTGV;SS\NG^\:U9P=3[/J-
M!]YF1/"P\4K\2>/F6_-W@E\Q;?P>]=7@71U_.#YK\+\^>.X0S7]H/*!YH_7A
MAT;[M-5NM$XOSLXO/GQH]!X:S6;1K^@'F*V^XV/\'>V+T_9%Z[31B;_#(>[?
M`\1P@\-VV>>CB>_/+DY.7E]?C]\&U#GVZ/BD?7IZ=A(W/(I:7KPQDFC]>A:W
M;9W\^7#_;$_P%#6)RWSDVBLIT4V:7.O\_/PD_%?>E)$+%LK?>S;R0R(R]6I(
M6XC_:\;-FN*C9JO=/&L=O['A$;?!=Y^HY^`G/&J$WW_ASV?X\Q$CTYDC]`X_
MFU`\^GSDC_VW85-8\O0LDO\^YJ;C#F]<G_CS.W?DT6FH]5%#=/SEZ2ZA/N]D
M@BF:X<`G-B.N?6Q[TQ/1\D39V4E15:^XUV&7X2'_"_,<,D0^'EXB1_#S/,'8
M9\8*:W2Y![5[B'*C33!7#SD[P)#L?S>`GGW^7\$]ZXZZ,ZZJX+PD0B1][QA(
M=W3S->`^7#*&9;=[4G\'SI7Q';MWL"O$)K>.][H#_UIU71A&EXZ12[Z%WLIG
MQ.=@.D5TWAT]D['+ET$;\8G2MKV`SY3NN,>5L0DV1Y3O6PJ#Z]B<>49R+1/K
MLH45>?8]^^^)YPSY'B+G@$WIHK!:C]W^S7.O\U?G\O[&6*&$<&%5[HDM7+XS
MICCR<F-]MGLHK-03=L30XS.'/^]3Y#)DYULQI!T5]ZQ@P/#7@..]><EEMJT.
M"JMTBPC]'3D!?L"(!30GG>F]F"F7MEMU*(V^P,5CP8G8JYZ+O6KKQU#[Q<?W
M:(`E*]'ZQO<\T5<DM#<=>Y@2CV]B\RF[(;UGK?ER1OT">J_)[TWSON<C)Y?.
M:Y)[T_81Y[/O4FY_=N5+&LYGUY5DJ=KZVYH:&S-AQ1G%C$]@X0;HGJN14!"_
M^9CO^(:QBJ*#4DZSXJN_^^1X=N+K'''>]VCF/!Y^9*F^H#-@/N5+6=R5(Q"'
M7V#I"UNGD8TT%5V8)33Y"+%!:/>`-<<(S;C]6ZT3[/@L_D0@:C5/6XM(Q/>+
MCZWE;KJ/!BO?6-,_O:'5BG5=)[1#DWHC:L<]\K]NL9D,G"Q:G,S"XTG3GA!G
MZ0@CZDUSF#-6QLN`TO`HWTU^/N(2`>,Z>C/1D3B`<70C3.EB15-H'ZK^@NG`
M2XQ#&"[YP,)W_*],A\]E8ZL-Q*F<EPS^UE6O%(<,V\=C[^5DB$E$'__+)FO\
M(RMRWB<\)L)G7?\13=/&H*RI=585QA),)%E3*"_E;#]VO^**4^3<\27G[3<\
M5QI^HZWUX:`LOZU];/K6WFU_%5`!\)8P&SE_843YSON:@Y&87];<^G@@#"@`
MQ"2T@0;`+7$PO>*ZC#VJ=O]$2^O'`S%]NNZQU<_V;O4^1>)F[WD^'7B.Q-Z)
M-M9/!V+I3:UC&W^`FMJ]Z=1SPU#A\X0C9=W`%W>#0DGU/*\0M'X^$#:TH,04
M?=P[1?'NO<^[E9"QWL0Z/Q"S;R@=&_C'O1NXP[48"DUN'21S]T0;JW5Z(#;>
M4CNV\D]@;KR,'RIV,:EMK1;4*3JO9V^I'UO_9S#K1_NJ2+%;_EG:F5?9WFI5
MYMRKR4(JA)B)<V`FQ`Y7GX=E:ZMU*&=9!8#5H2J=A$\GF^'/W<9$-1)FX()4
MW=$M<;DFA+NR%]TO*\*H)N+O@=0\;J\VZ'LHU2B46IG@A'DH]:,B-G18)'88
MXU.<QJ22;%C%\,9'&8%;JM=D`(K,KHX[%'^())\7Y(BTAXY_A2B=\P-LF!&A
MH%1+'CR\LLU>.LNZ:&I"?E?L:"+;+**G"J:W&X/':71I356]7K-O-G])_-"Q
M'EWJ-K66A_(-6?,W,F2*IBW<N3WJV9BQ)VY/;@LQCUSC%^QXLVDZ,5IR\!&C
M+*:T8<CO`PYKP/WJ><-7XJ1=+&PV@8\\Z8ZS=8WEEPJ'152$/7-*A`],F4V&
MZU&H[4N%_4R#Y1!T3]"`./P(C)E(TM]*.-<X4NAV4<FXE_2T88*J+ON81\_'
MK(?FXB"=O9M):6VUH)-%C&A+9UZ"JU8'CNCA38R26XI_0@..8&6^S'.(1A]6
M"SHZ5((_&*&MRU1PY_J8,^9KSP;I`E8+.L)4@@/(H95V%`)F>\U(V4QO-[9:
MT-&E$EA.AU7:B0EVE^>YXSZFT_6E3<5P2G.K!1UJ*H-C"3#XXY8BJ)&8?!X]
M5SY",R2L%G3(J0"%&MA*.Y%59S;6FX:M-G2$JMSY5^"1IY0=TL0K$A.)'[YC
M%9<:7OC8';NVFEJ%E-6&#F>50'4&/GF>VV&-XUS1%(5!V]!!LA*H5\.3Y]@=
M%O.]6-D0;M8%;DIKJPT?*U,2E<ZN!$E-0B=K6>:9=_(;3:TV=&`L%Y]I,.`C
M'-*]\G(E\9WY'6.!V")&[P&DFV6YB-6&CET94:8#IR[ABLYP2"+%>X@,[]PK
M-",^4MT&2B2L-G1X*M>P5*"IRPWOVL7ULX_&^$8<_&:4,'R-1\0FHG94,`W"
M$CO7`>4^ORFA\(;BG5MMZ(A7+L<I!WCQ:(FTA`[P_MQH7VZUH2-BN7P@'4@]
M;K,?B.O1L$9&%"92\+G9U&I#!\=RL9D&H[302>7.SW>N[03#L%X@#=GQ?4H&
M@2^V.7WOT7-MOO_AJG-5QAH^4,X76&?0T;>2YH&\X$N+UU0Z$Z9`!HQU5H.@
MG0Y(^<N\@IY0O>=DR=*R99Q>U[M/])Y9<BM3\OV9F':]+1U;2F?4]Q=B[\6V
MJLEA,C++';M+0[C#,*[7PS2,$FD'J64='$29+F-(M?2!*"S8"?P)/T!\6RV3
MF=QO"AY$@3!M*/#A[=V1+2+"QD1'0M5YYIN3Y"6,N@3!TT"J2S]I2E;Q4;`1
MU4DL\!%QZ8X_J?P]X>>H86CLZ!\PWX?*+AK-.@!__:M#J3$D^*R]TN^5<VS,
M-*3!7PF;C&@]/'7)]=NJ7*>U(5-(@3\KSLEU"HZZQ+&W4&;NPR02\"^1"Y&[
M`E&7##_#VILZ8O#OE0MQO(%DAPE]E0@)2WX!#N"Y%M<3+[71R#.52+Q'B@U&
MBMR&[Q'B]PCQ@7%XY;$P'?_F;2:F.9UB8C*1@XH"*T#4)1:87A!F`5C!KU(.
M/.RK(BZ=ZBP\]7CL^2MV^4;$$4_4AU/BAK]#XI,7O,"I,:XU>SBHF+`^)O@`
ML31@*-X[(C;ANVZA].*WL"6QP92VX)%=`Q+28H/ID&JR_H9E)C(,I!BS.N+@
M8>#<_!NBK,O"G=\=LFP$'1$N[`G9`*'K%)8T+411!7<<;W-4<\!F6_!@</$!
MGP*I'MNT);(HBG#O,2UJ5ZT/*QHL`5`/+N-LZ.QY>:,E?+27[ZF\)#6;8U-4
MUDCG-`5,\4FW&F^#>M0;$3]C4*X:P1>P-$N:6->[+M=LC]A?S2T%7X88]U7)
MXI92!\@%KRZ7=@GPNCX`7]DR-[_KQ2L+W\.!+K,WB+K<*5F<!W*)&+%%,(\X
M@:^\4,^0A*]3:<*N!IC2'N*4'\/Z`Y/QA*O9X5VC,7X,I@-,NZ/H^CB;4?-.
MX&M0ZF>_F>)2_`P7.-&+:%V8'"#?&$O;PA>5U+]@4(*`#T9)*0K#:8:_EJ"0
M@:\1:4I9!ACXJX"2MCQ9ASS5-DCG@%C]^=7LO%N3S.([]X5OWH5E(JA\7ZB,
M36RUAJ\L62P^D0JHPA/RU02Y8WSGWB)"PY3G[FA5XU14K947[S7K`+Z.9!YB
MS3'"O_[8\0R>9^:&KR199%0K894V<U>R`L':+Y@NBE+`I?KQ4TF^^J8:\N]9
MJ'EV/QD6E0RGVN>D1H8022.>*S*U.V]$*STU3>[P,E4E*&I"<O*UX`,6X1+E
MA<UV\^HDJ\JHDEWBI&(IBU@'_DE-)IU;;<%S4G-RF0:DM%,*%).2*J69K"KE
MJI-S:L9P%JC2(DUPXU96>5AC&*M%P=-6<X_J3%RE'4^A:$^_+LZD7"4&GJ6:
MD^X,3*6=3*&H?L(^(BX>QM>/F22G"X"GGN:D5XJFM%($4,1NV.':FW*@JLOT
MM/;@J:8Y:96!J4M65-&GF=5),C5_F]FJ0JR_+!H/HQ8R>#ZKQ`UD/E,6Z-+\
M;(8I\42@E_I@OF90RB*EZD-E0F1:'I"F?VF'L4)D9EP2LN@'&GKA5V26"%;(
M5#)U=9LQ+1QUN>[K#/\71#?7K.])8@=Q[I^X(EH]B'SB$Q(EMK^("WYQB<^>
M,)_;&/'Q,Z8OQ,:1W9ZP[8U=(GE$"J0)7)ZMGG_)HCM[-U*M-C919:AUHX?W
M^H_X-?P7]9950QXNO[>(5VE#JTN:F@1PM$87<(:-#N`2@G?@#2G8X!=!Z=9E
MO1!<N)V^VMY.WXD/76P+G?\@_N2>3X$NXPTZ8XJQ,C>UG.[A,H_S^$?9R.N2
M^W@P)^;*!,[V>6(^+^^)2G3(NG'A?D>NT'D9/,.VX'DYD5![\%P:OOL]).K6
MH?U3RG+&>9+E_UJ3_M=EQV:,NWK/C]3?3.4Q;M850UU3)7/>$54FZ\K\BJ@*
M@13-WX>(-O>*,D#90M7)GDHPD':@R8"QNY%7K06,=4?B3>FMX[T"E)5>FS"7
M6ICE^&^)O2]=^5+[TPSYODP9+5.5N9C\!U>9?L2^\&1^%GDA?,*\G'_A,]^=
MNZP.UK%]\A+]R*S&TV3CSJJS5;G7JN)B#@]^.P-3@`MZ9Y./K*R3^DYW.G`W
MVN(NT[6)@Q.%BOI>>5/#+KX./`^]3!_;D8'J,OVDW]9G!7:W!,!SV7=%LR(Z
MG&8$\$EL9U6*H+/9]T.P"G]I0]['%+)4BDTQ]]QK'/VY9J!%`H_>CRII=@*>
M+K_?B<'(,'5)9]D&W:-XALCP>@$BKGGA#L,Z5!W&L*_:[N;K$#Z%WXQ]70_2
MQ5YX[:E&1>(4(X8X;=L+^"!>U+P1E=9MFP9<3X(&Q`G'I]F,I=LK?*[_;OS*
MR`!UV>]NFR'.U5A8(*MT6+8X_,N`W?A+.M*Z+&+Z9\Y2`G7PCQ'*/&2;X:['
M#Y9(,$>U^$J*\"HZ.[A"W3GPU65N$=`[]M>`<'UON1W#O[.L%RD**?@ZWCD)
M3?>.#*3@095]3QBE3!3PY<!+]1$SX.7%:BJXQ-P2%[EV24N,HC/XRN0E+#$9
M^.#?D)15M&2&YHM$FN>)1_T^IM-K/%!YA%0&OKYY3C+3/4.)LR91$VXI&^,A
M$\MG6(/)M7%WM%9O37V[K):%?[M1JC]HX:U+P",=;#+KL.,.HP\P_\=\WI+5
M(?SSCSVXD(X1ZG*FZ:VFU#AQ51@A_&$*E?<HQ"I0J[U4'\F`6GSK48VE1]]H
MI>Q.*U#4O4PO,0.^L[+O^X^'N$/QAWB?\H(<,4ZB%\";<>>L`(EF-U8;.MYJ
M<I8Q159GM^CP\4'IG`^%L""$L3]LR%OM0XJ;:D,JK3AC!>IR[<D/H$.H._"#
M5:RT<#E'\!?*CY[+SV.8.^*\3Y'+4%C/02O2I9:TVM"!4</?\<H"`_^#M:K7
MP[Q3QK41OUWDXSC/H.\ESTK25$3=#JPV=*Q2AZ@DQ>8(P6]"I$0OLD:6VU;9
M.5#1VFJ#1QUS4BB%L\,@TKZ?;W;I&+GD6T2).WP.IE-N)GZV)6.7C(B-7'^1
M2Q262'&(+0Y\^W]^L:6#SB,*J1#,*TZ52?N<Q$M'':+3ZP#\U:?2[)+E4!M:
M?1Y.KV<+[-T7+P.N#&9L38EKOGGICM8^T!AA)MV`C+E8P2MO.N#3>*@@8;;C
ML8!BG3&GUP'XF#,D0C(*M<'69Q1N%P2#*%.PJ8/8,&H5*E`)`I4J2%/);,QI
M]P$^[#()D"UW!@CK,]8>N_V;YU[GK\[E_<W^1YG(#%A96&-TI0N`C*JD*CIC
M2"(!/F*D1I6,%#F.^HR+J)`I7I8Q-3I?28_NF[UFUG&3"1AZO+9">@ZM+0M<
MJ$UAO=3@@AZB^CCY$W;$;78/43\1A=G_0B#31&-)R!(%61QD2IDM&`:]@"\B
M&C1(EA,SE/49?<_!@.&O`>_[YL5TA2GI8+"A@<[Q1B("<[#94$;K(".3`1]!
M"M/*CBP*+/49)[>(T/#2]0$C,1L8;\?*<;:E&JMY26?`J,1`!DV:0CH#1RD'
M/G@RS"P90%F8]CR(/IT(+0>(8?X__P=02P,$%`````@`LHFN0&?C*0EB"```
M]3L``!(`'`!T9W1X9"TR,#$R,#,S,2YX<V155`D``W]UL4]_=;%/=7@+``$$
M)0X```0Y`0``[5M;;^,V%GZ>`OL?6+_L2QW9<3)MC&0*Q9&SQOJ26DXZT\6B
MH"7:)BI3'I)*XO[Z'E*292N2(E^")IGVH9#%\YW;1QY2.9SSGQ_G'KHG7%"?
M753J1[4*(LSQ7<JF%Y7;4;OZ4^7G3__Z[OS[*OP7/7R^'';1E>\$<\(DZH'P
MA!(7/5`Y0]:?U3M*'@A'=Z%2!#J/3H[J"!Y[/G/Q\@?4PTM4/_D!'=?JQZA^
MW#SYL=FH(;.']C+1R#=1:S;.FB<GZ.80)D8!$8F-TR2,VG&S7D_"$,Z,S#$B
M'E$6VCZ?7Y$)#CQY4?D:8$^;JR#(/Q,7E9F4BZ9A/#P\'#TTCGP^-8YKM;KQ
MN=>UM9I(L.E1]L>&]..8>[%\PU##8RQ(+*Y&7;D"K`N?&N'@2M0KT/NY"XK7
ME=("8<J$Q,Q)G'CB=!1B_>SLS-"CL2@C4RR)FZO\S."^1XQ(+$8%HCK%>+%"
M3;`8:T0T`,AZO5JK5QOU%*2*I<R'P2"GXT`2$<,</V"2+S<3*HAS-/7OC6@P
MPYH3<`[+*@\7C68`74*S,3"0(4X>G5FVO!K)`%!V3X3,AH1C&2"&J2.R,7HH
M`R*HDPV`@6QVY')!1"8U>B3+AESP'",PD@'@9)([T3X:,)JPL.#$>69B8N[H
MN3G!CJR2QX6'&98^7[;A]RIS/F/!/%N)*[FA0C-`J`I2A%,G61;R^2616'G>
M1*Q>8CXELH_G1"RP0S9@<BIGA.,%"2202IESY/ASE<;C6B-)(D@]NMO@H#1^
M.,>,^1)+J*R?SO%B0=G$5^\_?#A7U:"I(AJ!HXB"ZKA&F\RUF*1RV0%I/M?H
M"E*BM\-."0]TF@J5A2Y$/KAD0AG5+D(E1M5DKUA[Q,Q%H1ZTINC<2&M85QP(
MX@[8)_T,\TJ`'HU2)39"1B)YJ$1Q>8R#/2?PB@Q%K^+<Y_+1@BV6,`#"@_`]
MZJJ%<8D]5?+M&2%2;,U*"97YW!P#(3:DD$3DK)2A=6TH4H="?=\Z13<8MAS@
M`ZC`W@OPM:D_G[S&+N2A_VVH__\W2.8J9V(P&2R`)F7H0`LO1W<^B2?E2$ST
M(G^"$LW?,GV#B?4U@.WCP,RMU.:3=KHE:8JS4.D_?,GE"]3/9VSD,_EQ9R;_
M*:0;Q:Z%Q:SM^0\O4$<3U?D\_KA+&56*D=;\OLD;\"EF]$^M"@[O=C"?8[X<
M3&PZ970"LQ?.]([^`J=L>@/)<BC9GL?=K.13^I/Z6*#"\7P1<`(_!L-KL]_Y
MS1QU!GUD]J^0?=OKF<,O:-!&=N>ZWVEW6F9_A,Q6:W#;'W7ZU^AFT.VT.I;]
MOODU':A(@N[T4;>.S>6B7DMS8;9^N>W8'47%^\ZM+7WGCYGON82+'8\;&2KR
M,UU/9]H>#5K__<^@>V4-[7\C"](^^O*^4]X?C"S[QOQB7G:MK9.]`<Y/\W$Z
MS1J'(N#[SF^7.FIK-*><A'OAUDE^JB$_TXUTIJ$B6WW;0N;UT+)Z5G_TSJOS
MD'CJ[`&G1;D<<<P$=G;[X,Q5E)_\DW3RAU;7'%E7,-&'HR]H-#3[MME25?R=
MDV`'8T&^!N"V=;_3E'^B(#_IIT]*^.VE#84;ICJR[M[_A&]CRN^P%Y`>P2H#
MN]68;"WYQ\6S=-;;9F>([LSNK85ZEFG?#M]IL5'_4WW+(9D@W1!LJC[%1470
M^<)3C43];J8[-KKC4(W[";]#A$>/<R^64=H+>I.:EG12(LNQBJB34]RQ!"7^
M@G`)YW\C]KYB'"@FR/^V,6U2]NHB\O!XVX@`0KQ7&0Q,]6V#2:V.`X=T;L1-
M-'A*6FNJTP;1^%PBEMGBR^O;AU<7NKZC]11`U*]JC*NJ5]7Z<;51/WH4;NC;
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M;-J19*X^2BH(1U*@D0?J'*BEX.!%?7>D<6[`H\M'C'IP2E4'MU!6P`<V&`W4
MZ#7W@T5LA(+ZS/@Z[(;[#A%B")\D,%UGX/@5N2>>OU!2ZZ$]*[H>U=R'58CY
M,BNN"?9$9F#A04[&0^/PT@4$3,94'B+:EJ\;)_#"6W:$")0V>X:YZM0D@19)
MO5B,#B?N88)<OP>ST5[-FJ\EA%_/9+V!CR$"1QM7=P.Z]&N@6I(`#P?@R$/T
M7SO6`RR/>0/4]GVF^JTM?[X@3$1Y36+-'-X[K(3!EUJ6OQ(ZG<&!P;PG'$\)
ME.<QX8-)N.8N,1RF5*FA7J"/(DF\V^$VYK$6V3$-!^-13TDX%Z@^0`:/F\-O
M@,>!^D/D\QM)H=@;"#.<7VIG(.[(5V3!A@'G/$^51B:AJ`C942\9T<V%7ZF<
MA=T>$%CU>]8S<BB-Q<DKCK0PE3EY?Z[$Y>S!):\<9>U7NZ!?ZP86\ATM<)&_
M::7EPGC@]*O\U%/G93@N1V;TC[<&D[XOB;C!2P49^9LAI"@LB7D#M<!T'$"Z
M;<I`,<RLEB_D!I4Y`F\@M'2#.FLYYLN\GD67]C%I<(W(H[ST4M.SE'BT!/4_
MIVG*^/W?=IZ(]XAH):D-1/\),/7]EBOT!HZ^K1F&3S)Q%:BI=*--9^X/16)%
M<_(@A3,,KDS=U&YVV*I!JTIAS(<JBA%)3T,K@WF-QX!S(_PK#3S^!5!+`0(>
M`Q0````(`+*)KD!4Y4/OI58``":]`@`2`!@```````$```"D@0````!T9W1X
M9"TR,#$R,#,S,2YX;6Q55`4``W]UL4]U>`L``00E#@``!#D!``!02P$"'@,4
M````"`"RB:Y`91YN?E`'```I5P``%@`8```````!````I('Q5@``=&=T>&0M
M,C`Q,C`S,S%?8V%L+GAM;%54!0`#?W6Q3W5X"P`!!"4.```$.0$``%!+`0(>
M`Q0````(`+*)KD"8?Z09N`X``/+6```6`!@```````$```"D@9%>``!T9W1X
M9"TR,#$R,#,S,5]D968N>&UL550%``-_=;%/=7@+``$$)0X```0Y`0``4$L!
M`AX#%`````@`LHFN0-O;Z,.K(@``"MP!`!8`&````````0```*2!F6T``'1G
M='AD+3(P,3(P,S,Q7VQA8BYX;6Q55`4``W]UL4]U>`L``00E#@``!#D!``!0
M2P$"'@,4````"`"RB:Y`GXW'0"82``#>(`$`%@`8```````!````I(&4D```
M=&=T>&0M,C`Q,C`S,S%?<')E+GAM;%54!0`#?W6Q3W5X"P`!!"4.```$.0$`
M`%!+`0(>`Q0````(`+*)KD!GXRD)8@@``/4[```2`!@```````$```"D@0JC
M``!T9W1X9"TR,#$R,#,S,2YX<V155`4``W]UL4]U>`L``00E#@``!#D!``!0
52P4&``````8`!@`@`@``N*L`````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EQD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Condensed Consolidated Statement of Equity [Parenthetical] (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtxd_PreferredStockIssuedExpenses', window );">Preferred stock issued net of expenses</a></td>
        <td class="nump">$ 20.00<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtxd_PreferredStockIssuedExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The value of expenses incurred for issuance of preferred stock during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tgtxd_PreferredStockIssuedExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tgtxd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.1.0.1
 *
 */

var moreDialog = null;
var Show = {
    Default:'raw',

    more:function( obj ){
        var bClosed = false;
        if( moreDialog != null )
        {
			try
			{
				bClosed = moreDialog.closed;
			}
			catch(e)
			{
				//Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control
				// that somtimes causes it to throw when checking the closed property on a child window that has been
				//closed.  So if the exception occurs we assume the window is closed and move on from there.
				bClosed = true;
			}

			if( !bClosed ){
				moreDialog.close();
			}
        }

        obj = obj.parentNode.getElementsByTagName( 'pre' )[0];
		var hasHtmlTag = false;
		var objHtml = '';
		var raw = '';

		//Check for raw HTML
		var nodes = obj.getElementsByTagName( '*' );
		if( nodes.length ){
			objHtml = obj.innerHTML;
		}else{
			if( obj.innerText ){
				raw = obj.innerText;
			}else{
				raw = obj.textContent;
			}

			var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g );
			if( matches && matches.length ){
				objHtml = raw;

				//If there is an html node it will be 1st or 2nd,
				//   but we can check a little further.
				var n = Math.min( 5, matches.length );
				for( var i = 0; i < n; i++ ){
					var el = matches[ i ].toString().toLowerCase();
					if( el.indexOf( '<html' ) >= 0 ){
						hasHtmlTag = true;
						break;
					}
				}
			}
		}

        if( objHtml.length ){
			var html = '';

			if( hasHtmlTag ){
				html = objHtml;
			}else{
				html = '<html>'+
					"\n"+'<head>'+
					"\n"+'    <title>Report Preview Details</title>'+
					"\n"+'    <style type="text/css">'+
					"\n"+'    body {'+
					"\n"+'    }'+
					"\n"+'    table {'+
					"\n"+'    }'+
					"\n"+'    </style>'+
					"\n"+'</head>'+
					"\n"+'<body>'+
						objHtml +
					"\n"+'</body>'+
					"\n"+'</html>';
			}

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write( html );
			moreDialog.document.close();

			if( !hasHtmlTag ){
				moreDialog.document.body.style.margin = '0.5em';
			}
        }
        else
        {
			//default view logic
			var lines = raw.split( "\n" );
			var longest = 0;

			if( lines.length > 0 ){
				for( var p = 0; p < lines.length; p++ ){
					longest = Math.max( longest, lines[p].length );
				}
			}

			//Decide on the default view
			this.Default = longest < 120 ? 'raw' : 'formatted';

			//Build formatted view
			var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ;
			var formatted = '';

			if( text.length > 0 ){
				if( text.length == 1 ){
					text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ;
					formatted = "<p>"+ text.join( "<br /><br />\n" ) +"</p>";
				}else{
					for( var p = 0; p < text.length; p++ ){
						formatted += "<p>" + text[p] + "</p>\n";
					}
				}
			}else{
				formatted = '<p>' + raw + '</p>';
			}

			html = '<html>'+
				"\n"+'<head>'+
				"\n"+'    <title>Report Preview Details</title>'+
				"\n"+'    <style type="text/css">'+
				"\n"+'    body {'+
				"\n"+'       background-color: #f0f9ee;'+
				"\n"+'       font-family: Arial, san-serif; font-size: 0.8em;'+
				"\n"+'    }'+
				"\n"+'    table {'+
				"\n"+'       font-size: 1em;'+
				"\n"+'    }'+
				"\n"+'    </style>'+
				"\n"+'</head>'+
				"\n"+'<body>'+
				"\n"+'    <table border="0" width="100%">'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            formatted: <a href="javascript:void(0);" onclick="opener.Show.toggle( window, this );">'+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +'</a>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <div id="formatted" style="display: none;">'+formatted+'</div>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <pre id="raw" style="display: none; font-size: 1.2em;">'+raw+'</pre>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    </table>'+
				"\n"+'</body>'+
				"\n"+'</html>';

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write(html);
			moreDialog.document.close();

			this.toggle( moreDialog );
        }

		moreDialog.document.title = 'Report Preview Details';
    },

    toggle:function( win, domLink ){
        var domId = this.Default;

        var doc = win.document;
        var domEl = doc.getElementById( domId );
        domEl.style.display = 'block';

        this.Default = domId == 'raw' ? 'formatted' : 'raw';

        if( domLink ){
            domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed';
        }

        var domElOpposite = doc.getElementById( this.Default );
        domElOpposite.style.display = 'none';
    },

	LastAR : null,
	showAR : function ( link, id, win ){
		if( Show.LastAR ){
			Show.hideAR();
		}

		var ref = link;
		do {
			ref = ref.nextSibling;
		} while (ref && ref.nodeName != 'TABLE');

		if (!ref || ref.nodeName != 'TABLE') {
			var tmp = win ?
				win.document.getElementById(id) :
				document.getElementById(id);

			if( tmp ){
				ref = tmp.cloneNode(true);
				ref.id = '';
				link.parentNode.appendChild(ref);
			}
		}

		if( ref ){
			ref.style.display = 'block';
			Show.LastAR = ref;
		}
	},

	toggleNext : function( link ){
		var ref = link;

		do{
			ref = ref.nextSibling;
		}while( ref.nodeName != 'DIV' );

		if( ref.style &&
			ref.style.display &&
			ref.style.display == 'none' ){
			ref.style.display = 'block';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '+', '-' );
			}else{
				link.innerText = link.innerText.replace( '+', '-' );
			}
		}else{
			ref.style.display = 'none';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '-', '+' );
			}else{
				link.innerText = link.innerText.replace( '-', '+' );
			}
		}
	},

	hideAR : function(){
		Show.LastAR.style.display = 'none';
	}
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E63AE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
        <td class="num">$ (17,396,538)<span></span></td>
        <td class="num">$ (18,285,609)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock compensation expense</a></td>
        <td class="nump">188,509<span></span></td>
        <td class="nump">275,003<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtxd_NonCashStockExpense', window );">Stock issued in connection with in-licensing agreement</a></td>
        <td class="nump">16,578,000<span></span></td>
        <td class="nump">16,875,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities, net of effects of acquisition:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Decrease in other current assets</a></td>
        <td class="nump">8,147<span></span></td>
        <td class="nump">11,740<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Increase in accounts payable and accrued expenses</a></td>
        <td class="num">(254,604)<span></span></td>
        <td class="nump">153,706<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Increase in interest payable</a></td>
        <td class="nump">14,852<span></span></td>
        <td class="nump">21,949<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
        <td class="num">(861,634)<span></span></td>
        <td class="num">(948,211)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash acquired in connection with acquisition</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">10,386<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">10,386<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Payments of short-term loans</a></td>
        <td class="num">(200,000)<span></span></td>
        <td class="num">(200,000)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock, net</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">9,824,682<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from sale of preferred stock, net</a></td>
        <td class="nump">12,257,309<span></span></td>
        <td class="nump">12,257,309<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering costs paid</a></td>
        <td class="num">(20,416)<span></span></td>
        <td class="num">(20,416)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
        <td class="nump">12,036,893<span></span></td>
        <td class="nump">21,861,575<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">NET INCREASE IN CASH AND CASH EQUIVALENTS</a></td>
        <td class="nump">11,175,259<span></span></td>
        <td class="nump">20,923,750<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
        <td class="nump">9,748,491<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS AT END OF PERIOD</a></td>
        <td class="nump">20,923,750<span></span></td>
        <td class="nump">20,923,750<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonmonetaryTransactionsAbstract', window );"><strong>NON-CASH TRANSACTIONS:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtxd_ConversionOfNotesPayableToPreferredStock', window );">Conversion of notes payable to preferred stock</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">55,271<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtxd_AccruedFinancingCosts', window );">Accrued financing costs</a></td>
        <td class="nump">$ 55,487<span></span></td>
        <td class="nump">$ 116,626<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtxd_AccruedFinancingCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accrued Financing Costs during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tgtxd_AccruedFinancingCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tgtxd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtxd_ConversionOfNotesPayableToPreferredStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Conversion Of Notes Payable To Preferred Stock during the year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tgtxd_ConversionOfNotesPayableToPreferredStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tgtxd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtxd_NonCashStockExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense related to the issuance of stock in connection with in-licensing agreements during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tgtxd_NonCashStockExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tgtxd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15, 16, 17<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAcquiredFromAcquisition</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7<br><br> -Footnote 1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 8, 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7, 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in cash and cash equivalents. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInInterestPayableNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets,or  income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from financing activity for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from investing activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonmonetaryTransactionsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonmonetaryTransactionsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for cost incurred directly with the issuance of an equity security.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18, 19, 20<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsOfStockIssuanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4J<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6922042&amp;loc=SL4591551-111686<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A1, A4, A5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph c(1)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 29<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -Subparagraph (a),(c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6921930&amp;loc=SL4573702-111684<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4K<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6922042&amp;loc=SL4591552-111686<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 5<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6921628&amp;loc=SL4569616-111683<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProfitLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 20<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RepaymentsOfShortTermDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EWOAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets [Parenthetical] (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
        <td class="nump">10,000,000<span></span></td>
        <td class="nump">10,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
        <td class="nump">1,108,816<span></span></td>
        <td class="nump">413,388<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
        <td class="nump">1,108,816<span></span></td>
        <td class="nump">413,388<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtxd_PreferredStockLiquidationPreferenceValue', window );">Preferred stock, liquidation preference per share (in dollars)</a></td>
        <td class="nump">$ 22,176,320<span></span></td>
        <td class="nump">$ 8,267,760<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump">500,000,000<span></span></td>
        <td class="nump">500,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump">5,061,399<span></span></td>
        <td class="nump">5,061,399<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump">5,061,399<span></span></td>
        <td class="nump">5,061,399<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtxd_PreferredStockLiquidationPreferenceValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tgtxd_PreferredStockLiquidationPreferenceValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tgtxd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of shares of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares represent the ownership interest of the common shareholders. Shares outstanding equals shares issued minus shares held in treasury and other adjustments, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ESAAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>May 10, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">TG THERAPEUTICS, INC.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001001316<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Smaller Reporting Company<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
        <td class="text">tgtxd<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">14,917,658<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Mar. 31,
         2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document as an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, N-1A, etc). The document type is limited to the same value as the supporting SEC submission type, minus any "/A" suffix. The acceptable values are as follows: S-1, S-3, S-4, S-11, F-1, F-3, F-4, F-9, F-10, 6-K, 8-K, 10, 10-K, 10-Q, 20-F, 40-F, N-1A, 485BPOS, 497, NCSR, N-CSR, N-CSRS, N-Q, 10-KT, 10-QT, 20-FT, POS AM and Other.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares outstanding of each of registrant's classes of common stock, as of latest practicable date. Where multiple classes exist define each class by adding class of stock items such as Common Class A [Member], Common Class B [Member] onto the Instrument [Domain] of the Entity Listings, Instrument</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, or (4) Smaller Reporting Company. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Trading symbol of an instrument as listed on an exchange.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_TradingSymbol</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E6TAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtxd_NonCashStockExpense', window );">Non-cash stock expense associated with in-licensing agreement</a></td>
        <td class="nump">$ 16,578,000<span></span></td>
        <td class="nump">$ 16,875,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtxd_OtherResearchAndDevelopment', window );">Other research and development</a></td>
        <td class="nump">163,353<span></span></td>
        <td class="nump">193,636<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development</a></td>
        <td class="nump">16,741,353<span></span></td>
        <td class="nump">17,068,636<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtxd_NonCashCompensation', window );">Non-cash compensation</a></td>
        <td class="nump">188,509<span></span></td>
        <td class="nump">275,003<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Other general and administrative</a></td>
        <td class="nump">455,492<span></span></td>
        <td class="nump">923,689<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative</a></td>
        <td class="nump">644,001<span></span></td>
        <td class="nump">1,198,692<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total costs and expenses</a></td>
        <td class="nump">17,385,354<span></span></td>
        <td class="nump">18,267,328<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
        <td class="num">(17,385,354)<span></span></td>
        <td class="num">(18,267,328)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (income) expense:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Interest income</a></td>
        <td class="num">(3,668)<span></span></td>
        <td class="num">(3,668)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
        <td class="nump">220,149<span></span></td>
        <td class="nump">227,246<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtxd_ChangeInFairValueOfNonCurrentNotePayable', window );">Change in fair value of non-current notes payable</a></td>
        <td class="num">(205,297)<span></span></td>
        <td class="num">(205,297)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (income) expense</a></td>
        <td class="nump">11,184<span></span></td>
        <td class="nump">18,281<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
        <td class="num">(17,396,538)<span></span></td>
        <td class="num">(18,285,609)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interest</a></td>
        <td class="num">(7,140,448)<span></span></td>
        <td class="num">(7,176,445)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to TG Therapeutics, Inc. and subsidiaries</a></td>
        <td class="num">$ (10,256,090)<span></span></td>
        <td class="num">$ (11,109,164)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per common share (in dollars per share)</a></td>
        <td class="num">$ (2.03)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtxd_WeightedAverageNumberOfSharesBasicAndDiluted', window );">Weighted average shares used in computing basic and diluted net loss per common share (in shares)</a></td>
        <td class="nump">5,061,399<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtxd_ChangeInFairValueOfNonCurrentNotePayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The change in the fair value of non current note payable recognized during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tgtxd_ChangeInFairValueOfNonCurrentNotePayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tgtxd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtxd_NonCashCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate compensation expense related to the grants of stock options and restricted stock that is attributable to general and administrative expenses during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tgtxd_NonCashCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tgtxd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtxd_NonCashStockExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense related to the issuance of stock in connection with in-licensing agreements during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tgtxd_NonCashStockExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tgtxd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtxd_OtherResearchAndDevelopment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Other research and development expense during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tgtxd_OtherResearchAndDevelopment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tgtxd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtxd_WeightedAverageNumberOfSharesBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The average number of shares issued and outstanding that are used in calculating common stock basic and diluted EPS, determined based on the timing of issuance of shares in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tgtxd_WeightedAverageNumberOfSharesBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tgtxd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostsAndExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpenseAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cost of borrowed funds accounted for as interest that was charged against earnings during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 34<br><br> -Paragraph 21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 9<br><br> -Article 9<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher OTS<br><br> -Name Federal Regulation (FR)<br><br> -Number Title 12<br><br> -Chapter V<br><br> -Section 563c.102<br><br> -Paragraph 9<br><br> -Subsection II<br><br> -LegacyDoc This is a non-GAAP reference that was included in the 2009 taxonomy.  It will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This item represents investment income derived from investments in debt and equity securities consisting of interest income earned from investments in debt securities and on cash and cash equivalents, dividend income from investments in equity securities, and income or expense derived from the amortization of investment related discounts or premiums, respectively, net of related investment expenses. This item does not include realized or unrealized gains or losses on the sale or holding of investments in debt and equity securities required to be included in earnings for the period or for other than temporary losses related to investments in debt and equity securities which are included in realized losses in the period recognized, and does not include investment income from real or personal property, such as rental income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7(a),(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Staff Position (FSP)<br><br> -Number FAS115-1/124-1<br><br> -Paragraph 13, 14, 15, 16<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 115<br><br> -Paragraph 14, 16<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentIncomeNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 19<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of net Income or Loss attributable to the noncontrolling interest (if any) deducted in order to derive the portion attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6921930&amp;loc=SL4573702-111684<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4J<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6922042&amp;loc=SL4591551-111686<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph c(1)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A1, A4, A5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4K<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6922042&amp;loc=SL4591552-111686<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 7<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpenseAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The sum of expenses not otherwise specified in the taxonomy for managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherGeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4J<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6922042&amp;loc=SL4591551-111686<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A1, A4, A5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph c(1)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 29<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -Subparagraph (a),(c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6921930&amp;loc=SL4573702-111684<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4K<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6922042&amp;loc=SL4591552-111686<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 5<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6921628&amp;loc=SL4569616-111683<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProfitLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 51<br><br> -Subparagraph g<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 2<br><br> -Paragraph 12, 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 86<br><br> -Paragraph 11, 12<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>NOTES PAYABLE<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt Disclosure [Text Block]</a></td>
        <td class="text"><p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>NOTE 5 &#8211; NOTES PAYABLE</b></p>
<p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The following is a summary of notes payable:</p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-align: left;">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="10">March&#160;31,&#160;2012</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="10">December&#160;31,&#160;2011</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left;">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Current <br />portion,&#160;net</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Non- <br />current <br />portion,&#160;net</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Total</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Current <br />portion,&#160;net</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Non- <br />current <br />portion,&#160;net</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Total</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; width: 40%;">Non-interest Bearing Note Payable, Net</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 7%;">&#8212;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 7%;">&#8212;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 7%;">&#8212;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 7%;">200,000</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 7%;">&#8212;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 7%;">200,000</td>
<td style="text-align: left; width: 1%;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">Convertible 5% Notes Payable</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#8212;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">4,664,697</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">4,664,697</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#8212;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">4,664,697</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">4,664,697</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt;">ICON Convertible Note</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">677,778</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">677,778</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">677,778</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align:
 right;">677,778</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt;">Total</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">677,778</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">4,664,697</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">5,342,475</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">877,778</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">4,664,697</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">5,542,475</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
</table>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">We assumed the preceding notes payable as the result of the Exchange Transaction. Accordingly, a valuation was performed and these notes have been presented at their fair value on the date of the transaction.</p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Non-Interest Bearing Note Payable</i></b></p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In October 2009, Manhattan entered into a Settlement Agreement and Mutual Release with Swiss Pharma Contract LTD (&#8220;Swiss Pharma&#8221;) pursuant to which Manhattan agreed to pay Swiss Pharma $200,000 and issue to Swiss Pharma an interest free promissory note due on October 27, 2011 in the principal amount of $250,000 in full satisfaction of a September 5, 2008 arbitration award. In November 2011, Manhattan renegotiated the $250,000 promissory note due October 27, 2011 in which the amount of the promissory note was reduced to $200,000 and the maturity date was extended to February 15, 2012. This amount was paid on February 14, 2012 in full settlement of this note.</p>
<p style="text-align: left; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Convertible 5% Notes Payable</i></b></p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On March 8, 2010, Manhattan entered into an Agreement and Plan of Merger (the "Merger Agreement") by and among the Company, Ariston Pharmaceuticals, Inc., a Delaware corporation ("Ariston") and Ariston Merger Corp., a Delaware corporation and wholly-owned subsidiary of the Company (the "Merger Sub").&#160; Pursuant to the terms and conditions set forth in the Merger Agreement, on March 8, 2010, the Merger Sub merged with and into Ariston (the "Merger"), with Ariston being the surviving corporation of the Merger.&#160; As a result of the Merger, Ariston became a wholly-owned subsidiary of the Company.&#160;</p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The 5% Notes and accrued and unpaid interest thereon are convertible at the option of the holder into Common Stock at the conversion price of $1,125 per share.&#160;&#160;Ariston agreed to make quarterly payments on the 5% Notes equal to 50% of the net product cash flow received from the exploitation or commercialization of Ariston&#8217;s product candidates, AST-726 and AST-915.&#160;&#160;<font style="color: black;">The Company has no obligations under the 5% Notes aside from a) 50% of the net product cash flows from Ariston&#8217;s product candidates, if any, payable to noteholders; and b) the conversion feature, discussed above.</font> Interest accrues monthly, is added to principal on an annual basis, every March 8, and is payable at maturity.</p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In connection with the Exchange Transaction in December 2011, the Company performed a valuation of the assets and liabilities of Manhattan immediately prior to the transaction. <font style="color: black;">The cumulative liability including accrued and unpaid interest of these notes was approximately $16,876,000 immediately prior to the Exchange Transaction, $16,883,000 at December 31, 2011, and $17,089,000 at March 31, 2012. </font>As these notes payable are tied directly to net product cash flows derived from the preexisting products of the Company, this note and accrued interest was recorded at fair value as of the date of the Exchange Transaction. No payments have been made on these notes as of March 31, 2012. See Note 2 for further details.</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>ICON Convertible Note Payable</i></b></p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In connection with the merger with Ariston as discussed above, Ariston satisfied an account payable of $1,275,188 to ICON
 Clinical Research Limited (&#8220;ICON&#8221;) through the payment of $275,188 in cash and the issuance of a three-year 5% note payable (the &#8220;ICON Note&#8221;).&#160;&#160;The principal was to be repaid in 36 monthly installments of $27,778 commencing in April 2010.&#160;&#160;Interest was payable monthly in arrears. &#160;&#160;On March 1, 2011, Ariston entered into an amended and restated convertible promissory note (the &#8220;Amended ICON Note&#8221;) with ICON. The principal terms of the Amended ICON Note are that monthly payments of principal and interest will be waived for the thirteen month period ended December 31, 2011 (the &#8220;Waiver Period&#8221;) in exchange for a single payment of $100,000 on March 31, 2011, an increase in the interest on the Amended ICON Note from 5% to 8% per annum during the Waiver Period and a balloon payment on January 31, 2012. The Amended ICON Note is convertible at the option of the holder into the Company&#8217;s Common Stock at the conversion price of $562.50 per share. During the three months ended March 31, 2012, the Company recorded $14,852 of interest expense on the Amended ICON Note. At March 31, 2012, the principal amount of the Amended ICON Note was $677,778, of which the entire balance has been classified as current, and interest payable on the Amended ICON Note was $76,793, and is reflected as notes payable, current portion, net, and interest payable, current portion, net, respectively, in the accompanying balance sheet as of March 31, 2012. This note is currently in default as the Company did not make the balloon payment due on January 31, 2012, or the monthly installment payments due in February 2012 and March 2012. The Company is currently attempting to negotiate a settlement or alternative arrangement in satisfaction of this note.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20,22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20, 22<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
        <td class="text"><p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>NOTE 4 - STOCKHOLDERS' EQUITY</b></p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Preferred Stock</i></b></p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Our amended and restated certificate of incorporation authorizes the issuance of up to 10,000,000 shares of preferred stock, $0.001 par value, with rights senior to those of our common stock, <font style="background-color: white; color: black;">issuable in one or more series. Upon issuance, the Company can determine the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of common stock.</font></p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="background-color: white; color: black;">There were 1,108,816 shares of Company Preferred Stock outstanding as of March 31, 2012. </font>In connection with the Exchange Transaction, the Company filed a Certificate of Designation with respect to its Company Preferred Stock with the Secretary of State of the State of Delaware.&#160;&#160;The Company Preferred Stock ranks senior to the Common Stock with regard to dividend rights, and has a liquidation preference of $20 per share over the Common Stock and any other junior securities.&#160;The Company Preferred Stock is automatically convertible into 8.89 shares of Common Stock provided that, prior to conversion, the Company has sufficient authorized Common Stock to effect such conversion.&#160;&#160;The Company Preferred Stock also automatically converts upon a change of control of the Company or the sale of substantially all of the assets of the Company.&#160;&#160;The Company Preferred Stock votes on an as-converted basis with the Common Stock.</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In conjunction with the reverse split effected on April 30, 2012 (as discussed in Note 1), our Company Preferred Stock automatically converted to 9,856,259 shares of Common Stock as of that date.</p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Common Stock</i></b></p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Our amended and restated certificate of incorporation authorizes the issuance of up to 500,000,000 shares of $0.001 par value common stock.</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On December 30, 2011, we <font style="color: black;">completed the first closing of the private placement of our securities, issuing 4,929,523 shares of Common Stock at a price per share of $2.25 for total gross proceeds, before placement commissions and expenses, of $11,091,425 (the &#8220;2011 Equity PIPE&#8221;).&#160;Investors also received warrants to purchase 1,232,381 shares of Common Stock. The warrants have an exercise price of $2.25 per share and are exercisable for five years.</font></p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In 2012, we completed two additional closings of the 2011 Equity PIPE. These closings were held on January 31, 2012, and February 24, 2012. In these closings, the Company issued 695,428 shares of our Company Preferred Stock at a price per share of $20.00 for total gross proceeds, before placement commissions and expenses, of $13,908,560. E<font style="background-color: white;">ach share of Company Preferred Stock is convertible into 8.89 shares of Common Stock provided that such conversion rights are subject to sufficient available authorized shares of Common Stock.</font> Investors also received warrants to purchase 1,545,396 shares of Common Stock. The warrants have an exercise price of $2.25 per share and are exercisable for five years.&#160;<font style="background-color: white;">The shares of Company Preferred Stock and warrants sold in these closings were offered and sold to accredited investors, including members of management, without registration under the Securities Act, or state securities laws, in reliance on the exemptions provided by Section&#160;4(2) of the Securities Act, and Regulation&#160;D promulgated thereunder and in reliance on similar exemptions under applicable state laws. Accordingly, the securities issued in the offering have not been registered under the Securities Act, and until so registered, these securities may not be offered or sold in the United States absent registration or availability of an applicable exemption from registration. The placement agent received cash commissions equal to 10% of the gross proceeds of the offering, five-year warrants to purchase shares of the Company&#8217;s stock equal to 10% of shares sold in the offering, and a non-accountable expense allowance equal to two percent of the gross proceeds of the offering for their expenses.&#160;&#160;</font></p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="background-color: white;">&#160;</font></p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Equity Incentive Plans</i></b></p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>&#160;</i></b></p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">A summary of the status of the Company&#8217;s stock options as of March 31, 2012 and changes during the period then ended is presented
 below:</p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"></p>
<p style="margin: 0px;"></p>
<p style="margin: 0px;"></p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><u>Stock Options</u></p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The following table summarizes stock option activity for the three months ended March 31, 2012:</p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2">
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>&#160;</b></p>
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>Number</b></p>
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>of&#160;shares</b></p>
</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2">
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>Weighted-</b></p>
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>average</b></p>
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>exercise&#160;price</b></p>
</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2">
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>Weighted-</b></p>
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>average</b></p>
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>Contractual</b></p>
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>Term</b></p>
</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2">
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>&#160;</b></p>
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>Aggregate</b></p>
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>Intrinsic<br />Value</b></p>
</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: right;" colspan="2">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;" colspan="2">&#160;</td>
<td>&#160;</td>
<td style="font-weight: bold;">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2">(in years)</td>
<td style="font-weight: bold;">&#160;</td>
<td style="font-weight: bold;">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2">&#160;</td>
<td style="font-weight: bold;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; width: 48%;">Outstanding at December 31, 2011</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: right; width: 10%;">3,379</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">1,315.62</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: right; width: 10%;">6.39</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: right; width: 10%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-left: 9pt;">Granted</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#8212;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#8212;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-left: 9pt;">Exercised</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#8212;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#8212;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-left: 9pt;">Forfeited</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(2,475</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">720.45</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td
 style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt;">Expired</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">&#8212;</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="text-align: right; padding-bottom: 1pt;">&#8212;</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="text-align: right; padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="text-align: right; padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt;">Outstanding at March 31, 2012</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">904</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">2,945.09</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">2.49</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">&#8212;</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt;">Vested and expected to vest at March 31, 2012</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">904</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">2,945.09</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">2.49</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">&#8212;</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt;">Exercisable at March 31, 2012</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">898</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">2,963.46</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">2.43</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">&#8212;</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
</table>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">As of March 31, 2012, the total compensation cost related to unvested option awards not yet recognized is less than $1,000. The weighted average period over which it is expected to be recognized is approximately 1 year.</p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><u>Restricted Stock</u></p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Certain employees have been awarded restricted Company Preferred Stock. The restricted stock vesting consists of milestone and time-based vesting. The following table summarizes restricted share activity for the three months ended March 31, 2012:</p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td
 style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid;" colspan="2">
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>&#160;</b></p>
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>Number&#160;of Shares</b></p>
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>Restricted&#160;Series&#160;</b></p>
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>A Preferred</b></p>
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>Stock<sup>(1)</sup></b></p>
</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid;" colspan="2">
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>Weighted&#160;</b></p>
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>Average</b></p>
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>Grant&#160;Date&#160;</b></p>
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>Fair Value</b></p>
</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid;" colspan="2">
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>Aggregate</b></p>
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>Intrinsic</b></p>
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>Value</b></p>
</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="width: 45%;">Outstanding at December 31, 2011</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: right; width: 15%;">129,375</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%;">$</td>
<td style="text-align: right; width: 15%;">20.00</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: right; width: 15%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 9pt;">Granted</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;">&#8212;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;">&#8212;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;">&#160;</td>
<td>&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="padding-left: 9pt;">Vested</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;">&#8212;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;">&#8212;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;">&#160;</td>
<td>&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 9pt;">Forfeited</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">&#8212;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="text-align: right; padding-bottom: 1pt;">&#8212;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="text-align: right; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="padding-bottom: 2.25pt;">Outstanding at March 31, 2012</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.25pt double;">&#160;</td>
<td style="border-bottom: black 2.25pt double; text-align: right;">129,375</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.25pt double;">$</td>
<td style="border-bottom: black 2.25pt double; text-align: right;">20.00</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.25pt double;">$</td>
<td style="border-bottom: black 2.25pt double; text-align: right;">7,762,500</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
</tr>
</table>
<p style="text-align: left; text-indent: -1pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>&#160;</b></p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="font-family: times new roman, times, serif;"><b><sup>(1) </sup></b></font>The restricted Company Preferred Stock listed in the table above was granted in connection with the Exchange Transaction to certain executives as discussed above. Each share of Company Preferred Stock is convertible into 8.89 shares of the Company&#8217;s Common Stock, provided that such conversion right is subject to sufficient available authorized shares of the registrant&#8217;s common stock.</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Total expense associated with restricted stock was $188,509 during the three months ended March 31, 2012.</p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><u>Warrants</u></p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The following table summarizes warrant activity for the three months ended March 31, 2012:</p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="padding-bottom:
 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid;" colspan="2">
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>&#160;</b></p>
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>Warrants</b></p>
</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid;" colspan="2">
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>Weighted-</b></p>
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>average</b></p>
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>exercise price</b></p>
</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><b>Aggregate<br />Intrinsic <br />Value</b></td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="width: 45%;">Outstanding at December 31, 2011</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: right; width: 15%;">2,118,768</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%;">$</td>
<td style="text-align: right; width: 15%;">4.62</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: right; width: 15%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 9pt;">Issued</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;">2,163,555</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;">2.31</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;">&#160;</td>
<td>&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="padding-left: 9pt;">Exercised</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;">&#8212;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;">&#8212;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;">&#160;</td>
<td>&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; text-decoration: none;">
<td style="padding-bottom: 1pt; padding-left: 9pt; text-decoration: none;">Expired</td>
<td style="padding-bottom: 1pt; text-decoration: none;">&#160;</td>
<td style="padding-bottom: 1pt; text-decoration: none;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-decoration: none;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right; text-decoration: none;">(1,449</td>
<td style="padding-bottom: 1pt; text-decoration: none;">)</td>
<td style="padding-bottom: 1pt; text-decoration: none;">&#160;</td>
<td style="padding-bottom: 1pt; text-decoration: none;"></td>
<td style="text-align: right; padding-bottom: 1pt; text-decoration: none;">2,812.50</td>
<td style="padding-bottom: 1pt; text-decoration: none;"></td>
<td style="padding-bottom: 1pt; text-decoration: none;"></td>
<td style="padding-bottom: 1pt; text-decoration: none;"></td>
<td style="text-align: right; padding-bottom: 1pt; text-decoration: none;">&#160;</td>
<td style="padding-bottom: 1pt; text-decoration: none;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="padding-bottom: 2.25pt;">Outstanding at March 31, 2012</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.25pt double;">&#160;</td>
<td style="border-bottom: black 2.25pt double; text-align: right;">4,280,874</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.25pt double;">$</td>
<td style="border-bottom: black 2.25pt double; text-align: right;">2.50</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.25pt double;">$</td>
<td style="border-bottom: black 2.25pt double; text-align: right;">&#8212;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
</tr>
</table>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>&#160;</i></b></p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i></i></b>During the three months ended March 31, 2011, as part of the 2011 Equity PIPE, we issued warrants to purchase up to 1,545,396 shares of our Company Common Stock to investors in the 2011 Equity PIPE, none of which have been exercised as of March 31, 2012. The warrants have an exercise price of $2.25 per warrant share. In addition, we issued to the placement agent in the transaction warrants to purchase up to 618,159 shares of our Company Common Stock at an exercise price of $2.48 per warrant share, none of which have been exercised as of March 31, 2012.</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Stock-Based Compensation</i></b></p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The fair value of stock options granted is estimated at the date of grant using the Black-Scholes pricing model. The expected term of options granted is derived from historical data and the expected vesting period. Expected volatility is based on the historical volatility of our common stock. The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. We have assumed no expected dividend yield, as dividends have never been paid to stock or option holders and will not be paid for the foreseeable future. The Company did not grant any stock options during the three months ended March 31, 2012.</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The following table summarizes stock-based compensation
 expense information about stock options and restricted stock for the three months ended March 31, 2012:</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; text-indent: -14.2pt; padding-left: 14.2pt; width: 87%;">Stock-based compensation expense associated with restricted stock</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">188,509</td>
<td style="text-align: left; width: 1%;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; text-indent: -14.2pt; padding-left: 14.2pt;">Stock-based compensation expense associated with option grants</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">&#8212;</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt; text-indent: -14.2pt; padding-left: 14.2pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">188,509</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
</table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable).  Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187143-122770<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 5<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 4<br><br> -Section 08<br><br> -Paragraph d<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Chapter 1<br><br> -Section B<br><br> -Paragraph 7, 11A<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 20: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 21: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 22: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 23: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events [Text Block]</a></td>
        <td class="text"><p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>NOTE 8 &#8211; SUBSEQUENT EVENTS</b></p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On April 30, 2012, the Company filed a Certificate of Amendment to its Certificate of Incorporation to change its name from Manhattan Pharmaceuticals, Inc. to TG Therapeutics, Inc. In conjunction with this change, the subsidiary formerly named TG Therapeutics, Inc. filed a Certificate of Amendment changing its name to TG Biologics, Inc.</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On April 30, 2012, the Company effected a reverse split of its Common Stock at a ratio of 56.25 for 1, pursuant to a previously obtained shareholder authorization. All share amounts and per share prices in this Quarterly Report on Form 10-Q have been retroactively adjusted to reflect the effect of our reverse stock split, on a fifty six and one quarter (56.25) for one (1) basis, unless otherwise indicated.&#160;&#160;The exercise price for all stock options and warrants and the conversion price for convertible securities in the accompanying condensed consolidated financial statements have been adjusted to reflect the reverse stock split by multiplying the original exercise or conversion price by fifty six and one quarter (56.25).</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>LICENSE AGREEMENTS<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtxd_LicenseAgreementAbstract', window );"><strong>License Agreement [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtxd_LicenseAgreementDisclosureTextBlock', window );">License Agreement Disclosure [Text Block]</a></td>
        <td class="text"><p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>NOTE 6 &#8211; LICENSE AGREEMENTS</b></p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In April 2011, TG Bio, acquired from LFB Biotechnologies, a fully owned subsidiary of France based LFB S.A., an option (the &#8220;License Option&#8221;) for exclusive worldwide rights (except France/Belgium) to develop and market ublituximab (&#8220;TGTX-1101&#8221;), a monoclonal antibody that targets a specific epitope on the B-cell lymphocyte CD20 antigen. In exchange for the License Option, TG Bio issued 132,000 shares of its common stock to LFB.</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">On January 30, 2012, TG Bio exercised the License Option and </font>entered into an exclusive license agreement with LFB Biotechnologies, GTC Biotherapeutics and LFB/GTC LLC, all wholly-owned subsidiaries of LFB Group, relating to the development of ublituximab (the &#8220;License Agreement&#8221;)<font style="color: black;">. </font>Under the License Agreement, we have acquired the exclusive worldwide rights (exclusive of France/Belgium) for the development and commercialization of TGTX-1101 (ublituximab). To date, we have made no payments to LFB Group and LFB Group is eligible to receive payments of up to an aggregate of approximately $31.0 million upon our successful achievement of certain clinical development, regulatory and sales milestones, in addition to royalty payments on net sales of ublituximab. The license will terminate on a country by country basis upon the expiration of the last licensed patent right or 15 years after the first commercial sale of a product in such country, unless the agreement is earlier terminated.</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In connection with the license agreement, our subsidiary TG Biologics issued 7,368,000 shares of its common stock to LFB, and the Company agreed to contribute $15 million, less applicable fees and expenses associated with the financing, to TG Bio to fund the development of ublituximab under the License Agreement in exchange for 7,500,000 shares of TG Bio common stock. The Company recognized approximately $16,578,000 of non-cash research and development expense during the three months ended March 31, 2012 in connection with the issuance of these shares. In addition, in connection with the issuance of 7,368,000 shares of TG Bio common stock, the Company and TG Bio provided LFB Group the option to,&#160;in its sole discretion, elect to convert all, and not less than all, of the shares of TG Bio common stock into 7,500,000 shares of the Company&#8217;s Common Stock. This option may be exercised by LFB Group at any time before May 14, 2012.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Furthermore, should LFB Group choose to exercise the option for Company Common Stock, the Board of Directors of the Company shall appoint&#160;an individual designated by LFB Group to serve as a director of the Company until the next annual meeting of the stockholders and until his or her successor has been duly elected. Thereafter the Board of Directors of the Company shall nominate a designee named by LFB Group for election at each annual meeting of the stockholders until such time as LFB Group owns less than 10% of the outstanding Company Common Stock.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtxd_LicenseAgreementAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tgtxd_LicenseAgreementAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tgtxd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtxd_LicenseAgreementDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for research, development, and License Agreement activities, including contracts and arrangements to be performed for others and with federal government.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tgtxd_LicenseAgreementDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tgtxd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions Disclosure [Text Block]</a></td>
        <td class="text"><p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>NOTE 7 &#8211; RELATED PARTY TRANSACTIONS</b></p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>&#160;</b></p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On December 30, 2011, OPN Capital Markets (&#8220;OPNCM&#8221;) and its affiliated broker-dealer, National Securities Corporation (&#8220;NSC&#8221; and collectively with OPNCM, &#8220;National&#8221;), both affiliates of National Holdings Corporation (&#8220;National Holdings&#8221;), entered into a Placement Agency Agreement (the &#8220;PAA&#8221;) with the Company in connection with the initial closing of the 2011 Equity PIPE, offering of up to $25 million of stock and warrants of the Company.&#160;&#160;Pursuant to the PAA, National acted as the Company&#8217;s placement agent for 2011 Equity PIPE.</p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Until April 2012, Michael S. Weiss was a director and Non-Executive Chairman of the Board of Directors of National Holdings.&#160;&#160;He is also a stockholder of National Holdings and, when combined with his ownership indirectly through Opus and its affiliates, beneficially owns 23.6% of National Holdings, the parent company of NSC.&#160;Mr. Weiss disclaims such beneficiary ownership other than to the extent of his pecuniary interest. In addition, at the time, Opus and NSC were parties to a 50/50 joint venture that shared profits from OPNCM, the investment banking division of NSC that was responsible for managing the Offering. This joint venture was dissolved in April 2012.</p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; background-color: white; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="font-family: times new roman, times, serif;">The Company completed the initial closing of the 2011 Equity PIPE on December 30, 2011, </font><font style="color: black;">issuing 4,929,523 shares of Common Stock at a price per share of $2.25 for total gross proceeds, before placement commissions and expenses, of $11,091,425 (the &#8220;2011 Equity PIPE&#8221;).&#160;Investors also received warrants to purchase 1,232,381 shares of Common Stock. The warrants have an exercise price of $2.25 per share and are exercisable for five years</font><font style="font-family: times new roman, times, serif;">. The Company </font><font style="color: black;">completed two additional closings of the 2011 Equity PIPE. These closings were held on January 31, 2012 and February 24, 2012. In these closings, the Company issued 695,428 shares of our Company Preferred Stock (&#8220;Preferred Stock&#8221;) at a price per share of $20.00 for total gross proceeds, before placement commissions and expenses, of $13,908,560. Each share of Company Preferred Stock is convertible into 8.89 shares of Common Stock provided that such conversion rights are subject to sufficient available authorized shares of Common Stock. Investors will also receive warrants to purchase 1,545,396 shares of Common Stock. The warrants have an exercise price of $2.25 per share and are exercisable for five years.&#160; </font></p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; margin-top: 0px; text-indent: 0.5in; font: 10pt times new roman, times, serif; margin-bottom: 6pt; margin-left: 0in;">As placement agent, National received cash commissions equal to 10% of the gross proceeds of the 2011 Equity PIPE, five-year warrants to purchase shares of Company Preferred Stock equal to 10% of shares sold in the 2011 Equity PIPE, and a non-accountable expense allowance equal to two percent of the gross proceeds of the 2011 Equity PIPE for National&#8217;s expenses (not including up to $80,000 of National&#8217;s legal expenses and any blue sky fees, both of which the Company also reimbursed).&#160;In addition to acting as placement, National provided advisory services in connection with the Exchange Transaction and received an advisory fee of $150,000 for such services.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for related party transactions, including the nature of the relationship(s), a description of the transactions, the amount of the transactions, the effects of any change in the method of establishing the terms of the transaction from the previous period, stated interest rate, expiration date, terms and manner of settlement per the agreement with the related party, and amounts due to or from related parties. If the entity and one or more other entities are under common ownership or management control and this control affects the operating results or financial position, disclosure includes the nature of the control relationship even if there are no transactions between the entities. Disclosure may also include the aggregate amount of current and deferred tax expense for each statement of earnings presented where the entity is a member of a group that files a consolidated tax return, the amount of any tax related balances due to or from affiliates as of the date of each statement of financial position presented, the principal provisions of the method by which the consolidated amount of current and deferred tax expense is allocated to the members of the group and the nature and effect of any changes in that method. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(k))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 3A<br><br> -Section 04<br><br> -Paragraph b<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 57<br><br> -Paragraph 1-4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 4<br><br> -Section 08<br><br> -Paragraph k<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ED1AG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Condensed Consolidated Statement of Equity (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Preferred Stock [Member]</div>
        </th>
        <th class="th">
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Additional Paid-in Capital [Member]</div>
        </th>
        <th class="th">
          <div>Contingently Issuable Shares [Member]</div>
        </th>
        <th class="th">
          <div>Noncontrolling Interest [Member]</div>
        </th>
        <th class="th">
          <div>Retained Earnings [Member]</div>
        </th>
        <th class="th">
          <div>Total</div>
        </th>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2011</a></td>
        <td class="nump">$ 413<span></span></td>
        <td class="nump">$ 5,061<span></span></td>
        <td class="nump">$ 10,472,115<span></span></td>
        <td class="nump">$ 6<span></span></td>
        <td class="nump">$ 11,681<span></span></td>
        <td class="num">$ (853,074)<span></span></td>
        <td class="nump">$ 9,636,202<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2011</a></td>
        <td class="nump">413,388<span></span></td>
        <td class="nump">5,061,399<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtxd_ChangesDuringPeriodAbstract', window );"><strong>Changes during the period:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition', window );">Compensation in respect of restricted preferred stock granted to employees</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">188,509<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">188,509<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Preferred stock issued at $20.00 per share, net of expenses</a></td>
        <td class="nump">696<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">12,180,710<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">12,181,406<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Preferred stock issued at $20.00 per share, net of expenses (in shares)</a></td>
        <td class="nump">695,428<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtxd_SharesIssuedToNonControllingInterestInConnectionWithLicensingAgreement', window );">Shares issued in subsidiary to non-controlling interest in connection with in-licensing agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">16,578,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">16,578,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(7,140,448)<span></span></td>
        <td class="num">(10,256,090)<span></span></td>
        <td class="num">(17,396,538)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2012</a></td>
        <td class="nump">$ 1,109<span></span></td>
        <td class="nump">$ 5,061<span></span></td>
        <td class="nump">$ 22,841,334<span></span></td>
        <td class="nump">$ 6<span></span></td>
        <td class="nump">$ 9,449,233<span></span></td>
        <td class="num">$ (11,109,164)<span></span></td>
        <td class="nump">$ 21,187,579<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2012</a></td>
        <td class="nump">1,108,816<span></span></td>
        <td class="nump">5,061,399<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtxd_ChangesDuringPeriodAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tgtxd_ChangesDuringPeriodAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tgtxd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtxd_SharesIssuedToNonControllingInterestInConnectionWithLicensingAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The value of shares issued to non controlling interest in connection with licensing agreement during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>tgtxd_SharesIssuedToNonControllingInterestInConnectionWithLicensingAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>tgtxd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the amount of recognized equity-based compensation related to restricted stock units during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4J<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6922042&amp;loc=SL4591551-111686<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A1, A4, A5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph c(1)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 29<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -Subparagraph (a),(c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6921930&amp;loc=SL4573702-111684<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4K<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6922042&amp;loc=SL4591552-111686<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 5<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6921628&amp;loc=SL4569616-111683<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProfitLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued and outstanding as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of Stockholders' Equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity including portions attributable to both the parent and noncontrolling interests (previously referred to as minority interest), if any. The entity including portions attributable to the parent and noncontrolling interests is sometimes referred to as the economic entity. This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6921628&amp;loc=SL4568740-111683<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4I<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6922042&amp;loc=SL4590271-111686<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Publisher AICPA<br><br> -Number 51<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A3<br><br> -Appendix A<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 25<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6921628&amp;loc=SL4568447-111683<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>ACQUISITION<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDateOfAcquisitionAbstract', window );"><strong>Business Acquisition, Date of Acquisition [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combination Disclosure [Text Block]</a></td>
        <td class="text"><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>NOTE 3 - ACQUISITION</b></p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On December 29, 2011, the Company completed a reverse acquisition of privately held TG Bio, a Delaware Corporation. The acquisition was effected pursuant to an Exchange Transaction Agreement (the &#8220;Agreement&#8221;) dated December 29, 2011 by and among the Company, TG Bio and Opus, the largest shareholder of TG Bio. In accordance with the terms of the Agreement, 95% of the holders of common stock of TG Bio (one (1) minority shareholder of TG Bio holding in aggregate 132,000 shares of common stock of TG Bio did not participate) surrendered their TG Bio common stock. The Agreement caused the Company to issue to TG Bio&#8217;s shareholders 281,250 shares of Company Preferred Stock. <font style="background-color: white; color: black;">Each share of Company Preferred Stock is convertible into 8.89 shares of the Common Stock provided that such conversion rights are subject to sufficient available authorized shares of Common Stock. </font>The Company Preferred Stock has the same voting rights (on an as-converted basis), and other attributes as Common Stock. The Company Preferred Stock will automatically be exchanged for Common Stock when sufficient authorized shares are available to allow for such conversion. The Company Preferred Stock issued in connection with the Agreement, provided the former TG Bio shareholders with direct and/or indirect ownership of approximately 95% of the Company&#8217;s outstanding Company Common Stock immediately following the consummation of the transaction.</p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company Preferred Stock issued (and the underlying Common Stock once converted) are not registered for resale and, therefore, shall remain subject to the rights and restrictions of Rule 144. All Company Preferred Stock received by the TG Bio shareholders in exchange for their shares of TG Bio common stock will not be registered for resale prior to six (6) months following December 29, 2011 and, therefore, shall remain subject to the rights and restrictions of Rule 144 prior to any such registration.</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company Preferred Stock issued in connection with the agreement provided the former TG Bio shareholders with direct and/or indirect ownership of approximately 95% of the Company&#8217;s outstanding common stock as of December 29, 2011. Based on fair value of the Company&#8217;s Common Stock of $0.04 per share, the purchase price was $295,933, plus the fair value of restricted stock assumed of $82,305. In connection with the Exchange Transaction, the Company incurred $231,580 of acquisition related costs.</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">A summary of the purchase price calculation is as follows:</p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="width: 70%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.5in;" cellspacing="0" cellpadding="0">
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; text-indent: -12.6pt; padding-left: 12.6pt; width: 74%;">Number of shares of Manhattan common stock outstanding at the time of the transaction</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: right; width: 10%;">131,526</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: right; width: 10%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in;">Multiplied by Manhattan&#8217;s fair value of the Common Stock</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">$</td>
<td style="border-bottom: black 1pt solid; text-align: right;">2.25</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt;">$</td>
<td style="text-align: right; padding-bottom: 1pt;">295,933</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt;">Fair value of restricted stock assumed</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="text-align: right; padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">82,305</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt; padding-left: 12.6pt;">Total purchase price</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: right; padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">378,238</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
</table>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The purchase price has been allocated as follows based on the fair values of the assets and liabilities acquired:</p>
<p style="text-align: left; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="width: 70%;
 border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.5in;" cellspacing="0" cellpadding="0">
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in; width: 87%;">Cash and cash equivalents</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">10,386</td>
<td style="text-align: left; width: 1%;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in;">Other assets</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">90,769</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; text-indent: -0.25in; padding-left: 0.25in;">In-process research and development acquired</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">5,441,840</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; text-indent: -0.25in; padding-left: 0.36in;">Total identifiable assets</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">5,542,995</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in;">Accounts payable and accrued expenses</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">197,191</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in;">Notes payable (ICON and Swiss Pharma)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">939,718</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; text-indent: -0.25in; padding-left: 0.25in;">5% notes payable and accrued interest</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">4,657,600</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; text-indent: -0.25in; padding-left: 0.36in;">Total identifiable liabilities</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">5,794,509</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in;">Net identifiable liabilities</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(251,514</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; text-indent: -0.25in; padding-left: 0.25in;">Goodwill</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">629,752</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; text-indent: -0.25in; padding-left: 0.36in;">Total</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">378,238</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
</table>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">A valuation was performed to determine the fair value of certain identifiable intangible assets of Manhattan.</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The fair value of certain identifiable intangible assets was determined using the income approach. This method starts with a forecast of the expected future net cash flows. These cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk of achieving the asset&#8217;s projected cash flows. The present value of the estimated cash flows are then added to the present value equivalent of the residual value of the asset, if any, at the end of the discrete projection period to estimate the fair value.</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The valuations are based on information that is available as of the acquisition date and the expectations and assumptions that have been deemed reasonable by our management. No assurance can be given, however, that the underlying assumptions or events associated with such assets will occur as projected. For these reasons, among others, the actual results may vary from the projected results.</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The following supplemental pro forma information presents the financial results as if the transaction had occurred on January 1, 2011 for the three months ended March 31, 2011.&#160;This supplemental pro forma information has been prepared for comparative purposes and does not purport to be indicative of what would have occurred had the acquisition been made on January 1, 2011, nor are they indicative of future results.</p>
<p style="text-align: left; text-indent: 0.5in; margin: 0pt 0px; font:
 10pt times new roman, times, serif;">&#160;</p>
<table style="width: 60%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.5in;" cellspacing="0" cellpadding="0">
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt;">Revenue</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">&#8212;</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt; width: 82%;">Net income</td>
<td style="padding-bottom: 2.5pt; width: 1%;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left; width: 1%;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right; width: 15%;">3,832,383</td>
<td style="text-align: left; padding-bottom: 2.5pt; width: 1%;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt;">Basic and diluted income per common share</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">1.51</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
</table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionDateOfAcquisitionAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessAcquisitionDateOfAcquisitionAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 51, 52<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6909870&amp;loc=d3e1500-128463<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911361&amp;loc=d3e7000-128479<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911361&amp;loc=d3e6927-128479<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911361&amp;loc=d3e7008-128479<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6909870&amp;loc=d3e1490-128463<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911361&amp;loc=d3e6996-128479<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4922-128472<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4934-128472<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141R<br><br> -Appendix F<br><br> -Paragraph F4<br><br> -Subparagraph e<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4926-128472<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6909870&amp;loc=d3e1383-128463<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6909870&amp;loc=d3e1392-128463<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6909870&amp;loc=d3e1497-128463<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141R<br><br> -Paragraph 67-73<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6909870&amp;loc=d3e1524-128463<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 88-16<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6909870&amp;loc=d3e1486-128463<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4845-128472<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <Version>2.4.0.6</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>22</ContextCount>
  <ElementCount>88</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>6</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tgtherapeuticsinc.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tgtherapeuticsinc.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>003 - Statement - Condensed Consolidated Balance Sheets [Parenthetical]</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tgtherapeuticsinc.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets [Parenthetical]</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>004 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tgtherapeuticsinc.com/role/CondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>005 - Statement - Condensed Consolidated Statement of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tgtherapeuticsinc.com/role/CondensedConsolidatedStatementOfEquity</Role>
      <ShortName>Condensed Consolidated Statement of Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>006 - Statement - Condensed Consolidated Statement of Equity [Parenthetical]</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tgtherapeuticsinc.com/role/CondensedConsolidatedStatementOfEquityParenthetical</Role>
      <ShortName>Condensed Consolidated Statement of Equity [Parenthetical]</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>007 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tgtherapeuticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>008 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>009 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tgtherapeuticsinc.com/role/FairValueMeasurements</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>010 - Disclosure - ACQUISITION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tgtherapeuticsinc.com/role/Acquisition</Role>
      <ShortName>ACQUISITION</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>011 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tgtherapeuticsinc.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>012 - Disclosure - NOTES PAYABLE</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.tgtherapeuticsinc.com/role/NOTESPAYABLE</Role>
      <ShortName>NOTES PAYABLE</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>013 - Disclosure - LICENSE AGREEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tgtherapeuticsinc.com/role/LicenseAgreements</Role>
      <ShortName>LICENSE AGREEMENTS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>014 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tgtherapeuticsinc.com/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>015 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tgtherapeuticsinc.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Process Flow-Through: 002 - Statement - Condensed Consolidated Balance Sheets</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Mar. 31, 2011'</Log>
    <Log type="Info">Process Flow-Through: 003 - Statement - Condensed Consolidated Balance Sheets [Parenthetical]</Log>
    <Log type="Info">Process Flow-Through: 004 - Statement - Condensed Consolidated Statements of Operations</Log>
    <Log type="Info">Process Flow-Through: 006 - Statement - Condensed Consolidated Statement of Equity [Parenthetical]</Log>
    <Log type="Info">Process Flow-Through: 007 - Statement - Condensed Consolidated Statements of Cash Flows</Log>
  </Logs>
  <InputFiles>
    <File>tgtxd-20120331.xml</File>
    <File>tgtxd-20120331.xsd</File>
    <File>tgtxd-20120331_cal.xml</File>
    <File>tgtxd-20120331_def.xml</File>
    <File>tgtxd-20120331_lab.xml</File>
    <File>tgtxd-20120331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
